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Abstract  
Title: Improving Biopharmaceutical Production in Chinese Hamster Ovary 
Cells using Targeted Genome Engineering Tools 
Author: Kevin Kellner 
Chinese Hamster Ovary (CHO) cells are the prominent cell line used in 
biopharmaceutical production. Over 70% of all therapeutically used recombinant proteins 
are produced by CHO cells with a market size predicted to exceed €250bn by 2021. 
Their favourable attributes over other cell lines are properties like resistance to viral 
infections, growth in chemical defined media, human like glycosylation patterns, good 
productivity and ease of genetic engineering. Due to the complexity of mammalian 
expression systems yields achieved are not phenomenal by any means. However, 
compared to 1986 with product concentrations of 50 mg/L, titres up to 10 g/L have been 
reported recently. Improvement of bioprocesses and media development contributed 
their part in facilitating higher titres but genetic engineering to improve host cells came 
to the foreground. MicroRNAs (miRNAs) have hereby been highlighted as attractive 
targets due to their involvement in processes like viability, secretion, productivity, product 
quality to mention only a few. MiRNAs are small non-coding RNAs which are about 22 
nucleotides in length and were first discovered in the early 90’s. A single miRNA can 
target 100-200 mRNAs which highlights them as key regulators for translational control. 
The miRNA-23 cluster was first identified as upregulated during induced hypothermic 
conditions. Hypothermia is a commonly used process to reduce growth and thrive CHO 
cells to improved productivities. Therefore, we hypothesised involvement of the miR-23 
cluster or individual miRNA members in viability and productivity phenotypes. In this work 
we investigated the depletion of the miR-23 cluster as well as miR-23, miR-24 and miR-
27 in a panel of industrially relevant cell lines expressing various recombinant products. 
In fact, miR-24 was identified as thriver of productivity and growth by upregulating 
ribosomal biogenesis, assembly of ribosomal subunits, translation as well as unfolded 
protein response (UPR). This was demonstrated in several cell lines and was not product 
specific. Furthermore, the depletion of the whole miR-23 cluster as well as miR-27 has 
been shown to improve productivity although in a cell line specific context. To overcome 
challenges of sponge technology we also implemented the recently developed 
CRISPR/Cas9 system to target miRNAs. When phenotypes after sponge and 
CRISPR/Cas9 mediated depletion of members of the miR-23 cluster were assessed, it 
was demonstrated that even enhanced properties were exhibited using CRISPR/Cas9 
in case of miR-24 and miR-27 regarding productivity and longevity. Furthermore, we 
implemented a CRISPR/Cas9 library for genome wide recessive knockout screens to 
identify proteins involved in high productivity phenotypes or are important for survival of 
stress conditions i.e. hyperosmolality. Mixed populations expressing the sgRNA-library 
were sorted for high productivity using low temperature stains and were adapted to high 
salt conditions. Enrichment or depletion of sgRNAs was subsequently analyzed using 
Next-Generation Sequencing. SgRNA abundance analysed after low temperature stain 
showed enrichment of distinct populations. Functional annotation of enriched genes 
showed no evidence in relation to productivity. Exploiting miRNAs and genome-wide 
knockout studies to improve the bioprocess phenotype highlights these methods as 
interesting tools for further investigation regarding applications within biopharmaceutical 
industry.  
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3 
1 Introduction 
1.1 CHO cells in biopharmaceutical industry 
The first recombinant protein expressed by mammalian cells was tissue plasminogen 
activator (tPA) in 1986 used for the treatment of thrombosis and myocardial infarctions. 
The production of recombinant proteins by mammalian cells offered a wide field of 
possibilities for therapeutic applications in treatment for cancer, infectious diseases and 
diseases like haemophilia. The volumetric yields reached about 50 mg/l over a period of 
7 days. Nowadays yields up to 5-10 g/L were reported (F. M. Wurm, 2004) and 70% of 
all recombinant proteins used as biopharmaceuticals are produced by mammalian cell 
lines. Prominent cell lines used for their production are Chinese hamster ovary (CHO), 
Mouse myeloma (NS0), baby hamster kidney (BHK) and human embryonic kidney cells 
(HEK293). The market size reached up to €140bn in 2013 and is predicted to exceed 
€250bn by 2021 (Walsh, 2014). Approved recombinant proteins are for example 
Erythropoietin (EPO), Cetuximab and Trastuzumab which are used as common 
therapeutics for the treatment of anaemia, colorectal cancer and breast cancer. 
However, recombinant proteins describe a diversity of different molecules like cytokines, 
monoclonal antibodies (mAb), Fc fusions, antibody fragments and enzymes.  
CHO cells are the most commonly used cell line due to their beneficial properties like 
resistance to viral infections, growth in chemical defined media, human like glycosylation 
patterns, medium productivity and ease of genetic engineering. CHO cells are genetically 
well known and different selection systems like dihydrofolate reductase deficient (DHFR) 
or glutamine synthetase deficient (GS) strains are well established and studied. 
However, the optimisation approaches like improvement of media formulations and 
bioprocess regimes are limited pathways and genetic engineering to identify beneficial 
phenotypes and improve the bioprocess behaviour came to the foreground and was 
highlighted as a promising research field. Furthermore, the demand of more therapeutic 
proteins with high qualities and yields drive the development of new strategies. The focus 
of cell line engineering lies hereby not only on a phenotype with high productivities but 
equally important are other features like growth behaviour, apoptosis and stress 
resistance, glycosylation pattern, viability and improved secretion of products. 
The development of new therapeutic proteins follows a distinct route from start to the 
finished approved product. Firstly, the host producer cell is transfected with the 
transgene of interest and cells are selected due to a selection marker which is usually 
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encoded by the same vector. The selection method depends hereby on the expression 
system. If DHFR deficient cells (dhfr-) are used the selection and amplification process 
is performed with the help of methotrexate (MTX). MTX inhibits the dihydrofolate 
reductase (DHFR) which is an essential gene for the conversion of dihydrofolate to 
tetrahydrofolate. Tetrahydrofolate is required for purine and pyrimidine synthesis and 
therefore plays an essential role in cell growth by providing DNA precursors. The GS 
gene is a vital gene and is crucial for the synthesis of glutamine out of glutamate and 
ammonia. A GS deficient strain can be transfected with the gene of interest and the GS 
gene which allows the selection in glutamine free medium of positively transfected cells. 
Methionine sulphoximine (MSX) is a potent GS inhibitor and can be used for amplification 
processes but is often not necessary. Amplification processes are mainly based on the 
genetic instability of CHO cells which leads to genetic aberrations like for example gene 
amplifications (Derouazi et al., 2006). This genetic instability is used for the amplification 
of transgenes as higher copy numbers are usually associated with higher product 
expression (Schuster-Bockler et al., 2010; Stranger et al., 2007). Following selection and 
amplification clonal cell lines are established and individual clones are assessed for high 
productivities as well as their growth performance. Once high producers are identified 
the further development and screening is based on the cultivation process optimisation 
and individual growth characteristics. Design of experiments (DoE) is nowadays a vital 
part of process optimisation. DoE can be for example used to predict the growth 
behaviour of cells and to optimise media as well as feed characteristics without the need 
of large scale experiments. Only initial and final experiments are needed to assess the 
bioprocess at its best (Horowitz et al., 2009; Mandenius & Brundin 2008). After the 
bioprocess is defined and pilot-scales were successfully completed the 
commercialisation process begins which involves scale-ups and validation of 
manufacturing as well as clinical studies with the therapeutic protein (F. Li et al., 2006). 
Besides the process development the major cost factor are clinical trials for the approval 
of the newly developed therapeutic protein by the regulatory authorities like FDA and 
EMA. Clinical trials are studies important for the investigation of the functional bioprocess 
product and are divided into three different phases (I, II and III). All trials aim to study the 
potential of the developed therapeutic drug with hindsight on potential side effects and 
efficacy. Total development costs of only one biopharmaceutical are estimated to be ~ 
US $ 1 billion including development, pre-clinical and clinical trials (DiMasi & Grabwoski, 
2007). However, phase II and phase III are critical and success rates are in general very 
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low (~18% for II, ~5% for III) leading to high risk factors for the developing company. This 
explains why one of the main focuses is to reduce development and process costs 
implementing genetic engineering which are linked to immense amounts of savings 
potential.  
 
1.1.1 Cell culture regimes and formats 
For the large-scale production of recombinant proteins, bioprocesses are usually 
performed in dimensions up to 20,000 L. However, for process optimisation and 
development usually smaller scales are applied as up-scaling effects are well 
characterised and follow distinct rules. Furthermore, costs of goods increase drastically 
for larger scales e.g. media costs. The optimisation is usually performed in small scale 
cultures e.g. 96-well plates, shake flasks and benchtop bioreactors which allows process 
development in high-throughput (Li et al., 2010). One important factor hereby is the 
optimisation of the basal media and feed for fed-batch modes. These media are 
chemically defined for suspension cultures without the usage of animal derived 
components but including recombinantly derived products like albumin in exact 
concentrations. Defined media is optimal as process environments are defined and 
downstream applications are straight forward if no serum or other animal compounds are 
involved. Common carbon sources used are high levels of glucose and glutamine as well 
as other essential amino acids. Lipid sources are usually sterol, glycerol phospholipids 
and sphingolipids. Lipids are essential for energy storage and as structural element for 
e.g. membranes (Landauer, 2014). However, carbon sources are consumed very easily 
and waste products like lactate and ammonia have been shown to influence product 
quality as well as growth (Altamirano et al., 2000; Hansen & Emborg 1994; Lao & Toth 
1997).  
For the ideal production of the biopharmaceutical the choice of the bioprocess regime is 
essential. Besides batch and perfusion, the fed-batch culture is the most commonly used 
bioreactor mode for the production of recombinant proteins. However, the choice of the 
culture system can have significant influences on the product qualities and properties. It 
was reported that different culture conditions have an influence on the glycosylation 
pattern of IgGs (Patel et al., 1992). Furthermore, it was described that the pH influences 
the glycosylation of the product leading to the addition of buffering solutions in fed-batch 
cultivation to maintain a constant pH over the whole period of the bioprocess (Muthing 
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et al., 2003). Counteracting a pH drop using bases will however, ultimately increase 
burden on cells due to high osmolality conditions. Cultivation under high osmotic 
conditions has been considered to influence glycosylation pattern as well (Schmelzer & 
Miller, 2002) making the understanding of processes inalienable. The glycosylation 
pattern of a recombinant protein is essential to ensure efficacy, pharmacokinetics and 
prevent immune system response. Many process related factors were described to alter 
glycosylation pattern of the therapeutic product including the cell type, medium and feed 
supplements (Hossler, Khattak, & Li, 2009a).  
Traditional cultivations in batch have become very uncommon over the past few years 
for mammalian cells due to major disadvantages of fast nutrient depletion, low cell 
densities and high waste accumulation. However, a batch-refeed strategy was applied 
for the removal of toxic waste products and has been shown to be applicable in small 
scale bioreactors up to 200 L (Xie et al., 2003) as a strategy to simplify perfusion.  
Two major bioreactor systems are commonly used for the large-scale production of 
recombinant proteins using mammalian cells: fed-batch and perfusion cultivation. Fed-
batch cultures are applicable with working volumes up to 20,000 L. The fed-batch mode 
works in two phases: initial cell growth is supported by basal media. Once a certain cell 
density is reached a concentrated nutrient feed is added to prevent nutrient depletion 
which would ultimately lead to declining cell densities and viability (Birch & Racher, 
2006). Feed strategies have to be optimised for each cell line which is implemented by 
using small scale experiments and DoE (Horowitz et al., 2009; N. Ma et al., 2009). 
Optimisation of feed strategies and supplements has been shown to increase product 
yields. A DoE study implementing several different feeds and supplements showed 
increased yields of about 167 %, respectively (Kochanowski et al., 2011). However, the 
effect on the protein product itself was not investigated. DoE involves mathematical 
approaches linking the effect of the inputs given into the bioprocess on the output 
variables. It involves the inclusion of several parameters e.g. metabolism, media 
supplements and stress factors which can be extrapolated using stoichiometric 
calculations (Mandenius & Brundin, 2008b). However, even though input variables are 
constant a biological system usually never behaves the same but DoE is essential to 
reach the regulatory demands set by medical safety agencies. Fed-batch has been 
proven to be a consistent bioprocess system leading to high yields of up to 5-13 g/L 
(Huang et al., 2010; F. M. Wurm, 2004). The stationary phase in batch cultures is usually 
very short but is highly prolonged in fed-batch cultures and is usually associated with 
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high productivities due to inhibited proliferation. A common fed-batch process continuous 
on for 12-14 days in total. Nevertheless, due to enhanced cell number and the long 
cultivation times, accumulation of toxic catabolites like ammonia and lactate is one of the 
major problems of this bioprocess mode. Due to high lactate levels the pH starts to 
decrease over culture time and furthermore the osmolality increases due to feed addition 
of pH additives which are necessary to maintain constant bioprocess parameters. Low 
pH values and high osmolality have been shown to influence the glycosylation pattern 
as well as growth and ultimately lead to reduced quality of the bioprocess product. 
Furthermore, ammonia has been reported to impact the glycosylation pattern of IgGs. 
Gawlitzek and colleagues (Gawlitzek et al., 2000) reported a decrease in N-
acetylneuraminic acid and galactose residues with increased levels of ammonia in the 
bioprocess. It was suggested that the alteration of galactosylation and sialyation is 
dosage dependent on the concentration of ammonia in the media. Several strategies 
have been described to control the waste accumulation due to controlled stoichiometric 
feeding of key metabolites like glutamine and glucose (Glacken et al., 1986). 
Besides, controlling feeds to overcome high concentrations of catabolites in the culture 
media over time the perfusion bioprocess mode was developed. In comparison to fed-
batch cultivation, perfusion can last up to months, whereas cells are fed constantly with 
fresh media whilst old media and product is removed. Cells remain in the bioreactor and 
different approaches have been proven to be successful. One way for example is to use 
polyester matrices, fibres or membranes to keep cells entrapped in the bioreactor 
(Meuwly et al., 2007; Zhang et al., 2015). Another approach is the usage of filtrations 
systems like tangential flow filters to maintain cells in the bioreactor (Clincke et al., 2013) 
or centrifugation. The removal of toxic waste products ensures optimal growth conditions 
for cells in the perfusion bioreactor. Furthermore, cells are usually cultivated in high cell 
densities up to 2 x 108 cells/mL (Y. Zhang et al., 2015) increasing yields drastically. One 
major advantage is as well that perfusion reactor scales are considerably smaller in 
comparison to fed-batch reactors. It was observed that the perfusion bioreactor with a 
working volume of 50 L can achieve same yields compared to a fed-batch reactor with a 
volume of 1,000 L. However, cultivation times regarding perfusion reactors are much 
longer compared to fed-batch cultures and fed-batch cultures are the most prominent 
cultivation methods in industry. Another advantage of the perfusion bioreactor is as well 
that the process conditions are not changed over time. Waste accumulation and addition 
of feed as well as alkali changes osmolality in a fed-batch cultivation process. Using 
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basal media or media with low percentages of feed for the perfusion reactor maintains 
the bioprocess constant. Furthermore, removal of therapeutic product out of the 
bioprocess environment increases the product stability as the product might be prone to 
degradation or cleaving by proteases in a closed bioprocess at late stages of the culture.  
Studies showed that the perfusion reactor led to dramatically increased yields of an IgG 
when compared to the same product using the same cells in cultures. Zhang and 
colleagues showed a final IgG yield of 1.42 g in comparison to only 40.5 mg for a batch 
process. Same drastic impact on the titre was shown using Drosophila Schneider 2 cells 
with a final yield of 8 g for perfusion and 200 mg for batch cultures (L. Wang et al., 2012). 
However, cultivation times using the perfusion reactor are significantly longer.  
Bioprocesses under hypothermic conditions is a well-established method for the 
production of recombinant proteins in biopharmaceutical industry. Commonly known as 
“biphasic culture” process the initial growth is promoted by a temperature of usually 37°C 
(cell line dependent). After reaching a critical cell density the temperature is decreased 
to 30-31°C. This hypothermic condition arrests cells in G0/G1 phase and ultimately 
reduces proliferation. However, due to inhibited growth the productivity is highly elevated 
as energy is shifted towards protein production instead of growth (Kaufmann et al., 1999; 
Trummer et al., 2006; Yoon et al., 2003). Furthermore, the nutrient consumption rate, 
protease activity as well as the O2 consumption are reduced and thus longevity of the 
culture is significantly prolonged (Barnabe & Butler, 1994; Moore et al., 1997). In 
addition, lower nutrient consumption leads ultimately into lower accumulation of toxic 
waste products. Temperature shift can be applied in combination with fed-batch or 
perfusion bioprocesses and showed highly increased product titres in the past (Y. Zhang 
et al., 2015). However, it has been shown that the beneficial effect using temperature 
shift can be cell line and product specific as well the optimal temperature can vary from 
cell line to cell line (Yoon et al., 2003; Yoon et al., 2004). It has also been shown that low 
temperature can alter the abundance of glycosylation pattern which are exhibited on 
certain residues of the product (Andersen et al., 2000; Gawlitzek 2009) and certainly can 
influence the product quality as well as efficacy in vivo.  
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1.1.2 CHO cell heterogeneity  
The diploid CHO genome consists of 22 chromosomes (2n=22) and its genome size is 
about 2.45 billion bases (haploid). The total number of predicted genes is 24,383 and 
most show sequence homology to human (19,711) and mouse (20,612) genes (Xu et 
al., 2011). The CHO genome shows a high level of genetic instability and the frequency 
of chromosome rearrangements as well as homologous recombination is higher than in 
other immortalised cell lines. However, their ease of genetic manipulation makes them a 
favourable cell line for recombinant protein production. These genetic changes are often 
exploited in gene amplification procedures used for the generation of stable, high 
producing cell lines.  
The original cell line was first described in 1958 by Dr. Theodor Puck (Puck et al., 1958). 
The cell line was established out of 0.1 g Chinese hamster ovary tissue and exhibited a 
fibroblast like cell morphology. CHO cells were very popular for studies due to their large 
chromosomes and their ease of cultivation under simple media conditions. Furthermore, 
researchers were able to select cells for mutations in genes involved in metabolism due 
the usage of selective media. The original diploid cell line exhibited 11 chromosome pairs 
and only 1% of the total population exhibited an unusual number of chromosomes. After 
ten month of sub-cultivation the cells in the population changed morphology (epithelioid) 
and cells became spontaneously immortalised. However, CHO cells were distributed to 
many labs and were able to be grown with low concentrations of serum and in protein 
free media (Hamilton & Ham, 1977). Ten years after describing the original cell line the 
first CHO-K1 cell line as we know it was established and further distributed to other 
researchers as well as to the American tissue and cell culture collection (ATCC) (Kao & 
Puck, 1967; Kao & Puck, 1968) (Figure 1).  
Ever since many different CHO cell lines were established and can be described 
nowadays as their own cell line (“Quasispecies”) exhibiting different phenotypes and 
genetic variations (M. F. Wurm, 2013). The genetic instability is most likely a result of 
gene aberrations like deletions and rearrangements as well as epigenetic events (Kim et 
al., 2011; Yang et al., 2010). Common CHO cell lines like CHO-S, DG44i, CHO-DXB11 
and CHO-K1 were established and they exhibit different traits as well as phenotypes. 
CHO-S for example was first described to grow in suspension and was isolated from a 
sister cell line of CHO-K1 (Thompson & Baker, 1973). The DG44i cell line originated from 
CHO-K1 and both loci of the DHFR gene were deleted which were located on 
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chromosome 2 (Urlaub et al., 1983). This allows the rapid generation of stable cell lines 
transfected with a transgene and amplification using the DHFR inhibitor MTX.  
 
 
 
 
 
 
 
 
 
Due to their ease of growth in chemically defined media and their ease in genetic 
engineering CHO cells are the commonly used production cell line in industrial 
production of recombinant proteins. Hereby, tPA was the first approved therapeutic for 
the treatment of thrombosis marketed by Genentech on 1986. In 2014 the total amount 
of approvals in Europe and the US has reached 246 overall (Walsh, 2014). Although 
media and bioprocess regime optimisation led to high yields and robust growing cells 
under defined conditions, the overall bioprocess including R&D, process optimisation, 
product commercialisation, pre-clinical trials and clinical trials requires tremendous 
amounts of capital. However, media and bioprocess optimisation are limited pathways 
and genetic engineering became one major tool to improve the bioprocess phenotype of 
CHO cells. This involves the better understanding of CHO cells gaining knowledge about 
the transcriptome, proteome, phospho-proteome, glycome, regulatory networks and 
metabolome (Datta, Linhardt, & Sharfstein, 2013a). That knowledge can be used to 
engineer pathways for improving secretion, growth, preventing apoptosis and many 
more applications. Recent advances and developments in targeted genome engineering 
tools led the way to a whole new path of genetically engineered cells and better 
understanding of global regulatory networks. 
 
Figure 1: Summary of CHO cell quasispecies and variations. The original fibroblast like cell line was 
isolated out of 0.1g tissue originally in 1957 and had a near diploid state. Over cultivation of 10 month and 
spontaneoues immortalisation the first CHO progenitor cell line was described in 1958. Different CHO cell 
lineages were developed by adaption to suspension (CHO-Toronto and CHO-S) or deletion of the DHFR gene 
(DG44i). 
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1.2 CHO cell engineering  
The major limiting factor for the application of new techniques was the lack of sequence 
information for the Chinese hamster genome. A major breakthrough was achieved in 
2012 when the complete sequence of the CHO-K1 ancestral cell line was published (Xu 
et al., 2011). The whole genomic sequence of other CHO cell lines i.e. CHO DXB11 
(Kaas et al., 2015) or DG44 and CHO-S (Hefzi et al., 2016) followed consequently. The 
public availability of the genomic sequence led the way for the use of a variety of Next 
Generation Sequencing (NGS) approaches i.e. to identify transcripts and perform 
expression profiling under for example different growth conditions (Becker et al., 2011). 
Before the assembly of transcriptomics data, expressed sequence tags (EST) were used 
for the generation of expression data which limited the datasets to only hundred proteins 
(Wei et al., 2011). NGS and the comparison to Mus musculus and Rattus norvegicus 
enabled the analysis and identification of expressed genes and isoforms. Furthermore, 
it enabled first insight into the regulatory network of CHO which is essential for the 
analysis and application of integrated ‘omic approaches.  
 
1.2.1 Implication of ‘omic approaches 
The genomic sequence of the CHO genome combined with the rapid increase of 
transcriptomic data enabled the establishment of proteomic profiling studies using LC-
MS/MS. The identification of thousands of proteins and studies to identify differential 
expression (DE) with regard to the bioprocess conditions like different media, stress 
environments, miRNA dysregulations and many more can give information about 
function or highlights engineering targets. In comparison to using ESTs, a proteomic 
study can give information about hundreds of differential expressed proteins which can 
be combined with transcriptomic datasets for gene expression to evolve deeper 
knowledge about regulatory networks (Clarke et al., 2012a; Xu et al., 2011). The 
identification of differential expressed proteins gives insight into many production 
relevant pathways like apoptosis, glycosylation, growth, translation as well as protein 
processing and metabolism (Baycin-Hizal et al., 2012). With the implementation of ‘omic 
studies and better understanding of pathways and protein regulatory networks as well 
as mRNA expression under certain conditions, more potential targets for cell line 
engineering were identified which can be used to improve the bioprocess phenotype of 
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CHO cells. Different approaches for cell line engineering exist and have been used for 
the improvement of the bioprocess phenotype. 
 
1.2.2 Apoptosis engineering 
Apoptosis engineering is based on the principle that genes are overexpressed which 
show anti-apoptotic functions or the downregulation/knockout of genes which function 
pro-apoptotic. The idea behind this approach is that cells exhibit higher viabilities in late 
stages of the culture which can improve the overall yield. Apoptosis in late stages of the 
culture is mainly induced by nutrient depletion, hyper-osmolality, shear stress or toxic 
catabolite accumulation. Furthermore, apoptosis has been shown to impair therapeutic 
protein quality regarding glycosylation. The overexpression of the apoptosis inhibitor Bcl-
2 and Bcl-Xl has been shown to increase the resistance to apoptosis in many industrial 
relevant cell lines like CHO, NS0 myeloma and SF9 cells (Goswami et al., 1999; 
Mastrangelo et al., 2000; Mitchell-Logean & Murhammer 1997) due to numerous stress 
factors like shear stress, oxygen limitation, ammonia and nutrient depletion. However, it 
was also shown that the phenotype exhibited by the overexpression of both factors is 
cell line dependent. In some cases, a growth inhibition or an improved growth rate was 
observed (reviewed by Vives et al., 2003) suggesting a cell line dependent interaction of 
Bcl-2 and Bcl-Xl with the apoptosome. Both regulators mainly act by the inhibition of 
caspases which are the prominent proteases during induction of programmed cell death. 
Another interesting protein for the protection against apoptosis was shown to be X-linked 
inhibitor of apoptosis (XIAP). Sauerwald and colleagues showed that overexpression of 
XIAP or XIAP-mutants protect CHO and HEK293 cells from apoptosis induced by 
nutrient deprivation as well as programmed cell death induced by Sindbis-virus infections 
(Sauerwald et al., 2002; Sauerwald et al., 2003). Besides delaying apoptosis, XIAP has 
been demonstrated to be involved in productivity in two CHO-K1 cell lines (Griffith et al., 
2018). XIAP is a specific inhibitor for caspase-3, -7 and -9 and interestingly it is a 
predicted target of miRNA-23a as well as miRNA-7 in CHO cells.  
For the downregulation of pro-apoptotic genes, caspase-3 and caspase-7 were obvious 
targets for siRNA induced silencing. Studies showed an enhanced longevity due to the 
knockdown of caspase-3 and subsequent delay of apoptosis induction. However, no 
increase in productivity was reflected presumably due to lower mitochondrial function 
upon the knockdown of caspase-3 in a CHO mAb producing cell line. A co-silencing of 
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caspase-3 and caspase-7 showed increased product titres due to elongated culture 
times in a CHO cell line expressing thrombopoietin (Kim et al., 2002; Sung et al., 2007). 
However, the effect on expressing anti-apoptotic genes had a greater effect and seems 
to remain the prominent strategy in CHO cell engineering to prolong culture times with 
extended stationary phases to boost CHO cell productivity.  
 
1.2.3 Metabolic engineering 
Metabolic engineering involves for example the avoidance of toxic metabolite build-up 
which are exhibited in late stages of the culture e.g. ammonia and lactate. Lactate or 
lactic acid is a by-product of glycolysis and is enzymatically converted from pyruvate by 
lactate dehydrogenase (LDH). Glycolysis is usually enhanced in immortalised cell lines 
due to the Warburg effect. However, lactate in a bioprocess leads to low pH values which 
influences cell growth and product expression. To counteract low pH values alkali like 
NaOH is usually added to the medium which again changes the osmolality of the media 
and increases the stress levels on cells. Knockdown of LDH has been shown to limit 
lactate production and a decrease in glucose consumption rates was observed without 
effects on proliferation or expression of thrombopoietin or an IgG (Chen et al., 2001; Kim 
et al., 2007). Another group investigated the effect after transfection of a GLUT5 fructose 
transporter into CHO cells to use fructose as alternative primary carbon source which 
would ultimately lead to lower levels of lactate. Wlaschin and Hu identified clones which 
showed high product expression and reduced accumulation of lactate (Wlaschin & Hu, 
2007).  
Ammonia can inhibit cell growth at much lower concentrations compared to lactate and 
can also impair productivity. Furthermore, it was shown that ammonia possibly alters the 
glycosylation pattern of recombinant proteins (Gawlitzek et al., 2000) presumably due to 
inhibition of enzymes involved in providing sialic acid precursors. One approach to 
reduce ammonia was the use of CHO-K1 cells expressing GS and the addition of 
glutamate supplements to the media. Glutamate is enzymatically converted with 
ammonia to glutamine and Zhang and colleagues showed reduced ammonia formation 
(Zhang et al., 2006). The overexpression of two enzymes involved in the urea cycle 
which is most likely inactive in CHO-K1 showed beneficial effects on ammonium 
production as well. The expression of carbamoyl phosphatase synthetase I and ornithine 
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transcarbamoylase showed a 33% reduction of ammonium ions in CHO-K1 cell cultures 
and increased cell proliferation (Park et al., 2000).  
 
1.2.4 Secretion and molecular chaperone engineering 
Secretion engineering has been shown to be an efficient tool to enhance specific 
productivity. A common problem in industry resulting in low yields are difficult-to-express 
(DTE) mAbs. The difference in easy and DTE proteins are most likely related to protein 
processing. In a study two mAbs were selected and transfected, with Trastuzumab being 
easy to express and Infliximab being DTE. Trastuzumab showed higher expression 
compared to Infliximab over a panel of selected clones. This study showed that the 
processing of the DTE IgG is impaired due to lack of response of the unfolded protein 
response (UPR) ultimately leading to degradation and loss of the product (Le Foum et 
al., 2014). It was also demonstrated that the limitation shown in CHO cells due to high 
level expression of transgene can be solved by the simultaneous expression of human 
secretory proteins like SPR14. Furthermore, it was also shown that the expression of 
SPR14 not only restores the expression of the DTE IgG it also enhances the expression 
of the already highly produced Trastuzumab. This identified that bottlenecks in secretion 
can be overcome by the expression of limiting factors in that process. Further studies 
revealed that the introduction of other components of the secretory pathway like SNAP-
23, VAMP8 and SM protein can improve secretion and boost the specific productivity in 
CHO cells (Peng & Fussenegger, 2009; Peng, Abellan, & Fussenegger, 2011). SNAP-
23 and VAMP8 are proteins associated with the SNARE protein family which mediate 
the fusion of vesicles to the target membrane. It was shown that the introduction of 
SNAREs solves the bottleneck in secretion however, proliferation is impaired due to 
higher specific productivities. It is commonly observed that higher productivity is 
associated with lower investment of resources into the establishment of biomass 
resulting in lower proliferation rates. 
A further bottleneck for the expression of proteins is the protein folding and processing 
machinery which is performed in the endoplasmic reticulum (ER). Chaperones are 
proteins which are involved in folding and unfolding of proteins and are also able to 
reduce protein aggregation which can occur due to high expression of recombinant 
proteins especially with high molecular weights. Common chaperone families are trigger 
factors, heat shock proteins and BiP. Overexpression of chaperones like 
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calnexin/calreticulin which are located in the ER has been shown to elevate specific 
productivity in CHO-K1 cells expressing thrombopoietin (Chung et al., 2004). 
Furthermore, overexpression of protein-disulphide isomerase (PDI) showed beneficial 
effects on recombinant protein expression in CHO cells. PDI is located in the ER and 
mediates the breakdown of randomly formed disulphide bridges to allow the peptide 
chain to form again. Enhanced productivity was observed CHO-K1 cells expressing 
IgGs, Fc receptor fusions and thrombopoietin (Borth et al., 2000; Davis et al., 2000; 
Mohan et al., 2007).  
 
1.2.5 Promoter engineering and optimisation of expression systems 
The reduction of transgene expression over time is a commonly observed phenomenon 
in cultures despite exhibiting multiple genomic copies (Kim et al., 1998; Strutzenberger 
et al., 1999) despite regular “pulsing” using selection agents. In one study a high 
producer was selected and cultivated for 18 months as well as routinely sub-cultivated 
twice a week (Kim et al., 2011). The transgene expression steadily declined over the 18-
month period. The effect was investigated by several groups and it was observed that 
the commonly used CMV promoter is prone to DNA methylation at the 5’ and 3’ region 
of the promoter sequence which eventually led to a decrease in expression. Position -
179 relative to the transcriptional start site off the CMV promoter is frequently methylated 
as well as positions -508, -41 and -13. However, it was reported that a single base pair 
mutation at position -179 can enhance and stabilise transgene expression over long 
cultivation times (M. Kim et al., 2011b; Moritz, Becker, & Gopfert, 2015; Osterlehner, 
Simmeth, & Gopfert, 2011). Besides DNA methylation, histone modifications may also 
play a role in the silencing of genes due to condensation of DNA and enabling DNA-
binding factors to access the chromatin. 
A promoter is defined by two regions: the proximal and the core elements. Both regions 
contain binding sites for proteins which are associated with transcription and the 
preinitiation complex formation. Transcription factors as well as transcription regulators 
bind to their target sequences and regulate the frequency of binding, the level of 
transcription and duration. Thus, promoters and their engineering are highlighted as 
potential tools for increasing stable expression over time. In CHO-K1 cells the promoter 
of a high and stable expressed protein (elongation factor-1α – EF-1α) was used including 
flanking regions and inserted into expression vectors. Six different genes were inserted 
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into the vector and transfected into CHO cells to investigate their expression. Four stable 
cell lines expressed 6 to 35-fold higher levels of transgenes compared to traditional, 
commercial plasmids (Running Deer & Allison, 2004).  
The possible usage of synthetic promoters consisting of multiple elements from different 
origins in CHO cells have been proposed as potential tool for stable and high transgene 
expression. Transcription factor regulatory elements and binding sites were identified 
from viral promoters known to be active in CHO using bioinformatics tools. After 
transfection of constructed promoters with the SEAP gene downstream, one promoter 
was identified which showed increased transcriptional activity and yields (Brown et al., 
2014).  
The usage of site specific integration allows the prediction of target gene expression due 
to insertion into transcriptional active regions (hot-spots) which ensures the stable 
transcription of the transgene (Kuystermans et al., 2007). Recombinase-mediated 
cassette exchange (RCME) has been used for the site-specific integration of transgenes 
using viral recombinase systems like Cre/LoxP (Kito et al., 2002). Studies have also 
shown that the usage of ubiquitous chromatin opening elements (UCOE) can be 
beneficial due to resistance to DNA methylation which ensures high, stable expression 
of the gene of interest (F. Zhang et al., 2010). Gained knowledge about CHO cell 
promoters and regulatory elements will drive research and identify new possible 
synthetic promoters which can be used for stable long-term transgene expression.  
 
1.2.6 Glycosylation-engineering 
The dominant use of CHO cells in biopharmaceutical production is mainly because of 
the human-like glycosylation pattern. The attachment of saccharides to proteins can 
occur in two different distinct forms: N-linked glycosylation occurs on asparagine 
residues and O-linked glycosylation occurs on serine/threonine residues. N-linked 
glycosylation was demonstrated to be the more prominent posttranslational modification 
and the pattern is essential for the efficacy of the therapeutic protein as well as for 
possible side effects or pharmacokinetics (Elliott et al., 2003). To ensure quality over 
time in production of recombinant therapeutics, the bioprocess as well as the 
glycosylation pattern of the therapeutic protein must be investigated extensively to meet 
FDA regulations. Culture conditions as well as media components, the cell type and the 
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bioprocess itself can have a significant influence on the glycosylation pattern of 
therapeutic protein. The addition of N-linked glycoforms is mainly enzymatically 
catalysed in the ER and the addition of O-linked glycoforms is catalysed in the Golgi 
apparatus.  
It has been demonstrated that different glycosylation patterns can influence the 
circulation half-life of IgGs and are potential engineering targets (reviewed by Hossler et 
al., 2009). Overexpression of human α2,6-sialyltransferase (ST6Gal1) for example has 
been used to enhance sialic acid content of erythropoietin in CHO-K1. The same 
approach was used for therapeutic products like tPA and Interferon γ (Fukuta et al., 2000; 
Minch, Kallio, & Bailey, 1995; B. Yin et al., 2015). The sialic acid residues are important 
for N-glycan capping which again plays a key role in the biological activity of recombinant 
proteins including adsorption, half-life and clearance (Bork et al., 2009).  
Nevertheless, glycoforms are not only important for half-life of the recombinant protein 
but also can influence target binding efficiencies. The existence of N-linked glycans on 
heavy chains of mAbs have been shown to be important for the interaction of Fc 
receptors and their mediated function in the cell (Rothman et al., 1989). Fucosylation of 
antibodies has been shown to impair antibody-dependent cellular cytotoxicity (ADCC) 
and the knockout of fucosyl-transferases like α-1,6-fucosyltransferase (FUT8) was 
suggested to be clinical relevant for improved functions of recombinant proteins. Thus, 
production using CHO cells with knockouts of fucosyltransferases was highlighted as a 
“next-generation” for antibody engineering (Mori et al., 2007; Ronda et al., 2014a).  
 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
18 
1.3 MicroRNAs 
Small noncoding RNAs (20-30 nt) are classified into three groups: PIWI interacting RNAs 
(piRNAs), small interfering RNAs (siRNAs) and microRNAs (miRNAs). MiRNAs are 
highly conserved over species and have been shown to be extensive regulators of gene 
expression. After the discovery of the first miRNA by Ambros and colleagues in 1993 
(Lee et al., 1993) in Caenorhabditis elegans, their function remained unknown for a long 
time. Studies revealed that miRNAs can regulate gene expression in a post-
transcriptional manner by either inhibiting translation of its mRNA target or degradation 
of it. Sequencing data showed that over 1,800 conserved miRNAs are expressed in 
human cells and exhibited a high sequence complementary (~60 %) to many protein-
coding mRNAs (Friedman et al., 2009; Kozomara & Griffiths-Jones 2014). MiRNAs are 
usually transcribed by RNA-Polymerase II and play an essential role in gene regulation 
by two different distinct mechanisms: degradation of the target mRNA or the repression 
of translation by inhibition of the polyribosome (Figure 2).  
 
 
 
 
 
 
 
 
 
 
The mature miRNA (~22 nt) is assembled into the RNA-induced silencing complex 
(RISC) which can act as an endonuclease whereas the miRNA acts as a guide, dictating 
target specificity (Hammond et al., 2000). Many proteins and domains are involved e.g. 
RNA binding domains which interact with dsRNA and single stranded RNA as well as 
Figure 2: Mechanisms of translational inhibition of miRNAs. After guidance of the RISC by 
the incorporated mature miRNA the mRNA translation is inhibited by the physical hindrance of 
the polyribosome. The second act of mechanism is the destabilisation and degradation of the 
mRNA which usually occurs due to perfect binding of the miRNA. Figure was sourced and 
altered from Lodish and colleagues (Lodish et al., 2008). 
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endonuclease domains, contributing to the RISC function (Pratt & MacRae, 2009). The 
loading of the RISC is supported by Ago2 and Dcr-2 proteins which binds to the 
premature miRNA duplex. The mRNA is specificly cleaved by the RISC if it shows a high 
complementary to the incorporated miRNA. Translational inhibition can also be exhibited 
by the binding of only the seed region (nucleotides 2 to 7 of the mature miRNA) to the 
mRNA target. If mismatches occur, the RISC prevents the translation of the mRNA by 
blocking the ribosomal propagation along the mRNA transcript. Furthermore, the 3´-
untranslated region (3´UTR) is essential for translation due to regulatory elements and 
translation can be efficiently blocked by RISC binding to these regions or interfering with 
essential translation factors which bind to this highly regulatory region of the transcript 
(Doench & Sharp, 2004; Grimson et al., 2007; Humphreys, Westman, Martin, & Preiss, 
2005). One mRNA can have several binding sites for miRNAs and it was also shown that 
one mRNA can be targeted by various miRNA families. The miR-23-24-27 constituting 
of three miRNAs with different seed families has been shown to target same mRNAs and 
pathways (Liang et al., 2004). Target prediction analysis showed further evidence that 
one single miRNA can have hundreds of targets by showing complementarity in the 
3`UTR alone. Critical for the wide range of different targets is the seed region of the 
miRNA. This seed region is conserved in vertebrates and is located at the 5`-end of the 
mature miRNA. A requirement for the repression is the degree of matching of the seed 
region to the target mRNA but further factors seem to be involved such as sequence 
composition proximal to the seed region and position of miRNA binding sequence (MBS) 
(Grimson et al., 2007). The efficiency of miRNAs/mRNA binding and the miRNA acting 
mechanism seems to have alternative modes which are cell line and tissue dependent 
(Kulkami et al., 2016). Ten cell lines were co-transfected with miRNA mimics and a target 
sequence located in 3’UTR of a renilla reporter for the miRNA. All cells exhibited a lower 
level of fluorescence levels. However, five cell lines stabilised the mRNA transcript, three 
cell lines did not show any effect and two cell lines showed a translational inhibition due 
to degradation suggesting a cell and tissue specific preference of miRNA regulation 
mechanistic. 
Target efficacy and number of binding sites on the mRNA transcript is proposed to vary 
dependent on the 3’UTR isoform usage which can show high variations across species. 
Alternative long and shorter isoforms have been reported in the same ORF due to 
different poly-A signals which can occur distal or proximal (Decker & Parker 1995; 
Miyamoto et al., 1996). Longer or shorter isoforms can exhibit a different number of 
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binding sites and the usage seems to be dependent on the cellular context to “fine-tune” 
expression (Nam et al., 2014). The difference in the 3’UTRs can strongly effect gene 
regulation in this context by adding or deleting miRNA binding sites and ultimately have 
tremendous impact on miRNA inhibitory function. It was also suggested that the amount 
of gene copies per cell influences miRNA regulation of the target mRNA. Studies showed 
that a dosage dependent effect of mRNA transcript effects the target selection of miRNAs 
(Shu et al., 2012).  
 
1.3.1 Biogenesis of miRNAs 
MiRNAs inhabit either their own genomic locus including promoter regions or are the 
results of mRNA splicing events when located intronicly of their host gene. Transcription 
of miRNAs is initiated by RNA-Polymerase II and the primary miRNA (pri-miRNA) 
transcript exhibits 5´- 7-methylguanosine caps as well as a 3´-poly-A tail. This nascent 
transcript forms a RNA-RNA duplex by complementary base pairing with several stem 
loops. The first step after transcription is the cleavage by Drosha RNase III which 
processes the pri-miRNA into a ~70 nucleotide long precursor miRNA (pre-miRNA). If 
the miRNA is located in introns, mRNA splicing can lead to formation of pre-miRNAs (Y. 
Lee et al., 2003). The pre-miRNA exhibits a 5´-phosphate and a 2 nucleotide 3`-overhang 
resulting from the RNase III cleavage. The second step is the export of the pre-miRNA 
into the cytoplasm mediated by exportin-5 which binds dsRNA and uses RanGTP as a 
cofactor (Lund et al., 2004). In the cytoplasm the pre-miRNA is further processed by the 
Dicer RNase III multi protein complex into a 22-nucleotide miRNA-miRNA* duplex with 
a two nucleotide 3`-overhang (Y. Lee et al., 2003) and the duplex is incorporated into a 
pre-RISC. The pre-RISC consists of Argonaute protein (AGO) and Dicer-2 which are 
supported by the chaperone machinery including HSP90 and HSC70. In this complex 
the miRNA-miRNA* duplex is separated to form the mature RISC. It is thought that the 
mature miRNA is selected from the miRNA-miRNA* duplex based on thermodynamic 
stability of their 5`-ends. The less stable 5´-end shows a preferential association with 
RISC due to the easier separation from the duplex (Schwarz et al., 2003). Assembled in 
the RISC, the miRNA plays its role in target recognition and binding by guiding the 
multiprotein RISC to the mRNA target.  
The whole process of miRNA maturation is shown in Figure 3. Another type of non-
coding RNA referred to as siRNA is similar in their target characteristics, their biogenesis 
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and their size. In the case of biogenesis, siRNAs and miRNAs share the Dicer complex 
as well as the RISC. Their difference is just related on their origin, as miRNAs are 
encoded in the host genome but siRNAs exhibit an exogenous source like viral genomes. 
However, the function of a siRNA lies in the perfect match of the target mRNA whereas 
miRNAs can exhibit mismatches in target binding.  
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Figure 3: Biogenesis and processing of miRNAs. Firstly, the miRNA gene is transcribed by RNA-
Polymerase II into pri-miRNA transcripts containing a 5’-7-methylguanosine cap and 3’-poly-A signal. The pri-
miRNA is further processed into a ~ 70 nucleotide long pre-miRNA and is exported into the cytosol by exportin-
5, a RanGTP dependent exporter. The pre-miRNA is further processes by a Dicer complex and incorporated 
into the pre-RISC with the help of molecular chaperones. Alternatively, the pre-miRNA can be processed by 
AGO2 before incorporation into the RISC. The pre-RISC matures by degrading miRNA* passenger strand and 
the final assembly of the mature miRNA before following its mechanistic function in translational inhibition. 
Figure was sourced and altered from (Ameres & Zamore, 2013). 
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1.3.1.1 Genomic organisation and nomenclature of miRNAs 
Due to the rapidly increasing data which evolved with the development of NGS and better 
bioinformatics tools an organised nomenclature for miRNAs was proposed by Ambros 
and colleagues (Ambros et al., 2003). A mature miRNA is named in the way of discovery 
by continuous counting: miR-1, miR-2… and further. A gene which encodes for the 
miRNA is named in the same way with capital or lower-case letters (MIR-1 or mir-1) 
depending on the species. If a known miRNA is discovered in a new species and shows 
no difference or only a small discrepancy to the already known miRNA it is named equally 
(e.g. known miR-23 in human and recent discovered miRNA with the same sequence in 
CHO is named miR-23 as well). In addition, if miRNAs exhibit very similar sequences 
(homologs) in the same species a number or letter is added e.g. miR-23a and miR-23b. 
To name the origin of the miRNA also the species abbreviation was added e.g. hsa-miR-
23a for human miRNA and cgr-miR-23a for the Chinese hamster miRNA-23a. Some of 
the known miRNAs are transcribed from a so-called cluster and are processed from one 
pre-miRNA precursor transcript. Several miRNAs can result from one pri-miRNA 
transcript (polycistronic) as well as from one precursor transcript (monocistronic). 
Examples for nomenclature of a cluster is the miR-23a-27a-24-2 cluster or miR-17-92 
describing clustering of three miRNAs for the miR-23 cluster or six different miRNAs in 
case of the miR-17-92 cluster.  
 
1.3.1.2 Identification of miRNA and validation of targets 
MiRNAs are usually identified by miRNA profiling studies however, the validation of 
possible targets has been shown to be more difficult. Kuhn and colleagues (Kuhn et al., 
2008) suggested an experimental approach for the experimental validation of possible 
miRNA targets. Bioinformatics tools like TargetScan, PicTar and miRanda are algorithms 
which can predict possible miRNA:mRNA interactions. Kuhn and colleagues showed a 
discrepancy as well in comparing these tools with each other leading to no overlaps and 
inconclusive identification of mRNA targets between the tools. Nevertheless, the 
interaction should be experimentally proven to be certain about the gene regulation by 
its target miRNA. The proposed workflow was to analyse possible mRNA targets using 
mentioned bioinformatics tools. Furthermore, a miRNA/mRNA co-expression study 
followed by an investigation of the miRNA effect on the protein and the assessment of 
the miRNA on the biological function.  
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1.3.2 MicroRNAs as potential tools for cell line engineering  
As mentioned miRNAs regulate complex mechanism and a single miRNA can target 
~100 mRNAs to prevent or “fine-tune” their translation. Thus, one miRNA regulates a 
whole network of proteins and plays a global role in cellular behaviour and phenotype. 
In addition, it is proven that miRNAs play an essential role in a variety of bioprocess 
related phenotypes like proliferation, apoptosis, protein expression and response to 
cellular stress such as hypoxia or low nutrient availability (Jadhav et al., 2013a). This 
highlights miRNAs as an interesting tool for cell line engineering to improve the 
bioprocess phenotype of CHO cells. Moreover, as miRNAs are processed from their non-
coding precursors they do not impose translational burden if they are introduced on 
plasmids for overexpression.  
Several studies prove the effects and benefits of dysregulating miRNAs on the 
phenotype of CHO cells. The depletion of miR-7 using sponge decoy technology for 
example showed positive effects like the increase of cell growth and specific productivity 
in CHO-K1 SEAP expressing cells (Sanchez et al., 2013). The inhibition enriched cells 
in G2/M phase of the cell cycle enabling a faster progression through cell cycle steps. In 
contrast the overexpression showed an inhibition of cell cycle progression with cells 
enriched in G1/S transition (Barron et al., 2011). Another interesting study showed that 
stable depletion of miR-23b can result in an increased productivity in CHO-K1 SEAP 
expressing cells. MiR-23b was identified to be differentially expressed in a panel of 
miRNAs identified using temperature shift to reduce cell growth and increase productivity 
(Gammell et al., 2007). Further investigation indicated that the depletion of miR-23b 
increases the mitochondrial oxidative phosphorylation capacity which ultimately led to 
higher specific productivity. However, the effect was inconsistent in a different CHO-K1 
cell line expressing a mAb but nevertheless beneficial. Stable depletion of miR-23b led 
to increased viabilities during late stages of the culture possibly by higher intracellular 
XIAP levels which was confirmed to be targeted by miR-23 (Kelly et al., 2015). 
Overexpression of miR-17 increased the specific productivity and growth rate of CHO 
EpoFc expressing cells (Jadhav et al., 2012a; Jadhav et al., 2014) 
Increased cell growth was also shown in HeLa cells due to inhibition of miR-21 and miR-
24 (Cheng et al., 2005) and miR-24 and miR-27a have been shown to be up-regulated 
during hypothermia induced growth arrest in CHO-K1 cultures (Gammell et al., 2007). 
Transient inhibition of miR-24 in CHO-K1 SEAP expressing cells confirmed enhanced 
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growth rates and the effect was reversed by overexpressing miR-24 which led to growth 
inhibition. Clarke and colleagues investigated differential expressed miRNAs using an 
integrated approach combining microarrays and proteomic profiling (Clarke et al., 
2012b). Sixteen miRNAs including miR-204, miR-338, miR-497, miR-30e, miR-206, miR-
451 have been shown to be downregulated during high growth rates and 35 miRNAs 
were upregulated during high growth rates which turn them into potential aims for 
targeted proliferation engineering. A further study showed the link between miRNA 
expression patterns due to different phases in the culture process. Lag-, exponential and 
stationary phase were investigated and 117 miRNAs were found to be differential 
expressed displaying involvement in biological processes like cell growth and arrest 
(Hernandez Bort et al., 2012).  
Other miRNAs like miR-15 and miR-16 can induce apoptosis by targeting Bcl-2 and a 
stable depletion of these miRNAs could be useful for preventing apoptosis in CHO 
cultures (Cimmino et al., 2005). More miRNAs linked to apoptosis in late stages of the 
cultivation process were investigated due to nutrient depletion. It was demonstrated that 
70 miRNAs were differentially expressed in mouse including miR-466 and the miR-297-
669 cluster which is possibly involved in initiating apoptosis (Druz et al., 2012). MiR-466 
was further investigated and delayed activation of apoptosis in late stages of batch 
cultures was observed leading to increased maximum cell densities (Druz et al., 2013). 
More miRNAs which could be possibly used as engineering tools and studies which 
investigated the dysregulation under different culture conditions were summarised and 
reviewed by Jadhav and colleagues (Jadhav et al., 2013b).  
Recent developed genome editing tools, such as transcriptional activator like nucleases 
(TALEN), zinc finger nucleases (ZNFs) and especially CRISPR/Cas9, opened a wide 
field of possibilities to target miRNAs more effectively for a possible application in 
industrial used cell lines. Beneficial phenotypes can exhibit for example higher specific 
productivities, lower apoptosis, increased cell viability and proliferation rates. It was 
shown, that targeted genome editing tools can be used for both, either gene knockouts 
or depletion of miRNAs. Thus, these tools might play an essential role in future cell line 
engineering approaches of CHO cells. 
1.3.3 Biological function of the miR-23-24-27 cluster and its role in disease 
Studies have shown that the miRNA cluster is derived from one primary transcript but 
the expression pattern of each member can vary possibly due to the specific biological 
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circumstances or diseases (Y. Lee et al., 2004). However, the paralogs are located on 
different genomic loci and are derived from different primary transcripts which would also 
suggest a different expression pattern (summarised by (Chhabra, Dubey, & Saini, 
2010a). In human the miR-23a cluster is located intergenic (chromosome 9) and the miR-
23b cluster is located intronic (chromosome 19). The appearance of two clusters is most 
likely due to gene duplication in evolution of mammals. In Chinese hamster the miR-23a 
cluster is similarly located intergenic and its paralog is located intronicly in the 
Aminopeptidase O-like gene (AMPO). The miR-23a cluster exhibits all core elements 
needed for a promoter region including TATA box and initiation sequences making 
transcription RNA-polymerase II dependent (Chhabra et al., 2010). The miR-23b cluster 
seems to lack common promoter elements which may suggest processing through intron 
splicing. The expression of both clusters seems to be highly variable over cell lines (Yu 
et al., 2006). In certain diseases each member can be simultaneously up- or 
downregulated i.e. in acute lymphoblastic leukaemia as well as acute myeloid leukaemia 
(Mi et al., 2007). In fact, several studies showed as well that single members of both 
miR-23 clusters were dysregulated in many diseases. For example, an upregulation of 
all single members was osberved in cardiac hypertrophy (Sayed et al., 2007) or a down 
regulation of each member was reported in schizophrenia and autism (Abu-Elneel et al., 
2008; F. Wu et al., 2008). The function of each member or a co-operative function 
remains however, unclear. Although evidence exists that similar targets as well as 
pathways are targeted (T. Liang et al., 2014) which also may be the evolutionary result 
of why some miRNAs are clustered. Nevertheless, individual functions of each member 
were observed as well. Indicated differential expression could suggest that the function 
and a possible impact on a bioprocess phenotype in CHO cells is highly cell line or cell 
type dependent.  
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1.3.3.1 MicroRNA 23-24-27 cluster and its individual members 
MiR-23a and miR-23b 
With their role as posttranscriptional regulators it was observed that repression of miR-
23a/b influences proliferation and metabolism of human B lymphocytes (Gao et al., 
2009). Gao and colleagues showed also that high expression levels of the oncogene c-
Myc represses the transcription of miR-23a as well as miR-23b. The repression leads to 
higher levels of mitochondrial glutaminase which is normally targeted by both miRNAs. 
Higher glutaminase levels led ultimately to enhanced mitochondrial capacity of Complex 
I/Complex II which again led to increased oxidative phosphorylation in CHO cells (Kelly 
et al., 2015). Due to the Warburg effect immortalised cells convert high amounts of 
glucose into lactate using glycolysis which increases cell proliferation but provides less 
substrate for mitochondrial based oxidative phosphorylation. While increased 
glutaminase levels strengthens the mitochondrial function by the conversion of glutamine 
to glutamate and subsequently to α-ketoglutarate which enters the TCA cycle. This 
reflects an alternative pathway to strengthen specific productivity in CHO-K1 SEAP 
expressing cells. However, the effect of miR-23 depletion seemed highly cell line and 
tissue specific. The dysregulation of miR-23 showed increased viability in late stages of 
the culture in a different CHO-K1 cell line expressing a mAb (Kelly et al., 2014). Another 
target for miR-23 is XIAP which is responsible for the inhibition of apoptosis by binding 
of caspase-3, -7 and -9 and could be responsible for observed prolonged cultures 
(Sauerwald et al., 2002). Furthermore, it was observed that miR-23a and miR-23b 
expression levels are decreased in some cancer types like prostate cancer and 
leukaemia (Porkka et al., 2007; Saumet et al., 2009). However, there is evidence that 
miR-23a/b can prevent apoptosis during hypoxia by targeting important key components 
of the apoptosis pathway like Bax-like BH3 protein (BID), caspase-7 or BCL2/Adenovirus 
E1B 19kDa Interacting Protein 3-Like (BNIP3L) (Agrawal et al., 2014). The positive 
effects of miR-23a/b on cell proliferation and apoptosis prevention highlights a possible 
strong tool for optimisation of cellular behaviour in a bioprocess dependent manner.  
 
MiR-24 
Similar to miR-23a/b, miR-24-1/2 has been shown to target essential proteins of the 
apoptotic pathway in human cells. The targets are pro-apoptotic proteins like Bim, FAF-
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1, Caspase-9 and Apaf-1 (Agrawal et al., 2014; Cheng et al., 2005; Qin et al., 2010) as 
well as targets which are responsible for cell survival e.g. Bcl-2 (Singh & Saini, 2012a). 
It seems that the role of miR-24-1/2 in a pro- or anti-apoptotic manner depends on 
specific circumstances of the cell and is cell/tissue type specific. Overexpression of miR-
24 inhibited cell proliferation of six different human cancer cell lines by inducing the 
expression of p53 and p21 (Mishra et al., 2009a). E2F2 and MYC are proteins which are 
involved in rapid cell cycle progression and a study showed that miR-24 targets both 
mRNAs and blocks uncontrolled proliferation. However, E2F2 and MYC do not exhibit 
binding sites for miR-24 in the 3’UTR (Lal et al., 2009). This was confirmed by transient 
overexpression of miR-24 using mimics in CHO cells resulting in significantly reduced 
cell growth (Noèlia Sanchez, 2013). Mishra and colleagues showed as well that miR-24 
targets the DHFR gene which catalyses the reaction of dihydrofolate into 
tetrahydrofolate. Tetrahydrofolate is required for purine and pyrimidine synthesis and 
therefore plays an essential role in cell growth and proliferation. Consequently, a down 
regulation of miR-24 showed an increase of proliferation in human epithelial cells (Cheng 
et al., 2005). Dr. Sanchez showed in her thesis as well that transient inhibition of miR-24 
resulted in increased proliferation in CHO-K1 SEAP expressing cells (Noèlia Sanchez, 
2013). This suggests that deregulation of miR-24 could be used as potential target for 
improving bioprocess characteristics in CHO cells regarding growth behaviour.  
 
MiR-27a and miR-27b 
Several studies showed that miR-27 plays a role in apoptosis by either targeting pro-
apoptotic or anti-apoptotic proteins possibly dependent on the specific circumstances of 
the cell environment. Agrawal and colleagues showed that miR-27 targets APAF1 which 
inhibits apoptosis under hypoxia (Agrawal et al., 2014). Further studies also showed that 
miR-27 negatively regulates FADD which interacts with caspase-8 in the apoptotic 
signalling pathway and prevents apoptosis in human cell lines (Chhabra et al., 2009). 
Up-regulation of miR-27a seems also to increase cell proliferation in human breast 
cancer cells by targeting the tumour suppressor FOXO1 (Guttilla & White, 2009). 
However, Guttilla and White reported an involvement of miR-96 and miR-186 as well 
which could involve a synergistic effect or shared targeting. Moreover, miR-27 stimulates 
cell survival by targeting Myt-1 which inhibits G2-M phase progression (Mertens-Talcott 
et al., 2007). This leads to a higher percentage of cells in S phase and to higher 
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proliferation rates. Downregulation of miR-27a seemed to have an anti-apoptotic function 
by increased levels of Bcl-2 proteins. Interaction studies indicated that miR-27 targets 
are involved in many more cellular pathways like insulin signalling, Mitogen-activated 
protein kinase (MAPK) signalling and p53 signalling (S. Yang et al., 2012). Regarding 
CHO cells, the overexpression of miR-27a resulted in a decrease of growth (CHO-K1 
mAb) but also increased proliferation in a different cell line (CHO2B6) showing 
mentioned cell type specific phenotype (Noèlia Sanchez, 2013). However, the 
involvement in proliferation and apoptosis highlights miR-27a and miR-27b as interesting 
engineering targets. 
 
1.4 Targeted genome engineering tools 
A better understanding of the genome and transcriptome with projects like the ENCODE 
consortium and recently developed targeted genome engineering tools have paved a 
whole era of new possibilities for treatment of diseases. Targeted engineering tools 
include transcriptional activator like nucleases (TALENs), zinc finger nucleases (ZNFs) 
and CRISPR/Cas9. For miRNA engineering and the investigation of miRNA function the 
common approach is either the overexpression of pre-miRNAs, transient mimics or the 
depletion using antisense molecules (antagomiRs) as well as sponge decoy vectors.  
 
1.4.1 Sponge decoy technology for the stable or transient depletion of miRNAs 
Sponge decoy technology is based on mimicking the natural binding sites of miRNAs 
using exogenous artificial miRNA binding sites (MBS) located in the 3’UTR of a reporter 
gene (reviewed by (Ebert & Sharp, 2010). A selection of reporters can be used e.g. 
destabilised GFP, mCherry or firefly luciferase. Reporter expression is usually driven by 
a CMV promoter located on a plasmid enabling transient screens as well as a permanent 
depletion by generating stable expressing cell populations. Transcription by RNA-
polymerase II also increases mRNA stability due to the presence of a poly-A tail and a 
5’-cap. Two different designs of the MBS have been utilised. The first approach is the 
perfect antisense sequence which can lead to degradation of the sponge mRNA. On the 
other hand, creating a four-base pair mismatch in the MBS between the mRNA and the 
miRNA has been shown to protect from AGO2 mediated endonucleolytic cleavage by 
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the RISC (Ebert et al., 2007; Kluvier et al., 2012). The same study showed that miRNAs 
sharing the same seed family can be targeted effectively by the same antisense 
sequence. The successful binding and function of the sponge is indicated by the 
reduction of the reporter signal (Figure 4).  
 
 
 
 
 
However, the function needs to be validated by quantifying target genes of the miRNA 
which should be higher abundant due to the depletion of its target miRNA. It has been 
reported that sponges containing ten binding sites are optimal as every binding site 
enhances the probability of mRNA cleavage. However, also dosage dependent effects 
and off target effects should be considered. High abundance of miRNAs with the same 
seed family require high amounts of sponge transcipt and can possibly influence the 
phenotype due to the posed transcriptional burden. Furthermore, the expression of 
sufficient levels of transgene can be challenging when stable cell lines are created as 
well as a decrease in transgene expression over time.  
 
 
 
 
 
 
 
Figure 4: Basic mechanism of the sponge decoy approach. MBS can be cloned into 
the 3’UTR of a reporter gene. MiRNA binding and associated translational inhibition can 
be subsequently analysed and compared to a control without functional binding sites. The 
usage of a resistance gene allows the generation of stably expressing cell lines.  
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1.4.2 Clustered regularly interspaced short palindromic repeats (CRISPR) 
Due to the challenge of mobile genetic elements (MGEs) such as plasmids or viral DNA 
several defence mechanisms have evolved in prokaryotes, eukaryotes and archaea. The 
CRISPR system is a common defence system used in ~39% of bacteria and ~88% 
archaea (Makarova et al., 2006). This system, first discovered in Escherichia coli by 
Ishino and colleagues in 1987 (Ishino et al., 1987), provides acquired immunity against 
invading viral and plasmid DNA by integrating foreign nucleic acid into the hosts 
chromosome (Grissa et al., 2007; Jansen et al., 2002). A CRISPR locus normally 
consists of variable foreign sequences, so called spacers which are separated by 
conserved repeats. The loci are flanked by genes encoding CRISPR-associated (Cas) 
proteins which are required for the processing of transcripts, the integration of new 
spacers as well as the cleavage of invading DNA (Haft et al., 2005; Makarova et al., 
2006). CRISPR loci are conserved but the amount of spacer–repeats differs between 
loci and between species. Studies have revealed that spacers can have a length 
between 27-72 base pairs and repeats vary between 21-48 base pairs. Furthermore, the 
lead sequence upstream is A/T-rich and was shown to serve as the promoter region for 
the transcription of spacer-repeat sequences by RNA-Polymerase II (Horvath et al., 
2008; Jansen et al., 2002; Kunin, Sorek, & Hugenholtz, 2007). A CRISPR locus is first 
transcribed into a pre-CRISPR-RNA (pre-crRNA). This transcript is further processed 
into small CRISPR-RNAs (crRNA) by cleavage of the pre-crRNA into spacers which are 
flanked by two repeats (Carte et al., 2008; Hale et al., 2009). Different systems have 
evolved over time and the maturing of the crRNAs depends on the classification of the 
system. Thereby CRISPR/Cas systems are divided into three major types: Type I, Type 
II and Type III. These types are further segmented into subtypes depending on their 
evolutionary relationship between the associated protein machinery and CRISPR/Cas 
clusters (Makarova et al., 2011). In addition, protospacers of crRNAs are flanked by short 
sequences which are called protospacer adjacent motifs (PAM). The PAM is essential 
for target recognition and varies between the species origin. To prevent self-targeting of 
chromosomal direct repeats CRISPR loci show a lack of PAM (Marraffini & Sontheimer, 
2010b). The PAM used in Streptococcus pyogenes for example uses 5´-NGG whereas 
Streptococcus thermophilus uses 5´-NAAAAC. Depending on the type the PAM is 
located either at the 5`- (type I system) or 3`- (type II system) and is absent in the type 
III system (Marraffini & Sontheimer, 2010b). Repeat-spacer sequences are processed 
by CRISPR specific ribonucleases (Cas5 and Cas6) in type I and type III systems. In 
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type II systems a trans-activating RNA (tracrRNA), which is complementary to the repeat 
sequence of the crRNA binds and forms a double-stranded guide RNA (gRNA). In the 
Streptococcus pyogenes CRISPR/Cas system which is mainly used for targeted genome 
editing, two different tracrRNAs are expressed upstream of the CRISPR locus. The 
formed gRNA is recognized and cleaved by a cellular RNase III (Deltcheva et al., 2011). 
The whole crRNA biogenesis of the type II system consists of only four Cas proteins and 
Cas9 is described as playing the key role as endonuclease which is responsible for the 
cleavage of the target sequence (Deltcheva et al., 2011; Garneau et al., 2010). The 
mature gRNA forms a complex with Cas9 to follow its role in target binding and 
recognition. The recognition is followed through Watson-Crick base pairing and provides 
acquired immunity against invading MGEs by their recognition and cleavage. The 
process of cleavage and degradation of invading DNA is called CRISPR interference 
(CRISPRi). The adaption of new spacers, biogenesis of CRISPR and finally the 
interference is summarized in Figure 5 A and B. 
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Figure 5: Organisation of CRISPR loci, adaption and biogenesis. A) Adaption of new spacers is initiated by 
the recognition of foreign DNA with involvement of Cas proteins. The foreign DNA is cleaved and integrated as 
spacer into the host’s genome with flanking repeats in 5’- and 3’-. The length of the spacer as well as the repeat 
depends hereby highly on the species. The CRISPR locus also exhibits the coding sequences proximal to the 
spacer-repeat region. The locus itself is transcribed by RNA-Polymerase II. B) After transcription of the pre-crRNA, 
the precursor is further processed by cleavage into repeat-spacer sequences. This step is proceeded by CRISPR 
specific ribonucleases in type I and type III systems. In type II systems a complementary trans-activating crRNA 
binds to the repeat sequence of the crRNA and the dsRNA is recognized and cleaved by RNase III. The mature 
gRNA forms dependent on the type a complex with a Cas protein to follow its role in target binding or recognition. 
Figures were sourced and altered from: (Makarova et al., 2011). 
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1.4.3 CRISPR/Cas9 as targeted genome engineering tool 
For targeted genome editing the type II CRISPR system was adapted and a single guide 
RNA (sgRNA), which is a fusion of the protospacer containing crRNA and the tracrRNA, 
was introduced (Jinek et al., 2012). The sgRNA is usually under control of a U6 promoter 
and is transcribed by RNA-Polymerase III. The Cas9 endonuclease, with origin in 
Streptococcus pyogenes, incorporates the sgRNA and is guided to its target region by 
Watson-Crick base pairing between the target sequence and the protospacer. The PAM, 
essential for the target recognition, is located directly 3`- of the target region (Figure 6).  
 
 
Thus, Cas9 can possibly target every sequence in the host genome by altering the 
sequence of the 20 nucleotides protospacer. The only limitation is the PAM which must 
be present at the genomic target site. However, the PAM used by the Streptococcus 
pyogenes Cas9 (spCas9) can be found every 8 bp in the human genome (Cong et al., 
2013). Furthermore, it was demonstrated that the region 1-12 nucleotides upstream the 
PAM is necessary to determine Cas9 target specificity whereas mismatches further 
Figure 6: Overview of Cas9 targeting and function. The sgRNA is assembled into the Cas9 
endonuclease which dictates the target specificity. The target specificity is exceptional high however, 
mismatches at the 5’-end of the sgRNA are tolerated which could possibly lead to off-target effects. After 
binding the target sequence, a double strand break (DSB) is induced by two DNA cleaving domains: RuvC-
like and HNH-like nuclease domain. The DSB is catalysed between the base pairs 17 and 18 proximal to 
the PAM. Figure was sourced and altered from: (Mali et al., 2013). 
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upstream the PAM region are more likely to be tolerated (Cong et al., 2013; Jinek et al., 
2012). It was further shown that not only the complementarity of the sgRNA plays a role 
in target binding but also epigenetic features like DNA methylation as well as chromatin 
structures seem to be an important criterion. Genome-wide analysis of spCas9 binding 
predicts that 19% of binding variations occur due to epigenetic features like chromatin 
accessibility and DNA methylation pattern (Wu et al., 2014). As Cas9 was led to its target 
sequence the function relies on two domains: HNH-like nuclease domain and RuvC-like 
nuclease domain. Thereby the HNH-like nuclease domain cleaves the complementary 
strand and RuvC-like nuclease domain cleaves the opposite strand (Chylinski et al., 
2013; Fonfara et al., 2014). Together the two domains mediate DSBs between the base 
pairs 17 and 18 of the target sequence. The DSB initiates two of the major DNA repair 
pathways, either non-homologous end joining (NHEJ) or homology direct repair (HDR). 
Due the fact that NHEJ requires no homologous sequence and is active during all phases 
of the cell cycle it is the prominent pathway.  
DSBs are repaired by first creating a blunt end of the break if necessary (resection) and 
re-ligation by recruited ligases. Due to the process of NHEJ, indels of several base pairs 
are common which can lead to a shift of the open reading frame (ORF) in case of protein 
coding sequences. Alterations of the ORF are called frame-shift mutations and can have 
a significant effect on the target gene by changing the amino acid sequence. The 
introduction of a premature stop codon or the shift of the ORF can lead to nonsense 
mediated protein decay. However, the most common indels that seem to occur are 
deletions up to -9 and insertions of +1-2 base pairs (Canver et al., 2014; Hsu et al., 2013; 
Hwang et al., 2013). The CRISPR system allows also the introduction of repair templates 
which can be used to introduce a specific sequence at the DSB using HDR. 
Several expression systems were established for the integration of Cas9 and the sgRNA 
into the host’s genome. Thereby transient transfection methods e.g. lipid based reagents 
and electroporation as well as stable insertion into the host genome by viral delivery 
systems are applicable depending on the experimental design. After transfection, Cas9 
and the sgRNA are co-expressed by corresponding promoters like human U6 RNA-
Polymerase III promoter or cytomegalovirus (CMV) promoter. It was proven that 
CRISPR/Cas9 can target a wide range of endogenous genes in different organisms and 
cells. Cas9 was hereby used to edit genomes of e.g. Mouse (H. Yin et al., 2014), Chinese 
Hamster (Ronda et al., 2014b), Zebrafish (Hwang et al., 2013), Human (Mali et al., 2013) 
and many more organisms as well as cell lines.  
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As mentioned above, CRISPR/Cas9 needs only the PAM at the genomic target site to 
induce a DSB but also mismatches located upstream the PAM are likely to be tolerated. 
Up to five mismatches are tolerated which can lead to undesirable off-target effects on 
non-related sites (Fu et al., 2013a; Mali et al., 2013). To use the CRISPR system in 
industrial or therapeutic applications several strategies are available which can reduce 
potential off target effects. First, the usage of CRISPR design tools and second by using 
spCas9 nickases. A nickase induces a single strand break, which is referred to a nick 
and is quickly repaired. However, if two nickases cut proximal on opposite strands, the 
DNA damage is repaired as DSB and NHEJ is induced. The reduction of off-target effects 
is an essential issue for CRISPR/Cas9 in future therapeutic applications to use it as an 
efficient tool for genome editing. Several studies have shown that CRISPR/Cas9 could 
be applied for repairing mutation based diseases like cystic fibrosis (Schwank et al., 
2013; Y. Wu et al., 2013) as well as the deletion/mutation of whole distinct loci (Ebina et 
al., 2013). Thus, the CRISPR system has been proven to be an easy, highly valuable 
system for cell line engineering and for applications in CHO cells to improve bioprocess 
phenotypes. 
 
1.4.3.1 CRISPR/Cas9 variants 
Since the first mentioning of CRISPR/Cas9 several different Cas9 variants have been 
described. The CRISPR/Cas9 system is in general not only limited to the induction of 
DSBs but can be used as transcriptional repressor/activator by recruitment or fusion to 
transcription factors, DNA or chromatin modifiers. Gilbert and colleagues performed 
investigations with two Cas9 fusions with Krueppel associated box (KRAB) and a so 
called “suntag” consisting of several VP64 repeats. KRAB hereby is a transcriptional 
repressor and VP64 is a transcriptional activator with viral origin (Gilbert et al., 2014). 
Another Cas9 variant is impaired in the DNA cleavage domains and is fused to FokI. The 
unspecific FokI endonuclease is only active as dimer and allows to target two proximal 
sequences to delete large DNA fragments or induce HDR (Tsai et al., 2014). As 
mentioned the PAM dictates the target sequence which can be used for sgRNA design. 
Another CRISPR class II system was recently developed using a single RNA-guided 
endonuclease named Cpf1. The species origin was Francisella novicida and the PAM 
used is 5’-TNN (Zetsche et al., 2015). Interestingly the PAM is located 3’- and not 5’- as 
for Cas9 and that the DSB exhibits a five nucleotide 5’-overhang. Cas9 induces blunt 
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end DSBs proximal to the PAM whereas Cpf1 mediates the DSB 18 nucleotides 
downstream the PAM. To reduce off-target effects and the possibility to mediate HDR 
rather than the NHEJ pathway Cas9 “nickases” were developed. This particular variant 
only cuts one strand and two nickases which target a sequence in a proximal distance 
can be used for the introduction of HDR using repair templates to insert exogenous DNA 
into the host’s genome. Due to double nicking the off-target effects are highly reduced.  
 
1.4.3.2 CRISPR/Cas9 as potential tool to dysregulate miRNAs in CHO 
Not only coding genes are potential targets but also miRNAs can be targeted which play 
an important role in gene regulation, disease and phenotypic behaviour (Zhao et al., 
2014). It was recently demonstrated that miRNAs can be successfully targeted using 
CRISPR/Cas9 (Chang et al., 2016; Jiang et al., 2014). Targeted was the miR-27-92 
cluster which consists of six induvial members with four different seed families. MiR-93 
which is a member of the miR-106b cluster was targeted in the seed region and a 
successful reduced miRNA expression by over 90% was reported in single cell clones 
exhibiting various indel sizes. MiR-93 is critical in regulating cell growth and the 
expression of three targets (PTEN, E2F1 and p21) was assessed as well as the growth 
phenotype proving that miR-93 lost its function in regulating these proliferation relevant 
genes. It was also shown that small deletions can impair the Drosha processing and 
ultimately the maturation of miRNAs. Thus, CRISPR can be used as tool to stably deplete 
if not possibly knockout miRNAs besides using sponge decoy technology.  
 
1.4.3.3 Genome wide studies using libraries 
Due to the unique mechanism of the CRISPR/Cas9 system it provides high target 
specificity and is applicable for a wide range of different methods beginning with targeted 
knockouts of genes up to whole genomic screens using library-based methods to 
overcome pitfalls in RNAi libraries (Wang et al., 2014). Wang and colleagues hereby 
identified genes involved in etoposide protection as well as proliferation associated 
genes. Different library approaches were summarised recently by Shalem and 
colleagues (Shalem et al., 2015). Previously Shalem and colleagues performed a 
genome wide “loss of gene function” screen in human cells (HEK293T) using ~65,000 
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sgRNAs to target 18,080 genes. Investigated was the positive and negative selection 
with vemurafenib for the treatment of melanoma and already validated genes by RNAi 
were identified with high confidence using the CRISPR approach (Shalem et al., 2014). 
Another genome wide study identified unknown genes for the resistance to alpha-toxin 
and 6-thioguanine after the knockout of 19,150 genes using an 87,897 sgRNA-library in 
mouse embryonic stem cells. A total of 26 genes were identified including four unknown 
genes which are responsible for the resistance to mentioned toxins (Koike-Yusa et al., 
2014). All known genes (22) were previously validated by an RNAi screen as well. A 
screen using two Cas9 variants with a transcriptional activator (VP64) and repressor 
(KRAB) using ~200,000 sgRNAs identified several unknown genes responsible for the 
sensitivity or resistance to diphtheria and cholera toxins (Gilbert et al., 2014). Mentioned 
studies highlight the power a genome-wide study for the investigation of genes using 
negative selection could potentially have for CHO cells to identify genes involved 
bioprocess relevant phenotypes. 
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2 Aims of the project 
Stable depletion of the miR-23-24-27 cluster and each individual member to 
investigate the impact on the phenotype in industrially relevant cell lines with the 
aim to improve the bioprocess performance 
• Investigation of the impact after stable depletion of miR-23, miR-27, miR-24 and miR-23-
24-27 on a panel of cell lines expressing different modern biopharmaceutical products 
• If a beneficial phenotype is observed further aim are the investigation of the molecular 
mechanisms and pathways in which the miRNAs are involved 
• Highlight new targets for cell line engineering and ultimately increase CHO cell 
productivity 
CRISPR/Cas9 as genome engineering tool to knockout miRNAs to improve the 
bioprocess performance of industrially relevant cell lines 
• Functional assessment of CRISPR/Cas9 in CHO cells as an engineering tool for miRNAs 
• Screen for single cell clones which show a significant knockdown/knockout of the 
targeted miRNA and the assessment of the bioprocess phenotype 
• Comparison of the impact of a sponge decoy technology on miRNA depletion compared 
to CRISPR/Cas9 mediated depletion 
• Investigation of interesting phenotypes obtained due to the depletion of miRNAs using 
CRISPR/Cas9 and investigation of what mechanisms are involved using proteomic 
profiling or transcriptomic analysis. 
Genome-wide “loss of gene function” studies in Chinese Hamster Ovary cells 
using a CRISPR/Cas9 library to identify genes which are functionally involved in 
stress resistance or productivity 
• Establishment of a stable cell line expressing human codon optimised spCas9 and 
investigation of function in CHO 
• Investigation of the optimal delivery method for a sgRNA-library containing 87,897 
different sgRNAs targeting 19,150 mouse genes to achieve low copy numbers per cell 
and optimal complexity of the library 
• Enrichment of CHO cell population using stress exposure or isolation of clones which 
show high productivity due to knockouts which are functionally involved in such 
phenotype 
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3 Material and Methods 
3.1 Cell culture techniques 
3.1.1 Ultrapure water 
Ultrapure water was prepared using Milli-RO 10 Plus system (Millipore) and it was used 
for the preparation of all media and buffer solutions if not otherwise specified. The water 
was pre-treated with activated carbon and purified by reverse osmosis. Water was 
sterilised prior use for 20 minutes at 121°C and 1 bar with saturated steam if used for 
cell culture purposes.  
 
3.1.2 Glassware 
Glassware was rinsed twice with ultrapure water prior sterilisation. To sterilise for cell 
culture purposes all glassware was autoclaved for 20 minutes at 121°C and 1 bar with 
saturated steam. 
 
3.1.3 Cell culture cabinet 
Cell culture work regarding Biosafety level 1 (BSL-1) was performed in class II laminar 
flow cabinets (LF, Holton). After a lead time of 15 minutes the surface was sterilized with 
70 % denatured alcohol (IMS). All materials which were used in the laminar were prior 
autoclaved and wiped with IMS. To avoid cross contaminations only one cell line at a 
time was used. Prior use of next cell line, a 15 minutes break was given and all surfaces 
were sterilised with IMS again. Before switching off the cabinet all surfaces were 
sterilised with IMS and a 15-minute break was applied to allow a sterile, aerosol free air 
flow. Laminar flow cabinets were cleaned on regular basis which involved incubation of 
all surfaces with a detergent solution (Virkon® DuPont) followed by water and 
sterilisation with IMS. 
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3.1.3.1 Work with lentiviral systems in Biosafety level-2 environment 
Lentiviral systems require work under Biosafety level 2 (BSL-2) conditions. Additionally, 
to the steps in BSL-I all materials which were in contact with virus containing liquids were 
treated with 1% Virkon® solution (DuPont) for 15 minutes and separately autoclaved as 
clinical waste. Additonally, waste solid waste required a pre-autoclavation step. The work 
was performed in a laminar flow cabinet class II (S@feflow 1.2). Spills were first 
incubated with 1% Virkon® solution for 15 minutes and rinsed with water before the 
surface was sterilised with IMS.  
 
3.1.4 Culturing of mammalian cells 
All cells used for experiments were in general cultured without the use of antibiotics. All 
solutions, glassware as well as tips were sterilised for 20 minutes at 121°C and 1 bar 
with saturated steam prior usage. Thermal labile solutions were filtered through 0.22 µm 
or 0.45 µm PVDF filters with the help of sterile syringes. Antibiotics were only used for 
the selection of cells after transfection or lentiviral transduction. Cells were also routinely 
“pulsed” with selection agent for three passages to maintain stable transgene 
expression. All cells were routinely assessed for mycoplasma contamination. In context 
of this PhD thesis no mycoplasma contamination was detected in any cell line used.  
 
3.1.4.1 Trypsin/EDTA solution 
For the subcultivation of cells growing in adherence Trypsin/EDTA (TV) solution was 
used. The TV solution consists of 0.25 % (w/v) Trypsin and 0.02 % EDTA. Trypsin is an 
endopeptidase normally found in the digestive system of mammals. It is commonly used 
in the detachment of monolayer cultured cells and is supported by the usage of EDTA 
which acts as chelator for divalent ions like Ca2+ or Mg2+. The solution was prepared by 
dilution of 2.5 % (w/v) Trypsin (Gibco®) and 1% (w/v) EDTA solution in 500 ml of sterile 
phosphate buffered saline (PBS). The TV solution was aliquoted and stored at -20°C. 
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3.1.4.2 Incubators 
Incubators were cleaned on regular basis which involved an incubation of all surfaces 
with a detergent solution (Virkon® DuPont) followed by water and sterilisation with IMS. 
 
3.1.4.3 Anchorage dependent cells 
Adherent cells were cultivated in a Steri-cycle® CO2 incubator with heap-filter (Thermo 
Scientific). Cells were grown at 37°C, 5 % CO2 and 80 % humidity. For the sub-cultivation 
media was removed into a sterile waste container using pipettes. The monolayer was 
washed with 5 mL of sterile PBS to remove residual media and serum. PBS was 
discarded and 2-5 mL prewarmed TV solution was added to the flask. Trypsin has its 
optimum at 37°C and cells were incubated for 2-5 minutes in an incubator. Cells were 
visually monitored using a microscope to observe detachment was observed. Serum 
containing media was added to neutralise TV and cells were transferred into sterile 30 
mL universal containers and spun down for five minutes at 200 g. The supernatant 
containing TV was removed and the cell pellet was resuspended into fresh, prewarmed 
media. Cells were counted using Trypan Blue exclusion method and an aliquot was 
appropriately diluted as well as counted using a haemocytometer (Neubauer chamber). 
The required number of cells was then transferred into a new cell culture flask (Corning®) 
and the required amount of media was added. 
 
3.1.4.4 Suspension cells 
Cells were cultivated in a Kuhner Clima-shaker incubator (ISF1-X) with a process 
environment set to 37°C, 170 rpm and 80% humidity. Cells from Biogen Idec were 
cultivated in a Kuhner Clima-shaker incubator (ISF1-X) with a process environment set 
to 35°C, 170 rpm and 80% humidity. For routine growth TPP 50 ml TubeSpin® bioreactor 
tubes for 5 mL batch cultures or 250 ml Erlenmeyer shake flasks (Corning®) were used. 
For routine subcultivation cells were counted using Trypan Blue exclusion method and 
an aliquot was appropriately diluted as well as counted using a haemocytometer 
(Neubauer chamber). The number of cells was calculated and cells were seeded with 
initial cell density of 2x105 cells/mL in TPP 50 ml TubeSpin® bioreactor tubes (5 mL 
culture volume) or 250 ml Erlenmeyer shake flasks (Corning®) (30 mL culture volume). 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
46 
3.1.4.5 Counting cells and assessment of viability 
Trypan Blue exclusion method 
Trypan Blue is a method for the assessment of viability by staining dead cells and not 
viable cells. The dye does not permeate the membrane of viable cells whereas 
senescent and apoptotic cells are stained. For counting cells using Trypan Blue attached 
cells had to be trypsinised and an aliquot of the cell suspension was taken (as described 
in 3.1.4). The aliquot was diluted if necessary and the diluted sample was added to 
Trypan Blue (Gibco®) in a 1:1 ratio and incubated for ~3 minutes at RT. The 
sample/Trypan Blue mix was then transferred into a coverslip containing 
haemocytometer (Neubauer-chamber). All 16 squares for all four corner grids were 
counted using a light microscope. The average was multiplied by 104 and further by the 
dilution factor if used to obtain the amount of cells/mL. Trypan Blue exclusion method 
was usually used for routine subcultivation. 
 
GuavaTM ViaCount® reagent 
The Guava ViaCount® assay (Merck Millipore, 4000-0040) is an easy, rapid and precise 
method for the assessment of dead and viable cells in a cell population. With the 
ViaCount® it is possible to read plates with replicates in high-throughput which is ideal 
for the assessment of viability and viable cell densities in small scale batch and Fed-
batch bioprocesses. The assay uses two specifically DNA binding dyes: A nuclear dye 
binds to DNA in the nucleus (viable cells) and another dye binds to DNA of dying cells. 
Cell debris are excluded from this staining method. The ViaCount® reagent is supplied 
as 2x solution and cells were first appropriately diluted to obtain between 1x104 and 
5x105 cells/mL. ViaCount® reagent was added afterwards and was incubated for at least 
10 minutes at room temperature. The cell count was assessed in a GuavaTM benchtop 
flow cytometer. A viable cell is detected if a positive fluorescence signal occurs when the 
forward light scatter (FSC) was positive as well. The FSC is produced and detected by 
a cell above a particular size. Cell debris are excluded that way by resulting in no or low 
FSC signal.  
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GuavaTM ExpressPlus programme for assessment of GFP intensities 
Measuring of GFP intensities was performed using a GuavaTM benchtop flow cytometer 
with the GuavaTM ExpressPlus programme. GFP negative cells were used to adjust 
settings and exclude the negative population. Cells were diluted appropriately using PBS 
and GFP was excited at λ 488 nm with a blue laser diode. The cell size is measured with 
the forward scatter, whereas the shape and the overall size is assessed with the forward 
scatter to exclude small cells or possible cell aggregates. The negative population was 
excluded by a rectangular gating and excited cells reaching the threshold were counted 
as positive. The gating had to be adjusted for every experiment.  
 
Fluorescence assisted cell sorting (FACS) 
For the sample preparation cells were trypsinised and trypsin was inactivated by adding 
basal media supplemented with 5 % foetal bovine serum (when cultures in adherent 
conditions). The pellet was resuspended and washed three times in particle free 
Dulbecco´s phosphate buffered saline (DPBS, Gibco®). After washing the cells were 
fixed in 3.7 % Paraformaldehyde solved in H2O at 4°C for 10 minutes. After fixation the 
cells where washed again for three times in DPBS and samples were filtered through a 
cell strainer cap into a polystyrene falcon (5 mL, BD Falcon). A sample size of 300 µL 
was used for the analysis of viral integration events using a BFP reporter. The excitation 
wavelength was λ 402 nm and emission was measured at λ 457 nm. For the generation 
of single cell clones FACS was used as well. No fixation was necessary and cells were 
sorted for low, medium and high GFP intensities into 96-well plates (Corning®) 
containing prewarmed growth media supplemented with 10% conditioned media.  
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3.1.5 Cell lines and expressed products 
All cells were routinely sub-cultivated as described in 3.1.4.3 and 3.1.4.4. The culture 
conditions and all used cell lines are listed in Table 1.  
 
 
3.1.6 Cryopreservation of cells 
For the cryopreservation of mammalian cells the storage condition is usually -196°C in 
the vapour phase of liquid nitrogen and cells can be stored for years under the right 
conditions. Firstly, cells were trypsinised (monolayer) and counted using Trypan Blue 
exclusion method. Depending on the cell line 2x106 up to 1x107 cells were used per 
cryopreservation vial (CRYO.STM Greiner Bio One) in one mL. Cells were spun down at 
200 g for 5 minutes and resuspended in basal media without serum. A pre-chilled 2x 
freezing media (e.g. DMEM, supplemented with 20% foetal bovine serum and 10-20% 
DMSO) was added to reach 1x concentration and cells were transferred into 
cryopreservation vials. DMSO hereby prevents the formation of ice crystals. Cells were 
transferred immediately into -20°C and stored for 2 to 3 hours as well as to -80°C for 24 
hours before they were stored in the vapour phase of liquid nitrogen at -196°C. 
 
3.1.7 Thawing of cryopreserved cells 
Given the cytotoxic effect of DMSO in high concentrations long incubation with media 
containing DMSO was avoided. Cells were thawed in a pre-warmed water bath for two 
minutes and immediately transferred into 9 mL of pre-warmed media without 
Table 1: Cell lines used for experiments and culture conditions 
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supplementation. Cells were spun down at 200 g for five minutes and the supernatant 
was discarded. The pellet was resuspended into appropriate media for suspension 
culture or cultivation in monolayer (3.1.5). Suspension cells were transferred into TPP 
50 ml TubeSpin® bioreactor tubes or T75 cell culture flasks (Corning®) for adherent cells 
in a culture volume of 10 mL. To remove dead cells and debris the culture media was 
exchanged 24 hours after thawing and viability was assessed. 
 
3.1.8 Lipid- and PEI-based transfection methods 
Lipid-based transfection reagents are based on cationic liposomes which interact and 
form complexes with negatively charged DNA or RNA molecules. The transfection is 
usually highly efficient for some cell lines and can be used as transient approach or for 
the generation of stable cell lines. After the complex formation the liposome fuses with 
the phospholipid bilayer and the complex is taken up as vesicle by endocytosis. In the 
cytoplasm the vesicle can follow two routes: the formation of endosomes which results 
in degradation of the nucleic acid or the release which results into expression for e.g. 
plasmids with a transgene. Expression using the transient approach is usually 
maintained for up to 96 h. For the stable selection and integration into the host’s genome, 
resistance genes e.g. hygromycin B phosphotransferase (hbh) or puromycin N-acetyl 
transferase (pac) can be used.  
 
3.1.8.1 TransIT®-X2 Mirus for plasmid DNA 
Cells were seeded with 5x105 cells total for adherent cultures and 1x106 cells for cells in 
suspension 24 hours prior transfection in 6-well plates (Corning®) or TPP 50 ml 
TubeSpin® bioreactor tubes. The complex formation was performed in CHO-S-SFMII 
media (Gibco®) without any supplements in 1.7 ml Eppendorf tubes. Firstly, the DNA 
was added to 250 µL of media and 1 µL Mirus transfection reagent (Mirus Bio® LCC, 
catalog number MIR6003) was added for every µg of plasmid DNA used. To allow the 
complex formation the reagent mix was incubated for 20 minutes at room temperature. 
The complexes were added drop wise to the cells and incubated for 3-4 hours before the 
media was refreshed. After 24 hours selection pressure was added for the generation of 
stable cell lines.  
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3.1.8.2 Lipofectamine® 2000 
Cells were seeded with 5x105 cells total for adherent cultures and 1x106 cells for cells in 
suspension 24 hours prior transfection in 6-well plates (Corning®) or TPP 50 ml 
TubeSpin® bioreactor tubes. The complex formation was performed in CHO-S-SFMII 
media (Gibco®) without any supplements in 1.7 ml Eppendorf tubes. Firstly, the DNA 
was added to 250 µL of media and incubated for 10 minutes. For the complex formation 
3 µL Lipofectamine2000 (Invitrogen, catalog number 11668) reagent was added for 
every µg of plasmid DNA used and the mix was incubated for 30 minutes at room 
temperature. The complexes were added drop wise to the cells and incubated for 6-8 
hours before the media was refreshed. 
 
3.1.9 Physical transfection methods – Electroporation 
Not every cell line can be transfected using lipid-based reagents with high efficiencies. 
For those cell lines electroporation can be used to achieve higher efficiencies in delivery 
of the plasmid DNA or RNA. Media was refreshed the day before electroporation to 
ensure healthy growth. Adherent cultures were trypsinised and resuspended in basal 
media supplemented with 5% foetal bovine serum. Cells were washed with PBS and 
resuspended as well as counted. For the electroporation 1x107 cells were spun down 
again and resuspended in 800 µL of HEBS (HEPES-buffered saline, Sigma-Aldrich, 
catalog number 51558). Cells were transferred into electroporation cuvettes (Bio-Rad 
Gene Pulser®, 0.4 cm gap, catalog number 1652088) and 10-50 µg plasmid DNA was 
added. Electroporation settings were set to 2.8 kV, 950 µF and ∞ Ω (Ohm, resistance) 
and cells were pulsed within 11-14 milliseconds. The suspension was acclimatised for 
10 minutes at room temperature and cells were transferred into 10 mL of warm basal 
media and spun down for 5 minutes at 200 g. The supernatant was discarded and cells 
were resuspended in basal media and added into a T75 cell culture flask (Corning®). 
The media contained foetal bovine serum for adherent cells and only SFM media was 
used for suspension cells. However, cells grown in suspension were kept under static 
conditions for the whole selection period. After 24 hours the media was refreshed and 
selection agent was added. For the period of selection, the media was exchanged every 
3-4 days and the cell density was adjusted to 2x105 cells/mL. The selection pressure 
was maintained for 3-4 weeks. Nucleofection is another electroporation method which 
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was used according to the manufacturer’s guidelines (4D-NucleofectorTM system, 
Lonza).  
 
3.1.10 Generation of lentiviral particles 
For the introduction of the sgRNA-library into CHO-K1 cells a lentiviral based approach 
was used. Therefore, HEK293T cells were seeded with a density of 2x106 cells in a 10 
cm Petri dish the day before transfection. Before transfection the media was refreshed 
and for the transfection lipid based Lipofectamine®2000 (Invitrogen) was used. As the 
cells are not able to produce lentiviral proteins two packaging plasmids were co-
transfected (GeneCopoeia PLv-PK-01). Each of the packaging plasmids (6 µg) was 
transferred into 200 µl of serum free media together with 12 µg of the sgRNA-library 
plasmid. A total amount of 80 µl Lipofectamine®2000 reagent was transferred into 200 
µl of serum free media and incubated for 5 minutes. Both solutions were combined in a 
1:1 ratio. The mixture was incubated for 30 minutes at RT and added drop wise to the 
cells. After 24 hours the media was refreshed with DMEM supplemented with 2% foetal 
bovine serum. At 48 hours post transfection media was harvested and the volume of 
fresh media was decreased to 8 ml. At 72 hours post transfection the media was 
harvested again. To get rid of cell debris the conditioned media was filtered through 0.45 
µm syringe low protein binding filters and the virus containing media was stored at -80°C 
until concentration was performed. Quantification of lentiviral particles was not 
performed.  
 
3.1.10.1 Transduction of lentiviral particles 
For the transduction of the sgRNA-library into CHO-KI mAb expressing cells the cells 
were seeded with 4x106 cells into a T-75 vented flask and media was refreshed prior 
transduction. To ensure single copy integrations the used MOI was lowered to 0.04 and 
a dilution of 1:1 of the concentrated virus was performed. Media was removed and the 
virus containing media was added to the cells using 8 µg/ml polybrene. The virus was 
incubated for 8 hours to overnight and media was refreshed. After 48 hours post 
transduction cells were transferred into to T-75 vented flasks and selection pressure with 
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10 µg/ml puromycin was applied. The selection pressure was maintained for 7-10 days 
before integration events were analysed. 
 
3.1.10.2 Concentration of lentiviral particles 
To concentrate the lentivirus the conditioned media containing the virus was centrifuged. 
Therefore, the virus was transferred into sterile centrifuge tubes and pelleted at 4°C for 
2.5 hours at 20,000 g. After centrifugation the supernatant was discarded and the virus 
pellet was solved in 5 ml of serum free media and stored at -80°C. 
 
3.1.11 Limited dilution cloning 
Limited dilution cloning besides FACS, is a suitable method for the generation of single 
cell clones and panels. However, the efficiency of single cell cloning is usually very low 
and several 96-well plates have to be seeded to obtain large numbers of clones 
compared to FACS. For limited dilution cloning the media was refreshed 24 hours before 
seeding to maintain healthy growth. Cells were counted as triplicate to ensure an 
accurate cell number. The cell suspension was diluted to obtain five cells per mL and 
100 µL were transferred into each well (statistically 0.5 cells/well) to avoid colonies 
resulting from more than one cell. As the efficiency is generally very low, the final dilution 
contained 20% conditioned media which was harvested from the same culture after 24 
hours. Conditioned media was prepared by removing cells by centrifugation for 5 minutes 
at 200 g. The supernatant was filtered through a 0.45 µm PVDF low protein binding 
membrane with the help of a sterile syringe. To ensure sufficient nutrients 100 µL basal 
media was added to the 96-well plate to obtain a final volume of 200 µL. The plates were 
sealed using ParafilmM® (Bemis) and positive wells were visually analysed using a 
microscope after 8-10 days. Adherent cells were trypsinised and transferred into a larger 
scale for further analysis.  
 
3.1.12 Plasmid and vector maps 
Plasmids which were used for the generation of stable cell lines for work related to 
CRISPR/Cas9, lentiviral library, assessment of transfection efficiencies and sponge 
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experiments are listed below. Plasmids were purchased from Addgene, Clonentech and 
Invitrogen.  
 
SpCas9(BB)-2A-Puro (PX459) 
PX459 contains two BbsI site downstream of a U6 promoter for the integration of gRNAs. 
Located downstream the cloning site the tracrRNA is expressed together with the 
protospacer forming the sgRNA. A Cas9 variant fused to pac with a 2A self-cleavage 
domain is driven by CMV promoter (Figure 7). Before ligating the gRNA the vector was 
digested with Bbs1 and gRNAs were designed with 5’- and 3’-overhangs to match the 
overhangs resulting out of restriction enzyme digest. 
 
Figure 7: SpCas9(BB)-2A-Puro for the simultaneous expression of sgRNA and Cas9. The sgRNA is 
under control of a U6 promoter and the Cas9 fusion uses a CMV promoter. The mammalian selection marker 
is pac and ampicillin was used for the selection of positive clones after transformation of DH5-α.  
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pKLV-U6gRNA (BbsI)-PGKpuro-2A-BFP (lentiviral sgRNA-library) 
Vector used for the generation of the sgRNA-library by Koike-Yusa and colleagues 
(Koike-Yusa et al., 2014). The backbone used was originated from pBlueScript. The 
sgRNA pool was created using 79 nucleotide long oligo sequences and obtained by 
CustomArray Inc. The sgRNA is under control of a U6 promoter whereas the puro-2A-
BFP variant is PGK driven.  
 
Figure 8: Vector used for the generation of the sgRNA-library containing 87,897 different sgRNAs 
targeting 19,150 Mus musculus genes. The sgRNA is expressed as chimeric construct under control of a 
U6 promoter. The backbone was sourced from pBlueScript. A pac variant fused to BFP by a 2A self-cleavage 
peptide.  
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pKLV-U6 (BbsI)-PGKpuro-2A-BFP (empty control vector) 
Vector used for the generation of the sgRNA-library by Koike-Yusa and colleagues 
(Koike-Yusa et al., 2014). The vector exhibits BbsI sites for the integration of sgRNAs 
but was purchased as empty vector control for lentiviral packaging and transduction. The 
backbone used was originated from pBlueScript. The chimeric sgRNA would be under 
control of a U6 promoter whereas the puro-2A-BFP variant is PGK driven (Figure 9). 
 
Figure 9: Vector used for the generation of the sgRNA-library without containing sgRNAs which was 
used as control for lentiviral transduction. The sgRNA (if used) would be expressed as chimeric construct 
under control of a U6 promoter. The backbone was sourced from pBlueScript. A pac variant fused to BFP 
by a 2A self-cleavage peptide. 
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pEGFP-C1 plasmid (Clontech Laboratories, Inc.) 
Plasmid used for the assessment of transfection efficiency using the EGFP reporter. The 
EGFP is a red shifted variant with excitation maximum at λ 488 nm and emission 
maximum at λ 508 nm. The vector was originally designed for the cloning of fusion 
proteins which are then expressed with GFP to investigate their localisation. The MCS 
therefore is downstream the EGFP reporter. The vector can be selected in mammalian 
cells using the neomycin resistance gene (aph) which is also used for selection in 
bacteria using kanamycin (Figure 10).  
 
 
Figure 10: Plasmid used for the assessment of transfection efficiency using the EGFP reporter. The 
MCS therefore is downstream the EGFP reporter which can be used for the creation of fusion proteins. The 
vector can be selected in mammalian cells using the neomycin resistance gene (aph) which is also used for 
selection in bacteria using kanamycin. 
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pcDNA3.1/Hyg+ (backbone for the expression of destabilised GFP combined with 
sponge) 
As backbone for the creation of sponge constructs pcDNA3.1/Hyg+ was the plasmid of 
choice. A destabilised EGFP reporter sequence (d2EGFP) was cloned into the MCS 
using NotI and BamHI. The spare MCS was removed and a new MCS was engineered 
using Not1 and EcoRI. The new MCS contained one SanDI site which allows the fast, 
site directed integration of sponge constructs with multiple fragments as previously 
reported by Kluiver and colleagues (Kluiver et al., 2012a). The d2EGFP-sponge 
construct is under control of a CMV promoter and the hph gene is driven by a SV40 
promoter (Figure 11).  
 
Figure 11: The pcDNA3.1/Hyg+ backbone was engineered for the expression of d2EGFP and a 
sponge construct. A destabilised EGFP variant was used and ligated using NotI and BamHI. The spare 
MCS was removed and a new MCS containing SanDI sites was integrated for the rapid ligation of miRNA 
binding sites downstream the reporter.  
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3.2 DNA based methods 
3.2.1 DNA isolation 
Genomic DNA was extracted using Qiagen DNA Mini Kit (Catalog number 51304) 
following the manufacturer’s protocol. Cells growing in a monolayer were trypsinised and 
the reaction was stopped with basal media containing 5% foetal bovine serum. Cells 
were counted using Trypan Blue exclusion method and 2-3x106 cells were spun down 
and washed with PBS. The cell pellet was resuspended in 200 µl of PBS. The same 
amount of lysis buffer as added as well as 20 µL Proteinase K (1 mg/mL) and incubated 
for 10 minutes at 56°C. For enabling binding to the silica membrane 200 µL 100% EtOH 
was added and the lysed sample was transferred to a column proved in the kit and spun 
down at 6,000 g. Two wash steps were included using the buffers provided in the kit. 
Genomic DNA was eluted using nuclease free H2O.  
 
3.2.2 RNA isolation using TRIzol® reagent  
TRIzol® (Life technologies) was used for the extraction of RNA following the 
manufacturer’s protocol. Cells grown in adherence were trypsinised and counted using 
Trypan Blue exclusion method. All centrifugation steps were performed at 4°C. For the 
RNA isolation 2-3 x 106 cells were spun down at 200 g for 5 minutes and excess media 
was discarded. Cells were resuspended in 1 mL TRIzol® reagent as well as transferred 
into a 1.7 mL Eppendorf tube and incubated for 2-3 minutes at room temperature. The 
lysed sample was either stored at -80°C or immediately processed by adding 200 µL 
Chloroform (Sigma-Aldrich) and the sample was mixed for 15 seconds. The 
TRIzol®/Chloroform mix was spun down at > 16000 g for 10 minutes and the upper 
aqueous phase was carefully removed and transferred into a new 1.7 mL Eppendorf 
tube. Per mL of TRIzol® 500 µL of isopropanol was added and incubated for 10 minutes 
at room temperature. The sample was spun down at > 16000 g for 10 minutes and the 
supernatant was carefully removed. To remove residual isopropanol 1 mL of 75 % EtOH 
was added and the sample was centrifuged again for 5 minutes at > 8000 g. The EtOH 
was removed and the pellet was dried for 10 minutes before RNase-free H2O was added 
and the sample was incubated for 10 minutes at 55°C. RNA was in general stored at -
80°C to prevent degradation. 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
59 
3.2.2.1 Qualitative and quantitative determination of DNA and RNA using NanoDrop® 
1000 
For the validation of DNA and RNA concentrations the NanoDropTM1000 (Thermo 
Scientific) spectrophotometer was used. The NanoDropTM1000 was first calibrated using 
a 2 µL H2O sample and it was blanked using 2 µL of sample diluent. For the actual 
measurement 2 µL of the sample was dropped directly on the optical measurement 
surface of the NanoDropTM1000. The spectrophotometer can be used for evaluation of 
DNA and RNA concentrations at an absorbance of λ260 nm. Furthermore, information 
about the purity of a sample is provided by absorbance ratios of 280/260 nm and 260/230 
nm. 
 
3.2.3 High capacity cDNA reverse transcription 
To assess mRNA expression extracted total RNA had to be reverse transcribed into 
complementary DNA (cDNA). Therefore, a reverse transcriptase is commonly used with 
viral origin. For the reaction 1 or 2 µg of total RNA with high quality in a volume of 20 µL 
was used (280/260 nm between 1.8 and 2.0; 260/230 nm > 1.8). The kit used was 
purchased from Applied Biosystems (Applied Biosystems, High-Capacity cDNA Reverse 
Transcription Kit, Catalog number 4368814). Depending on the reaction volume 10 x RT 
buffer, 25 x dNTPs (100 nM), 1 µL MultiScribeTM reverse transcriptase (50 U/ml) and 10x 
random primers were mixed as well as added to the total RNA. To reach a reaction 
volume of 20 µL the volume was increased with nuclease free H2O. For the first strand 
synthesis primers were annealed at 25°C for 10 minutes. The reverse transcription was 
performed at 37°C for 120 minutes and the reaction was stopped at 85°C for 5 minutes 
in a Thermo cycler system (G-STORM). The cDNA was stored at -20°C till usage. 
 
3.2.4 Fast SYBR® green based real time quantitative qPCR 
For real-time PCR (RT-qPCR) MicroAmp optical 96-well plates (Applied Biosystems, 
Cat. No. 4346906) with corresponding Fast SYBR® green 2x master mix (Applied 
Biosystems, Fast SYBR® Green Master Mix, Cat. No. 4385612) was used. The prior 
reverse transcribed cDNA was diluted 1 to 5 to obtain a concentration of 20 ng/µL. The 
master mix was prepared using 10 µL 2x Fast® SYBR green master mix, 10 nM of each 
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primer targeting the gene of interest and 20 ng cDNA. Additional nuclease free water 
was added to reach a reaction volume of 20 µL and samples were measured as triplicate. 
The reaction was carried out with an Applied Biosystems 7500 Fast Real-Time PCR 
system using 40 cycles. Cycles contained a denaturation step at 95°C for 30 seconds 
and a annealing/elongation step at 60°C for 15 seconds.  
 
3.2.5 TaqMan® small RNA assays 
For TaqMan® small RNA assays total RNA was isolated as described in 3.2.2 and same 
High-Capacity cDNA Reverse Transcription Kit was used for reverse transcription. 
However, the TaqMan® assay provided looped primers which specifically bind mature 
miRNAs. The principle of the assay is displayed in Figure 12.  
 
Figure 12: Principle of the TaqMan® small RNA assay. A looped primer binds to the mature miRNA and 
is extended by a reverse transcriptase which catalyses the first strand synthesis into cDNA. The second step 
is the binding of primers and amplification as well as the binding of a specific probe which contains a 
fluorophore and a quencher. Due to amplification the fluorophore is released and the signal can read. Picture 
was sourced from Life technologies TaqMan® miRNA assays protocol handbook.  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
61 
A total amount of 100 ng RNA was reverse transcribed using specific looped primers. 
Primer annealing was performed at 16°C for 30 minutes. The reverse transcription was 
performed at 37°C for 30 minutes and the reaction was stopped at 85°C for 5 minutes in 
a Thermo cycler system (G-STORM). The cDNA was stored at -20°C till usage.  
For the RT-qPCR step 6.67 ng cDNA (1 µL) was used for the amplification. The total 
reaction was 20 µL using 2x TaqMan Universal PCR Master Mix (Applied Biosystems, 
catalog number 4304437) and 20x TaqMan® probe provide in the TaqMan® assay. The 
reaction was carried out with an Applied Biosystems 7500 Fast Real-Time PCR system 
using 40 cycles in MicroAmp optical 96-well plates (Applied Biosystems, Cat. No. 
4346906). To activate the enzyme a hold step was comprises at 95°C for 10 minutes. 
Cycles comprised a denaturation step at 95°C for 15 seconds and a annealing/elongation 
step at 60°C for 60 seconds. 
 
3.2.6 General Polymerase Chain Reaction (PCR) 
For the amplification of specific sequences out of genomic DNA, plasmid DNA or cDNA 
several different PCR kits were used. For a general purpose the MyTaqTM DNA 
polymerase (Bioline, catalog number BIO-21105) was used. If high-fidelity with 
proofreading was required the Phusion® kit (New England BioLabs Inc. catalog number 
M0530S) or Platinum® high fidelity DNA Polymerase (Thermo Fisher Scientific, catalog 
number 11304011) were used. The master mixes (2 x) contained all required ingredients 
e.g. MgCl2, dNTPs and reaction buffer. The reaction volume was set usually between 
20-50 µL and a primer concentration of 10 nM for forward and reverse primer was used. 
If plasmid DNA was used as template an amount of 10 pg was used. For the amplification 
of cDNA and genomic DNA 10-100 ng of template was used. Furthermore, the template 
and expected abundance dictated the number of cycles used which was 28 to 35. 
Depending on the kit a single denaturation step was performed at 95-98°C for 2-3 
minutes followed by cycles. One cycle consists of a denaturation step (95-98°C for 0.5 
to 2 minutes), a annealing step (Tm-3°C for 30 seconds) followed by the elongation (68-
72°C, 0.5-1 minute/kb). A final elongation for 5 minutes at 68-72°C was applied. 
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3.2.6.1 PCR purification 
If the PCR product is used for cloning or other enzymatic reactions the reaction mix had 
to be purified to ensure correct buffer conditions and the removal of primers as well as 
enzymes. Therefore, the QIAquick PCR Purification Kit (Qiagen, catalog number 28104) 
was used. Binding buffer was added containing a pH indicator. If the buffer/PCR mix was 
orange or purple 10 µL of 3 M sodium acetate was added to ensure correct binding 
conditions. The mix was added into provided columns and spun down at 12000 g for one 
minute. Bound DNA was washed using PE buffer contained in the kit and the column 
was spun down again at 12000 g for one minute. DNA was eluted using water and the 
DNA concentration was measured using NanodropTM 1000 (3.2.2.1). 
 
3.2.6.2 Generation of standard curves for copy number investigations 
For the investigation of copy numbers MyTaqTM DNA polymerase (Bioline, catalog 
number BIO-21105) was used. DNA was isolated as described in 3.2.1 and DNA 
concentrations were measured as triplicate. For the generation of the standard curve the 
corresponding plasmid concentration was measured as triplicate and diluted. The 
plasmid DNA was diluted to 10 ng/µL and serial dilutions were used to obtain plasmid 
concentrations between 10 ng/µL and 10-8 ng/µL. The diluent thereby was nuclease free 
H2O spiked with 30 ng genomic wild type DNA and 1 µL of the diluted plasmid was used. 
One serial dilution should hereby statistically result in a difference in Ct values of 3.3. 
The reaction volume for the samples was 20 µL using MicroAmp optical 96-well plates 
(Applied Biosystems, Cat. No. 4346906) with corresponding Fast SYBR® green 2x 
master mix (Applied Biosystems, Fast SYBR® Green Master Mix, Cat. No. 4385612) 
and 10 nM of forward and reverse primer. The sample concentration was 20 ng total 
genomic DNA and samples were amplified as quadruplicate. For the purpose of 
normalisation the β-actin gene was amplified with specific primers. The reaction was 
carried out with an Applied Biosystems 7500 Fast Real-Time PCR system using 40 
cycles. Cycles contained a denaturation step at 95°C for 30 seconds and a 
annealing/elongation step at 60°C for 15 seconds. Obtained Ct values for the standard 
curve were displayed over the calculated copies in the sample using knowledge about 
the size of the plasmid and the amount which was used for RT-qPCR. The resulting 
logarithmic graph was linearised and the function was used to calculate the copies which 
were in the analysed sample. The copies per genome were calculated using the amount 
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of copies which are statistically in the sample with 20 ng total DNA (4075.39 genomes) 
assuming diploidy. The Chinese hamster genome size of 2,447,154,408 base pairs is 
resulting in a theoretical weight of 4.9075 pg.  
 
3.2.7 Cloning methods 
3.2.7.1 LB-media and agar plates  
For the preparation of LB media (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, Sigma-
Aldrich, catalog number L3022) 20 g of powder was solved in H2O and autoclaved for 20 
minutes at 121°C and 1 bar with saturated steam.  
For the preparation of LB Agar plates (15 g/L Agar, 10 g/L tryptone, 5 g/L yeast extract, 
5 g/L NaCl, Sigma-Aldrich, catalog number L2897) 35 g of powder was solved in H2O 
and autoclaved for 20 minutes at 121°C and 1 bar with saturated steam. After reaching 
a temperature of 50°C heat sensitive ampicillin or kanamycin was added and liquid agar 
was poured into 90 cm petri dishes (Corning®). After solidification plates were stored at 
4°C.  
 
3.2.7.2 Restriction enzyme digest 
Restriction enzymes were purchased from New England BioLabs or Thermo Fisher 
Scientific and most of the enzymes use their own buffer system for the optimal reaction 
conditions. Usually 1 µg of plasmid DNA was digested using 10x reaction buffer and the 
appropriate amount of nuclease free H2O. The mix was incubated for the suggested 
amount of time with the optimal temperature which depends on the origin of the 
restriction enzyme. Many enzymes can be heat inactivated. If the enzyme could not be 
inactivated the mix was purified using gel electrophoresis and gel extraction.  
 
3.2.7.3 Gel electrophoresis 
For the visualisation of the prior amplified DNA an agarose gel used in combination with 
Ethidium bromide (EtBr) or SafeView nucleic acid stain (NBS Biologicals, catalog number 
NBS-SV1) was used. The amount of agarose used depends on the expected length of 
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the DNA sample. For fragments longer than 2 kilo bases 0.8 % (w/v) agarose and for 
smaller fragments 2 % (w/v) agarose was used. The agarose was diluted in 1x TAE (50x 
TAE: 242 g Tris base, 57.1 mL acetic acid and 100 mL EDTA (0.5 M, in 1 L and pH 8.5) 
and brought into solution by heating in a microwave. After the solution was cooled down 
to approximately 50°C EtBr (0.5 µg/mL) was added. For the analysis of the fragments 
10x loading dye (25 mg bromophenol blue, 30 % glycerol, 25 mg xylene cyanol in 6.25 
mL H2O) was added to the sample and transferred into a pocket in the agarose gel. The 
samples were separated by running the gel for 30 minutes at 90 volts. 
 
Gel extraction and purification 
Gel extraction was performed using QIAquick® Gel extraction kit (Qiagen, catalog 
number 28704). The expected band was visualised as well as cut out and transferred 
into a 1.7 mL Eppendorf tube. Depending on the weight of the agarose piece, dissolving 
buffer was added and incubated at 55°C for 10 minutes until the agarose was dissolved. 
Isopropanol (0.2 volumes) was added and the mix was transferred into a provided 
column and spun down for 1 minute at 12000 g. The DNA was washed using 750 µL PE 
buffer and spun down again for 1 minute at 12000 g. The DNA was eluted using H2O 
and quantified using NanodropTM 1000 as well as used for following approaches. 
 
3.2.7.4 Alkaline phosphatase treatment 
Alkaline phosphatase was purchased from Roche (1 U/µL, catalog number 
10713023001) and was used for the removal of the 5’-phosphate of digested plasmid 
DNA. The removal prevents the re-ligation of plasmid DNA after enzymatic digestion and 
the bacterial repair machinery from ligating the double strand as well. One unit per µg of 
plasmid DNA was used with 10 x reaction buffer in an appropriate volume topped up with 
nuclease free H2O. The enzyme was heat inactivated at 65°C for 10 minutes with addition 
of 1/10 volume of 200 mM EGTA. For further applications the DNA was purified using 
PCR Purification Kit described in 3.2.6.1.  
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3.2.7.5 Polynucleotide kinase treatment 
Ordered oligo nucleotide sequences usually exhibit no 5’-phosphate. However, for the 
ligation of annealed oligo sequences the 5’-phosphate group is essential and had to be 
added. The annealing and addition was performed simultaneously. Therefore, 100 µM 
of top and bottom strand were mixed together and 1U T4 Polynucleotide kinase was 
added using provided 10 x reaction buffer (New England BioLabs, catalog number 
M0201S). Nuclease free H2O was added to a total volume of 10 µL and the reaction was 
incubated for 30 minutes at 37°C in a Thermo cycler system (G-STORM). For the 
inactivation and annealing, the reaction mix was heated up to 95°C for 5 minutes and 
the temperature as step wise decreased to 25°C. The annealed oligo was diluted and 
was used for ligation or stored at -20°C. 
 
3.2.7.6 Ligation 
For the ligation of 10-50 ng dephosphorylated plasmid was added into the reaction with 
10x reaction buffer in a total volume of 20. Insert was added in a standard ratio of 1 to 3 
for large inserts. For the ligation of sgRNAs 1 µM annealed oligo sequences were added 
for 100 ng digested vector. For the ligation 1U of T4 DNA ligase (Rapid DNA ligation kit 
Roche, catalog number 11635379001) was used and incubated for 1 hour at room 
temperature. For the transformation into chemically competent cells 2-5 µL ligation mix 
were used.  
 
3.2.7.7 TOPO®-TA cloning 
TOPO®-TA cloning kits can be used for the ligation of blunt end and sticky end fragments 
into pCR™2.1 TOPO® vector (Thermo Fisher Scientific, catalog number 450641). The 
principle is based on a topoisomerase I isolated from Vaccinia virus which is covalently 
bound to the broken phosphodiester backbone of the vector. The covalent binding can 
be attacked by a 5’-hydroxyl group of a PCR amplified fragment or a previously digested 
DNA fragment and the topoisomerase is released resulting in ligation of the DNA 
fragment into the vector. For the ligation of PCR fragments containing an A’-overhang 4 
µL purified PCR product was used and 1 µL topoisomerase I as well as 1 µL salt solution 
was added. The salt solution prevents topoisomerase from attacking the previously 
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ligated site as the binding motif (5’-CCCTT-3’) is still exhibited. The mix was incubated 
for 5-30 minutes and transformed into chemically competent cells.  
 
3.2.8 Transformation of competent cells 
For the transformation of cells two different methods were used: Heat shock and 
electroporation. Heat shock is hereby based on the pre-treatment of Escherichia coli 
cells with a series of salts which disrupt the membrane. A temperature change to 42°C 
allows the DNA to enter the cell and the immediate incubation on ice closes the pores 
again. Electroporation is used to increase the permeability of the bacterial cell wall with 
the following uptake of exogenous DNA. 
 
3.2.8.1 Heat shock based transformation 
For the heat shock of chemically competent cells (Thermo Fisher Scientific, Subcloning 
EfficiencyTM DH5αTM Competent cells, catalog number 18265017) the cells were thawed 
on ice and 10 pg of plasmid DNA was added and incubated for 30 minutes in ice. The 
heat shock was performed in a water bath at 42°C for 40 seconds and cells were 
incubated on ice again for 2 minutes. For the recovery pre-warmed S.O.C media (2 % 
(w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 20 mM glucose, 10 
mM MgCl2, 10 mM MgSO4) was added cells were incubated for 1 hour at 37°C at 300 
rpm in an incubator. Cells were spun down at 3000 g for 5 minutes and the pellet was 
resuspended in 200 µL LB broth and plates on agar plates containing 100 µg/mL 
ampicillin or kanamycin.  
 
3.2.8.2 Electroporation based transformation 
For the efficient transfer and amplification of plasmid DNA ElectroMAXTM DH-5α-ETM 
Escherichia coli cells (Thermo Fisher Scientific, catalog number 11319019) were used. 
The cells were stored at -80°C and were thawed on ice before usage. For the 
transformation 10 pg plasmid DNA was added to 25 µL of electro competent cells and 
the suspension was transferred into pre-chilled cuvettes for electroporation (BioRad 
GenPulser® 0.1 cm, catalog number 1652083). For the validation of the transformation 
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efficiency 10 pg pUC19 vector was used. The settings for the electroporation were 2.0 
kV, 200 Ω and 25 µF. After electroporation the cells where immediately transferred into 
1 mL of pre-warmed S.O.C. media and recovered for 1 hour at 37°C before plated on 
ampicillin/kanamycin (100 µg/mL) containing agar plates.  
 
3.2.8.3 Amplification procedure for the sgRNA-library 
For the amplification of the sgRNA-library (3.1.12) it was necessary to ensure high 
transformation efficiencies. Therefore, ElectroMAXTM DH-5α-ETM Escherichia coli cells 
(Thermo Fisher Scientific, catalog number 11319019) were used. The cells were stored 
at -80°C and were thawed on ice before usage. For the transformation 10 ng of the 
sgRNA-library plasmid was added to 25 µL of electro competent cells and the suspension 
was transferred into pre-chilled cuvettes for electroporation (BioRad GenPulser® 0.1 cm, 
catalog number 1652083). For the validation of the transformation efficiency 10 pg 
pUC19 vector was used. The settings for the electroporation were 2.0 kV, 200 Ω and 25 
µF. After electroporation the cells where immediately transferred into 1ml of pre-warmed 
S.O.C. media and recovered for 1h at 37°C. For the cultivation 2 mL of recovered cells 
were directly transferred into 500 mL 2x TY media (1.6% (w/v) peptone, 1% (w/v) yeast 
extract, 0.5% (w/v) NaCl, containing 100 µg/mL ampicillin) and cultivated over night at 
30°C. The plasmid was isolated using the Qiagen Maxi Prep Plasmid Isolation Kit 
(Qiagen, catalog number 12162). For the transformation efficiency the cell suspension 
was diluted 1:10, 1:100 and 1:200 in S.O.C. media and 100 µL of the dilutions was plated 
on pre-warmed LB-Agar plates containing 50 µg/mL Ampicillin. The efficiency was 
calculated by following formula: 
𝐶𝐹𝑈 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑝𝑙𝑎𝑡𝑒
𝑝𝑔 𝑝𝑈𝐶19 𝐷𝑁𝐴
∗
1 ∗ 106𝑝𝑔
µ𝑔
∗
𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑎𝑛𝑡𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 𝑝𝑙𝑎𝑡𝑒𝑑
∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
To ensure the amplification of the whole library a transformation efficiency of > 1 x 1010 
CFU/µg DNA is recommended.  
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3.2.8.4 Plasmid mini and maxi preparation 
For mini preps (Qiagen, catalog number 27104) single colonies of agar plates were 
inoculated in 5 mL LB media containing selection agent. For maxi preps (Qiagen, catalog 
number 12162) the culture volume was 50 mL. Both methods are based on the same 
principles with the exception that plasmids prepped using maxi kits are endotoxin free 
and can be used for transfections. Firstly, cells are harvested and resuspended in RNase 
containing buffer. The cells are lysed using alkaline lysis and protein as well as cell debris 
are separated using centrifugation. The DNA is bound to positively charged silica 
membranes and washed to remove endotoxins, lipids and polysaccharides before 
elution. The DNA was isolated following the manufacturer’s protocol.  
 
3.2.8.5 Sanger sequencing 
For analysing InDel frequencies and the conformation of positive inserts after ligation 
samples were sent for sequencing. Therefore, miniprep cultures were prepped and the 
DNA was quantified. One µg was transferred into a 1.7 mL Eppendorf tube and the 
volume was increased to 15 µL if necessary. For the sequencing reaction 20 nM primer 
was added and the reaction was sent to Eurofins Genomics. 
 
3.2.9 Surveyor® assay 
The Surveyor® assay uses a nuclease which recognises mismatches between wild type 
strands and mutated strands which can be used for the assessment of InDels. The 
genomic region was first amplified using PCR and purified using PCR purification kit. It 
was essential that no unspecific bands were exhibited and otherwise the PCR product 
was purified using gel extraction. The hetero-duplex formation was performed in a 
Thermo cycler system (G-STORM) using 400 ng purified PCR product. If the PCR 
product was gel extracted 10x PCR reaction buffer (Phusion® High Fidelity buffer) was 
added as the Surveyor® nuclease which uses MgCl2 as essential cofactor. The reaction 
was denatured at 95°C for 10 minutes and the temperature was decreased step wise 
using a programme displayed in 
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After hetero-duplex formation 1 µL Surveyor Nuclease S as well 1 µL Surveyor Enhancer 
S was added and the reaction mix was incubated at 60°C for 60 minutes. Stop solution 
(1 µL) containing EDTA was added and 10x loading buffer. For the visualisation a 2% 
(w/v) agarose gel was used to achieve high resolution. 
3.2.10 High throughput DNA and RNA sequencing using NGS 
3.2.10.1 Indel sequencing using NGS for the analysis of CRISPR/Cas9 targeting 
efficiency 
Indel sequencing was used for the assessment of Cas9 function as well as investigation 
of indel frequency after targeting each member of the miR-23 cluster. Furthermore, it 
was used to assess if clones showed targeting as well as off-targeting on both clusters. 
For preparation of sequencing, genomic DNA was isolated from clones and mixed 
populations (3.2.1). Primers were designed to target 100 bp up- and downstream of each 
targeted region. Additionally, primers had linkers added which were used for library 
preparation. After amplification the PCR product was analysed on an agarose gel for 
unspecific products. As no unspecific bands occurred the PCR amplicon was purified 
using a PCR purification kit (3.2.6.1) and sent for sequencing with our collaboration 
Table 2: Hetero-duplex formation for Surveyor® nuclease assay and ramping temperatures 
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partner (Helene Faustrup Kildegard and Thomas Amann at the The Novo Nordisk 
Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, 
Denmark).  
 
3.2.10.2 Sample preparation and RNA sequencing for transcripromic analysis 
For studying transcriptomic data whole RNA sequencing is a common method. 
Therefore, total RNA was isolated with samples taken during exponential growth phase 
in biological triplicates. For extraction of total RNA Direct-zol (Zymo research) was used 
to ensure high sample quality. Sample quality and concentration was measures on a 
Nanodrop1000 (Thermo) and send for sequencing on dry ice (Genewiz RNA-Seq). 
RNAseq using poly-A enrichment was used to allow the removal of ribosomal RNA. After 
fragmentation and addition of linkers the sample were run on an Illumina HiSeq 2500 
instrument with 47x106-66x106 reads. For differential expression analysis DESeq2 was 
used and Wald test to generate p-values as well as log2-fold changes. Raw dispersion 
values were fitted to a common mean to improve testing accuracy. Fitting was performed 
using dispersion information for all genes (black dots). For analysis of statistical 
significance, a p-value <0.05 was applied and a log2 fold change of 0.58/-0.58. Only 
genes with a base mean of >100 were considered true.  
 
Table 3: Primers including linkers for indel sequencing after targeting miRNAs with CRISPR/Cas9 
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3.2.10.3 Amplicon sequencing for the analysis of enriched or depleted sgRNAs 
regarding the CRISPR library  
For the investigation of which sgRNAs were enriched or depleted after the mixed 
CRISPR/Cas9 library mixed population was exposed to hyperosmotic conditions or 
selected for high productivity clones, NGS was used. As the library is very complex it 
was important to ensure coverage. Genomic DNA was isolated using Midiprep Plus Kits 
(Zymo research, Catalogue number D4075) to obtain high yields and good quality DNA. 
One mg of genomic DNA was used for PCR reactions to ensure ~200-fold coverage 
using primers (forward AAAGTATTTCGATTTCTTGG, reverse 
ACTCGGTGCCACTTTTTCAA) amplifying the sgRNA region of the CRISPR library 
plasmid. The PCR product was assessed for quality, unspecific amplification and 
subsequently purified. Samples were shipped on dryice for further processing by 
Genewiz in terms of library preparation, HiSeq sequencing (Illumina) and bioinformatical 
analysis. Illumina HiSeq was used to reach sequencing depths between 107-108 reads 
as enrichment/depletion of sgRNAs might be very subtle. To identify sgRNAs the 
constant region was excluded to highlight unique sequences and abundance was 
analysed.  
 
3.3 Protein based methods 
3.3.1 Enzyme-linked immunosorbent assay (ELISA) 
Sandwich ELISA method was used for the evaluation of product titres in conditioned 
media and specific productivity. Media was taken from batch or fed-batch cultures and 
spun down at 200 g for 5 minutes to remove cells. The supernatant was carefully 
removed without disturbing the pellet and stored at -80°C. For ELISA the conditioned 
media was diluted with corresponding to expected concentrations of product in the 
conditioned media. Solutions for ELISA were prepared as suggested by the 
manufacturer’s protocol (Bethyl Laboratories, Inc. catalog number E80-104). Nunc 
MaxiSorp C bottom well microtiter plates (Bethyl Laboratories, Inc. catalog number E105) 
were used and 1 µg coating antibody was used per well in coating buffer. The coating 
antibody was incubated for 1 hour at room temperature. The plate was rinsed five times 
with washing buffer and 200 µL blocking buffer was added as well as incubated for at 
least 30 minutes. The plate was washed again and dilutes sample was added. The 
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sample dilutions were made in diluent buffer shortly before adding the sample. For the 
standard curve human reference serum of Fc receptor fusion proved by Biogen was 
used. Concentrations for the standard curve ranged between 500 ng/mL to 7.8 ng/ml 
using serial dilutions in a 1 to 1 ratio. A volume of 100 µL was added to the wells whereas 
the standard curve was added as duplicate and the samples were added as triplicates. 
The sample was incubated for one hour and wells were rinsed for five times again using 
washing buffer. Secondary antibody was diluted in diluent buffer with a dilution of 
1:100,000 and 100 µL were added and incubated for 1 hour. The wells were washed 
again for five times and 100 µL 3’3,5’5-tetramethylbezidine (TMB) was added and 
incubated for 15 minutes. The solution turned into a blue colour and 100 µL 0.18 M 
H3PO4 was added to stop the solution which resulted into a yellow colour. Immediately 
after stopping the reaction the plate was assessed using MultiskanTM GO Microplate 
Spectrometer (Thermo Fisher Scientific, catalog number 51119280) at λ 450 nm. The 
standard curve as well as values were calculating using a four-parameter curve and 
obtained concentrations were multiplied by the dilution factor.  
 
3.3.2 Protein A Antibody Affinity Chromatography 
Protein A was originally found and isolated from Staphylococcus aureus as a protein 
incorporated in the cell wall which is able to specifically bind the Fc-part of 
immunoglobulins. The binding properties of protein A is commonly used as first step in 
industry to purify conditioned media containing a therapeutic protein e.g. mAbs or Fc-
fusions. The stationary phase is usually based on spherical agarose beads which are 
conjugated to protein A. 
For the investigation of posttranslational modifications conditioned media was spun 
down for 5 minutes at 200 g to remove cells. To further remove cell debris the conditioned 
media was spun down for 10 minutes at 2500 g. To ensure perfect binding conditions 
and a small sample volume the conditioned media was concentrated using Amicon® 
ultra centrifugal filter units (Merck KGaA, catalog number UFC905024) with a 10 kDa 
molecular weight cut off. The conditioned media was concentrated to a volume of 5 mL 
at 2500 g and 4°C. The buffer was exchanged to the corresponding binding buffer (20 
nM Sodium hydrogen phosphate, pH 7.00) at 2500 g and 4°C using Amicon® ultra 
centrifugal filter units.  
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Before the application of the conditioned media the column (HiTrap MabSelect 1 mL, 
catalog number 28-4082-53) was equilibrated with 5 column volumes of binding buffer 
to ensure correct binding conditions with a flowrate of 1 mL/minute using a 5 mL syringe. 
The sample was applied and the column was washed with 10 volumes of binding buffer. 
The product was eluted using 3 column volumes 10 % acetic acid (pH 4.00). To avoid 
degradation of the product due to exposure of low pH 1 mL 1 M Tris (pH 8.00) was added. 
To ensure no unspecific binding all fractions were analysed using denatured 
polyacrylamide gel electrophoresis. For the further investigation of the glycosylation 
pattern the buffer was exchanged to PBS using Amicon® ultra centrifugal filter units and 
the sample was concentrated to a volume of 1 mL. 
 
3.3.3 Investigation of changes in glycosylation pattern 
A process can have dramatic effect on the glycosylation of the therapeutic product. 
Therefore, depletion of a miRNA may have a crucial impact on glycosylation as well and 
the function/efficacy of the product. Therefore, product quality had to be assessed after 
knockdown of miRNAs. Conditioned media (~50 mL) was taken from control cultures as 
well as knockdown cultures. The conditioned media was prepared and purified using 
protein A chromatography as described in 3.3.2. For the analysis of changes in 
glycosylation species, LC/LFR-MS/MS was used according to Carillo and colleagues 
(Carillo et al., 2017). The work was carried out by Jonathan Bones and Sara Carillo in 
the National Institute for Bioprocessing Research and Training (NIBRT) as part of a 
collaboration.   
 
3.3.4 Analysis of oxygen uptake rate and extracellular acidification rate 
For the investigation of oxygen uptake rates (OCR) and extracellular acidification rates 
(EACR) the Seahorse XFe96 Analyser (Agilent) was used. OCR and EACR can give 
indication for energy phenotypes by measuring indicators for increased glycolysis or 
oxidative phosphorylation. EACR hereby is the indicator for glycolysis which results in 
the production of lactic acid and protons without consumption of oxygen. For 
mitochondiral respiration oxygen is used and OCR can therefore give indications for 
increased mitochondrial function. For measuring OCR and EACR the Agilent Seahorse 
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XFp Cell Energy Phenotype Test Kit (Cat No 103275-100) was used according to the 
manufacturer’s recommendations.  
 
3.3.5 Sodium dodecyl sulphate - Polyacrylamide gel electrophoresis 
The sodium dodecyl sulphate – Polyacrylamide gel electrophoresis (SDS-PAGE) is a 
method used in biochemistry to separate proteins corresponding to their molecular 
weight. For the separation 4-12% Bis-Tris protein gels (NuPAGETM NovexTM, Thermo 
Fisher catalog number NP0322BOX) under denaturing condition in an XCell SureLockTM 
Minicell electrophoresis chamber (Thermo Fisher, catalog number EI0001) for the 
optimal separation of medium to small sized proteins. The sample was prepared using 
10 µg of total protein by adding 2x laemmli buffer (Sigma, catalog number 3401) to a 
final 1x concentration. To equalize final sample volumes PBS was added. The sample 
was incubated at 95°C for 5 minutes and allowed to cool down before being centrifuged. 
A maximum of 30 µL sample was loaded and the gel was run for 45 minutes at 200 V 
using 1x MOPS running buffer (Sigma, catalog number M1245). To maintain denaturing 
conditions NuPAGE® antioxidant (Thermo Fisher, catalog number NP0005) was added 
in the upper chamber.  
 
3.3.6 Staining and detaining of protein gels 
Staining for proteins after SDS-PAGE was performed using 50% Methanol, 40% H2O, 
10% acetic acid as well as 0.25% Coomassie Brilliant Blue G250. The gel was incubated 
for one hour at RT following detaining in H2O overnight.  
 
3.3.7 Bradford protein assay 
The Bradford assay is an accurate colorimetric measurement to determine protein 
concentrations in a sample. The assay is based on Coomassie Brilliant Blue G250, a dye 
which binds protein due to hydrophobic and electrostatic interactions. The shift in 
absorbance is directly proportional to the amount of protein in the sample. For the 
measurement of protein concentrations 5 µL of each standard (Bovine serum albumin, 1 
mg/mL, 0.75 mg/mL, 0.5 mg/mL, 0.25 mg/mL and 0.125 mg/mL, Thermo Scientific 
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catalog number 23208) was prepared and transferred as triplicate into a 96-well plate. 
The sample was diluted corresponding to the expected amount of protein in the range of 
the standard curve and 5 µL were transferred into the same plate. A total volume of 250 
µL Coomassie Brilliant Blue G250 (Quick StartTM Bradford Protein Assay, Bio-Rad 
catalog number 5000201) was added to each standard as well as sample and incubated 
for 10 minutes. The absorbance was read using MultiskanTM GO Microplate 
Spectrometer at λ 595 nm.  
 
3.3.8 Filter-aided sample preparation for label free LC/MS 
For the analysis of DE protein abundance due to the knockdown of different miRNAs 
quantitative label-free LC-MS/MS profiling was used. The samples were lysed, digested 
and prepared using filter-aided sample preparation (FASP) according to a protocol 
published by Coleman and colleagues (Coleman et al., 2017). 
 
3.3.9 Label free quantitative LC/MS 
Peptides were initially separated using a reverse-phased capillary High-pressure Liquid 
Chromatography on an UltiMate 3000 nano system (Thermo Scientific) coupled directly 
in-line with the Thermo Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Scientific). 
4 μL of digested sample was loaded onto the trapping column (PepMap100, C18, 300 
μm × 5 mm) at a flow rate of 25 μL/min with 2% (v/v) ACN, 0.1% (v/v) TFA for 3 minutes 
before being resolved onto an analytical column (Easy-Spray C18 75 μm × 500 mm, 2 
μm bead diameter column) using a binary gradient of 98% A (0.1% (v/v) formic acid 
(FA)): 2% B (80% (v/v) ACN, 0.08% (v/v) FA) to 27.5% B over 110 min at a flow rate of 
300 nL/min. 
For peptide ionization, 1900 V was applied and a 320 °C capillary temperature was used. 
For the Orbitrap Fusion MS detection, a precursor scan was performed in the Orbitrap 
by scanning from m/z 375–1500 with a resolution of 120,000 (at m/z 200), a targeted 
automatic gain control (AGC) value of 4e5 and a maximum injection time of 50 ms. The 
ions selected under top-speed mode were isolated in the Quadrupole with an isolation 
width of 1.6 Da, and they were fragmented by higher energy collision-induced 
dissociation (HCD) with a normalized collision energy of 28%, then measured in the 
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linear ion trap. The typical MS/MS scan conditions were as follows: a targeted AGC value 
of 2e4, a maximum fill time of 35 ms, included charge states of 2+ to 6+ and the dynamic 
exclusion was employed for 60 s. The resulting files were analysed using Progenesis QI 
for Proteomics version 4.1 for label-free LC-MS/MS analysis as recommended from the 
manufacturer (Nonlinear Dynamics). The LC retention times were aligned to the 
reference run and samples were set up into two experimental groups. Peptide features 
were filtered for an ANOVA value ≤ 0.05 between experimental groups, mass peaks with 
charge states between +1 and +3 and greater thanone isotope per peptide. Spectra were 
exported as a MASCOT generic file (.mgf) and identified within Proteome Discover 2.1 
using Sequest HT (Thermo Fisher Scientific), MASCOT and percolator. Data was 
searched against the NCBI Cricetulus griseus database containing 44,065 sequences 
(fasta file downloaded November 2016). Identified peptides were imported into 
Progensis QI and filtered applying the following criteria: an ANOVA value < 0.05, a fold 
change of ≥ 1.25 between experimental groups and ≥ 2 peptides contributing to protein 
identifications. 
 
3.3.10 Selection for high-producing CHO cell subpopulations using FACS  
For enrichment of high producing clones, FACS has been shown to be a reliant tool in 
cell line development. The principle is based on staining an IgG producing cell line with 
an antibody-FITC conjugate. For our purpose, CHO-K1 mAb was used which was 
transfected with a sgRNA library. Knockout of certain genes was proposed to increase 
productivity and clones can be isolated applying several rounds of sorting whilst isolating 
the highest 10-15% cells in intensity (Figure 13). Cells were washed, treated with staining 
antibody (anti-human IgG Fab specific-FITC antibody, goat) and sorted as described by 
(Gallagher & Kelly, 2017). Cells were hereby kept at 4°C to decrease secretion kinetics 
and ensure stable labelling with the antibody. Obtained subpopulations were then 
recovered in 6-well plates until high confluency was reached.  
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Antibody concentration was tested prior sorting using a range of dilutions from 1:10 to 
1:100. The ideal concentration for sorting for high producing subpopulations was found 
to be 1:50. 
 
3.3.11 Statistical analysis  
For analysis of statistical significance, an unpaired two tailed student’s t-test was applied 
unless otherwise stated (*P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001) on biological triplicates 
between two independent sets of samples.  
 
 
Figure 13: Enrichment of high-producing clones using FACS combined 
with low temperature stain of an IgG. Using an antibody labelled with FITC in 
combination with a low temperature setting high producing cells can be selected. 
Due to low temperature secretion is slowed down and IgGs can be stained using 
an anti-IgG/FITC conjugate. Isolating cells showing high FITC intensities can 
then be sorted and should show higher producitivity or secretion properties. 
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4 Results 
4.1 Stable depletion of the miR-23 cluster and single miRNA members in industrial 
relevant cell lines 
4.1.1 MicroRNA expression of each indicidual member of the miR-23 cluster across a 
panel of cell lines 
The first task was to establish the endogenous levels of each miR in each cell line. The 
levels of each mature miRNA of each parental producer cell line was assessed by qPCR. 
Total RNA was extracted and miRNA expression was analysed using TaqMan® small 
RNA assays. Seven different cell lines were assessed using CHO-K1 parental cells as 
the native miRNA expression control. The expression of each miRNA was normalised to 
an endogenous control (U6 snRNA) and relative expression was quantified using the 
∆∆Ct method. Cell lines chosen expressed different industrially relevant molecules i.e. 
an Fc receptor fusion (Fc) and monoclonal antibodies (mAbs). Samples for RNA 
extraction were taken in exponential growth phase and Figure 14 shows the relative 
expression when compared to the CHO-K1 parental cell line. 
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Figure 14: Endogenous miRNA expression of mature miR-23a/b, miR-27a/b and miR-24 in 
a panel of CHO cell lines. A to E) MiRNA expression was compared to a CHO-K1 non- 
producing cell line. The overall miRNA expression was very similar over the panel of cell lines. 
However, miR-24 was significantly lower expressed in CHO-K1 SEAPs, CHO-K1 Fc, DG44i Fc 
and DG44i mAb. MiR-23b and miR-27b was more abundant in CHO-K1 SEAPs compared to 
parental CHO-K1. (* p < 0.05 vs parental, ** p < 0.01 vs parental; n=3). 
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Expression of mature miR-23a, miR-23b, miR-24, miR-27a and miR-27b did not vary 
hugely across all tested cell lines was similar (Figure 14 A to D). However, miR-24 was 
significantly lower expressed in all the cell lines compared to the parental CHO-K1 cell 
line (Figure 14 E). However, miR-24 is the highest expressed miRNA amongst all 
member with Ct-values of ~18 compared to the lowest expressed miRNA (miR-23b) with 
Ct-values of ~26. Furthermore, it was found, that miR-23b and miR-27b were significantly 
upregulated in CHO-K1 SEAP expressing cells when compared to the CHO-K1 parental 
cell line (Figure 14 B to D). In contrast miR-23a was decreased in CHO-K1 SEAP 
expressing cells (Figure 14 A).  
 
4.1.2 Sponge design considerations for the depletion of the miR-23 cluster as well as 
single miRNA members 
The sponge sequences were designed to be complementary to their miRNA targets 
except for a four-base pair mismatch between nucleotides 10 to 14 to create an imperfect 
binding site. The introduced mismatches create a bulged sponge which should protect 
against endonucleolytic cleavage mediated by Ago2 in the RISC (Ebert et al., 2007; 
Kluiver et al., 2012a). The same study showed that miRNAs sharing the same seed 
family can be targeted effectively. The miRNA binding sites (MBS) are located 
downstream of a destabilised EGFP reporter (d2EGFP) in the 3’UTR which allows 
estimation of the binding efficiency of endogenous target miRNAs based on a decrease 
in GFP intensity and the percentage of total GFP positive cells. The vector is based on 
pcDNA3.1-hyg and the d2EGFP with the 3’UTR including SanDI restriction sites were 
cloned by Dr. Nga Lao. The control sponge was similar with the exception that the MBS 
were designed not to target any known expressed sequence (Figure 15 A to D). 
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Figure 15: Construction of sponge decoy constructs for the depletion of miRNAs in CHO-K1 cells.  
Schematic overview of the sponge expression plasmid used. A) The d2EGFP reporter is expressed under 
control of a CMV promoter together with the sponge in the 3’UTR and a poly-A tail. B) The MBS were cloned 
into the vector using SanDI sites which are located between the poly-A tail and the d2EGFP reporter. The 
sponge sequence (highlighted in blue) has a four-nucleotide mismatch which introduces a bulge after 
binding of the miRNA target and increases the stability of the mRNA due to protection against cleavage by 
AGO2 comprised in the RISC complex. To create a stable expressing CHO population the vector has an 
additional mammalian selection marker (hygromycin resistance gene). C) GFP mean intensity as well as 
GFP positive population compared beween control and sponge construct (miR-NC spg). D) Expression of 
miR-24 in CHO-K1 cell transfected with the sponge (* p < 0.05 vs NC, ** p < 0.01 vs NC, *** p < 0.001 vs 
NC; n=3). 
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To assess their impact on cell growth and productivity, the previously tested panel of cell 
lines was transfected with decoys for the depletion of the miR-23 cluster. The transfection 
was performed using electroporation or a PEI based transfection reagent (Mirus 
TransIT®-X2) depending on the cell line. To ensure stable integration of the sponge 
constructs the selection pressure was maintained for four weeks using hygromycin B. 
The transfection efficiency was assessed using Guava® easyCyte flow cytometer using 
ExpressPlus programme for measuring GFP intensity 24 hours post-transfection on a 
GuavaTM benchtop cytometer. To assess the functionality of binding miRNAs to the 
sponge construct the same programme was used after selection. Successful binding 
should result in lower GFP signals due to the translational inhibition or degradation of 
GFP mRNA (Figure 15 C). Besides using GFP as an indication of miRNA binding, 
TaqMan® small RNA assays (section 3.2.5) were used (Figure 15 D). Lower miRNA 
abundance would indicate a depletion of the endogenous miRNA. This apparent 
increase in miRNA levels has been observed by others previously and has been 
attributed to the miRNA accumulating on the sponge transcript and not being turned over. 
Upon cell lysis for qPCR the bound (and protected) miRNA is then released and appears 
to be elevated - though it has been sequestered away from it's endogenous targets and 
therefore functionally depleted (see section 5.2.3). Both observations ultimately indicate 
a reduction of miRNAs being available to bind endogenous targets. 
Phenotyping was first performed in four different industrially relevant cell lines which 
were provided by Biogen (Cambridge MA). The initial screen showed that depletion of 
miR-23-24-27 led to increased productivity in CHO-S Fc. Other cell lines did not show 
any phenotype after stable depletion. Reducing endogenous levels of miR-23 had no 
effect in all four cell lines (compare Figure S 1, Figure S 2 and Figure S 3).  
 
4.1.2.1 Stable depletion of the miR-23 cluster in CHO-S Fc leads to increased productivity  
As mentioned depletion of miR-23-24-27 led to increased productivity in a mixed 
population of Fc fusion expressing CHO-S. Initial screens for an impact on the phenotype 
upon stable depletion of the miR-23 cluster was performed in 5 mL batch cultures using 
TPP 50 mL TubeSpin® bioreactor tubes. Media was supplied by Biogen (Cambridge 
MA) for all cell lines and cells were grown at 35°C, 170 rpm and 80% humidity. Cells 
were cultivated in a Kuhner Clima-shaker incubator (ISF1-X). Cells were seeded at 2x105 
cells/mL and samples were taken every second day for ELISA, GFP and viable cell 
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density. Depletion of miR-23-24-27 led to no observed change in growth nor viability 
(Figure 16 A and B). However, Fc fusion levels were significantly elevated (n=4, * p<0.05) 
on day 6 and 9 of the batch culture (Figure 16 C) Elevated productivity led to 1.5-fold 
increase (n=4, * p<0.05) in titre on day 8. This increase in product level was due to a 
significant increase in productivity on day 8 of the culture (Figure 16 D). GFP mean 
intensity as well as percentage of GFP positive population was decreased in the miR-
23-24-27 sponge compared to the control indicating successful depletion of targeted 
miRNAs (Figure 16 E). Lower miRNA abundance would indicate a depletion of the 
endogenous miRNA. Expression of miR-23 and miR-27 was reduced and miR-24 was 
slightly enriched when compared to the control (Figure 16 F).  This apparent increase in 
miRNA levels has been observed by others previously and has been attributed to the 
miRNA accumulating on the sponge transcript and not being turned over (see section 
5.2.3). 
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Figure 16: Impact of stable depletion of miR-23-24-27 in CHO-S Fc. Growth, viability and productivity 
was compared to a control sponge containing a scrambled sequence instead of MBS. A) Viable cell density 
on day 2, day 4, day 6 and day 8. B) Cellular viability on day 2, day 4, day 6 and day 8. C and D) Titre of 
Fc receptor fusion and specific productivity on all days of the batch culture. E) GFP positive population as 
well as mean intensity. F) Expression of miR-23, miR-24 and miR-27 compared to the control sponge 
(miR-NC spg) in CHO-S cells (* p < 0.05 vs control; *** p < 0.001 vs control: n=4). 
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4.1.2.1.1 Performance of CHO-S Fc-fusion cells stably expressing a miR-23-24-
27 sponge in fed-batch mode 
Most biopharmaceutical manufacturing processes nowadays are based on fed-batch 
cultures, whereby a standard basal medium supports initial growth and a concentrated 
feed is added in exponential phase to boost cell growth and prevent depletion of nutrients 
during stationary phase. Fed-batch cultivation has several benefits as it increases 
maximum cell densities, productivity and prolongs cultivation times due to increased 
viability in late culture stages. Fed-batch experiments cells were seeded with an initial 
cell density of 4x105 cells/mL in 30 mL using 250 mL Erlenmeyer shake flasks. Media 
and feed was supplied by Biogen and culture conditions were set to 160 rpm, 35°C and 
80% humidity in a Kuhner Clima-shaker incubator (ISF1-X). Samples were taken on a 
daily basis for the assessment of viable cell density and media was taken every 48 hours 
for investigation of product titres using ELISA. A 14-day extrapolated feeding strategy 
was provided by Biogen but had never been used for CHO-S Fc. Optimisation was 
necessary to prolong culture times to 14 days. However, initial optimisation increased 
the cultivation time up to 11 days. The CHO-S Fc cell line reached a peak cell density of 
approximately ~38x106 cells/mL on day 8 (n=2) (Figure 17 A). The viability declined from 
day 8 on but no difference in viability were observed between control and miR-23-24-27 
sponge in the early or late stages of the culture (Figure 17 B). However, product titres 
were increased compared to batch cultivations. In batch mode Fc-fusion titre reached a 
peak of 97 mg/L from cells expressing the miR-23-24-27 sponge on day 8. In fed-batch 
cultivation, a product titre of about 750 mg/L on day 11 in CHO-S Fc was observed. 
Furthermore, the titre was higher compared to the control on day 10 and day 11 (Figure 
17 C). However, the fed-batch culture was not as reproducible as desired and further 
optimisation would be necessary. Nevertheless, the same trend in higher productivity 
was seen in fed-batch culture as well as in batch cultures. 
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Higher productivity was exhibited in batch as well as in fed-batch cultures using the 
miR-23-24-27 sponge compared to the control. However, the fed-batch was only 
repeated twice as variations in feed occurred which may have led to different growth 
behaviours. Furthermore, the feed was never optimised for the CHO-S Fc-fusion cell 
line and further adaption of feed volumes would be necessary to repeat results and 
prolong culture times. Optimisation efforts might be very beneficial and can even result 
in higher titres. However, the observed increase in productivity was very encouraging, 
prompting us to investigate whether this phenotype was reflected, and to what extent, 
at the clonal level. 
 
Figure 17: Impact of stable depletion of miR-23-24-27 in CHO-S Fc cultivated in fed-batch mode. 
Feed (highlighted in broken gray line) was added on daily basis beginning from day 3. A and B) 
Assessment of viable cell density and viability over a period of 11 days. C) Fc receptor fusion for day 10 
and day 11 in miR-23-24-27 depleted CHO-S Fc cells in fed-batch cultivation (n=2).  
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4.1.2.2 Generation of single cell clones expressing miR-23-24-27 sponge 
Limited dilution cloning was used to generate a panel of single cell clones expressing 
either a control sponge or miR-23-24-27 sponge. Cells were grown in 96-well format 
using 10 % conditioned media to improve cloning efficiency and positive colonies 
resulting from only one cell were transferred into 24-well plates under maintenance of 
selection pressure using hygromycin B. Clones were analysed for GFP expression and 
nine clones expressing the control sponge or miR-23-24-27 sponge were selected based 
on GFP intensities to ensure an excess of sponge mRNA. Clones were further assessed 
for growth behaviour and productivity. The GFP intensity was assessed using Guava 
easyCyte with ExpressPlus programme on the GuavaTM benchtop cytometer. It was 
shown that the GFP expression in all nine control clones was significantly higher 
compared to miR-23-24-27 sponge clones. The miR-NC sponge showed an average 
GFP mean intensity of 223 (Figure 18 E) and the percentage of GFP positive cells was 
~90 % of the total population, respectively (Figure 18 F). In comparison, the GFP mean 
intensity of all nine miR-23-24-27 sponge clones was 16.97 (Figure 18 E) and ~30 % of 
the total population was shown to be GFP positive (Figure 18 F) which indicates further 
that the GFP sponge is working by translational inhibition or degradation of GFP mRNA. 
Similar results were obtained for the mixed populations in previous results. However, the 
average GFP mean intensities were higher in all selected clones compared to mixed 
populations.  
After selecting clones, the growth behaviour was analysed in batch mode over a period 
of six days. Cells were seeded in 24-well suspension plates in a culture volume of 1 mL. 
The initial cell density was 1 x 105 cells/mL and samples for assessment of viable cell 
density as well as for ELISA were taken every 48 hours (Figure 18 C and D). Across the 
panel all clones grew differently and reached different viable cell densities on day 4 and 
day 6. No significant difference in cell densities in control clones compared to cells 
expressing the miR-23-24-27 sponge was observed but a great variation in the panel 
was shown.  
To investigate the impact of miR-23-24-27 sponge on productivity ELISA was performed 
for all 18 clones with samples taken every 48 hours. Average titre between miR-NC 
cultures compared to miR-23-24-27 did not show any significant difference (miR-NC 
sponge: 101 mg/L ± 44 mg/L and miR-23-24-27 sponge: 82 mg/L ± 41 mg/L) on day 6. 
Furthermore, clones expressing the miR-23-24-27 sponge did not show higher specific 
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productivity unlike the phenotype obtained in batch and fed-batch mode with mixed 
populations would suggest (Figure 18 C and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Assessment of individual clones derived from control and miR-23-24-27 sponge 
expressing mixed populations (CHO-S Fc). A and B) Viable cell density for each clone on day 2, 
4 and 6. C and D) Titres for every individual clone from both panels assessed on day 6. E and F) 
GFP intensity and positive population of all nine clones selected for control and miR-23-24-27 
sponge (n=3, technicals).  
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The impact on productivity using a sponge depleting miR-23-24-27 in CHO-S Fc resulted 
in a ~1.5-fold increase in titres in a mixed population. However, the productivity 
phenotype in a mixed population was not reflected in the clonal panel. Average Fc-fusion 
levels reached 101 mg/L on day 6 for the negative control and 82 mg/L for miR-23-24-
27 sponge. Analysing growth compared with productivity showed however, that high 
productivity in clones seemed to be at the expense of growth which is a commonly 
observed phenomenon. Highest specific productivity (in pg/cell/day) were exhibited with 
clones showing reduced proliferation. Clones 6, 8 and 9 expressing miR-23-24-27 
sponge showed high specific productivities however, these clones only grew to low cell 
densities of about 2x106 to 4x106 cells/mL on day 6. These clones also exhibited low 
GFP mean intensities but showed a high percentage of GFP positive cells in the total 
population. The possible reasons for this outcome will be discussed later. At this point 
we decided to revert to the mixed population where the productivity gains were observed 
to investigate whether the depletion of the three miRNAs had any impact on another 
important aspect of a recombinant protein - glycosylation.  
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4.1.2.3 Impact on glycosylation due to the depletion of miR-23-24-27 
To investigate if the depletion of the miR-23 cluster had an impact on glycosylation 
species, 50 mL of cell culture supernatant was taken and the product was purified using 
protein-A chromatography as described in 3.3.2 (Figure 19 A and B). Samples were 
analysed for changes in glycosylation pattern using LC/LFR-MS/MS as described in 
3.3.3. This work was performed by Dr. Sara Carillo (NIBRT) as part of a collaboration. 
Depletion of miR-23-24-27 was shown to have some minor effects on glycosylation 
pattern of the Fc-fusion product (Figure 19 C).  
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Figure 19: Changes in glycosylation pattern on expressed Fc fusion protein after depletion 
of miR-23-24-27. A) Chromatogramm for control and miR-23-24-27 sponge obtained by LC/LFR-
MS/MS. B) Protein-A chromatography and SDS-PAGE for Fc fusion which was purified out of 
conditioned media. Sucessful purification was confirmed by SDS-PAGE. C) Abundance of key 
glycosylations which were differential after depletion of miR-23-24-27 (n=3, technicals).  
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Stable depletion of miR-23-24-27 had a very slight affect on the glycosylation pattern of 
the Fc-fusion protein. Increased levels of mannose-5 and mannose-6 can potentially 
have a drastic impact on antibody-dependent cell-mediated cytotoxicity (ADCC) of mAbs 
due to accompanying reduction of A-fucosylation. Therefore, increased mannose 
species may reduce ADCC. Higher levels of galactosylation has no impact on ADCC but 
can have significant impacts on complement-dependent cytotoxicity (CDC) as G2F as 
well as SG1F were significantly elevated in miR-23-24-27 depleted cells compared to 
the control. The impact of glycosylation on the therapeutic protein are discussed later.  
 
Summary of impact of miR-23-24-27 on CHO-S Fc-fusion expressing cells 
A CHO-S cell line expressing an Fc receptor fusion with stable depletion of miR-23-24-
27 using a sponge resulted in a ~1.5-fold increase in productivity compared to the 
negative control in batch culture. In a fed-batch process preliminary data showed that an 
increase in productivity was obtained as well. The same effect was observed in CHO-K1 
SEAP expressing cells as well as higher proliferation (Noèlia Sanchez, 2013). Single cell 
clones were generated using limited dilution cloning and selected by GFP intensity to 
ensure an excess of sponge mRNA. The clonal panel showed a significant difference in 
GFP intensity indicating that the sponge was working as expected.  
Both clonal panels were analysed for growth behaviour in 1 mL suspension cultures in 
24-well plates. All clones differed in proliferation and growth rates as well as productivity. 
However, the productivity phenotype observed in mixed population in batch and fed-
batch culture was not reproduced. 
Analysis of the product glycosylation pattern revealed changes in galactose content as 
well as mannose content which could possibly impact ADCC as well as CDC.  
The results achieved with the mixed population cluster depletion prompted us to 
investigate whether the effect was due to synergistic activities of the cluster members or 
whether one miRNA in particular was responsible. We designed individual sponges for 
miR-24 as well as miR-27. The action of miR-23 depletion was already tested at this 
point and did not show any impact (shown in Figure S 1, Figure S 2 and Figure S 3). 
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4.1.3 Impact of miR-24 and miR-27 sponge overexpression on the bioprocess 
phenotype of CHO-S Fc 
To investigate which miRNA was responsible for higher titres and specific productivities 
observed, individual sponges for miR-24 and miR-27 were designed. Once again, the 
miR-24 and miR-27 sponge sequences were designed to be complementary to their 
miRNA targets (see Figure 15) except for four base pair mismatches between 
nucleotides 10 to 14 to create an imperfect binding site. The control sponge was 
designed similarly with the exception that the sequence was designed not to target any 
known miRNA. Oligo sequences containing MBS were annealed and ligated into the 
sponge expression vector (engineered pcDNA3.1/Hyg+). Due to SanDI restriction sites 
several inserts can be directionally ligated into the expression vector. The ligation mix 
was transformed and clones were picked. The insert size was assessed using PCR and 
confirmed by Sanger sequencing (Figure S 4). For the miR-NC sponge a plasmid 
containing ten scrambled MBS was picked. For the miR-24 and miR-27 sponge both 
plasmids contained twelve MBS which has been shown to be sufficient for high efficacy 
(Kluiver et al., 2012a). The CHO-S Fc-fusion expressing cell line was transfected with 
each sponge construct and selected using hygromycin B over a period of four weeks 
before being assessed in batch culture. Over a period of eight days samples were taken 
every 48 hours for assessment of viable cell density and for ELISA. Cells were seeded 
with at a cell density of 2x105 cells/mL in a culture volume of 5 mL with media provided 
by Biogen without using antibiotics or selection markers.  
No difference in proliferation was observed due to stable depletion of miR-24 or miR-27 
compared to the negative control. Furthermore, no difference in viability was observed 
(Figure 20 A and B). The depletion of miR-24 led to slightly increased levels of Fc-fusion 
on day 4. Titres on day 6 and 8 were significantly increased compared to the control 
sponge with increased of 1,3-fold to 2-fold respectively. The depletion of miR-27 had a 
similar effect resulting in a 2-fold increase of Fc-fusion on day 6 and 8 (Figure 20 C). 
This increase was due to significantly increased specific productivity (Qp) on day 4 (1.5-
fold), 6 (1.2-fold) and 8 (3-fold) of the batch culture with depletion of miR-24 (Figure 20 
D). For the depletion of miR-27 the increase in specific productivity (Qp) was even higher 
on day 4 (3-fold), 6 (2-fold) and 8 (3-fold) of the batch culture (Figure 20 D). 
The decrease in GFP mean intensity compared to the control suggested that both 
sponges bound endogenous miR-24 or miR-27 effectively (Figure 20 E and F). MiRNA 
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abundance was also measured using TaqMan® assays. Surprisingly, miR-24 levels 
appeared slightly higher, compared to the control despite suppression of GFP 
expression. Possible reasons for this will be discussed later. The abundance of miR-27 
was significantly reduced compared to the control (Figure 20 G) which is what would be 
expected when using sponges for a knockdown.  
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Figure 20: Impact of stable depletion of miR-24 and miR-27 on CHO-S Fc in batch cultures. A) Viable 
cell density on day 2, day 4, day 6 and day 8. B) Viability assessed on day 2, day 4, day 6 and day 8. C) Fc 
fusion levels compared to the control after depletion of miR-24 and miR-27 in CHO-S. D) Specific productivity 
on day 4, 6 and 8 for both depleted miRNAs. E and F) Reduced levels of GFP positive population as well as 
mean G) MicroRNA abundance for the depletion of miR-24 and miR-27. Statistical significance was calculated 
using standard student’s t-test (* p < 0.05 vs control, ** p < 0.01 vs control, *** p < 0.001 vs control; n=3). 
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As in the case of the overexpression of the miR-23-24-27 sponge we then analysed the 
Fc-fusion protein for changes in glycosylation.  
 
4.1.3.1 Investigation of impact on glycosylation due to the depletion of miR-23, miR-24 or 
miR-27.  
To investigate the potential effects on glycosylation of each individual miRNA depletion, 
50 mL of cell culture supernatant was taken and the Fc-protein was purified using 
protein-A chromatography as described in 3.3.2 (Figure 21 A). Samples were analysed 
for changes in glycosylation pattern using LC/LFR-MS/MS as described in 3.3.3 and the 
work was performed by Dr. Sara Carillo (NIBRT). Even though no phenotype was 
observed for the depletion of miR-23 we wanted to include it in our approach to get a 
bigger picture of the impact of the cluster depletion on glycoslation.  
The depletion of all three miRNAs had significant effects on glycosylation patterns on the 
Fc-fusion (Figure 21 B, C and D). Each point on the graphs represent a different species 
which was compared to the control. A different species for mannose are for example M3. 
M3F, M5 etc. All differential glycosylation species are represented in Figure S 5. The 
control sponge was additionally assessed to investigate if GFP expression alone might 
have an impact on glycosylation.  
 Reduced levels of miR-23 led to higher levels of mannose as well as non-sialylated 
complex N-glycans. Depletion of miR-24 led to an increase in terminal sialic acid, 
mannose as well as non-sialylated complex N-glycans. Lower endogenous levels of miR-
27 led to slightly elevated levels of mannose as well as non-sialylated complex N-
glycans. Interestingly depletion of the whole cluster increased levels in mannose species 
and terminal sialic acid species as well (see 4.1.2.3). Each miRNA might be involved in 
a different aspect of changed glycosylation and will be further discussed later.  
Increased levels of mannose and terminal sialic acid can influence ADCC and target 
binding efficacy negatively. Taken together results from depleting the miR-23 cluster as 
well as each individual miRNA indicates that the dysregulation of transcriptional networks 
using miRNAs can impact the glycosylation pattern of the Fc-fusion protein.  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Assessment of glycosylation pattern after depletion of miR-23, miR-24 and miR-
27 on expressed Fc fusion. Each point on graphs represent a different glycosylation species i.e. 
for mannose M3, FM3, M5 etc. A) SDS-PAGE of whole cell lysate after and before protein-A 
purification. B) Species of terminal sialic acid which were shown to be differential for each member 
of the miR-23 cluster. C) Mannose species demonstrated to be differential for each member of the 
miR-23 cluster. D) Non-sialylated glycans which were differential for each member of the miR-23 
cluster (n=3, technicals). 
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As mentioned earlier miRNAs can have multiple mRNA targets in a cell. Perturbing the 
levels of three miRNAs would therefore be likely to impact even more genes. Given the 
phenotypic impact we had seen so far and the potential cross talk between miRs from 
the same genomic cluster, we decided it would be really interesting to investigate 
proteins being differentially expressed in response to the various sponge decoys. We 
chose proteomic analysis for this purpose due to the inherent challenge of interpreting 
transcriptomic data after dysregulation of miRNAs.  
 
4.1.4 Identification of potential targets of miR-23-24-27, miR-23, miR-24 and miR-27 
using proteomic profiling and pathway analysis 
As miRNAs mainly act at the post-transcriptional level, we sought to find differentially 
expressed (DE) proteins due to the knockdown of a miRNA with the aim to identify 
potential direct targets. For the study we compared the knockdown of miR-23-24-27, 
miR-23, miR-24 as well as miR-27 to control sponge. There is evidence in the literature 
that each individual member of a miRNA cluster is potentially involved in similar 
pathways which will be discussed later. Therefore, we included miR-23 even though no 
phenotype was observed in this particular CHO-S Fc cell line. Samples for label-free 
proteomic profiling using HPLC-MS/MS were taken in exponential growth phase and 
prepared as described in 3.3.9. Using mass spectrometry, we identifed 3893 to 4010 
proteins with an overlap of 74.3% between samples (Figure 22). Due to the fundamental 
mechanism of miRNA action we focused on proteins which showed higher abundance 
compared to the control sponge. Depletion of the whole cluster led to 49 (17 with >1.5-
fold change) proteins with higher abundance and 100 which showed reduced levels. 
Depletion of miR-23, miR-24 and miR-27 individually showed generally higher numbers 
of DE proteins. One posibble explanation for this could be the difference in MBS in the 
miR-23-24-27 sponge which only had two binding-sites per miRNA compared to the 
individual sponges which had 10-12 MBS. Depletion of miR-23 resulted in 385 more 
abundant proteins with 135 >1.5-fold change. Reduced levels of miR-24 led to increased 
levels of 219 proteins (72 with >1.5-fold change). Lastly miR-27 depletion increased 
levels of 210 proteins with 146 having a fold-change of >1.5. 
Comparing all the DE proteins (>1.5-fold change) due to miR-23, miR-24 and miR-27 
depletion showed that 17 proteins were upregulated in all three sample sets indicating 
some overlap in target mRNAs between the cluster members.  
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To try to understand which DE proteins were potentially contributing to the observed 
higher productivity phenotype, we looked at what pathways were overrepresented based 
on the known function of the proteins identified. We used the Database for Annotation, 
Visualization and Integrated Discovery (DAVID 6.7) to identify enriched biological 
processes (BP) after knockdown of each individual miRNA and cluster (Table 4). 
 
Figure 22: Overlap of proteins identified using Label-free proteomic profiling after depletion 
of miR-23-24-27, miR-23, miR-24 and miR-27 in CHO-S Fc. A range of 3893 to 4010 total proteins 
was identified with a coverage of 74.3% between the samples, respectively. Proteins having a fold-
change of >1.25, an Anova value <0.05 with 2 peptides were included in analysis of differential 
expression. Depletion of miR-23-24-27 depletion showed a total of 149 DE proteins.  
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Table 4: Pathway analysis of DE proteins after knockdown of miR-23-24-27 simoultaneously or miR-
23, miR-24 and miR-27 individually. 
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In our analysis we focused on the most significant pathways with low false discovery 
rates (Benjamini-Hochberg procedure) and all proteins in our DE lists with a fold change 
of >1.25. Depletion of miR-23-24-27, miR-23 and miR-24 resulted in an enrichment of 
biological processes involved in translational initiation, elongation and protein folding 
were enriched. Interestingly processes involved in activation of amino acids as well as 
tRNA biosynthesis were enriched, indicating potential upregulation of the translational 
machinery. For miR-23 depletion alone (no phenotype observed in CHO-S), higher levels 
of proteins involved in cellular respiration, oxidation and generation of precursors for 
metabolites and energy were enriched. Depletion of miR-24 resulted in enrichment of 
pathways involved in rRNA biogenesis, ribosome assembly, translation and protein 
folding as well as tRNA aminoacylation, which are consistent with what might be 
expected in a high productivity phenotype.  
Reduced levels of miR-27 seem to result in activation of stress response pathways. No 
pathways associated with a high productivity phenotype were observed for miR-27. 
Interestingly an increase in proteins involved in apoptotic regulation were observed.  
 
4.1.4.1 Identification of differential expressed proteins involved in glycosylation 
As described in 4.1.2.3 and 4.1.3.1, depletion of miR-23, miR-24, miR-27 or the complete 
cluster, impacted the glycosylation pattern of the Fc-fusion protein. Generating lists of 
DE proteins also allowed the analysis of potential proteins involved in glycosylation 
(Figure 23). Depletion of miR-23 led to upregulation of Glucosidase 2 (PRKCSH), 
Phosphomannomutase 2 (PMM2) and Neutral alpha-glucosidase AB (GANAB). 
PRKCSH and GANAB are both involved in N-glycan metabolism. Furthermore, PMM2 is 
important for catalysing the transfer of mannosyl groups to proteins in the early stages 
of N-glycan maturation.  
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Depletion of miR-23 led to increased mannose content on the expressed Fc-fusion which 
correlates with the observation of upregulation of GANAB, PRKCSH and PMM2. 
Knockdown of miR-24 increased terminal sialic acid as well as non-sialylated complex 
N-glycans however, none of the detected DE protein are involved in these modifications. 
Furthermore, miR-27 led to slightly increased mannose and non-sialylated complex N-
glycans content. PMM2 is more abundant in miR-27 depleted cells which might 
potentially explain the increase in mannose species.  
 
Figure 23: Differential proteins identified by proteomic profiling which can be related to 
changes in glycosylation after depletion of individual miRNA members of the miR-23 cluster. 
Three genes involved in processing of glycosylation were identified. These three proteins were 
Glucosidase 2 (PRKCSH), Phosphomannomutase 2 (PMM2) and Neutral alpha-glucosidase AB 
(GANAB). GANAB is important for the conversion of ER localised glycans into high-mannose N-
glycans. PMM2 is responsible for providing mannose precurosers ffor the addition of mannose to N-
glycans.  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
104 
4.1.4.2 Depletion of miR-24 in CHO-S Fc leads to an upregulation of ribosomal RNA 
biogenesis and the translational machinery resulting in a high productivity 
phenotype 
Reduced levels of miR-23-24-27 led to increased productivity in one of four tested cell 
lines (CHO-S Fc). To get a better insight into which miRNA was responsible for the 
increase in productivity, individual sponges were designed and tested. Depletion of either 
miR-24 as well as miR-27 led to significantly elevated Fc-fusion protein titre compared 
to the control sponge. To analyse further which proteins were dysregulated and 
potentially involved in the observed phenotype, we performed proteomic profiling 
combined with pathway analysis. This comparison showed that for miR-27 no obvious 
pathway involved in increased productivity was identifiable. In contrast, depletion of miR-
24 resulted in 72 (Anova value < 0.05, fold-change >1.5) more abundant proteins which 
are involved in several biological processes which could be associated with increased 
Fc-fusion levels (Figure 24 A to E). Several more proteins are involved in pre-rRNA and 
rRNA-processing including the members of the PeBoW complex (Figure 24 A). 
Interestingly, proteins involved in the assembly of ribosomal subunits were upregulated 
including RACK1 and EIF6 as well as proteins building the ribosomal subunits itself 
(Figure 24 B). Furthermore, TUFM and GFM1, critical proteins involved in recruiting of 
aminoacyl-tRNAs and removal of deacetylated tRNAs, were more abundant (Figure 24 
C). Upregulation of TUFM and GFM1 is accompanied by synthetases of aminoacyl-
tRNAs i.e. AARS, WARS, IARS, NARS and YARS (Figure 24 E). Perhaps, as a result of 
increased productivity other proteins involved in unfolded protein response (UPR) were 
upregulated as well e.g. RUVBL2, LONP1 and CCT8 (Figure 24 D). 
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Pathway analysis revealed the potential mechanisms leading to increased productivity 
in response to miR-24 depletion in CHO-S Fc cells. In order to investigate whether this 
phenomenon was cell line specific or more broadly applicable we engineered several 
other CHO cell lines to reduce mir-24 expression and measured the impact on the 
productivity.   
 
 
 
Figure 24: Schematic diagram of how various proteins dysregulated by miR-24 
depletion could impact translation in the cell. A and B) Several proteins showed 
elevated levels involved in pre-rRNA processing, rRNA processing as well as assembly of 
ribosomal subunits. C) Proteins involved in recruiting and removal of aminoacyl-tRNAs 
was observed. D) Accompanied by increased levels of translation, UPR seems to be more 
abundant in miR-24 depleted cells. E) An increase in translational machinery, aminoacyl-
tRNA synthases showed elevated levels as well.  
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4.1.5 Depletion of miR-24 improved productivityof CHO-K1 mAb expressing an IgG 
To test if reduced miR-24 levels could impact positively on other cell lines we transfected 
a CHO-K1 mAb producer cell line. For completeness we also generated stable CHO-K1 
mAb pools overexpressing a miR-27 and miR-23-24-27 sponge. The impact of miR-23 
individually was assessed by Dr. Paul Kelly (Paul S. Kelly, 2014b) in the same cell line 
and is therefore not displayed in this thesis. After transfection we performed experiments 
in 5 mL batch cultures using TPP 50 mL TubeSpin® bioreactor tubes. Cells were grown 
CHO-SFM II media using CHO-SFM II in a Kuhner Clima-shaker incubator (ISF1-X) at 
37°C, 170 rpm and 80 % humidity.  
Depletion of miR-23-24-27 or miR-27 individually had no impact in CHO-K1 mAb 
expressing cells (Figure S 6). However, depletion of miR-24 resulted in slight but 
significantly elevated levels of IgG (Figure 25 A to E). Viable cell density as well as 
viability on day 7 was slightly reduced for miR-24 depleted cells compared to the control 
(Figure 25 A and B). However, IgG titre was elevated on day 2, day 4, day 6 and 
significantly on day 7 (Figure 25 C). The increase in yield was due to an increase in 
specific productivity on day 7 of the culture (Figure 25 D). The GFP positive population 
as well as GFP mean intensity was reduced which indicated binding of endogenous miR-
24 to the sponge sequence compared to the control.  
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Figure 25: Depletion of miR-24 in CHO-K1 mAb expressing a miR-24 sponge. A and B) 
Viable cell density and viability compared to the control. C) IgG levels of miR-24 depleted cells 
compared to the control. D) Specific specific productivity after depletion of miR-24. E and F) 
GFP positive population and mean intensity. (** p < 0.01 vs control, *** p < 0.001 vs control; 
n=3). 
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In summary, the depletion of miR-24 led to an increase of product level as well as specific 
productivity in two different CHO cell lineages producing two different therapeutic 
proteins (CHO-S Fc and CHO-K1 mAb). Next, we expanded our investigation to assess 
miR-24 depletion on a panel of industrially relevant CHO cell lines expressing different 
therapeutic proteins. Sponges were transfected in other industrially relevant cell lines 
including CHO-K1 Fc, DG44i Fc and DG44i mAb. These three cell lines were provided 
by Biogen. CHO-K1 DP12 (IgG) was purchased from ATCC and CHO-K1 EPO was 
generated in house by Dr. Srinivas Suda. All functional assessments of these cell lines 
are summarized in Table 5.  
 
 
 
 
 
 
Depletion of miR-23 in CHO-K1 SEAP as well as CHO-K1 mAb were performed 
previously by Dr. Paul Kelly which led to positive effects on longevity as well as 
productivity. Dr. Noelia Sanchez used a miR-23-24-27 sponge in CHO-K1 SEAP 
expressing cells which resulted in elevated SEAP levels while compromising cell growth.  
As in the CHO-S Fc and CHO-K1 mAb cell lines, the depletion of miR-24 led to increased 
levels of expressed therapeutic product. An increase was observed in CHO-K1 Fc, CHO-
K1 EPO, CHO-K1 DP12 as well as DG44i mAb (experiments performed by Dr. Srinivas 
Suda). This broadly observed beneficial impact on specific productivity demonstrated the 
potential of miR-24 depletion as cell line engineering tool.  
One drawback of using sponge decoys is the introduction of a reporter/transgene. 
Furthermore, the specificity of a sponge is not guaranteed as many miRNAs with a 
similar “seed” family could potentially bind to the MBS. Therefore, we decided to target 
the genomic locus using the recently developed CRISPR/Cas9 system. As we did see 
beneficial phenotypes regarding the knockdown of individual members of the miR-23 
Table 5: Summary of all cell lines tested with sponges for miR-23-24-27 and single members of the 
cluster. 
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cluster we selected them as targets for establishing CRISPR/Cas9 in our laboratory. 
Additionally, we proposed that a knockout of a miRNA may enhance the phenotype 
observed.  
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4.2 CRISPR/Cas9 as genome engineering tool to target miRNAs 
Previous results had shown that stable depletion of individual members of the miR-23 
cluster (miR-23, miR-24 and miR-27) can have an influence on proliferation, viability and 
productivity. These phenotypes make the miR-23 cluster and each member a potential 
target for cell line engineering. The sponge approach has been proven to be an efficient 
method to deplete mature miRNAs in CHO cells. However, for an eventual application in 
industry it would be beneficial to avoid the introduction of transgenes. Rather than 
depleting the target miRNA we decided to attempt a complete knockout of the target 
miRNA. Therefore, the CRISPR/Cas9 system for rapid generation of knockout cell lines 
was chosen. CRISPR/Cas9 is not only an efficient tool to knockout proteins but it has 
been shown to be efficient in knocking out miRNAs as well (Chang et al., 2016a; Q. 
Jiang, Meng, Meng, Chang, Xiong, Cao, & Liang, 2014b). Efficiency was an important 
factor for us given the existence of cluster paralogues in the genome as well as the 
possibility of there being >2 or more alleles due to the aneyploid nature of the CHO 
genome. The organisation of the miR-23a and miR-23b cluster are shown in Figure 26 
A.  
To knockdown or completely knockout miRNAs, single guide RNAs (sgRNAs) were 
designed to target the seed sequence of the target miRNAs if possible. The selection of 
the target genomic locus depends on the presence of a protospacer adjacent motif 
(PAM) which must be located proximally. The specific PAM sequence is dependent on 
the Cas9 endonuclease species of origin (NGG for S. pyogenes). SgRNAs were 
delivered as single stranded oligos and were first annealed and then ligated into 
pSpCas9 (BB)-2A-puro (further referred as PX459) which was digested with BbsI. The 
sgRNA was expressed off a U6 RNA polymerase III promoter and Cas9/puromycin was 
under the control of a CMV promoter (Figure 26 B).  
To investigate if nucleotide sequence changes proximal to the seed region could 
potentially alter the stem loop sequence we used RNAfold (http://rna.tbi.univie.ac.at/cgi-
bin/RNAWebSuite/RNAfold.cgi) to predict the secondary structure of the wildtype as well 
as with insertions and deletions (indels) of ± 2bp (Figure 26 C). This demonstrated that 
both deletions and insertions can have a considerable effect on the secondary structure 
of the non-processed miRNA precursor which might lead to impairement of processing 
or inability to recognise its native mRNA target.  
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Figure 26: Design and ligation of sgRNAs for targeting miRNAs in CHO cells. A) Organisation of the miR-
23a and miR-23b cluster. B) Oligos were designed to target the seed region of the miRNA where possible. 
Oligos were annealed and ligated upstream the scaffold which enables the co-expression as sgRNA instead 
of a separate transfection of a guideRNA. C) RNA stability analysis showed that deletions proximal to the seed 
region could change the structure of the miRNA hairpin.  
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The Cas9 used was a fusion protein with the puromycin resistance gene enabling 
selection using puromycin after transfection. The ligation mixes were transformed into 
DH5-α competent cells and clones were picked and sent for sequencing to confirm 
successful ligation. Verified plasmids were amplified in DH5-α and midi-prepped to 
isolate the plasmid DNA and to remove endotoxins. Several gRNAs were used for 
targeting every single member of the miR-23 cluster including the paralogues (Table 6).  
 
For miR-24 we were able to use a single sgRNA to target both paralogues as miR-24-1 
and miR-24-2 are identical in their sequence. As a control we utilised PX459 only 
expressing the scaffold construct containing a non-specific gRNA sequence. CHO-K1 
mAb expressing cells were transfected with each plasmid and selected for two weeks. 
DNA was isolated and the miR-23a-27a-24-2 and the miR-23b-27b-24-1 cluster were 
amplified using standard PCR. Analysis of indels was performed using either the T7E1 
endonuclase assay, Sanger sequencing or NGS. After selection, mixed populations and 
clones were analysed using TaqMan® miRNA assays. For each assay primers were 
designed to target up- and downstream of each miRNA. A general workflow for the 
generation of stable cell lines and analysis of indels as well as phenotypic analysis using 
growth curves and ELISAs is displayed in Figure 27.  
 
 
 
Table 6: Guide RNAs used for targeting each miRNA member of the miR-23-24-27 cluster. 
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As mentioned above we used three different methods for the analysis of indels 
generated: 
Firstly, the PCR product was cloned into TOPO-TA® and positive colonies were 
amplified and sequenced using standard Sanger sequencing (Figure 28). We found that 
for every targeted miRNA insertions and deletions were detectable. Most common indels 
were between ±3 bps. However, larger deletions were found for miR-27a (-62 bps) and 
miR-24 (-40 bps), respectively.  
Figure 27: General workflow used for the generation of stable cell lines with CRISPR/Cas9 
targeting miRNAs. After design and amplification of the plasmid a CHO-K1 mAb expressing cell line 
was transfected with and selected using puromycin to ensure stable integration of the plasmid into the 
hosts genome. Plasmids were generated with sgRNAs targeting each miRNA. However, to avoid co-
transfections we targeted only one miRNA at a time. Genomic DNA was extracted and each cluster was 
amplified using standard PCR with high fidelity polymerases to ensure no unspecific mismatches. 
Analysis of indels was performed using NGS, Surveyor® assay or standard Sanger sequencing after 
TOPO-TA® cloning. MiRNA expression was analysed in mixed populations as well as in single cell 
clones. After a successful knockdown was obtained the phenotype was analysed using growth curves 
and ELISA.  
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Another method to analyse indels is the use of Surveyor® assays which utilise a T7 
endonuclease. The PCR product was purified and mixed with wt amplicon. The mix was 
then denatured and re-annealed as well as treated with Surveyor® nuclease which is an 
enzyme that cuts DNA at mismatches. Mismatches will occur where amplicons with 
indels re-aneal with wt amplicons. The cleavage of the PCR product was analysed on a 
2 % agarose gel for higher resolution. To calculate indel frequencies the intensity of the 
digested product was compared to wildtype PCR amplicon. By comparing the intensity 
of each band the amount of cleaved PCR product was calculated by following formula: 
 
fcut = (b+c)/(a+b+c)  
With b and c being the integrated intensities of each cleaved product and a being the 
undigested PCR product. To calculate the indel percentage the following formula was 
used: 
Indel (%) = 100 x (1 - √(1 – fcut)) 
All sgRNAs except for miR-23a were shown to target their corresponding miRNA target 
loci and induce indels. At this point it was necessary to re-clone and prove targeting for 
the sgRNA which was used to target miR-23a. However, the Surveyor® assay was not 
repeated for miR-23a but NGS was used instead. The Surveyor® assay showed that the 
sgRNA for miR-23b induced an indel occurance of 64 %. Mir-24-1 and miR-24-2 induced 
indels at 40 % and 34 % efficiency, respectively. Furthermore, miR-27a and miR-27b 
were targeted with an efficiency of 48 % and 41 % (Figure 28 B).  
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Having established that we can target all members of the miR-23 cluster with high 
efficacy we wanted to observe the influence on mature miRNA expression. 
Figure 28: Analysis of indels generated by CRISPR/Cas9 using Sanger sequencing and 
Surveryor® assays. A) Targeted region was amplified using PCR and cloned into TOPO plasmids.  
Subsequent Sanger sequencing showed a wide range of deletions and insertions ranging from ±1 to ±3 
bps. The mature miRNA sequence is displayed in orange and the PAM is shown in blue. B) After 
targeting with CRISPR the genomic DNA for each miRNA was amplified and Surveyor® assay was used 
to visualise indel induction. A represented the undigested product, b and c were the cleaved products.  
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4.2.1 MicroRNA expression in mixed populations targeted with CRISPR/Cas9  
Both Sanger sequencing after TOPO-TA cloning and the Surveyor® assay showed that 
the loci of interest could be successfully targeted, obtaining high percentages of indels. 
To investigate the effect of these indels on mature miRNA expression, total RNA of 
selected mixed populations was isolated and first strand cDNA synthesis was performed 
with specific looped primers contained in the TaqMan® small RNA assay kit. The cDNA 
was amplified using specific forward and reverse primers and a TaqMan® probe labelled 
with a fluorophore was included in the kit for specific detection of miRNAs. To normalise 
expression U6 snRNA was used as an endogenous control. Expression was calibrated 
to the control (PX459) which was also transfected into CHO cells (CHO-K1 mAb control).  
The expression of each mature miRNA was significantly reduced in all mixed populations 
(Figure 29 A). MiR-27a showed a 65% reduction (* p < 0.05 vs control) and miR-27b 
showed an 90% reduction (** p < 0.01) compared to the control. The greatest reduction 
was observed for miR-24 with a 98% (*** p < 0.01 vs control). However, the TaqMan® 
assay does not distinguish between miR-24-1 and miR-24-2 as both mature miRNA 
sequences are completely identical. Furthermore, miR-24 is in general highly expressed 
which was observed by testing a panel of cell lines for individual expression of all miRNAs 
located in the miR-23 cluster and paralog. The highest fold change in a mixed CHO 
population was observed when targeting miR-23a with 98% less mature miRNA 
compared to a control population (*** p < 0.001 vs control). Targeting miR-23b also led 
to respective reduction of mature miRNA of 95% (*** p < 0.001 vs control).  
When investigating the full range of deletions or insertions obtained in mixed populations, 
the Surveyor® assay and Sanger sequencing only give information on a small sample of 
events. Therefore, we decided to use Next-generation sequencing to investigate which 
insertions or deletions are most common. For indel sequencing it was necessary to 
design primers ±100 bps up- and downstream of the presumed mutated site. 
Furthermore, linker sequences were added to the primers and a high-fidelity polymerase 
with proofreading function was used. Figure 29 B shows the targeting efficiencies and 
most common deletions/insertions observed.  
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Figure 29: CRISPR/Cas9 mediated targeting of miRNA led to reduced mature miRNA levels. A) Mature 
miRNA expression was assessed and abundance of miRNAs was significantly reduced for each targeted 
miRNA compared to the control. B) NGS was used to analyse indels and a variety of indels was observed. 
C) Summary of phenotypes obtained in mixed population for each miRNA targeted with CRISPR/Cas9. 
Phenotypes correlated with experiments performed using sponge decoys in the same cell line. (* p< 0.05 vs 
control, ** p < 0.01 vs control, *** p < 0.001 vs control; n=3). 
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This demonstrates that miR-24-1 and miR-24-2 were most effectively targeted with a 
%indel of ~95-96 in mixed population. Interestingly, miR-24-2 showed a high variety of 
common deletions up to -22 bps. At the miR-24-1 locus an insertion of +1bp was more 
common. Both guides for miR-27a and miR-27b seemed to induce insertions of +1bp 
with relatively high indel percentage of 83-89%. For miR-23a, 64% of all reads showed 
indels with -2, -1 and +1bp being the most common. Targeting miR-23b resulted in 87% 
indels in a mixed population with insertions and deletions of ±1bp, respectively.  
Having shown that we can effectively induce a variety of indels we wanted to investigate 
if these indels result in similar phenotypes to these observed during the earlier sponge 
decoy work. Therefore, we analysed the phenotype of mixed populations and it 
demonstrated that targeting miRs by CRISPR/Cas9 led to similar phenotypes when 
compared to sponge decoy approach (Figure 29 C).  
As the miR-23 cluster consists of two genomic paralogues (miR-23a and miR-23b) and 
the sgRNAs used were very similar we wanted to investigate if the sgRNA for miR-23a 
targeted miR-23b and vice versa. Similarly, we wanted to assess this for miR-27a and 
miR-27b. We assessed the mature expression of miR-23a in two mixed populations: 
firstly, the mixed population in which miR-23a was targeted and secondarly the mixed 
population in which miR-23b was targeted. We followed the same approach for miR-23b, 
miR-27a and miR-27b (Figure 30 A and B). In mixed populations where miR-23a was 
targeted, both paralogues were downregulated. This was also demonstrated for miR-
23b. The sgRNAs used for targeting miR-23a and miR-23b showed a high level of 
similarity especially in the 3’ region close to the PAM. When miR-27a was targeted the 
expression of both paralogues was downregulated. The same result was observed for 
miR-27b and again both sgRNAs showed similarity in the 3’ region. However, the 
sgRNAs for miR-27a and miR-27b showed only a 50% sequence overlap. As mentioned 
before we have no way in differenciating between the levels of miR-24-1 and miR-24-2.  
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Figure 30: Investigation of off-targeting between similar sgRNAs used for targeting 
paralogues and analysis of mature miRNA expression. A) Analysis of mature expression of miR-
23a and miR-23b after using sgRNAs for miR-23a and miR-23b in mixed population. Furthermore, 
the sequence of both sgRNAs was compared. B) Analysis of mature expression of miR-27a and 
miR-27b after using sgRNAs for both in mixed population. Furthermore, the sequence of both 
sgRNAs was compared ((* p< 0.05 vs control, ** p < 0.01 vs control, *** p < 0.001 vs control; n=3).  
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To investigate the cross-targeting of the genomic paralogues further and to ensure the 
accuracy of the Taqman® assays, we performed NGS on mixed populations where miR-
23a, miR-23b, miR-27a and miR-27b were targeted (Table 7).  
 
 
 
 
 
 
When we investigated cross-targeting by the sgRNA used for targeting miR-23a we 
amplified the region where miR-23a was located in the genome as well as miR-23b. We 
used the same approach for the miR-27a and miR-27b loci. It was observed that when 
miR-23a was targeted, miR-23b was targeted also. However, frequencies of targeting 
were much lower with only 6.51% showing indels of -1bp. For miR-23b it was 
demonstrated that miR-23a was targeted as well with 16.45% showing mutations of -
1bp. When miR-27a was targeted, miR-27b was also affected with 11.16% of reads 
showing a mutation. When targeting miR-27b the miR-27a locus showed the highest 
indel frequency of 21.60% with -1 and -2 bp being observed most frequently. Therefore, 
cross targeting effects must be considered and it confirmed the assessment of mature 
miRNA expression using Taqman® assays. 
Having proved that we can target miRNAs effectively we wanted to investigate the impact 
on the phenotype after depletion of each individual miRNA member of the miR-23 cluster 
further.  
 
 
 
 
 
Table 7: Investigation of cross-targeting using NGS. 
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4.2.1.1 Bioprocess phenotype on mixed populations after targeting miRNA members of 
the miR-23 cluster using CRISPR/Cas9 
Our experiments demonstrated that CRISPR/Cas9 can be successfully used to 
knockdown miRNAs in mixed populations. It is known that the targeting efficiency is 
dependent on individual sgRNAs. The high efficiencies observed would suggest that 
there should be many clones within the population that have a complete knockout of the 
miRNA target. Before exploring clones, the mixed populations were assessed in batch 
culture (Figure 31 A to C) in a culture volume of 5 mL with an initial cell density of 2 x 105 
cells/mL using TPP 50 mL TubeSpin® bioreactor tubes. Cells were grown BalanCD CHO 
Growth A media and samples were taken every 48 hours to assess viable cell density 
and for ELISA to assess productivity. Targeting miR-23a, miR-23b and miR-27b had no 
or neglectable effect on cell growth (Figure 31 A). However, for all three miRNAs a 
significant increase in viability was observed on day 10 of the culture (Figure 31 B). The 
same phenotype was observed as depletion of miR-23a and miR-23b in the sponge 
experiments. Targeting of miR-27a led to a decrease in growth which also had been 
observed in the same cell line using antagomiRs. Depletion of miR-24 on the other hand 
led to a significant increase in growth on day 2, day 4 and day 6. However, elevated 
proliferation presumably led to the decrease in viability on day 10 due to higher nutrient 
demands. Interestingly, titres were significantly elevated as well at all stages of the 
culture (Figure 31 C). Targeting of miR-27b and miR-23a similarly led to increased (not 
significant) IgG levels.  
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Figure 31: Impact of targeting each miRNA of the miR-23 cluster with CRISPR on 
phenotype in mixed population in batch cultures. A) Viable cell density for the depletion of 
miR-23a, miR-23b, miR-27a, miR-27b and miR-24. B) Viability for the depletion of miR-23a, miR-
23b, miR-27a, miR-27b and miR-24. C) Impact on titre IgG density for the depletion of miR-23a, 
miR-23b, miR-27a, miR-27b and miR-24. (* p< 0.05 vs control, ** p < 0.01 vs control, *** p < 
0.001 vs control; n=3). 
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Previous work in our lab using miRNAs mimics or antagomiRs has shown that up- or 
downregulation of individual members of the miRNA cluster can influence the bioprocess 
phenotype of CHO-K1 cells. Transfection of mimics for miR-23a and miR-24 inhibited 
proliferation in CHO-K1 mAb. However, knockdown of miR-24 resulted in enhanced 
growth rates. Transient depletion of miR-27a resulted in a decrease of growth in CHO-
K1 mAb but increased proliferation in a different cell line CHO2B6 showing a cell type 
specific phenotype (Noèlia Sanchez, 2013). To further investigate the impact of a 
complete knockout of a miRNA in a clonal population we used limited dilution cloning to 
generate single cell clones from each mixed population.  
 
4.2.1.2 Identification of clones with complete miRNA knockouts induced by CRISPR/Cas9 
Targeting each miRNA member of the miR-23 cluster was possible using CRISPR/Cas9. 
To investigate if it is possible to identify single cell clones exhibiting a complete knockout, 
limited dilution cloning was used. After two weeks clones were picked, expanded and 
total RNA was isolated. Mature miRNA levels were analysed using TaqMan® microRNA 
assays. For each targeted microRNA a lower abundance was observed. For miR-23a 
and miR-23b a reduction similar to the mixed populations was exhibited (Figure 32 A and 
B). Targeting miR-27a was less effective compared to targeting each other miRNA 
member. This was also observed for isolated single cell clones (Figure 32 C). 
Furthermore, clones derived from the miR-27b targeted mixed population showed either 
very low mature levels or moderate depletion (Figure 32 D). Targeting of miR-24 using 
CRISPR/Cas9 was very effective with all clones showing minimal levels of expression 
(Figure 32 E). We demonstrated that we could find clones with low levels of expression 
of each miRNA member. Some clones showed residual miRNA expression which could 
mean that e.g. expression is not inhibited if only an indel of ±1 bp occurs. Furthermore, 
it remains questionable if an assay for miR-23a will also recognize miR-23b and vice 
versa.  
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Figure 32: Single cell clones derived from CRISPR targeted mixed populations and 
assessment of miRNA expression. A and B) Derived single cell clones from miR-23a and 
miR-23b targeted mixed populations and assessment of mature miRNA expression. C and D) 
Derived single cell clones from miR-27a and miR-27b targeted mixed populations and analysis 
of mature miRNA expression for each clone compared to the control. E) Single cell clones 
derived from a mixed population where miR-24-1 and miR-24-2 was targeted. Mature miR-24 
expresseion was compared to the control. No differentiation between miR-24-1 and miR-24-2 
was possible. (n=3, technicals) 
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Having demonstrated that the isolation of clones exhibiting a significant reduction or 
elimination of mature miRNA is possible, we focused our future experiments on 
investigating the beneficial phenotypesreported in section 4.2.1.1. Most interesting was 
the increase of productivity and growth after targeting miR-24 as the same phenotype 
was exhibited in the sponge decoy experiments as well. Identifying the pathways 
involved might reveal other cell line engineering targets. Furthermore, depletion of miR-
27b led to increased viable cell densities in later stages of the culture. Therefore, 
depletion of miR-27b could be a valuable strategy to improve longevity and improve 
therapeutic protein production.  
 
4.2.2 CRISPR mediated depletion of miR-27b increased viability in late stages of batch 
and fed-batch cultures 
As described in 4.2.1.1, depletion of miR-27b led to increased viability in late stages of 
the culture. The phenotype was assessed in batch as well as fed-batch cultures in a 
culture volume of 5 mL with an initial cell density of 2x105 cells/mL using TPP 50 mL 
TubeSpin® bioreactor tubes or 250 mL Erlenmeyer flasks. Cells were grown BalanCD 
CHO Growth A media and samples were taken every 48 hours to assess viable cell 
density for ELISA to assess productivity. For experiments in fed-batch cultures BalanCD 
CHO Feed1 was used with 10% bolus feeds on day 1, day 5 and day 7. The results for 
both culture formats is shown in Figure 33 A to F. Reduced mature miR-27b levels led 
to an increase in viable cell density in late stages of batch and fed-batch cultures of ~50% 
(Figure 33 A and D). This was also reflected in percentage viability in late stages for day 
10 (batch) as well as on day 12 and 13 (fed-batch) was significantly higher compared to 
the control (~50%) (Figure 33 B and E). The general observation was that miR-27b 
depletion led to slightly reduced IgG titre. However, with extended culture times final 
titres were slightly but not significantly elevated compared to the control for both culture 
formats (Figure 33 C and F). 
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Figure 33: Batch and fed-batch experiments for miR-27b depleted cells led to prolonged cultivation 
times in batch and fed-batch cultures. A and B) Viable cell density as well as viability compared to the 
control. C) MiR-27b depletion resulted in lower IgG levels. However, due to increased longevity final titre on 
day 10 was elevated compared to control. D and E) Viable cell density and viability after depletion of miR-27b 
in fed-batch cultures. F) Levels of expressed mAb compared to the control. (** p < 0.01 vs control, *** p < 
0.001 vs control; n=3). 
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In this study it was demonstrated that the extension of longevity can elevate levels of 
expressed therapeutic protein and makes the depletion of miR-27b potential tool for cell 
line engineering. MiR-27 was first identified as more abundant during hypothermic 
conditions. RNA was extracted and mature miRNA expression was assessed. As 
targeting efficiency of miR-27b was low (4.2.1) in the mixed population (CRISPR) we 
wanted to investigate if the expression remains constant over time. Furthermore, we 
wanted to assess if the passenger strand was targeted as well. Therefore, the expression 
of miR-27b* (miR-27b-5p) was analysed as well in exponential phase (Figure 34 A and 
B). 
 
 
 
 
 
 
Significant depletion of miR-27b was observed in exponential growth (day 3) as well as 
stationary phase (day 5) compared to the control on the same days.  
The passenger strand (miR-27b-5p) exhibited lower abundance as well. Due to changes 
in confirmation of the precursor processing might be impaired after targeting with 
CRISPR/Cas9. As increasing productivity was generally the more interesting phenotype 
the depletion of miR-24 was further investigated. 
Extended viability in this cell line is accompanied by the observation, that targets of miR-
27 in CHO-S Fc (see section 4.1.4) seem to be involved in apoptosis. Therefore, a study 
for DE proteins using mass spectrometry could give further insight in how depletion of 
miR-27 increases viability in late culture stages. 
Figure 34: Expression of miR-27b in exponential/stationary growth phases and miR-27b* expression. 
A) Expression of miR-27b in exponential (day 3) and stationary phase (day 5) of batch cultures. B) Expression 
of miR-27b* in exponential phase (day 3) after targeting with CRISPR. (* p < 0.05 vs control, *** p < 0.001 vs 
control; n=3). 
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4.2.3 CRISPR mediated depletion of miR-24 boosts specific productivity and mAb titre 
in mixed populations of CHO-K1 cells 
As described in 4.2.1.1, depletion of miR-24 led to increased IgG titre on each day of the 
culture due to increased specific productivity. Growth was increased which led to 
reduced culture duration presumably due to higher nutrient demands or waste 
accumulation. It was indicated in the literature that the passenger strand might be 
targeted as well when CRISPR/Cas9 is used. To investigate whether this was the case 
for our cells, we analysed the expression of miR-24-3p and its passenger strand miR-
24-5p using TaqMan® small miRNA assays (Figure 35 A and B). We found, that both 
mature miR-24-3p levels and miR-24-5p were significantly downregulated. The original 
sgRNA was designed to target the seed region of miR-24-3p. This demonstrated that 
even when targeting miR-24-3p the cellular levels of the passenger strand miR-24-5p, 
was affected similarly. To assess if incorrect processing of the precursor was the cause 
of this simultaneous decrease of both miRNAs, the expression of pre-miR-24 was 
measured using specific primers by RT-qPCR. Pre-miR-24 was significantly more 
abundant compared to the control suggesting an inhibition of its processing due to 
changes in Drosha or Dicer recognition sequences (Figure 35 C). MiR-24 is located 
proximal to its cluster members and we were concerned about possible effects on the 
other miRNAs. As a result, we analysed the expression of miR-23a, miR-23b, miR-27a 
and miR-27b in cells where miR-24 was targeted. Targeting miR-24 had no effect on the 
abundance of other members of the cluster (Figure 35 D) which was evident based on 
comparable Ct values. However, the Ct of miR-24 was higher compared to the control 
which indicated lower expression. To analyse the effect of miR-24 depletion, cells were 
seeded with with an initial cell density of 2x105 cells/mL using TPP 50 mL TubeSpin® 
bioreactor tubes and a culture volume of 5 mL. Cells were grown BalanCD CHO Growth 
A media and samples were taken every 48 hours to assess viable cell density and for 
ELISA to assess productivity. Depletion of miR-24 led to a significant increase in growth 
on day 2, day 4 and day 6 (Figure 35 E). On day 8 significantly reduced viable cell density 
was observed compared to the control. This was reflected in viability (%) which started 
to decline earlier (day 8) when compared to the control (Figure 35 F). This reduction in 
viability could presumably be related to increased nutrient demands or faster waste 
accumulation in cultures with faster growth/enhanced productivity. And as before the titre 
appears to be negatively impacted perhaps due to the low viability on day 10 and an 
eventual release of proteases into the media.  
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Figure 35: Depletion of miR-24 using CRISPR/Cas9 led to increased producitivity and 
growth in batch cultures. A and B) Expression of miR-24-3p and miR-24-5p after targeting. 
C) Pre-miR-24 expression compared to control. D) Expression of proximal located members 
of the miR-23 cluster. E) Viable cell density after knockout of miR=24 compared to control F) 
Viability compared to control population. G and H) IgG levels and specific productivity after 
depletion of miR-24.  (* p < 0.05 vs control, *** p < 0.001 vs control; n=3   
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IgG levels were significantly elevated from day 2 onwards to day 8. Day 10 also exhibited 
increased titre but not significantly. The increase was due to also increased specific 
productivity on day 2 and day 4 compared to the control culture (Figure 35 G and H). 
Reduced levels of mature miRNA as well as passenger strand led us to question which 
miRNA was responsible for the observed effects. Therefore, miRNA mimics for miR-24-
3p, miR-24-5p and a control mimic were transiently transfected into the parental CHO-
K1 mAb expressing cell line (Figure 36 A to C). After transfection no effect on day 2 was 
observed for all mimics. However, four days post-transfection, growth of cells transfected 
with miR-24-3p mimic was significantly reduced compared to the control. An effect on 
cell growth was also observed on day 4 for control and miR-24-5p overexpression 
compared to transfection reagent only (Figure 36 A). Overexpression of miR-24-3p and 
miR-24-5p was quantified and an increase of ~60 fold for miR-24-3p and ~650 fold for 
miR-24-5p was seen. The general abundance of miR-24-5p is very low (Ct ~28) 
compared to miR-24-3p (Ct ~18) which explained the large fold change after transfection 
of mimics (Figure 36 A).  
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To investigate further if the phenotype is observed at the clonal level as well, clones were 
isolated and assessed in batch cultures. Six clones were selected out of 31 screened for 
miR-24 and which exhibited low miR-24 expression as well as showed fast proliferation 
rates (Figure S 9). All 6 clones showed increased growth behaviour compared to the 
control population (mixed population) and reached the peak cell density approximately 
two days earlier (Figure 37 A). Similar, to miR-24 depletion in a mixed population the 
culture duration and viability on day 8 and day 10 were reduced (Figure 37 B).  
 
 
Figure 36: Transient transfection of miR-24 mimics and resulting phenotype in CHO-
K1 mAb. A) Growth compared to control for overexpression of miR-24-3p and miR-24-
5p on day 2 and 4 after transfection. B and C) Overexpression of miR-24-3p as well as 
miR-24-5p using miRNA mimics (** p < 0.01 vs control; n=3) 
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Figure 37: MiR-24 depleted single cell clones showed increased growthrates at the 
expense of productivity. A and B) Viable cell density and compared to the control mixed 
population. Viability was reduced on late stages of the culture. C) IgG levels for each clone 
compared to the control population. (* p < 0.05 vs control, ** p < 0.01 vs control; *** p< 0.001 vs 
control: n=3) 
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The titres achieved showed no improvement but a considerable variation for all six 
clones. As clones were selected based on growth profiles the selection was biased 
purely on growth and not on productivity. Furthermore, it could come down to clonal 
effects as six clones represent a very limited panel.  
To investigate clones further for expression of miR-24-3p, miR-24-5p and pre-miR-24 we 
isolated total RNA from each clone. Expression of both mature miRNAs was quantified 
using TaqMan® miRNA assays. The ∆Ct levels were higher compared to the control 
which indicates lower abundance of miR-24-3p as well as miR-24-5p (Figure 38 A). 
Furthermore, levels of miR-24-5p seemed to be lower as part of targeting of miR-24-3p 
by CRISPR.  
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To investigate if pre-miR-24 was also accumulated in clones as previously observed for 
the mixed population (section 4.2.3), its levels were analysed using RT-qPCR. It was 
shown, that the expression in Clone 2 and 3 was significantly lower compared to the 
control (Figure 38 B). Clone 1, 5 and 6 showed an accumulation of pre-miR-24. Clone 4 
showed only a mild increase in the miR-24 precursor. Clone 4,5 and 6 were analysed by 
indel sequencing and it was shown that for clone 5 and 6 no wildtype sequence was 
Figure 38: Expression of miR-24-3p, miR-24-5p and pre-miR-24 in all single cell clones. A) 
Expression of miR-24-3p as well as miR-24-5p was displayed in ∆Ct values. Higher values indicate a 
lower abundance. B) Pre-miR-24 abundance for clones 1, 4, 5 and 6. Clone 2 and 3. C) NGS for indels 
for clones 4, 5 and 6. (* p < 0.05 vs control, ** p < 0.01 vs control, *** p < 0.001 vs control; n=3). 
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detectable for miR-24-1 and miR-24-2 which indicates a clonal origin (Figure 38 C). For 
clone 4 no wildtype sequence was detectable for miR-24-1 however, only 22% of miR-
24-2 reads showed insertions or deletions. This could mean that clone 4 did not originate 
from a single cell clone. Furthermore, the observation that pre-miR-24 is only slightly 
enriched, showed that pre-miR-24 processing is only partially impaired and that at laeast 
one allele of each paralogue is still fully functional and expressed.  
Due to the mechanism of a miRNA action, targets of miR-24 should be upregulated after 
depletion. To investigate if target mRNAs were upregulated we assessed the expression 
of c-Myc and CDKN1B in mixed depleted population as well as in three isolated clones 
(Clones 1, 2 and 3). Both were shown to be direct targets of miR-24 and are important 
regulator genes in terms of cell cycle progression, growth and showed important roles in 
cancer progression (Figure 39). The expression c-Myc as well as CDKN1b was 
signifcanlty higher in mixed population which indicates reduced levels of miR-24. For all 
three assessed clones the expression of c-Myc seemed inconclusive but CDKN1b was 
more abundant.  
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It is a commonly observed phenomenon that mammalian cells in cell culture including 
cancer cells use aerobic glycolysis instead of the more efficient mitochondrial based 
oxidative phosphorylation for energy production. Glycolysis and subsequent conversion 
of pyruvate to lactic acid decreases the pH of the media and measuring the extracellular 
acidification rate (EACR) is a good indicator for the assessment for cells undergoing 
enriched glycolysis. EACR can also be an indicator for higher CO2 production due to 
increased citric acid cycle activity. Anaerobic glycolysis does not require oxygen for the 
conversion. Oxidative phosphorylation however, uses electron acceptors such as 
oxygen for the synthesis of ATP. Therefore, measurement of the oxygen consumption 
rate (OCR) and EACR can provide information of the preferred metabolic process utilised 
by cells. As the phenotype of miR-24 depleted cells demonstrated enriched growth and 
increased specific productivity it could be assumed that energy demands are increased 
leading to higher rates of EACR or OCR. 
Assessing OCR and EACR for miR-24 depleted mixed population and all six derived 
clones showed that OCR and EACR were reduced compared to the non-targeted control 
(Figure 40). On the contrary the control showed higher OCR and EACR compared to 
miR-24 depleted mixed population and all six clones. Having observed a higher 
productivity or enhanced growth would indicated higher demands for nutrients and 
Figure 39: Expression of validated mRNA targets of miR-24 after CRISPR/Cas9 mediated depletion 
in CHO-K1 mAb mixed population. As validated targets c-Myc as well as CDKN1B were chosen and 
assessed for expression using RT-qPCR. Total RNA was extracted in exponential growth phase for mixed 
population and clone 1,2 and 3, reverse transcribed and specific primers of c-Myc and CDKN1B were used 
to assess expression. Expression was compares to beta-actin which served as endogenous control. (* p < 
0.05 vs control, ** p < 0.01 vs control; n=3). 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
137 
eventually an increase in OCR/EACR. In fact, the production of lactic acid or CO2 (EACR) 
remained low compared to the control. The metabolic potential which describes the 
ability to meet an energy demant using glycolosis or oxidative phosphorylation however, 
seemed similar for EACR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Depletion of miR-24 using sponge decoys in CHO-S Fc showed significant changes on 
glycosylation of the recombinant expressed protein. Hence, we wished to investigate if 
CRISPR/Cas9 mediated depletion of miR-24 resulted in changes in glycosylation on the 
expressed mAb. 
Figure 40: Impact of depletion of miR-24 on oxygen consumption rate as well as 
extracellular acidification rate. Both were measured using Seahorse FX analyser using a 
cell energy phenotype test. Stress was induced by small molecule-based blocking of either 
glycolysis or oxidatative phosphorylation. A) OCR baseline and stressed conditions for miR-
24 depleted mixed population and clones. B) Extracellular acidification rate baseline and stressed 
conditions for miR-24 depleted mixed population and clones. C) Metabolic potential for stressed 
OCR and EACR of miR-24 depleted mixed population and clones.  
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4.2.3.1 Impact on glycosylation due to the depletion of miR-24 using CRISPR/Cas9 
To investigate if the depletion of miR-24 had an impact on glycosylation, 50 mL of cell 
culture supernatant was taken and purified using protein-A chromatography as described 
in 3.3.2 (Figure 41 A). Samples were analysed for changes in glycosylation pattern using 
LC/LFR-MS/MS as described in 3.3.3 and the work was performed by Dr. Sara Carillo 
(NIBRT). Figure 41 B shows all identified glycoforms regarding their intensity and 
retention time in the chromatogram. Figure 41 C and D shows differential abundance of 
glycosylation. Each dot on the line represents a different species e.g. M3, FM3 etc. It 
was observed that all mannose species were downregulated due to CRISPR mediated 
depletion of miR-24. When compared to the Fc fusion depletion of miR-24 using sponges 
resulted in higher abundance of mannose species with several genes being associated 
with it (compare 4.1.4.1). Proteomic profiling for CRISPR mediated depletion of miR-24 
(4.2.3.2) showed that several genes involved in conversion of high mannose species to 
complex N-glycans were downregulated. These genes were alpha-mannosidase 2 
(MAN2A1), alpha-mannosidase 2C1 (MAN2C1) and GDP-mannose 4,6 dehydratase 
(GMDS). Terminal sialic acid species was inconclusive with a trend to be less abundant 
with no obvious related genes being differential expressed.  
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Figure 41: Impact on glycosylation after CRISPR/Cas9 mediated depletion of miR-24 on 
expressed mAb. A) The expressed IgG was protein A purified out of conditioned media and analysed 
using SDS-PAGE. B) Chromatogram for retention time and intensity of glycospecies. C and D) Each 
point represented a different species of glycosylation for mannose and terminal sialic acid e.g. M5, 
FM3 etc.  
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Lower levels of mannose species could potentially have a beneficial effect on the IgG 
function as lower levels might be associated with increased ADCC. To furthermore 
investigate the proteins involved in the phenotype observed after targeting miR-24 using 
CRISPR/Cas9, proteomic profiling was the method chosen. As mentioned earlier we 
identified proteins which were potentially involved in lower abundance of mannose 
species.  
 
4.2.3.2 Depletion of miR-24 in CHO-K1 mAb leads to an upregulation of ribosomal RNA 
biogenesis and the translational machinery resulting in a high productivity 
phenotype 
After targeting miR-24 using CRISPR/Cas9, increased productivity and growth was 
observed as it was after sponge mediated depletion of miR-24 in several other cell lines. 
Consequently, we wanted to investigate which proteins were dysregulated and were 
potentially involved indriving this phenotype. Depletion of miR-24 using CRISPR resulted 
in 352 (Anova value < 0.05, fold-change >1.20, 2 or more peptides) more abundant 
proteins. Moreover, 119 had a fold-change higher 1.25 and only 15 showed a fold-
change higher than 1.5. For pathway analysis we used proteins with a fold-change of 
over 1.25. A total of 5098/5093 proteins (control/sgRNA-miR24) was identified before 
applying filters for DE and statistical analysis (Figure 42 A).  
To identify which proteins were potential targets of miR-24, predictive mRNA:miRNA 
analysis was used (miRWalk2.0). It was demonstrated that out of 119 more abundant 
proteins 77 were predicted targets of either miR-24-3p or miR-24-5p. Furthermore, 5 
proteins were also validated targets (Figure 42 B). Out of 77 predicted targets, 63 were 
targets of miR-24-3p and 24 being targets of miR-24-5p (10 are shared between both). 
This makes miR-24-3p the more prominent miRNA but showed that miR-24-5p plays its 
role as well. With over ~60% being predicted targets of miR-24 we were confident in the 
lists generated.  
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Figure 42: Summary of proteomic profiling for targeting miR-24 using CRISPR/Cas9. A) A total of 
5098 and 5093 unique IDs were identified for both groups. A total of 355 proteins were DE with 119 over 
1.25-fold and 15 >1.5-fold. B) Out of all 355 DE proteins 67% were predicted or validated targets of miR-
24-3p or miR-24-5p.   
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Figure 43: Proteomic profiling combined with pathway analysis for the depletion of miR-24 using 
CRISPR/Cas9. A) Qualitative and differential expression data after depletion of miR-24 using an Anova-
value < 0.05, fold-change >1.20 fold and identification of more than 2 peptides. B) Analysis of predicted 
and validated targets for miR-24-3p and miR-24-5p. Approximately 60% of all upregulated proteins were 
targets of either miR-24-3 or miR-24-5p. C to G) Proteins upregulated seemed to be involved in translation, 
protein folding, rRNA processing and assembly of ribosomal subunits.  
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To investigate which pathways were overrepresented in the list of DE proteins, pathway 
analysis was used (Figure 43 C to G). Several more abundant proteins are involved in 
pre-rRNA and rRNA-processing including BOP1, WDR12 and PES1 which are members 
of the PeBoW complex (Figure 43 C). Interestingly, proteins involved in the assembly of 
ribosomal subunits were also upregulated as well including RACK1 and EIF6 (Figure 43 
D). Furthermore, TUFM and GFM1, critical proteins involved in recruiting of aminoacyl-
tRNAs and removal of deacetylated tRNAs, were more abundant (Figure 43 E). 
Upregulation of TUFM and GFM1 is accompanied by several tRNA synthetases of i.e. 
AARS, GARS, IARS and YARS (Figure 43 G). Increased productivity may also activate 
the unfolded protein response (UPR) which was upregulated. Several proteins were 
upregulated including RUVBL2, LONP1, HSPD1 and DNAJ3A (Figure 43 F). 
Interestingly, similar pathways were upregulated in CHO-S Fc expressing cells which 
were miR-24 depleted using sponges (section 4.1.4.2).  
The enrichment of particular biological processes is shown in Table 8.  
 
 
 
 
 
 
 
 
 
 
 
Table 8: Pathway analysis for depletion of miR-24 using CRISPR/Cas9. 
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To create a study which not only involved proteomic profiling but also transcriptomics, 
RNA sequencing was used. The purpose was to investigate further which genes and 
proteins are influenced by depletion of miR-24 and to increase the confidence in our lists 
generated by proteomics. Increased confidence might also help in the selection of cell 
line engineering targets. Therefore, total RNA was isolated with samples taken during 
exponential growth phase in biological triplicates. RNAseq using poly-A enrichment was 
used to allow the removal of ribosomal RNA. After fragmentation and addition of linkers 
the sample were run on an Illumina HiSeq 2500 instrument. For differential expression 
analysis DESeq2 was used and Wald test to generate p-values as well as log2-fold 
changes. Library preparation, sequencing and analysis was performed by Genewiz.  
On average samples showed total reads between 46,948,472 and 55,899,929 with good 
quality scores (>28). For all reads, ~71-78% were mapped to the reference genome 
(Figure 44 A). Raw dispersion values were fitted to a common mean to improve testing 
accuracy.  
Overall, 9810 genes were differentially expressed using no statistical restrictions. Using 
a p-value <0.05 showed 525 genes which are significantly differential expressed without 
applying log2 fold change. Out of 525 DE genes, 200 showed a higher abundance and 
325 showed lower expression compared to the control. The corresponding heatmap 
showed a good distribution of abundances between the genes and samples (Figure 44 
C). Applying a log2 fold change of 0.58/-0.58 showed that 32 genes were upregulated 
by 1.5-fold and 92 were 1.5-fold less abundant.  
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Figure 44: RNAseq data summary for the depletion of miR-24 using CRISPR/Cas9 in CHO-K1 mAb 
and predicted targets. A) Total and mapped reads in comparison with the CHO reference sequence. B) 
Heatmap of abundances of all 525 DE genes showed clear distribution for most genes. C) Predicted 
targets of miR-24-3p and miR-24-5p as well as shared genes. As DE was considered every gene with a 
fold change > ±1.50 and anova > 0.05.  
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We compared both lists obtained from proteomic profiling and RNAseq to investigate if 
we could relate same pathways previously identified (4.2.3.2), keeping in mind that 
transcription may or may not be reflected in protein expression. Comparing all 525 DE 
genes with 355 DE proteins showed that only 17 genes are common between our 
proteomics and transcriptomics data (Figure 45).  
 
 
 
 
 
 
 
Figure 45: Comparison of lists for DE proteins generated using proteomic profiling and RNAseq for 
CRISPR/Cas9 mediated depletion of miR-24 showed only a limited overlap. Overlap of DE genes and 
DE proteins showed that only 17 matched. Pathway analysis of 17 matched proteins/genes showed strong 
evidence for regulation of rRNA processing, tRNA processing and amino acid activation indicating 
involvement in translation.   
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However, the 17 common targets showed that miR-24 is involved in regulating genes in 
pathways for rRNA processing, tRNA processing and amino acid activation. The same 
pathways were upregulated in CHO-S Fc as well as CHO-K1 mAb (sponge mediated 
depletion of miR-24) providing a strong evidence that miR-24 is involved in regulation of 
ribosomal biogenesis as well as translational regulation (Figure 45 B).  
Three genes which were demonstrated higher abundance in all our lists were highlighted 
as potential engineering targets: TUFM, GFM1 and HSPD1. TUFM and GFM1 were also 
predicted miR-24 targets.  
 
4.2.4 Multiplex genome engineering of miRNAs using CRISPR/Cas9 to target two 
miRNAs simultaneously 
To investigate if it is possible to target two miRNAs at the same time or to delete a specific 
sequence within the miR-23 cluster we designed our vector to express two different 
sgRNAs which has been used by other laboratories to delete larger genomic sequences. 
Previous results demonstrated that the deletion of the whole miR-23 cluster may lead to 
a beneficial phenotype. We proposed the deletion of the whole cluster by using CRISPR 
to target up- and downstream of the cluster (compare section 1.3.3). To clone a second 
sgRNA into the same vector we designed primers to amplify the region which includes 
the U6 promoter, the integration site for the gRNA as well as the scaffold, including 
termination site. As a vector we chose our already proven plasmid which expressed 
sgRNA-miR-24 to target miR-24. To clone the second sgRNA we amplified the U6 
promoter, sgRNA, scaffold and terminator sequence for either miR-23a or miR-23b which 
were already cloned and proven to be functional into PX459. Primers including restriction 
enzyme sites for XbaI as well as KpnI were used to ensure directional ligation of the PCR 
product. Insertion was confirmed using standard Sanger sequencing. Figure 46 A shows 
the cloning strategy for the expression of two sgRNAs simultaneously. After successful 
ligation was confirmed the plasmids were amplified and transfected together with the 
control into CHO-K1 mAb expressing cells. It was demonstrated that miR-23a as well as 
miR-24 levels were significantly reduced upon targeting both with one plasmid (Figure 
46 B). Furthermore, mature miRNA expression of miR-23b and miR-24 was significantly 
reduced compared to the control (Figure 46 C).  
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By targeting miR-23 and miR-24 we assumed miR-27 located in the middle would be 
deleted. Mature levels of miR-27a and miR-27b were analysed however no changes in 
mature levels were evident.  
 
 
 
 
Figure 46: Cloning strategy for targeting more than one miRNA at the same time. A) A second 
sgRNA was cloned into the same vector including U6 promoter, sgRNA scaffold as well as 
termination sequence. B and C) The sgRNA for miR-23a as well as miR-23b were cloned into the 
vector already expressing the sgRNA for miR-24. Mature miRNA expression was analysed using 
TaqMan® miRNA assays. (** p < 0.01 vs control, *** p < 0.001 vs control; n=3). 
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Targeting miRNAs using CRISPR/Cas9 
Sponge decoy technology has been demonstrated to be a viable tool for miRNA 
engineering. However, certain drawbacks i.e. the necessity for a reporter gene led us to 
another strategy using the CRISPR/Cas9 system. Advantages are for example the ease 
of use and the possibility for transient use without integration of plasmids into the host 
genome. In CHO cells it has not been published that CRISPR can be used to target 
miRNAs and therefore we needed to demonstrate its utility. We designed sgRNAs to 
target the seed region of the functional miRNA (-3p) for each member of the miR-23 
cluster. It was also possible to target miR-24 with only one sgRNA. The reduction of each 
miRNA member of the cluster was observed compared to the control (Figure 29). 
Furthermore, NGS data as well as data generated from Sanger sequencing and 
Surveyor® assays indicated successful targeting and generation of indels in the seed 
sequence of every miRNA member (Figure 28). We additionally screened single cell 
clones to investigate if it was possible to obtain clones with complete knockouts of the 
miRNA target. We found clones for every miRNA target that showed a significant 
reduction of mature miRNA expression compared to the control (Figure 32). As a 
comparison to previous work in the same cell line performed by Dr. Paul Kelly and Dr. 
Noelia Sanchez, we analysed the phenotype which was shown to be very comparable 
to the sponge decoy approach (Figure 31). In addition, we found another interesting 
phenotype which has not been demonstrated using sponge decoy technology: depletion 
of miR-27b led to prolonged culture lengths in batch as well as fed-batch cultures. 
However, titres were compromised but due to longer cultures, elevated IgG levels were 
observed.  
Similarly, to the depletion of miR-24 using sponge decoy technology in CHO-K1 mAb a 
significant increase in IgG levels was observed when miR-24 was targeted with 
CRISPR/Cas9. Additionally, growth was boosted which has not been demonstrated 
using a decoy for miR-24. This phenotype was especially interesting and we followed up 
with several methods to investigate the molecular impact of the miR-24 depletion. We 
performed label-free HPLC-MS/MS for proteomic profiling as well as transcriptomic 
profiling using RNAseq. We demonstrated that several genes and proteins involved in 
pre-rRNA biogenesis, ribosome maturation, translation, tRNA activation as well as 
unfolded protein response showed higher abundance. 
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Lastly, we investigated if two miRNAs can be simultaneously targeted using a multiplex 
approach to investigate if we can delete larger sequences in the genome. We used a 
strategy by expressing two sgRNAs which were designed to target up- and downstream 
the miR-23 cluster. It was demonstrated that miR-23 and miR-24 could be targeted but 
miR-27 seemed to be unaffected. Local indels might inhibit miR-23 and miR-24 and 
another strategy to delete the whole cluster should be discovered in the future.  
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4.3 Establishing a platform for genome-wide “loss of gene function” studies in 
Chinese Hamster Ovary cells using a CRISPR/Cas9 library 
CRISPR/Cas9 can be used efficiently to target genes and miRNAs to generate 
gene/miRNA deficient cell lines. A further application of CRISPR/Cas9 is the 
implementation of genome wide “loss of gene function” studies as previously reported 
by several research groups (Agrotis & Ketteler, 2015; Shalem et al., 2015; T. Wang et 
al., 2014). Based on using a library of sgRNA this approach allows the targeting of all 
genes in the genome which enables the screen for gene-function. Our library contained 
87,897 different sgRNAs, targeting 19,150 mouse genes, which can be purchased as a 
lentiviral delivery system. For the library we chose to transduce a CHO-K1 cell line 
expressing a mAb and human codon optimised spCas9. The most critical step for this 
approach is to guarantee maximum coverage of the library but also to ensure a low 
number of integration events - ideally one copy per cell. However, one beneficial feature 
of CHO-K1 cells as recombinant protein production hosts is their resistance to viral 
infections. The aim of this project was to attempt to identify genes which are responsible 
for beneficial phenotypes created after exposure of bioprocess relevant conditions i.e. 
high osmolality, ammonia, lactate. Furthermore, a screen for genes linked to a high 
producing phenotype was conceived. The basic premise of the approach is that under 
certain environmental conditions certain genes can confer a survival advantage and 
others may compromise survival – essentially the Darwinian theory of “Survival of the 
fittest”. By sequencing the “surviving” cells in a given stress we expect to find some 
sgRNAs enriched (loss of their target gene is beneficial) and others depleted or lost (loss 
of the target gene is detramental). Many more sgRNAs would be expected to remain 
unchanged compared to the original library.  
Preliminary data showed, that it is possible to reduce integration events to three per cell 
using diluted lentiviral particles which would be sufficient to use the library. Nevertheless, 
the transduction efficiency was shown to be very low and would not ensure a multiple 
fold coverage of the library. To overcome that problem different transfection methods 
were considered and applied to investigate the effect on integration events. 
Nucleofection seemed to be the most suitable method to ensure high efficiency 
combined with low copy numbers of the plasmid. Figure 47 summarises the workflow for 
the CRISPR library. 
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The first step was to test whether the library can be delivered using a lentiviral delivery 
system.  
 
 
 
 
Figure 47: Workflow for the introduction of the CRISPR/Cas9 sgRNA library in CHO. Plasmids of 
the sgRNA library are packed into a lentiviral system which allows the integration of only 1-2 copies per 
cell. The libray did not express Cas9 which required the generation of a Cas9 expressing cell line before 
the introduction of the pooled library. After integration of the library, the mixed population was exposed 
to stress conditions to enrich for subpopulations in which the knocout of a gene led to survival or better 
adaption. Guide RNAs which were enriched or depleted were identified using NGS.  
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4.3.1 Amplification of the CRISPR/Cas9 library and determination of the optimal 
delivery method 
To ensure a sufficient level of amplification and coverage of every sgRNA, the plasmid 
library was transformed into highly electro-competent E. coli DH5α-E cells. As 
theoretically not every plasmid is amplified with the same efficiency the cells were grown 
for 16 hours in 2xTY rich nutrient media at 30°C under ampicillin selection. The 
transformation efficiency was calculated using pUC19 and was shown to be 1.43x1010 
cfu/µg DNA. The amplified sgRNA-library was isolated and HEK293T cells were co-
transfected with the sgRNA-library as well as two lentiviral packaging plasmids 
containing gag, pol and env genes using Lipofectamine®2000. An EGFP construct was 
also co-transfected into HEK293T cells to create a second set of lentiviral particles as a 
control. The lentivirus containing media was harvested 48/72 hours post transfection, 
filtered and concentrated by centrifugation of the supernatant for 2.5 hours at 20,000 g. 
For the introduction of the sgRNA-library in CHO-K1 mAb expressing cells it was 
necessary to determine the optimal multiplicity of infection for lentiviral transduction of 
the library. This is essential to ensure an optimal ratio between coverage of the library 
but also to integrate only one or two sgRNA per cell.  
CHO-K1 mAb expressing cells were transduced with both the EGFP and sgRNA-library 
lentiviral particles using serial dilutions (0, 2, 4, 6, 8, 10). Cells transduced with the 
sgRNA-library were analysed for BFP expression using flow cytometry 48 hours post-
transduction. Cells transduced with the EGFP-lenti were analysed using Guava 
easyCyte with ExpressPlus programme on the GuavaTM benchtop cytometer. As a 
control the sgRNA library control was transfected and cells were selected using 10 µg/ml 
puromycin (Figure 48 A and B).  
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Transduction using the EGFP construct containing lentiviral particles was more efficient 
(~22%) compared to the sgRNA-library lentivirus (~14%) using no dilution of the 
lentivirus containing supernatant. The transduction efficiency decreased as the 
supernatant was diluted. Higher dilution of the sgRNA-library lentivirus (6, 8 and 10) led 
to almost no BFP signal. Given that no dilution led to the highest amount of BFP signal, 
CHO-K1 mAb cells were transduced again with the sgRNA library and selected with two 
different concentrations of puromycin (10 µg/mL and 20 µg/mL) over a period of two 
weeks. Genomic DNA was isolated and a standard curve was generated using different 
dilutions of sgRNA-library plasmid spiked with genomic DNA imitating actual sample 
Figure 48: Lentiviral transduction of sgRNA library showed low transduction efficiency and 
high number integration events. A) The sgRNA library as well as a GFP control plasmid were 
packed into a lentiviral delivery system and CHO-K1 mAb was transduced with different dilutions. 
GFP or BFP intensity were analysed using FACS B) Postive BFP control generated by PEI based 
transfection. C) CHO-K1 mAb was transduced and selected with either 10 µg/mL or 20  µg/mL 
puromycin. Number of intergrated copies was analysed using PCR. 
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conditions for qPCR. The puromycin resistance gene was amplified which is a fusion 
with BFP. Using the standard curve, the copy number was calculated assuming diploidy 
and 4.9075 pg of DNA per cell (Xu et al., 2011). It was shown that no dilution of the 
sgRNA-library lentivirus led to ~4 integration events per cell regardless of the amount of 
puromycin used for selection (Figure 48 C). 
To knockout only one gene at a time it is crucial that only one or two sgRNAs are 
integrated per cell. This ideally goes along with a several fold coverage of the library. To 
investigate if lower integration events could be achieved, the same cells were transduced 
with different dilutions of the virus and assessed for integration events using qPCR after 
selection with 5 µg/mL puromycin. Cells were transduced using the following dilutions of 
sgRNA-library lentivirus: 3. 6, 9, 12, 16 and 20. To investigate further if other transfection 
methods would be suitable we used a PEI based transfection reagent TransIT-X2® 
(Mirus Bio LCC) as well as electroporation. For PEI-based transfections a ratio between 
plasmid DNA/transfection reagent of 1:1 was used. The following amounts of DNA were 
used to transfect 1x106 cells: 5, 2.5, 1, 0.5, 0.25 and 0.1 µg. For Nucleofection the 
following amounts were used to transfect 1x106 cells: 2, 1 and 0.5 µg. After selection the 
DNA was isolated and amplified using primers targeting puromycin and compared to a 
standard curve (Figure 49 A to C). The results indicated that dilution of the lentivirus 
following selection for 2 weeks had no effect on the number of integrations per cell 
suggesting that there may be subpopulations which are susceptible to transduction by 
lentiviral particles and others are resistant. Furthermore, the small number of cells 
surviving selection indicated that the library coverage would be severly compromised 
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(Figure 49 A). PEI based transfection resulted in a high number of copies per cell 
depending on the amount of DNA used (Figure 49 B). The most promising results for 
amount of integrations per cell were achieved using Nucleofection. Using 0.5 µg resulted 
in two copies per cell whereas 1 and 2 µg showed about 7 copies per cell (Figure 49 C). 
 
 
 
 
Figure 49: Delivery of the sgRNA library using lentivirus, PEI-based transfection and Nucleofection 
as well as resulting integrations per genome and cell. Cells were selected using 10 µg/mL puromycin 
over a period of two weeks. A) Lentivirus containing supernatant was diluted before added to the culture. 
D) PEI based transfection reagent and different concentrations of library plasmid. C) Nucleofection 
combined with low concentrations of plasmid DNA and a high viability program (n=2).  
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Lentiviral transduction as well as PEI based transfection were demonstrated to be 
unsuitable for the delivery of the sgRNA library. We aimed for one to two copies per cell 
which can be achieved using 0.5 µg plasmid DNA for electroporation.  
A further challenge for the integration of the library was that most commonly used Cas9 
plasmids use the puromycin resistance gene for selection of transfected populations. 
The sgRNA library contained a puromycin resistance marker as well and did not encode 
Cas9. Therefore, the puromycin resistance gene had to be exchanged on our vector to 
another resistance gene before generating a cell line stably expressing Cas9. 
For our experiments we wanted to use the same plasmid which was used for 
experiments used in section 4.2.1 for depletion of miRNAs. Exchange of the hygromycin 
b phosphotransferase (hph) gene was our preferred option as a selection marker. The 
cloning strategy for the exchange of the pac gene to hph is displayed in Figure 50 A. A 
plasmid with correct orientation of the hph gene was chosen and transfected into CHO-
K1 mAb then selected using 800 µg/mL hygromycin b. Optimal selection conditions were 
established in a separate experiment. Besides Sanger sequencing, Cas9 function was 
confirmed by transfecting a test sgRNA and confirmation of targeting by Cas9. The 
sgRNA library is based on a plasmid called pklv-U6gRNA(BbsI)-PGKpuro2ABFP (short 
pklv). This vector was utilised as our control plasmid and furthermore, can be used to 
express a sgRNA without Cas9. To investigate the function of our Cas9-2A-hyg plasmid, 
a sgRNA targeting miR-24 was cloned into pklv. Targeting miR-24 with this sgRNA 
sequence was very effective in section 4.2.1. The pklv-sgRNA-miR-24 plasmid was 
transfected into CHO-K1 mAb stably expressing Cas9-2A-hyg and selected using 10 
µg/mL puromycin over a period of two weeks. The abundance of miR-24 was significantly 
reduced compared to the control (pklv only) proving Cas9 function (Figure 50 B). 
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After Cas9-2A-hyg function was confirmed, limited dilution cloning was used to isolate 
single cell clones which were consequently assessed for growth and productivity. This 
step was important to select a clone which was properly performing i.e. similar to the 
parental CHO-K1 mAb and to generate a baseline for future experiments.  
 
 
Figure 50: Cloning strategy for exchanging the puromycin resistance gene to hygromycin in 
PX459 and test for function. A) Exchange of the pac gene to hph was performed using specific 
primers for hph under addition of EcoRI restriction sites including the 2A self-cleavage sequence. 
Correct ligation and if sequence was in frame was analysed using Sanger sequencing. B) Function of 
Cas9-2A-hyg was confirmed using a sgRNA expression vector (pklv). A sgRNA for miR-24 was cloned 
into pklv and transfected as well as selected. Expression of miR-24 was subsequently analysed to 
prove Cas9-2A-Hyg function. Statistical significance was calculated using standard student’s t-test (*** 
p < 0.001 vs control; n=3). 
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4.3.1.1 Generation and characterisation of a CHO-K1 mAb cell line stably expressing Cas9  
Limited dilution cloning was used to isolate single cell clones from the CHO-K1 mAb 
Cas9-2A-hyg expressing stable pool. The characterisation of single cell clones was 
necessary to start with a baseline cell population which performed similar to the parental 
cell line before introducing the CRISPR library. A total of ten clones were isolated and 
cultivated in CHO-SFM II media. Clone performance was assessed in batch cultures in 
a culture volume of 5 mL with an initial cell density of 2 x 105 cells/Ml and samples were 
taken every 48 hours to assess viable cell density as well as for ELISA to assess 
productivity. 
As expected various growth patterns were exhibited by all ten clones in batch cultures 
(Figure 51 A and B). Clone 2, 4 and 7 performed worst compared to other clones. Growth 
behaviour of all other clones was quite comparable with the original mixed population. 
Different growth pattern was also reflected in viability where clone 2, 4, 7 and 9 
demonstrated lower percentages. Furthermore, IgG titres showed differences on day 4 
and 6 for most clones (Figure 51 C). With an average IgG level of 10 mg/L to 20 mg/L 
the productivity was quite low compared to prior experiments with that cell line. Clone 4, 
6 and 8 performed best overall and were further expanded as well as cryopreserved for 
further experiments. Besides growth, Cas9-2A-hyg function was also important. The 
same control plasmid expressing a sgRNA for miR-24 (pklv-sgRNA-miR-24) was used 
to investigate targeting efficiency and successful indel generation. All clones were 
transfected with pklv-sgRNA-miR-24 and selected using puromycin over a period of two 
weeks. Mature miR-24 expression was analysed using TaqMan® miRNA assays and 
compared to the control vector (pklv only) (Figure 51 D). 
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Figure 51: Characterisation of clones expressing Cas9-2A-hyg for growth and titre as well as Cas9 
function. A and B) Viable cell density and viability for all ten derived clones showed differences in growth 
behaviour. C) IgG expression on day 4 and day 6. IgG levels averaged between 10mg/L to 20 mg/L. D) 
Cas9-2A-hyg function was analysed and showed that Cas9 is targeting miR-24 effectively in all clones 
(n=1).   
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Cas9 was fully functional in all ten clones and miR-24 expression was significantly 
reduced compared to the control. After assessing Cas9 function and performance we 
decided to use CLONE 8 for all further experiments regarding the CRISPR library. Clone 
8 was chosen as performing best of the panel of clones and closest to the parental mixed 
population. 
To progress with the sgRNA library, clone 8 was transfected using optimised conditions 
for Nucleofection (4.3.1) using 0.5 µg plasmid. To ensure high coverage of the library 
15x106 cells were transfected and cells were selected using 5 µg/mL puromycin for two 
weeks in CHO-SFM II supplemented with 5% FBS in T175 flasks. In addition, to the 
library plasmid the control plasmid (pklv) was also transfected. Media and dead cells 
were removed every 3 to 4 days. Once the T175 flasks reached 80% confluency, cells 
were readapted back to suspension conditions for two passages in CHO-SFM II media 
(Kuhner Clima-shaker incubator (ISF1-X) at 37°C, 170 rpm and 80 % humidity).  
To ensure that, for example, slower growing cells (after a knockout of a functionally 
important gene) were maintained in the population we followed a strategy to expand cells 
into larger volumes (250 mL Erlenmeyer flasks). For generating a master cell bank, 
media was only added without discarding cells. Once a cell density of 5x106 cells/ml was 
reached a cell bank was created by freezing 1x107 cells per vial. The same procedure 
was applied twice to ensure a sufficient number of cells and coverage of the sgRNA pool.  
To investigate the number of integration events per cell, genomic DNA was isolated and 
a standard curve was generated using different dilutions of sgRNA-library plasmid spiked 
with wildtype genomic DNA. The puromycin resistance gene was amplified and copy 
numbers were calculated assuming diploidy and 4.9075 pg of DNA per cell (Xu et al., 
2011). For the sgRNA library as well as the control ~1-2 copies per cell were observed 
(Figure 52).  
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Having established that cell expansion was sucessful and copy numbers per cell were 
low for our CRISPR library we wanted to use the pooled library for “loss-of-gene” function 
studies. Therefore, certain stress conditions to test the library were further explored. 
 
4.3.2 Investigation of genes involved in programmed cell death by induction of 
apoptosis 
Programmed cell death and its key regulators are well studied. Therefore, an obvious 
strategy to explore “loss-of-gene” function was to induce apoptosis and select for sub-
populations which are more resistant to programmed cell death due to a loss in gene 
function. Sodium butyrate (NaBu) is a Histone deacetylase inhibitor (HDAC) and is not 
only used for the improvement of productivity but can also induce apoptosis. 
Furthermore, hyperosmotic conditions are a potential stress condition in a bioreactor and 
it is known that high osmotic pressure can induce growth inhibition and programmed cell 
death. As a result, we wanted to explore both strategies as potential stress conditions 
for enrichment of sub populations showing a level of resistance. Firstly, we tested 
conditions suitable for induction of apoptosis by NaBu as well as for high salt conditions 
(Figure 53 A and B). Conditions were assessed in batch cultures for several 
concentrations of NaBu and NaCl in a culture volume of 5 mL with an initial cell density 
Figure 52: Integration events after 
transfection of the sgRNA library and control 
plasmid. It was shown, that transfection the 
sgRNA library under same conditions led to ~ 1-
2 copies per cell. Amount of copies is similar for 
the control plasmid as well (n=3).  
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of 2 x 105 cells/mL. Samples were taken every 48 hours to assess viable cell density. 
After 3 days the media was completely exchanged and either NaBu or NaCl was added.  
 
To change the osmolality, 5 M stock NaCl was added to reach conditions between 325 
mOsm/Kg to 600 mOsm/Kg (Figure 53 A). Growth was already inhibited by conditions of 
450-510 mOsm/Kg on day 4 and growth was inhibited until the end of the culture. 
Inhibition was more pronounced on higher salt concentrations. The effect on viability was 
very mild compared to the control. For NaBu all concentrations showed effects on both 
growth and viability from day 5 to the end of the culture compared to the control. For 
further exploration of genes involved in induction of apopotosis hypersomolality was the 
more controlable condition and was chosen for our further experiments  
 
Figure 53: Optimisation of NaBu and NaCl concentration for induction of apoptosis. A) Cells 
were seeded with a cell density of 2x105 cells/mL and media was exchanged after 3 days. With the 
media exchange, NaCl was added to reach an osmolality between 450 to 600 mOsm/Kg. Viable cell 
density and viability was monitored daily until day 7. B) Like NaCl a range from 1 mM to 12 mM 
NaBu was tested. Viable cell density and viability was monitored daily until day 7 (n=1). 
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4.3.2.1 Exposure of CHO cells to high osmolality conditions 
High salt conditions between 500-600 mOsm/Kg had a considerable affect on 
proliferation and viability. However, mild hyperosmotic conditions between 410-450 
mOsm/Kg decreased proliferation and viability but still permitted cells growth. Based on 
our preliminary experiment we cultured cells at 400 mOsm/Kg, batch cultures in a volume 
of 30 mL with an initial cell density of 2 x 105 cells/mL using 250 mL Erlenmeyer flasks 
(Corning). After 3 days the media was refreshed and NaCl was added to reach set 
osmolality. Samples were taken every 24 hours to assess viable cell density (Figure 54).  
 
  
Over a period of 23 days at 400 mOsm/kg a stepwise adaption of the treated culture was 
observed. Viability was generally reduced compared to the control. To investigate which 
genes were knocked out and which are potentially involved in adaption to hypersomotic 
stress we prepared samples for NGS.  
 
4.3.3 Efficient enrichment of CHO cell subpopulations with enhanced productivity  
One possible application of the library is to find cell line engineering targets or pathways 
which are associated with increased productivity or secretion. The hypothesis behind it 
is that after knockout of certain genes, productivity may be enriched and these clones 
Figure 54: Exposure of CHO-K1 mAb transfected with sgRNA library to hyperosmotic 
conditions. Addition of 5M NaCl to reach 400 mOsm/kg is indicated by a red arrow. Untreated cells 
transfected with the CRISPR/Cas9 library were used as a control. To permit recovery and promote 
growth a recovery phase between day 10 and 17 was applied. Further NaCl was added on day 20 
and cultures were harvested on day 23 for DNA extraction (VC = viability).  
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could be enriched using cell sorting. After transfection of the library into CHO-K1 mAb 
cells were selected over a period of two weeks. To enrich for clones and to maintain a 
good coverage of sgRNAs, 8x106 cells were collected, washed with PBS and 
immediately put on ice to slow down secretion of produced IgG. The membrane transiting 
IgG can then be stained with a FITC labelled anti-IgG using a “cold-capture” technique. 
All steps were performed at 4°C to prevent full secretion of the mAb and maintain staining 
(compare 3.3.10). As a negative control a parental CHO-K1 non-producing cell line was 
used to account for unspecific binding. Furthermore, a positive control population of 
CHO-K1 mAb (pklv negative control) was stained and analysed. Gating was performed 
using an unstained population as well as using the negative control to exclude FITC 
signals resulting from unspecific binding (Figure 55 A and B). The pklv control showed a 
shift towards higher fluorescence compared to nonproducing and unstained cells and 
was comparable to the library transfected population in intensity (Figure 55 C and D). 
For sgRNA library transfected cells, the highest 10-15% in intensity were selected and 
sorted into 6 well plates. Sorted populations were then further expanded and transferred 
into suspension when the appropriate cell density was reached. The obtained population 
(Sort I) was then resorted and cells showing the highest intensity (10-15%) were then 
again sorted (Sort II) and expanded (Figure 55 E). Compared to Sort I a distinct shift in 
intensity was observed in Sort II indicating a successful selection of high producing 
clones or subpopulations.  
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Sub-populations sorted for higher staining should theoretically show increased titres in 
batch cultures compared to the unsorted population. All three populations (Library 
unsorted, Sort I and Sort II) were cultivated in batch cultures in a volume of 30 mL with 
an initial cell density of 2 x 105 cells/mL using 250 mL Erlenmeyer flasks. Cells were 
grown CHO-SFM II media and samples were taken on a daily basis to assess viable cell 
density and IgG titre. No effect on growth nor viability was observed between the 
unsorted and sorted populations (Figure 56 A and B). Furthermore, elevated IgG levels 
were observed compared to the unsorted population indicating a successful selection of 
high producing cells using this method (Figure 56 C). From day 2 on IgG levels were 
elevated for Sort I and Sort II. Titres of 35 ± 5 mg/L were reached for the unsorted 
population and 45 ± 2 mg/L (Sort I). Sort II reached 52 ± 1.5 mg/L respectively. The 
increase in IgG levels was observed due to increased specific productivity Qp for all 
timepoints when compared to the unsorted populations (Figure 56 D) which is not 
unexpected given the staining method used.  
Figure 55: Selection of high producing subpopulations using FACS and low temperature antibody 
stains. A and B) An unstained (CHO-K1 mAb) and a nonproducing CHO-K1 cell line were used for selection 
of gates. The non-producing CHO-K1 cell line was treated with anti-IgG FITC to exclude unspecific binding. 
C) CHO-K1 mAb transfected with pklv negative. D) Cells transfected with the library were sorted 
corresponding to the gating to obtain the highest 10-15% in intensity (Sort I). E) SgRNA library transfected 
cells were re-sorted for the highest 10-15% in intensity (Sort II).  
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As the sort for high-producing cells was successful, the next step was to isolate genomic 
DNA to amplify the region containing the sgRNA. It was hypothesised that gene 
knockouts which led to increased productivity or secretion would be enriched in high 
producing cells. The genes can be then identified using NGS.  
 
 
 
 
 
Figure 56: Growth, viability and productivity of cells sorted using a low temperature antibody 
stain. A and B) Viable cell density as well as viability low temperature sorted populations (Sort I and 
Sort II) compared to the control (unsorted sgRNA library). C) IgG levels for unsorted and populations 
sorted for higher productivity. Titres reached 45 ± 2 for first sort and 52 ± 1.5 for the resorted population, 
respectively. D) Increase in IgG levels was presumably due to elevated specific productivity at each 
day compared to the control (n=1).  
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Summary CRISPR/Cas9 library for genome wide “loss of gene function” studies in 
Chinese Hamster Ovary cells 
The results showed that the sgRNA-library consisting of 87,897 different sgRNAs can be 
successfully packed into a lentiviral delivery system. However, transduction efficiencies 
using a CHO cell line expressing a mAb and human codon optimised spCas9 showed 
low (~10 %) transduction efficiency. Copy numbers were investigated and were shown 
be to average four integration events when selected with 10 µg/ml and 20 µg/ml 
puromycin using no dilution of the lentiviral supernatant. This number of integrations per 
genome was too high for our purpose. To reduce copy number the same cell line was 
transduced using several different dilutions of the lentiviral stock. The number of 
integration events was not dependent on the dilution used and averaged at three to four 
copies per genome suggesting that some cells in a population are susceptible to viral 
infection and integration and some are resistant. Furthermore, varying the amount of 
selective agent had no effect on the number of integration events. The conclusion was 
that the lentiviral delivery system was not suitable for this purpose in CHO cells.  
To investigate if other transfection based methods can be used, PEI-based TransIT-X2® 
was used with different amounts of plasmid concentrations. High amount of plasmid 
showed high transfection efficiencies but also high copy numbers of approximately ~11 
integrations. Lower amounts of plasmid showed a considerably low transfection 
efficiency and a reduction of integration events to approximately seven per genome as 
well.  
Nucleofection has been demonstrated to be an efficient transfection tool in the literature. 
It is an electroporation based method and low integration events can be achieved with 
high transfection efficiencies. As the sgRNA library was based on selection with 
puromycin our stable cell line had to be generated using Cas9-2A-Hyg (based on 
PX459). Therefore, the hygromycin resistance gene had to be cloned into corresponding 
vector. Function of the new fusion was confirmed by targeting miR-24-3p. Clones were 
isolated and characterised for growth and productivity. The clone performing most similar 
to the parental cell line (clone 8) was used for stable transfection of the sgRNA library. 
The library was transfected, selected and analysed for copy numbers. It was shown, that 
-2 copies were integrated. Adaption to hyperosmolality was used to induce apoptosis 
and to enrich for gene knockouts resulting in survival. Apoptosis is well investigated and 
hyperosmotic conditions were hypothesised to enrich for sgRNAs targeting pro-apoptotic 
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or stress related genes. Furthermore, we wanted to identify gene knockouts resulting in 
a high productivity phenotype. Therefore, selection of high producing clones using FACS 
combined with a surface cold stain was performed. Populations could be enriched which 
exhibited higher titres and specific productivity.  
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5 Discussion 
5.1 Stable depletion of the miR-23-24-27 cluster and individual cluster members in 
industrially relevant cell lines  
5.1.1 MicroRNAs as tools for CHO cell engineering 
Recent advances in genetic engineering as well as improved tools and techniques using 
different integrated omic’ approaches have been used to better understand regulatory 
networks in CHO cells and became a trending research field to improve the performance 
of CHO cells in recombinant protein production processes (Fischer et al., 2015). 
Integrated omic’ approaches include for example the transcriptome, proteome, glycome, 
and the phospho-proteome. MicroRNAs with their ability to regulate a whole network of 
target genes have been identified as novel targets for cell line engineering to improve 
numerous aspects of CHO cell performance in a production bioreactor.  
Recent studies have demonstrated the beneficial use of miRNA engineering to improve 
productivity (Barron et al., 2011; Fischer et al., 2015a; Fischer et al., 2015b; P. S. Kelly 
et al., 2015a), enhance longevity by preventing apoptosis (Druz et al., 2011) and 
improvement of growth (Jadhav et al., 2012b) to mention only a few. Numerous 
differential expression studies exist with the aim to identify more miRNAs which can be 
used as potential engineering tools to improve bioprocess relevant phenotype (reviewed 
by (Jadhav et al., 2013b).  
 
5.1.2 Selection of the miR-23-24-27 cluster and individual members for CHO cell 
engineering 
Previous results in our group demonstrated that the depletion of miR-23 resulted in 
increased productivity in CHO-K1 SEAP expressing cells (Kelly et al., 2015). MiR-23 was 
originally identified as differentially expressed together with other miRNAs in a 
temperature shift study by Gammell and colleagues (Gammell, 2007). Biphasic 
processes are commonly used in industry with cells maintained in growth promoting 
conditions to boost proliferation in the first stage of the culture. After reaching high cell 
densities the reduction of temperature leads to growth inhibition and promotes 
productivity. Due to reduced growth rates and lower nutrient consumption the longevity 
of the culture is often increased. Other miRNAs identified in the study were miR-21, let-
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7, miR-25/26 and several members of the miR-17 cluster. Interestingly, miR-27a and 
miR-24 were identified as being more abundant during hypothermic conditions. MiR-27 
and miR-24 are part of the miR-23 cluster. This cluster comprises two genomic 
paralogues, miR-23a-27a-24-2 and miR-23b-27b-24-1, and its members are quite well 
studied in terms of their function in certain diseases. The miR-23a cluster consists of 
miR-23a, miR-27a and miR-24-2, whereas the miR-23b cluster accompanies miR-23b 
miR-27b and miR-24-1 (Chhabra et al., 2010a). The two paralogues most likely resulted 
from gene duplications during evolution in mammals (Wang et al., 2016). The miR-23a 
cluster is intergenic and its paralog is intronic in human and reside on two different 
chromosomes. In Chinese hamster the miR-23b cluster is located in an intron of the 
Aminopeptidase O-like gene (AMPO). The mature sequences of the paralogues differ in 
only one base pair. The mature sequence of miR-24-1 and miR-24-2 are identical which 
makes their distinction during analysis of mature miRNA expression impossible. 
Furthermore, several multi-alignment studies have shown that all three miRNAs in the 
cluster are conserved in mammals (Chhabra et al., 2010a). Table 9 shows a sequence 
comparison of all miRNA members of the cluster between human (hsa), Chinese 
hamster (cgr) and mouse (mmu). 
 
 
Table 9: Comparison of the mature microRNA -3p sequence across different mammalian species 
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The seed regions of the miR-23 paralogues are almost identical to the seed region of 
miR-27 with only one base is exchanged from U to A in mouse, human and Chinese 
hamster. Similarly, a C to U is exchanged for miR-27a and miR-27b. The sequences of 
miR-24-1 and miR-24-2 are completely identical except for the mature microRNA in 
Chinese hamster. An addition of one guanine base is exhibited for miR-24 in Chinese 
hamster.  
The first step before using sponges for the depletion of the whole cluster or individual 
members, was to investigate the expression of each microRNA in a panel of different cell 
lines. In our study, expression seemed similar in all cell lines when compared to a 
parental CHO-K1 cell line (Figure S 7).  
A lower Ct value corresponds to a higher abundance and vice versa. The expression of 
miR-24 was in general the highest in all tested cell lines. However, the TaqMan® assay 
does not differentiate between miR-24-1 and miR-24-2. MiR-23a and miR-27a seemed 
to be higher expressed than their genomic paralogs. Comparing same members of the 
cluster it seemed that miR-27a was higher expressed compared to miR-23a suggesting 
an independent regulation of the members of the cluster. This was supported by 
comparison of the expression of miR-23b and miR-27b. Using TaqMan® assays may 
give a good indication of the miRNA abundance in a simple experiment e.g. knockdown 
of a particular miRNA at a given point in one cell line. When it comes to more complex 
approaches like comparing expression levels of several miRNAs in a miRNA cluster or 
a comparison over cell lines, NGS may be a more efficient method to use.  
MicroRNAs can be transcribed within their host genes. Prevoius work has demonstrated 
that the intergenic miR-23a-27a-24 cluster was RNA-Polymerase II dependent but 
shows a lack of common promoter core elements such as a TATA box or TFIIB 
recognition element yet exhibited evidence of expressed sequence tags which are a 
physical indication of a gene (Saini et al., 2007). However, given the observation that the 
cluster is initially transcribed as a single primary transcript sequencing indicated that 
abundances of the single members of the miR-23 cluster showed great differences 
(Hackl et al., 2011). This may indicate a differential processing of each member of the 
cluster.  
Depletion of miR-23-24-27 using a sponge decoy led to increased productivity in a CHO-
S Fc fusion expressing cell line (Figure 16). This prompted us to explore how much each 
individual miRNA contributed to this effect or whether depletion of all three miRNAs was 
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necessary. Therefore, sponges for all individual miRNA were designed, transfected and 
phenotype analysed. Depletion of miR-24 as well as miR-27 led to increased productivity 
and pathway analysis to identify cell line engineering targets was performed (see section 
4.1.3). The method of choice was proteomic profiling using HPLC-MS/MS to identify 
differentially expressed proteins. Besides the phenotype it was interesting to explore 
shared and individual targets of all three miRNAs.  
It was demonstrated that 88 protein targets seemed to be shared between miR-23 and 
miR-24 which was unexpected given that the seed region of miR-24 and miR-23 are very 
different. It has been previously reported that different miRNA seed families can target 
the same mRNA. MiR-23 and miR-27 seemed to have 13 shared targets and miR-27 
and miR-24 showed 31 overlapping proteins (Figure S 8). Between all three miRNAs, 
eight were common targets. Given that the seed region of miR-24 and miR-27 is very 
different it was unexpected to see overlapping targets.  
The seed region of a miRNA is crucial for mRNA target identification, binding of the RISC 
and subsequent translational inhibition. With the seed region of miR-23 and miR-27 
being very similar it could be that targets might be shared between the two microRNAs. 
In fact, prediction tools e.g. TargetScan suggest that shared binding of mRNA targets is 
likely and that similar pathways are targeted. Clustered microRNAs or miRNA families 
often share functionally related targets according to several studies (T. Liang et al., 2014; 
Ventura et al., 2008; J. Wang et al., 2011). Interestingly, Liang and colleagues explored 
predicted targets of the miR-23a and miR-23b cluster in silico. All six members possibly 
target genes involved in the same pathways as hypothesized. This co-targeting is 
observed in different regions of the target mRNAs (T. Liang et al., 2014).This is 
accompanied by the observation that entire miRNA families are conserved over 
mammals and vertebrates (Bartel, 2009). As one single miRNA can target several genes 
and evidence of involvement of whole miRNA families in pathways it is not a surprise 
that the defects in a miRNA regulation or expression can have tremendous effects on 
phenotype and development (Ambros, 2003; Bartel, 2009). Therefore, the hypothesis 
that miRNAs are clustered and conserved over species to avoid detrimental errors was 
topic of investigation by several research groups. Clustering of miRNAs might be 
important for the development of new miRNAs in many ways described by the functional 
co-adapting model (Y. Wang et al., 2016).  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
175 
When we investigated which pathways and biological processes are commonly targeted 
between all three members of the cluster it was demonstrated that 9 shared pathways 
were over-represented including nucleotide biosynthesis, oxidation reduction and 
biosynthesis of nucleotide as well as nucleoside precursors. Interestingly, 46 biological 
processes were impacted in common between miR-24 and miR-23 depleted cells. These 
were all translation, translational regulation, tRNA metabolism or RNA processing related 
which supports the observed productivity phenotype. When comparing shared protein 
targets of miR-23 and miR-27 as well as miR-27 and miR-24, only a limited number of 
pathways were identified, with the major ones involved in response to oxidative stress 
and protein complex assembly. The formation of disulphide bonds during protein folding 
and processing in the ER leads to the formation of reactive oxygen species (ROS) 
(Schröder & Kaufman, 2005). Due to increased demands in protein folding and a 
resulting increase in ROS the oxidative stress response in the form of upregulating genes 
encoding antioxidant enzymes and cytokines might be observed. Interestingly, miR-27 
had individual pathways targeted which seemed to be involved in regulation of apoptosis. 
ER stress has been demonstrated to trigger intrinsic apoptosis pathways which are 
controlled by a balance of pro- and antipoptotic proteins. With depletion of miR-24 being 
involved in an upregulation of translation and lower levels of miR-27 showing an increase 
in antiapoptotic proteins, observed productivity phenotype could be resulting of a 
synergetic effect of both. However, it is mentioned in the literature that miR-24 alone can 
target pro- or antiapoptotic genes (Agrawal et al., 2014; Singh & Saini, 2012b) and is 
further discussed in section 5.1.2.1.  
With many pathways being common, our data agrees with many studies that support the 
co-targeting theory (T. Liang et al., 2014). Besides co-targeting of a miRNA cluster, each 
single member may have a role of its own which is suggested by different expression 
pattern which is especially evident for the miR-23 cluster. Therefore, we wanted to 
investigate individual functions of each miRNA further.  
 
 
 
 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
176 
5.1.2.1 Role of individual miRNA members of the miR-23 cluster 
Each cluster member has been shown to be involved in different as well as common 
biological processes and pathways by our study and several others. Previous results for 
transient up- or downregulation as well as sponge mediated stable depletion of the miR-
23 cluster or individual members showed beneficial impact on growth, viability or 
productivity in several cell lines. The investigation of phenotypes after depletion of the 
miR-23 cluster or each individual member is discussed in the next section.  
 
5.1.2.1.1 Impact of miR-23-24-27 depletion on the phenotypes of CHO cells and their 
resulting bioprocess performance 
Transient upregulation of the miR-23-24-27 cluster led to enhanced productivity and 
viability at the expense of proliferation which was decreased in previous results 
generated in our lab. Normalised productivity was enriched by 1.35-fold and 1.7-fold in 
late stages of the culture in CHO-K1 SEAP expressing cells whereas viability was 
decreased by approximately 2-fold. Stable depletion of the cluster showed opposite 
effects leading a ~2.9-fold increase in cell density in mixed population and a 1.4-fold 
increase in a clonal panel of CHO-K1 SEAPs. The viability was improved in late stages 
of the culture by 12.5 %. To investigate the possible beneficial impact in other producer 
cell lines the cluster was depleted using a stable expressed sponge for miR-23-24-27. 
GFP intensity for all cell lines was reduced for sponge constructs indicating a successful 
binding if miRNAs.  
Only one cell line showed a beneficial phenotype after depletion of the miR-23 cluster 
which led to increased levels of fusion protein on day 6 (1.26-fold) and day 8 (1.56-fold) 
of batch cultures in CHO-S Fc due to increased specific productivity. The same 
productivity phenotype (1.86-fold increase, day 11) was observed in fed-batch cultures 
but experiments could not be reproduced due a non-ideal feed strategy and not enough 
data could be collected for calculation of statistical significance. Optimisation of feed 
strategies in biopharmaceutical industry is a critical process and is usually performed in 
high throughput studies using DoE with defined media compositions. However, it is time 
consuming and dependent on the balance of multiple factors like components, time 
points and volumes. Changing only one component at a time implies very long 
optimisation times and the usage of high amount of resources. DoE uses a statistical 
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approach to “predict” cellular behaviour based on preliminary experiments and delivers 
the optimal feeding strategy which can be verified by only one final experiment (Horowitz 
et al., 2009). However, our resources in the laboratory were limited and the fed-batch 
strategy was never optimised. To investigate if the observed phenotype in CHO-S Fc 
can be increased by isolation of single cell clones, limited dilution cloning was used. Nine 
clones were chosen for miR-23-24-27 depleted clones and control expressing clones 
each. The GFP intensity exhibited an average of 223 (control sponge) in comparison to 
miR-23-24-27 sponge with an average of 16.97. This indicates again that miRNAs are 
successfully binding to the sponge construct and GFP translation is inhibited. The 
assessment of clones in batch cultures showed to our surprise no increase in 
productivity. However, growth behaviour of all clones varied in comparison to the mixed 
population which is expected due to clonal variations of CHO cells. The genetic instability 
of CHO cells leads to chromosomal aberrations like rearrangements or deletions (M. F. 
Wurm, 2013). Those effects can lead to loss of transgenes but also to multiple copy 
numbers of the transgene (Osterlehner et al., 2011). This amplification effect is desirable 
for the establishment of producer cell lines and is used for DHFR and GS expression 
systems (Kito et al., 2002). However, the same effect is also involved in the appearance 
of many different phenotypes due to clonal stability (M. Kim et al., 2011b).  
For the generation of stable cell lines different systems are commonly used including 
lentiviral delivery or undirected random integration of plasmids. These systems do not 
give the possibility for a site directed integration of the transgene. Lentiviral delivery 
usually occurs in transcriptionally active regions (Bushman et al., 2005) running the risk 
of interupting gene function leading to a variety of phenotypes. Similarly transfecting our 
sponge constructs and random integration i.e. could lead to gene loss or integration in 
transcriptional active regions to increase the translational burden on cells. The 
consequence is a genotype which could result in different phenotypes i.e. slower or faster 
growth resulting in different subpopulations in a transfected mixed population. As a 
result, a great attention is focused on clone stability in biopharmaceutical industry (F. M. 
Wurm & Wurm, 2017).   
Davies and colleagues analysed a subpopulation of 199 clones from a parental CHO-
K1SV cell line (Davies et al., 2013). It was shown that over 100 generations specific 
growth rates vary and even increase towards later generations. It was concluded that 
subpopulations acquire traits due to mutations as well epigenetic events and are selected 
by for example by standard culture procedures like subcultivation or cryopreservation.  
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In biopharma industry a great effort is invested in for the selection of high producing 
clones ranging of up to over 1000 clones (F. Li et al., 2010). To find clones which show 
high productivity, a larger scale screen of clones would presumably be more appropriate 
and would give a view of the range of phenotypes in batch cultures. It is a commonly 
observed phenomenon that the expression of transgenes declines over time in culture 
and despite exhibiting multiple genomic copies (S. J. Kim et al., 1998; Strutzenberger et 
al., 1999). Kim and colleagues selected a high producing clone which was subsequently 
cultivated for 18 months and routinely sub-cultivated. It was demonstrated that the 
transgene expression steadily declined over a period of 18-month. The effect was 
investigated by several groups and it was shown that the commonly used CMV promoter 
is exposed to DNA methylation in the 5’ and 3’ end of the promoter sequence which 
eventually leads to a decrease in expression (M. Kim et al., 2011b; Moritz et al., 2015; 
Osterlehner et al., 2011). To target declining transgene expression promoter engineering 
is an extensive research field and it was observed that the induction of mutations in the 
promoter can prolong expression and counteract declining titres over cultivation time. As 
our sponge construct uses a CMV promoter the decline of sponge expression could be 
one reason why no phenotype in clones was observed. Furthermore, various copy 
numbers of sponge transcript for each clone might affect the phenotype where low 
sponge expression may not lead to increased productivity.  
Small scale cultures allow higher throughput and avoid the extensive use of recourses 
i.e. expensive media. It furthermore allows the prediction of growth and transgene 
expression even before upscaling experiments. However, the evaporation of media in 
outer wells (referred as “edge effect”) is a common drawback using 96- or 24-well plates 
(Patel et al., 2005). Sealing plates would solve the evaporation but allows insufficient 
exchange of oxygen between media and environment ultimately leading to reduced 
growth and changes in growth behaviour. All our single cell clones were cultivated in 24-
well suspension plates, however the plates were sealed to avoid evaporation and prevent 
bacterial or fungal contaminations. Limited oxygen and the different culture format could 
also potentially impact the phenotype. Therefore, clones should also be assessed in 
bigger scales for our experiment in order to get a true comparison with mixed population 
and hence a better appreciation of the range of productivity changes within the pools.  
To investigate which microRNA was responsible for the impact on productivity, individual 
sponges for miR-23, miR-24 as well as miR-27 were designed and tested in the same 
CHO-S Fc cell line.  
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5.1.2.1.2 Impact of miR-23 depletion on phenotype of CHO cells and bioprocess 
performance 
Transfection with miRNA mimics or antagomiR has shown that up- or downregulation of 
individual members of the miRNA cluster can impact the bioprocess phenotype of CHO 
cells. Overexpression of miR-23a for example inhibited proliferation in transient 
experiments in CHO-K1 SEAP expressing cells. Stable depletion of miR-23 led to an 
increase of SEAP productivity bu 50% in batch and fed-batch cultures due to an increase 
in mitochondrial capacity in terms of oxidative phosphorylation (Kelly et al., 2014; Kelly 
et al., 2015). In a range of tested cell lines including CHO-K1 Fc, CHO-S Fc, DG44i Fc 
and DG44i mAb no change in behaviour was observed. This could indicate that the 
phenotype observed for CHO-S Fc for the depletion of the miR-23-24-27 cluster is 
resulting from reduced levels of miR-24 and miR-27 only.  
 
5.1.2.1.3 Impact of miR-24 depletion on phenotype of CHO cells and bioprocess 
performance 
Overexpression of miR-24 using mimics inhibited proliferation in CHO-K1 mAb and 
transient knockdown with antagomiRs resulted in enhanced cell growth performance 
(Noèlia Sanchez, 2013). Stable depletion of miR-24 in CHO-S Fc led to an increase in 
productivity of 1.3-fold on day 6 and 1.8-fold on day 8 (Figure 20). This was also observed 
in CHO-K1 mAb however the increase in IgG was very mild with only 10% on day 6 and 
day 7 of the batch culture (Figure 25). 
To identify targets which are potentially involved in productivity due to the depletion of 
miR-24, we used proteomic profiling to investigate differential protein abundance. This 
approach has been shown to be very successful in CHO cells for the identification of 
potential targets of miR-7 (Meleady et al., 2012), miR-23 (Kelly et al., 2015) and other 
potentially growth related miRNAs including members of the miR-17-92 cluster (Clarke 
et al., 2012a).  
Using label-free LC-MS/MS we obtained two datasets for the depletion of miR-24: CHO-
S Fc using a sponge for miR-24 (see 4.1.4.2) and CHO-K1 mAb using CRISPR to target 
miR-24 (see 4.2.3.2). Although we used two different technologies for the depletion of 
miR-24, the phenotype was very comparable and therefore, we focused primarily on 
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genes which showed differential expression in both DE lists. Furthermore, we wanted to 
compare shared pathways and DE genes which may not be affected in CHO-S Fc but in 
CHO-K1 and vice versa as there is evidence that different CHO cell linages might not be 
as related as previously expected (M. F. Wurm, 2013). For the functional annotation 
DAVID as well as STRING® was used to identify pathways as well as protein 
interactions. Using that information, we were able to identify functions of dysregulated 
proteins and relate them back to the phenotype observed. For the depletion of miR-24 it 
was shown, that especially pathways related to translation, rRNA processing, tRNA 
processing as well as protein folding were upregulated (Figure 24 A to E).  
PES1, BOP1 and WDR12 were identified in our study as upregulated due to knockdown 
of miR-24. PES1 and WDR12 were predicted as being targeted by miR-24. Interestingly, 
PES1 and WDR12 together with BOP1 are associated in a protein complex, the so called 
PeBoW (Holzel et al., 2005; Rohrmoser et al., 2007). The PeBoW is crucial in ribosome 
maturation by processing parts of the pre-rRNA to generate pre40S and pre60S subunits 
which will be further processed and transported into the cytoplasm (reviewed by 
(Lafontaine, 2015). Consequently, it has been shown that the PeBoW complex is crucial 
for translation and proliferation. As additional part of the rRNA processing machinery, 
PA2G4 has been upregulated as well and was related to growth (Squatrito et al., 2004; 
Squatrito et al., 2006). Two other significantly upregulated proteins in our study are EIF6 
and RACK1/GNB2L1. EIF6 is responsible together with RACK1/GNB2L1 for the 
assembly and recycling of 40S and 60S ribosome subunits into the mature 80S 
translation initiation complex in the cytoplasm (Miluzio et al., 2009). Furthermore, 60S 
ribosomal protein L3 (RPL3), 60S ribosomal protein L7 (RPL7L1) and 40S ribosomal 
protein S15a (RPS15A) have shown to be upregulated as well. RPL3 and RPS15A are 
hereby interacting with each other in a structural context and have shown to be involved 
in translation (Ghanem et al., 2011; Lopez et al., 2012; Rosen et al., 2010). Further 
evidence that depletion of miR-24 results in upregulation of parts of the translational 
machinery is the higher abundance of TUFM and GFM1. Both are involved in recruitment 
of aminoacyl-tRNAs and release of deacetylated-tRNAs in the mitochondria (Christian & 
Spremulli, 2012; Simon et al., 2017). Upregulation of TUFM and GFM1 could presumably 
open a bottleneck as tRNAs are usually highly abundant and not a limiting factor. 
Interestingly, seven aminoacyl-transferases (EPRS, IARS, AARS, YARS, WARS, GARS 
and NARS) responsible for loading amino acids to its cognate tRNA were upregulated 
as well in our study. This strengthens that parts of the translational machinery are 
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upregulated eventually leading to higher specific productivity after knockdown of miR-
24. Not only parts of the translational machinery were upregulated but also proteins 
associated with response to UPR and ER stress response. One member is HSPD1 which 
interestingly previously described as associated with a high productivity phenotype 
(Meleady et al., 2011; Sommeregger et al., 2016). Besides, productivity HSPD1 
overexpression seems also to be associated with increased proliferation in tumour cell 
lines (W. Liang, Yang, Peng, Qian, & Wang, 2015) and CHO cells (Clarke et al., 2012c). 
Furthermore, Meleady and colleagues identified RUVBL which was also higher 
expressed in miR-24 depleted cells and is potentially associated with higher Qp.  
Agrawal and colleagues showed that miR-24 is involved in apoptosis through targeting 
pro-apoptotic genes like Bim, FAF-1, Caspase-9 and Apaf-1. On the other hand, studies 
showed targeting of antiapoptotic genes like BCL-2 (Singh & Saini, 2012b). It seems that 
the action of miR-24 in a pro- or antiapoptotic manner is cell type specific or that 
regulation is involved in keeping the sensitive balance of apoptotic mediators. 
Overexpression of miR-24 using mimics inhibits cell proliferation of six different human 
cancer cell lines by inducing the expression of p53 and p21 (Mishra et al., 2009a). The 
same study showed that miR-24 overexpression also targets DHFR which catalyses the 
conversion of dihydrofolate into tetrahydrofolate. Tetrahydrofolate is required for purine 
and pyrimidine synthesis and therefore plays an essential role in cell growth and 
proliferation. Consequently, down regulation of miR-24 causes an increase of 
proliferation in human epithelial cells (Cheng et al., 2005). In our DE protein lists after 
the depletion of miR-24, DHFR was more abundant (1.35-fold, ** p = 0.01) suggesting 
that proliferation could be influenced. However, in our sponge experiments no change in 
proliferation was observed in CHO-S Fc nor CHO-K1 mAb. Interestingly, growth was 
enhanced when miR-24 was either targeted using CRISPR/Cas9 and overexpression of 
miR-24-3p using mimics resulted in inhibited proliferation (Figure 35 and Figure 36).  
 
Therefore, targeting miR-24 is a valid strategy for the improvement of productivity for 
CHO cell lines. Due to the amount of genes targeted by miRNAs changes in the 
transcriptome as well as on the therapeutic protein quality should be explored further.   
To establish whether these effects were cell line or product dependent, five more cell 
lines were transfected including CHO-K1 Fc, CHO-K1 EPO, CHO-K1 DP12, DG44i Fc 
and DG44i mAb. All chosen cell lines originated from different CHO lineages and 
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expressed different recombinant therapeutics. The depletion of miR-24 in following cell 
lines was performed by Dr. Srinivas Suda and  
Depletion of miR-24 resulted in a high productivity for all tested cell line except DG44i Fc 
making miR-24 a broadly applicable tool for cell line engineering and the improvement 
of productivity in CHO.  
 
5.1.2.1.4 Impact of miR-27 depletion on phenotype of CHO cells and bioprocess 
performance 
Overexpression of miR-27a resulted in a decrease in growth (CHO-K1 mAb) but 
increased proliferation in a different cell line (CHO2B6) showing evidence for cell type 
specific effects (Noèlia Sanchez, 2013). Depletion of miR-27 in CHO-S Fc resulted in a 
2-fold (day 6) to 2.5-fold (day 8) increase in productivity. However, this productivity 
phenotype was only observed in CHO-S Fc and not in any other cell line tested. 
Comparing data from proteomic profiling no relation to the phenotype could be made 
when looking for DE proteins. When comparing with the literature miR-27 seemed to be 
involved in mediation of apoptosis. In fact, our pathway analysis of DE proteins showed 
a connection to oxidative stress as well as apoptosis in over-represented pathways. 
However, no increase in culture length was observed upon miR-27 depletion in CHO-S 
Fc (Figure 20) whereas an effect can not be excluded as samples were taken every 48h 
and anti-apoptotic effects might not be as long lasting. To overcome this growth curves 
with samples taken every 4-6 hours could be performed. However, when miR-27b was 
targeted in CHO-K1 mAb using CRISPR/Cas9, cultures were prolonged (further 
discussed in 5.2.2.2) indicating its involvement in apoptosis. Furthermore, it could be a 
cell line specific phenotype.  
 
5.1.2.2 Impact on the glycosylation pattern of a Fc fusion protein and a mAb after 
depletion of miR-23-24-27, miR-23, miR-24 and miR-27 
With their ability to regulate whole transcriptional networks, targeting miRNAs could be 
a route to impact complex phenotypes towards productivity, viability and growth as 
shown by our study. For this same reason, it is important to also check for any changes 
in product quality as a result of intervention. Culture conditions, media components, the 
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cell type and the bioprocess itself can have a significant influence on the glycosylation 
pattern of a therapeutic protein. Furthermore, the glycosylation pattern of a therapeutic 
protein must be investigated extensively to meet FDA regulations and to ensure that 
product quality is consistent at all times. It has been shown that different glycosylation 
patterns can influence the circulation half-life of IgGs, ADCC and biological activity. 
Changing product attributes have also been demonstrated to be a potential strategy for 
cell line engineering to improve recombinant protein quality (Bork et al., 2009; Hossler et 
al., 2009a). Depletion of miR-23, miR-24 and miR-27 resulted in significant changes in 
the glycosylation pattern on the Fc fusion product expressed by CHO-S (Figure 19). 
When miR-24 was depleted in CHO-K1 mAb significant changes were also observed on 
glycosylation of the IgG (Figure 23). This led us to investigate if the proteomic profiling 
datacould give more insight into differentially expressed proteins influencing 
glycosylation.  
In fact, it was shown that depletion of miR-23 led to increased levels of 
Phosphomannomutase 2 (PMM2), Glucosidase 2 subunit beta (PRKCSH) and Neutral 
alpha-glucosidase AB (GANAB) in CHO-S Fc. Depletion of miR-24 led also to increased 
levels of PRKCSH and reduced levels of miR-27 led to an increase in PMM2 in CHO-S 
Fc. PMM2 which is a predicted target of miR-24-3p is well studied in glycosylation 
disorders like congenital disorder of glycosylation (CDG). It is an enzyme responsible for 
catalyzing the reaction from 6-mannose phosphate to 1-mannose phosphate, a key 
metabolite in the generation of N-glycans. Defects in PMM2 often result in unoccupied 
N-glycosylation sites on proteins as PMM2 is involved in early stages of glycosyation 
(Sharma et al., 2011). GANAB is the catalytic active alpha subunit of Glucosidase II and 
forms together with the noncatalytic beta subunit PRKCSH, Glucosidase II. It is a crucial 
enzyme involved in correct folding of glycoproteins and processing of N-glycans 
(D’Alessio & Dahms, 2015; Pelletier et al., 2000). High mannose content on mAbs 
usually is accompanied by afucosylation impacting biological activity. High levels of 
sialylation has been shown to negatively impact ADCC as well as CDC for IgGs (CMC 
Biotech Working Group, 2009). As relatively new therapeutics Fc fusions are not as 
thoroughly studied as mAbs. However, similar to mAbs the efficacy depends heavily on 
glycosylation of the Fc fusion. Increased levels of sialylation could lead to increased 
sucess rates in terms of efficacy and serum half-life (Czajkowsky et al., 2012). Therefore, 
it seems that miRNAs of the miR-23 cluster are involved in the fine-tuning of protein 
glycosylation.  
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5.1.3 CHO cell lines, clonal variation and cell line specific behaviour 
Members of the miR-23 cluster were chosen because of a beneficial impact on the 
phenotype after their depletion or overexpression of such. For example, miR-23 has 
been shown to increase longevity in CHO-K1 mAb and productivity in CHO-K1 SEAP 
expressing cells (Kelly et al., 2014). Depletion of the miR-23 cluster resulted in higher 
productivity in CHO-K1 SEAP also (Sanchez et al., 2014). When we tested a panel of 
industrial relevant cell lines of CHO-K1, CHO-S and DG44i, only CHO-S showed 
increased productivity after depletion of miR-23-24-27 and no effect after depletion of 
miR-23 alone was observed at all. This cell line dependent behaviour may be a 
consequence of the origin and linage of CHO cells as well as evolutionary adaption in 
miRNA targets which will be discussed later.  
The original CHO cell line was first isolated in 1957 by Dr. Theodore Puck (Puck et al., 
1958) and CHO cells were used for intensive studies of chromosome aberrations and 
mutations due to their ease in culturing and large chromosomes. Furthermore, CHO cell 
populations were easy to select for metabolic mutations using selective media. The 
original fibroblast like cell type was isolated from 0.1 g of tissue and further cultivated for 
several passages. The original CHO cell line was diploid and had 22 chromosomes (11 
pairs). The morphology of the cells changed after ten months in culture and cells became 
spontaneously immortalised. Therefore, the genetic instability of CHO cell lines was well 
studied over the last decades.  
In the last 50 to 60 years several cell lines have been created and non-standardised 
culture conditions and the high genetic modulation of the CHO genome led to many 
different cell types. Each generated sub cell line from CHO-K1 e.g. CHO-S, DG44 to 
mention only a few can be more likely described as its own cell line with exhibiting 
different phenotypes and behaviours (M. F. Wurm, 2013). This genetic instability is a 
useful feature which is commonly exploited in the biopharmaceutical industry to amplify 
transgenes and ultimately increase copy numbers as well as the resulting higher 
expression (e.g. DHFR, GS systems). The variation inherent in a genetically unstable 
population also means that individual clones can be found, during screening, with a wide 
range of phenotypes including faster growth and/or high productivity. Hence clone 
screening is a very successful way in finding good performing clones. However, loss of 
expression is a common problem that can occur despite maintenance of selection 
pressure (M. Kim et al., 2011b). It has been shown that the generation of many 
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recombinant CHO cell lines led to several chromosome aberrations, deletions and 
rearrangements (Derouazi et al., 2006). Genetic instability and a loss or an increase in 
copy numbers could also influence miRNA target regulation. It is known that miRNA 
regulation is a “fine-tuning” process and can be easily dysregulated with dramatic impact 
on development or cell survival. 
In addition to genetic instability, the evolution of miRNA targeting as well as clustering of 
miRNAs may influence cell line specific behaviour observed. The efficiency with which a 
miRNAs to binds to its target and the regulation of miRNAs seem to have alternative 
modes which are cell line and tissue dependent (Kulkarni et al., 2016). Kulkarni and 
colleagues showed that after co-transfection of ten cell lines with let-7a and a plasmid 
containing the luciferase reporter gene renilla with binding sites for let-7a that differences 
in miRNA regulation can occur depending on the cell line. All tested cell lines showed a 
significant reduction in luminescence after binding and inhibition due to let-7a. However, 
the level of suppression was highly cell line dependent suggesting a difference in 
mediated mRNA stability due to regulation by let-7a. Five cell lines stabilised the mRNA 
transcript, three cell lines did not show any effect and two cell lines showed translational 
inhibition due to degradation. This suggests a cell line dependent regulation of genes by 
any particular miRNA regulator.  
A further reason why the depletion dependent impact of miRNAs could be cell line 
specific is the usage of 3’UTR isoforms which can change the number of binding sites in 
this highly regulatory region. The mRNA:miRNA interaction is usually located in the 
3’UTR of the mRNA resulting in translational inhibition or degradation. The 3’UTR is 
furthermore a regulatory region. However, alternative long and short UTR isoforms have 
been reported in the same ORF due to different poly-A signals which can occur distal or 
proximal (Decker & Parker, 1995; Miyamoto et al., 1996). Longer or shorter isoforms can 
have a different number of binding sites and a cell line dependent shift in using longer or 
shorter isoforms can weaken or enhance the miRNA regulation and seems to be 
dependent on the cellular context (Nam et al., 2014). In addition, one messenger of a 
gene can have multiple miRNA binding sites. The difference in the 3’UTR can strongly 
effect gene regulation in this context by adding or deleting miRNA binding sites due to 
the cell line specific and preferred isoform usage. As we accumulate a better 
understanding regarding the use of different 3’UTRs in CHO this may help explain some 
of the cell line differences observed. 
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Another element playing a role in miRNA binding to its target mRNA could be the 
variation of copy numbers occurring in the genome compared to the reference genome 
(e.g. a CHO-S cell line compared the original CHO-K1 tissue). This could involve copies 
of miRNAs itself or copies of the target gene. Higher abundance of mRNAs could 
possibly alter the gene expression significantly and could influence the phenotype and 
diversity (Veerappa et al., 2014). Furthermore, there is a strong evidence that multiple 
gene numbers increase the level of gene expression (Schuster-Bockler et al., 2010; 
Stranger et al., 2007). However, an increase in expression could unbalance to the normal 
gene regulation by its miRNA binding partner resulting in only partial silencing of the 
target gene. A dosage-dependent target selection for miRNAs has been reported for 
several miRNAs and their target mRNAs (Shu et al., 2012). This effect is suggested to 
be based on the miRNA expression level itself and mRNA levels in the cell triggering 
feedback loops as endogenous mRNAs can act as a “sponge” reducing miRNA 
availability in the cell and therefore dysregulates othe mRNAs. Let-7a-7f were co-
transfected with reporter plasmids containing DICER and c-MYC as reporter genes with 
MBS in the 3’UTR. Overexpression of let-7a downregulated the expression of DICER 
but downregulated the c-MYC reporter at even higher levels suggesting a selective 
behaviour of the miRNA itself supporting their role in “fine-tuning” gene expression and 
evolutionary development. Leading to genetic variability and an exploration of new 
functions due to gene overexpression as well as ultimately into a phenotype - desirable 
or not.  
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5.2 CRISPR/Cas9 as a genome engineering tool to target miRNAs in CHO cells 
Recent studies have demonstrated the beneficial use of miRNA engineering to improve 
productivity, enhance cultivation times and improved growth rates (Barron et al., 2011; 
Druz et al., 2011; Jadhav et al., 2012b; P. S. Kelly et al., 2015a). Besides transient 
depletion of miRNAs using antagomiRs, sponge decoy technology for the stable 
depletion of miRNAs is a commonly used tool to study miRNA function (Kluiver et al., 
2012a). However, the usage of sponges is a challenge due to the necessity for a reporter 
gene which will eventually siplay a translational burden and may decrease therapeutic 
protein production. Further challenges are for example generation of a stable cell line 
using plasmids leading to random integrations and the fact that it is rather a depletion 
than a knockout. We wanted to investigate as well if a complete knockout can be 
tolerated. This goes along with the observation that gene expression varies a lot during 
different growth phases making sponges susceptible to changes in expression 
consequently also allowing miRNA abundances to be differential. Previous results have 
shown depletion of mature miRNA but on the contrary enrichment was observed as well. 
The enrichment is most likely a result of miRNA mediated target protection (TMMP) 
whereby miRNA binds to a mRNA causing translational inhibition. In case of introducing 
sponges with aritifical MBS, miRNA binds to its target as well. However, after lysing of 
cells miRNA is released and appears to be “overexpressed”. This effect led to 
inconclusive results about miRNA expression in cell lines tested. It was demonstrated 
that whole miRNA families with similar seed sequence can bind to the sponge which can 
potentially lead to phenotypes not resulting from the miRNA studied (Kluiver et al., 
2012a).  
Consequently, we wanted to implement CRISPR/Cas9 as a tool to knockout miRNAs 
and to overcome these challenges. The miR-23 cluster has been demonstrated to be an 
interesting cluster for miRNA engineering which we wanted to target with CRISPR. It was 
demonstrated that miRNAs can be successfully targeted using CRISPR/Cas9 in human 
cell lines by Chang and colleagues (Chang et al., 2016) and coding genes have been 
targeted in CHO before FUT-8 (Ronda et al., 2014). However, miRNAs have not been 
targeted. To compare CRISPR/Cas9 to sponge decoy technology we chose CHO-K1 
mAb. We used this cell line for stable and transient miRNA depletion experiments as well 
as for overexpression. 
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5.2.1 Functionality of CRISPR/Cas9 in CHO cells 
Targeting coding genes with CRISPR/Cas9 is relatively easy and straight forward as 
even a small indel of ±1 bp will generate a frame shift resulting in premature stop codons 
and error prone mediated degradation of the amino acid chain. Targeting of miRNAs 
could therefore represent a special challenge as miRNAs are non-coding and a small 
indel close to the seed region may not affect function nor processing. The seed region is 
most crucial for target recognition (Lewis et al., 2003) but it was demonstrated that a 
complete pairing of the seed region to a mRNA might not be necessary (Didiano & 
Hobert, 2006). We designed sgRNAs to target either the seed region or proximal to the 
seed region. Physical and statistical analysis using RNA-fold predicted that small indels 
in the stem-loop sequence or the seed region of a miRNA has strong effects on the 
structure of the miRNA (Figure 26) precursor and might influence processing or target 
recognition of the mature miRNA. With ~22 nucleotides in length miRNAs are very small 
molecules and targeting the seed region can be a challenge due to the limiting factor of 
the PAM. The PAM must be located immediately downstream of the sgRNA binding site 
in the genomic locus and to allow Cas9 efficient function of endonucleolytic domains. 
The PAM is dependent on the species origin of Cas9. S. Pyogenes (spCas9) for example 
uses NGG as a PAM. Different Cas9 variants have been recently discovered which use 
different PAM like N. meningitides (NNNNGATT) or T. denticola (NAAAAC). 
CRISPR/Cas9 has been proven to be an efficient tool for genome engineering but the 
PAM limits the range of possible binding sites. However, the PAM used for S. pyogenes 
Cas9 (NGG) can be found approximately every eight base pairs in the human genome 
(Cong et al., 2013). In our case a PAM site was located upstream of the seed region for 
miR-23a, miR-23b, miR-27a and miR-27b. For miR-24 a PAM was located in the seed 
region of the miRNA itself. 
In our experiments we demonstrated by Sanger sequencing, Surveyor® assay and NGS 
that we can effectively target miRNAs proving that CRISPR/Cas9 can be used in CHO 
cells without the need of codon optimisation. We also observed a reduction in mature 
miRNA expression. Comparing targeting efficacy showed that not every miRNA is 
targeted with the same efficiency which was evident by the amount of indels generated 
and miRNA expression (Figure 28 and Figure 29). Targeting efficiency seems to be 
highly dependent on the nature of the locus or the sgRNA (Ronda et al., 2014). The 
sgRNA is critical for the specificity and binding efficiency of Cas9 to the genomic target 
locus. However, studies have shown that not every position of the 20-nucleotide long 
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sequence is equally important. 5’-truncated forms of the sgRNA did not reduce the 
cleavage efficiency. However, deletions at the 3’-end prevented cleavage of the target 
DNA (Fu et al., 2013b; Hsu et al., 2013; Jinek et al., 2012). Functional analysis of Cas9 
orthologues showed that the 3’- region works as a “seed” region and is indispensable for 
target binding and efficient cleavage of the target DNA. In addition, the amount and the 
position of mismatches which are tolerated is dependent on the sgRNA used and is 
highly variable but reasons for this effect remain unclear (Fu et al., 2013b; Hsu et al., 
2013). When we targeted miR-23a the expression of miR-23b was affected and vice 
versa. The same was observed for miR-27a and miR-27b (Figure 30). When the sgRNAs 
were compared it was apparent that the 3’ of the guide which is located close to the PAM 
had a high sequence similarity. Cross-targeting was also observed when indels were 
analysed using NGS (Table 7) supporting the observation that the 5’ region of the sgRNA 
is not as important for targeting.  
It has been suggested that the binding efficiency of Cas9 is dependent on DNA 
methylation and chromatin modifications. Wu and colleagues showed that DNA 
methylation of CpG target sites is related to a lower binding efficacy of Cas9 (X. Wu et 
al., 2014). Furthermore, they proposed that histone modifications, which affect the 
chromatin accessibility, could hinder sgRNA binding but it has yet to be proven. 
Our results demonstrated that targeting efficiency was either sgRNA or locus dependent 
with the highest efficacy observed for miR-23a, miR-23b and miR-24 with up to 98% 
indel frequency in mixed populations. For miR-27a and miR-27b lower targeting efficacy 
was observed which was also reflected in mature miRNA expression data which showed 
a range between ~3 and ~10-fold reduction in abundance for both. As we successfully 
proved that miRNAs could be targeted and miRNA expression could be reduced we 
wanted to explore whether the passenger strand or the processing of the precursor was 
affected. 
Both, miR-24-3p and miR-24-5p were shown to be less abundant in CHO-K1 mAb after 
targeting the seed region of miR-24-3p. Levels of miR-24-3p as well as miR-24-5p 
showed a comparable level of reduction. We also observed the same reduction for miR-
27b-3p and miR-27b-5p after targeting miR-27b-3p. The same reduction in mature levels 
of both miRNA strands was observed by Chang and colleagues after targeting miR-17, 
miR-200c and miR-141 in human HCT116 cells (Chang et al., 2016a). In contrast to 
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reduced expression levels of individual mature miRNA members, an increase in primary 
(pri-miR) microRNA levels were observed for miR-17-92, miR-200c and miR-144.  
To investigate whether this was also the fact in our cells, expression levels of the miR-
24 precursor was analysed. In fact, an accumulation of ~9-fold was observed for pre-
miR-24 in the mixed population (Figure 35). The same strong accumulation was 
observed in 3 out of 6 clones (clone 1, 5, 6) isolated from a mixed population where miR-
24 was targeted. Clone 4 showed a slight enrichment of pre-miR-24, however it was 
confirmed using NGS that this could be due to a non-clonal origin or reduced efficiency 
of targeting (22% indels in miR-24-2). Clone 5 and 6 on the other hand showed a high 
accumulation of precursor as well as complete targeting of miR-24-1/2 confirmed by NGS 
with >99% indels. Therefore, impaired processing is most likely the cause of 
accumulation after targeting of a microRNA. Upregulation of pre-miR-24 or the primary 
construct could also be the cells reaction of reduced mature miR-24 levels. However, 
when mature levels of all other members of the cluster was assessed no difference was 
observed.  
The first step after transcription of the primary construct is the cleavage by Drosha 
RNase III which processes the pri-miRNA into a ~70 nucleotide long precursor miRNA 
(pre-miRNA). If the miRNA is located in an intron, mRNA splicing can alternatively lead 
to formation of pre-miRNAs (Y. Lee et al., 2003). The pre-miRNA exhibits a 5´-phosphate 
and a 2 nucleotide 3`-overhang resulting from the RNase III cleavage. The second step 
is the export of the pre-miRNA into the cytoplasm mediated by exportin-5 which binds 
dsRNA and uses RanGTP as a cofactor (Lund et al., 2004). In the cytoplasm the pre-
miRNA is further processed by Dicer RNase III multi protein complex into a 22-nucleotide 
miRNA-miRNA* duplex with a two nucleotide 3`-overhang (Y. Lee et al., 2003) and the 
duplex is incorporated into a pre-RISC. Pre-miR maturation can alternatively be 
conducted by AGO2 (Y. P. Liu, Schopman, & Berkhout, 2013). The increase in 
accumulated pre-miR suggests an inhibition of maturation due to the loss of specific 
sequence features or structures (Starega-Roslan et al., 2015). The two main drivers for 
processing are the RNases Drosha and Dicer which recognise different sequence motifs. 
In the case of Dicer and Drosha, a bias towards uracil was observed at processing sites 
and a lack of guanine (Gu et al., 2012; Starega-Roslan et al., 2015). Loop positioning 
has been shown to be a determining factor of dsRNA recognition and processing for 
Dicer activity (Starega-Roslan et al., 2015). However, mutating Drosha recognition sites 
has shown, that structural changes may only cause alternative processing of the pri-
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miRNA (Ma et al., 2013). Targeting structural important regions of the miRNA i.e. the 
stem-loop or the seed region may be therefore the most effective strategy for miRNA 
engineering to impair miRNA processing and mature function.  
Keeping in mind that using CRISPR or other targeted genome engineering tools like 
ZNFs or TALENs (Jiang et al., 2014), may also inhibit the passenger strand it is important 
to remember that the phenotype potentially is a result of the miRNA partner. For a long 
time, the idea was that after recruitment and processing of miRNA/miRNA* duplex the 
passenger strand which usually shows a lower stability is degraded. However, several 
studies have shown that the miR* strand also has a role in transcriptional repression 
under certain circumstances. The miR* strand is usually found in much lower abundance 
than the mature counterpart (Lagos-Quintana et al., 2002). Studies have shown that the 
miRNA and miRNA* can function both in regulation of related pathways or independent 
roles (Shan et al., 2013; Yang et al., 2013).  
To establish whether the phenotype after depletion of miR-24 in CHO-K1 mAb was a 
result of miR-24-3p or miR-24-5p, mimics for miR-24-3p and miR-24-5p were transfected 
in expectation of opposing phenotypes. It was indeed the case that miR-24-3p inhibited 
proliferation significantly. Growth inhibition after overexpression of miR-24-3p was also 
observed by other groups in several cell lines (Mishra et al., 2007). MiR-24-5p however, 
had no effect on growth in this particular cell line.  
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5.2.2 Assessment of phenotypes after CRISPR/Cas9 mediated targeting of 
individual members of the miR-23 cluster 
5.2.2.1 Targeting of miR-23a and miR-23b using CRISPR/Cas9 leads to prolonged 
culture length 
Depletion of miR-23a and miR-23b led to increased viable cell densities in late stages of 
batch cultures at the expense of productivity. Sponge mediated depletion of miR-23 in 
the same cell line showed the same phenotype (Kelly et al., 2014). The involvement of 
miR-23 in regulation of apoptosis is well studied. The X-linked inhibitor of apoptosis 
(XIAP) is a direct target of miR-23a and was shown to increase viable cell densities upon 
overexpression in CHO-K1 and HEK293T cells (Sauerwald et al., 2002). Inhibition of 
programmed cell death is regulated by binding of XIAP to caspase-3, -7 and -9. 
Additionally, there is evidence that miR-23a/b can prevent apoptosis during hypoxia by 
targeting important key components like Bax-like BH3 protein (BID), caspase-7 and 
BCL2/Adenovirus E1B 19kDa Interacting Protein 3-Like (BNIP3L) (Agrawal et al., 2014). 
MiR-23a has also been shown be involved in regulating the survival of embryonic stem 
cells due to inhibiting BMP-4 which normally drives apoptosis by activating PUMA and 
BAX (Musto et al., 2015). Besides, regulating direct targets for apoptosis, miR-23a and 
miR-23b were shown to be involved in regulation of cancer progression (Hu et al., 2017). 
It was demonstrated that miR-23 is involved in proliferation as well as glutamine 
metabolism in human B-lymphocytes as well as in CHO cells by targeting GLS and 
contributing to the Warburg effect (Kelly et al., 2015).  
 
5.2.2.2 Targeting of miR-27a using CRISPR/Cas9 reduces growth and targeting of miR-
27b leads to prolonged cultures 
Targeting of miR-27a using CRISPR resulted in decreased growth rates compared to 
the control in CHO-K1 mAb. Transient depletion of miR-27a caused the same phenotype 
in the same cell line (Sanchez et al., 2014).  
CRISPR mediated depletion of miR-27b resulted in an increase of culture duration in 
batch and fed-batch cultures with CHO-K1 mAb. Prolonged culture times were at the 
expense of specific cellular productivity however, increased viable cell density still led to 
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higher final titers. Sponge mediated depletion of miR-27 however showed no effect in 
CHO-K1 mAb.  
Increased viability in late stages of the culture due to reduced levels of miR-27b could 
possibly be due to its role in regulation of apoptosis. Agrawal and colleagues showed 
that miR-27 targets APAF1 and consequently inhibits apoptosis in hypoxic conditions 
(Agrawal et al., 2014). Further studies proved that miR-27 negatively regulates FADD 
which interacts with caspase-8 and apoptotic signalling and prevents apoptosis in human 
cells (Chhabra et al., 2009). Studying the effects of miR-27 depletion in CHO-S Fc also 
showed upregulation of proteins which are involved in mediation of apoptosis (Figure S 
10) including BAG3, BCL-2 and CIAPIN1. 
BAG3 for example (Bcl-2 associated anthanogene 3) has been shown to be involved as 
co-chaperone together with Hsp70 in the regulation of several pro-apoptotic proteins i.e. 
Bim (Rosati et al., 2011) and is also involved in development of apoptosis resistance in 
lung cancer (Zhang et al., 2012). Another upregulated protein was CIAPIN1 (cytokine-
induced apoptosis inhibitor-1) which was shown to be involved in developing drug 
resistance in several cancer cell lines due to its role in regulation of BCL-2 and BAX (Li 
et al., 2007) as well as Bcl-L and MDR-1 (Zhang et al., 2011). Overexpression of BCL-2 
has been very well described as a cell line engineering tool to prevent apoptosis in many 
industrially relevant cell lines like CHO, NS0 myeloma and SF9 cells (Goswami et al., 
1999; Mastrangelo et al., 2000; Mitchell-Logean & Murhammer, 1997). Increased 
resistance to apoptosis was assessed in various circumstances including shear stress, 
oxygen limitation, ammonia and nutrient depletion. However, it was also shown that the 
phenotype exhibited by the overexpression of both factors is cell line dependent. 
Furthermore, depletion of Bax using siRNAs or deletion using ZFNs resulted in increased 
cell viability in late stage CHO cell culture (Cost et al., 2010; Lim et al., 2006).  
Therefore, depletion of miR-27 and the resulting extension of culture times could be 
interesting for cell line engineering. To understand the effect after depletion of miR-27b 
better, proteomic profiling combined with pathway analysis in CHO-K1 mAb was 
performed. 
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5.2.2.3 CRISPR/Cas9 mediated targeting of miR-24 enhances CHO cell growth rate and 
productivity  
Depletion of miR-24 using CRISPR/Cas9 led to increased growth rates and productivity 
in CHO-K1 mAb. Overexpression of miR-24-3p inhibited growth (Figure 38). This was 
also observed by Mishra and colleagues where overexpression of miR-24 inhibited cell 
proliferation in six different human cancer cell lines by inducing the expression of p53 
and p21 (Mishra et al., 2009a). E2F2 and MYC are proteins which are involved in rapid 
cell cycle progression and Lal and colleagues showed that miR-24 targets both mRNAs 
and blocks uncontrolled proliferation. However, E2F2 and MYC do not have predicted 
binding sites for miR-24 in the 3’UTR (Lal et al., 2009). Mishra and colleagues also 
showed that miR-24 targets the DHFR gene which catalyses the reaction of dihydrofolate 
into tetrahydrofolate. Tetrahydrofolate is required for purine and pyrimidine synthesis and 
therefore plays an essential role in cell growth and proliferation. Consequently, down 
regulation of miR-24 caused an increase of proliferation in human epithelial cells. For our 
DE protein lists generated by proteomic profiling an upregulation of DHFR (1.27-fold, *** 
p = 0.00083) was also observed upon targeting miR-24 using CRISPR.  
Besides growth, IgG productivity was signficanlty higher in miR-24 depleted CHO-K1 
mAb cells. The same was observed for sponge mediated depletion in both CHO-K1 mAb 
and in CHO-S Fc. Proteomic profiling of cells where miR-24 was targeted using 
CRISPR/Cas9 demonstrated that same proteins upregulated in CHO-S Fc after sponge 
depletion were also upregulated in a different CHO cell linage (CHO-K1 mAb) producing 
a different protein product (see section 5.1.2.1.3). These were involved in translation, 
rRNA processing, tRNA processing and protein folding and have been extensively 
discussed in this section.  
To investigate the effect of miR-24 depletion on the transcriptome, RNAseq was 
performed. This revealed that 700 DE genes after targeting of miR-24. However, only 17 
genes were actually to common when proteomic and transcriptomic data were 
compared. It is not an uncommon phenomenon to observe that transcriptomic data does 
not correlate with proteomic data (Ghazalpour et al., 2011; Schwanhausser et al., 2011). 
Noncorrelation can have several reasons i.e. when stability of mRNA is compared to 
protein stability. With a typical half life of 15-20h for mRNAs their stability is significantly 
less than protein stability with a half-life of up to 72h (Hargrove & Schmidt, 1989; 
Schwanhausser et al., 2011). Schwanhausser and colleagues also stated that mRNA 
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abundance was significantly less compared to protein. Furthermore, the half-life depends 
on the state of the protein including phosphorylation, localisation or other PTMs as well 
as N-terminal residues (Maier, Guell, & Serrano, 2009). Besides, considerably lower 
stability of mRNAs, it is also important to mention that if the mRNA is detectable it does 
not mean the mRNA is translated. Binding to the ribosome, the number of bound 
ribosomes and processing factors may influence the translation as well as accessibility 
(Ingolia, Ghaemmaghami, Newman, & Weissman, 2009). In addition, the phase of the 
cell cycle influences the correlation between mRNA expression and proteomic data (Cho 
et al., 1998). Therefore, a correlation between our proteomic data and transcriptomic 
data might not be as evident. Furthermore, as mRNA abundance is comparably lower 
slight changes may not be recognized by applying stringent statistics but still can have a 
considerably high effect on protein levels.  
Interestingly, miR-23b was significantly upregulated (*** p = 0.0000017, log2 fold change 
6.09) compared to the control. Although statistically significant the base mean was low 
and would be considered “noise” from sequencing. Chhabra and collegues showed that 
the miR-23b cluster has a RNA-polymerase II promoter and all core elements needed 
for initiation of transcription (Chhabra, Dubey, & Saini, 2010c). Transcription by RNA- 
polymerase II will result in a poly-A tail which will be enriched in common RNASeq 
approaches. As an enrichment of pre-miR-24 was demonstrated after targeting of miR-
24 using CRISPR, it is possible that the pri-miR-23-24-27 transcript is enriched as well. 
An increase in primary transcript has been shown by Chang and colleagues for targeting 
the miR-17-92 cluster (Chang et al., 2016b). For these reasons it could be possible that 
miR-23b is more present or is eventually upregulated as a compensation for less levels 
of miR-24. We showed that miR-24 and miR-23 have a coorporate function in regulating 
similar pathways (Figure S 8) which has also been predicted by Liang and colleagues 
(T. Liang et al., 2014). To investigate this further the expression of the primary construct 
could be assessed.  
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5.2.2.3.1 Role of miR-24 in cell cycle progression, increased proliferation and 
metabolism 
The function of miR-24 in proliferation, cell cycle, metabolism and apoptosis has been 
intensively studied by several research groups (Agrawal et al., 2014; Lal et al., 2009; 
Mishra et al., 2007; Mishra et al., 2009b; Qin et al., 2010). We showed that 
downregulation of miR-24 increased proliferation and furthermore boosted productivity. 
To ensure that the phenotype was a result of miR-24 depletion and upregulation of 
known targets we assessed the expression of c-MYC and CDKN1b in clones and mixed 
populations. Expression of c-Myc showed some inconsistency in three clones assessed 
but was upregulated in mixed population. As an oncogene c-Myc plays a crucial role in 
cell cycle progression and proliferation through the transcriptional control of important 
cell cycle regulators including cyclin-dependent protein kinases (cdks) and E2F 
transcription factors (Bretones, Delgado, & Leon, 2015). Furthermore, it antagonises the 
expression or function of proliferation inhibitors including p21, p27 or RAS (Born et al., 
1994; Obaya et al., 2002; Perez-Roger et al., 1999). Besides the regulation of cell cycle 
progression, c-Myc is involved in boosting ribosomal biogenesis and translation but is 
also regulated itself tightly by miR-24. Together with ribosomal proteins, miR-24 is 
recruited to the 3’UTR of the c-Myc mRNA to regulate its translation when ribosomal 
stress is induced by treatment with actomycin D (Challagundla et al., 2011). Other 
ribosome related targets of c-Myc are for example RPL3, RPL6 and RPS15a (J. Kim et 
al., 2010). RPL3 (* p = 0.03, 1.20-fold) and RPS15a (* p = 0.03, 1.22-fold) were 
upregulated in our DE protein lists after targeting miR-24. Our observations that c-Myc 
is increased after depletion of miR-24 and that ribosomal processing as well as 
translation is increased could be part of the mechanism of driving both growth and 
productivity.  
CDKN1b or p27 is a cyclin-dependent kinase (CDK) and is a cell cycle inhibitor important 
for progression through G1 to S phase. Interestingly CDKN1b is a target of miR-24 
(Lynch et al. 2016) and was more abundant when miR-24 was depleted in mixed 
population as well as in all assessed clones (Figure 39). Being more abundant it could 
be argued that cell cycle progression might be arrested. Besides being a target of miR-
24 however, it was demonstrated that c-Myc is involved in regulating p27 and therefore 
may rescue cell cycle arrest and drive progression into the next phase (Vlach et al., 1996) 
Even though CDKN1b is higher expressed, growth was increased for our miR-24 
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depleted CHO-K1 mAb cell line which might be due to antagonising effects of c-Myc. 
The active form of p27 is dephosphorylated and located in the nucleus. Deactivation 
occurs due to phosphorylation and subsequent relocation into the cytosol triggered by c-
Myc. Cyclin E-cdk2 which is responsible for the phosphorylation is presumably recruited 
and causes deactivation of CDKN1b.   
The role of c-Myc in metabolism was first described in the 1920’s by Otto Warburg and 
coworkers hypothesising the change of cancer cells from using more efficient oxidative 
phosphorylation to aerobic glycolysis. Glycolysis is preferred in low oxygen conditions 
such as hypoxia where the universal energy source is converted to lactic acid rather than 
entering the TCA cycle (Warburg et al., 1956). This goes along with the observation that 
glucose transporters as well as glycolytic enzymes were upregulated (Osthus et al., 
2000). One of these enzymes is ENO1 which was also upregulated upon depletion of 
miR-24 in our study. However, an increase or shift towards glycolysis was not observed 
in our study (Figure 40). On the contrary oxidative phosphorylation and lactic acid 
production remained low upon the depletion of miR-24. This was a surprise as the 
production of lactic acid in exponential phase of fast growing cells is usually very high 
(Zagari et al., 2013). The same study observed a correlation of increased EACR 
combined with a reduction in oxidative phosphorylation. Surprisingly our observed 
increase in growth combined with increased productivity did not lead to increased 
mitochondrial function or acidification. Rapid consumption of glutamine and upregulation 
of glutaminolysis has been demonstrated to be another characteristic of fast growing 
cells (Deberardinis et al., 2008). This process is driven by overexpression of c-Myc which 
consequently drives the expression of the mitochondrial glutamine synthetase (GLS) 
(Dang, 2011). Upregulation of GLS and the resulting drive of glutamate and α-
ketoglutarate into the TCA-cycle is usually accompanied by increased pyruvate levels as 
well as increased lactic acid production which was not observed. However, anabolic 
reactions can also be driven by glutaminolysis such as fatty acid production which is 
necessary for rapid cell proliferation (Figure 57).  
Besides metabolism, c-Myc has also been demonstrated to be directly involved in 
nucleotide synthesis which ultimately drives proliferation and translation (Liu et al., 2008; 
Mannava et al., 2008) as well as UPR/chaperone activation through LONP1, HSPD1, 
DNAJ3 and RUVBL2. The activation of UPR can also be independent of c-Myc but be in 
response to higher oxidative stress caused by higher translational demands. ROS are a 
side product of formation of disulphide bonds – and their formation would be increased 
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in a high productivity phenotype and could ultimately trigger the UPR (Schröder & 
Kaufman, 2005) which was also supported by our findings. UPR upregulation and ER 
stress are tighly co-regulated and it has been demonstrated that both can mediate 
intrinsic apoptosis pathway activation. Furthermore, it was shown that miR-24 is involved 
in targeting pro-apoptotic proteins like Bim, FAF-1, Caspase-9 and Apaf-1 (Agrawal et 
al., 2014; Cheng et al., 2005; Qin et al., 2010) or targets which are responsible for cell 
survival e.g. Bcl-2 (Singh & Saini, 2012a). Depletion of miR-24 resulted in an 
upregulation of NADH dehydrogenases which are associated with cell survival in 
instances of increased cellular stress (Ghosh & Girigoswami, 2008). However, increase 
in NADH dehydrogenase could also be a result of increased ROS and might be miR-24 
and c-Myc independent.  
 
 
 
Figure 57: Depletion of miR-24 abolishes the regulation of c-Myc. As oncogene c-Myc inhibits cell cycle 
regulators and activates the expression of cell cycle activators, ribosomal proteins, proliferation associated 
proteins as well as proteins involved in metabolism and translation.  
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Rather than promoting glycolysis, depletion of miR-24 and subsequent upregulation of 
c-Myc seem to preferably promote translation, ribosomal processing as well as 
nucleotide synthesis based on our results and findings by other groups. C-Myc and miR-
24 could also act cooperatively function as many targets seem to be targeted by c-Myc 
as transcription factor and miR-24 as transcriptional repressor.  
Taken together all results for targeting individual members of the miR-23 cluster shows 
that the phenotype obtained by transient upregulation or stable depletion are very 
comparable to our CRISPR experiments. However, it remains questionable if 
CRISPR/Cas9 is beneficial over sponge technology which is further discussed in 5.2.3.  
 
5.2.3 Comparison of sponge and CRISPR/Cas9 approaches for the knockdown of 
miRNAs  
Experiments performed by stable depletion using sponges correlate with our findings 
when targeting with CRISPR/Cas9 in the same cell line. Depletion of miR-23 with a 
sponge showed the same phenotype as when miR-23a/miR-23b was targeted with 
CRISPR. In the case of targeting miR-24 the productivity phenotype was stronger using 
CRISPR/Cas9 compared to sponge mediated depletion and growth was additionally 
enhanced. In this section the features of sponge decoy and CRISPR technology are 
compared to discuss which tool might be better for targeting miRNAs.  
One way to investigate if the sponge for a miRNA is working is the comparison of reporter 
presence compared to the control. In our case reduced GFP levels indicated the 
successful depletion of a miRNA target. Additionally, miRNA abundance can be 
measured using i.e. TaqMan® assays. Lower abundance of the miRNA would indicate 
successful depletion of miRNA presumably due to binding of miRNA:RISC to sponge 
mRNA (Chekulaeva & Filipowicz, 2009). However, for the depletion of miR-24 in CHO-
S Fc an increase in abundance was observed. This effect could be due to translational 
inhibition. Our sponges were designed with imperfect binding sites (Kluiver et al., 2012b). 
The degree of inhibition or cleavage is presumed to be determined by either imperfect 
binding or complete binding. Perfect complementarity in binding to the target mRNA will 
lead to cleavage (Chekulaeva & Filipowicz, 2009) whereas imperfect binding will most 
likely lead to inhibition and stabilisation of the miRNA:mRNA complex (Huntzinger & 
Izaurralde, 2011). Due to target mediated miRNA protection (TMMP) miRNA 
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expression/levels can appear to be increased possibly occur and consequently higher 
levels of mature miRNA despite translational inhibition of the mRNA target (Chatterjee 
et al., 2011).  
We demonstrated that when targeting one miRNA that the passenger strand was 
affected as well due to impaired processing of the precursor. Effects on the phenotype 
can however be further investigated by performing complementary transient experiments 
to deplete or overexpress both miRNAs. In the case of sponge decoys, it is hypothesised 
that not only the targeted miRNA can bind to the sponge but also whole miRNA seed 
families could potentially be bound (Kluiver et al., 2012a). The seed region is important 
for mRNA recognition but a perfect match of each nucleotide of the seed region is not 
necessary (Didiano & Hobert, 2006; Lewis et al., 2003). This increases the target range 
of a miRNA itself but also enables the binding of several different miRNAs to for example 
a sponge. However, binding of multiple different miRNAs with a similar seed region to a 
sponge could potentially reflect a false phenotype and the CRISPR/Cas9 system might 
be more suitable for direct targeting.  
One advantage of using the CRISPR/Cas9 system over sponge technology is that no 
transgene has to be expressed. This is an advantage as additional expression of a 
transgene may affect the expression of the therapeutic protein in industrially used cell 
lines. All our experiments were performed using CRISPR/Cas9 plasmids expressing 
Cas9 and a chimeric sgRNA however, the possibility of transfecting Cas9 as protein 
combined with a sgRNA exists. This could be an advantage when cytotoxicity of the 
reporter gene is a concern as demonstrated in neuronal cell lines (Detrait et al., 2002). 
Another concern could be changes in metabolome due to high expression of selection 
markers or reporter which was observed by Yang and collegues in mesenchymal stem 
cells (Yang et al., 2017). The same has been demonstrated in CHO cells where the 
usage of selection markers negatively influenced translation as well as metabolism 
(Yallop et al., 2003). For CHO cells clonal stability is an important concern (discussed in 
section 5.1.3) and random integrations in cell line development could be avoided using 
CRISPR/Cas9 and hence reduce clonal variability.  
In conclusion, the CRISPR/Cas9 system might be the more beneficial tool than sponges 
for miRNA targeting. Furthermore, we found that phenotypes were reproducible or even 
enhanced compared to depletion with the sponge counterpart at least in the case of 
members of the miR-23 cluster. 
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5.2.4 CRISPR/Cas9 as tool for improving biopharmaceutical production 
With CRISPR being an effective and easy to use tool for the generation of cell lines an 
industrial application to improve production or product attributes is conceivable. One 
main concern for the usage of CRISPR in therapeutic/cell therapy applications are off-
target effects. In fact, two recent studies showed that off-targeting might occur more often 
than it was presumed (Fu et al., 2013; Mali et al., 2013). For the use of CRISPR to 
improve productivity of CHO cells or product attributes of an expressed recombinant 
protein off-targets may not be as detrimental as long-term studies are applied to ensure 
genetic stability of production clones as well as intensive clinical studies to ensure patient 
safety. Furthermore, using CRISPR to alter product attributes like glycosylation could 
reduce immunogenicity and enhance efficacy of therapeutic proteins. One example is 
the knockout of FUT8 to reduce fucose levels on mAbs which ultimately will lead to 
enhanced ADCC (Ronda et al. 2014). Therefore, using CRISPR in biopharmaceutical 
industry could be a reliable tool to improve phenotypes and therapeutic protein products.  
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5.3 Genome-wide “loss of gene function” studies in Chinese Hamster Ovary cells 
using a CRISPR/Cas9 library 
CRISPR/Cas9 can be successfully and efficiently used to target genes as well as 
miRNAs and generate clones with complete knockouts of the target gene. As a further 
application we wanted to use CRISPR/Cas9 for the implementation of genome wide “loss 
of gene function” study as previously reported by several research groups (Agrotis & 
Ketteler, 2015; Shalem et al., 2015; T. Wang et al., 2014) in human cells. The principle 
is based in using a library containing 87,897 different sgRNAs, targeting 19,150 mouse 
genes, which can be packed into a lentiviral delivery system. The library was supposed 
to be transduced into a CHO-K1 cell line expressing a mAb and human codon optimised 
spCas9. However, many Cas9 expressing vectors are commercially available but the 
sgRNA-library used for this study expresses only the sgRNA scaffold under the control 
of U6 promoter. Consequently, the first step was the generation of a cell line and the 
selection of a clone which expressed Cas9 stably. The plasmid used for miRNA 
experiments had puromycin as the selection marker and was proven to be very effective 
in the same cell line. As the library was based on selection with puromycin as well, we 
had to exchange the Cas9-2A-puro version with Cas9-2A-hygromycin. After successful 
investigation if the Cas9-2A-hyg version was functional targeting (miR-24), it was 
transfected into CHO-K1 mAb and single cell clones were isolated. Ten clones were 
characterised and one final clone was selected for the introduction of the library. All 
analysed clones behaved differently in batch cultures which reflects discussed 
heterogenous populations of CHO cells (see section 5.1.3). For all ten isolated clones 
the Cas9-2A-hyg version was fully functional when tested on miR-24.   
The library consisted of 87,978 different sgRNAs which target every gene in mouse at 
least four times to ensure an efficient knockout as not every sgRNA will exhibit the same 
efficiencies, as previously discussed. Sequencing of the CHO-K1 genome shows, that 
20,612 genes in mouse are homologues to Chinese hamster genes (Xu et al., 2011). 
Therefore, the introduction of the mouse sgRNA-library should theoretically target most 
genes in CHO-K1 cells.  
The most critical step for this approach was to guarantee that the coverage of the library 
was maintained but also to ensure a low number of integration events - ideally one copy 
per cell. Amplification of the library using electroporation of highly competent E. coli cells 
and low temperatures for cell growth showed a transformation efficiency of 1.43 x 1010 
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cfu/µg DNA, which was sufficient enough to ensure a good coverage of sgRNAs after 
plasmid isolation. When CHO-K1 mAb was transduced with library containing lentivirus 
a very low efficiency was observed. The investigation was based on BFP which as a 
fusion protein shows low intensities. The EGFP lentiviral construct can be delivered more 
efficiently in comparison to the sgRNA-library (Figure 48) despite similar plasmid sizes. 
Therefore, the usage of lentivirus to deliver the library was not suitable for our approach. 
The ability to resist viral infections is one benefit of CHO cells and is desirable in a 
bioprocess environment. Transcriptome analysis and comparison of human genes which 
are important for viral entry and vesicular transport show a lack of expression in CHO-
K1 cells (Xu et al., 2011). Many of these non-expressed genes encode for cell surface 
proteins like integrins, cadherins and selectins which are important for viral attachment 
and recognition. Furthermore, CHO-K1 cells are also resistant to the Herpes simplex 
virus, Hepatitis B virus and human immunodeficiency virus type-1 (HIV-1) due to a lack 
of expression of their membrane surface binding receptors (Conner et al., 2005; Xie et 
al., 2005). These cell adhesion molecules include CD2, CD4, CD48 and CD 48. 
Interestingly the lentivirus is a replication deficient HIV-derived and uses CD4 as the cell 
surface receptor which is recognised by gp120 glycoprotein on the surface of the virus 
itself. These findings could explain the low efficiency of transduction using a lentiviral 
delivery system for CHO-K1s. As previously discussed, chromosome rearrangements 
and aberrations lead heterogenous populations. Our experiments showed that only a 
small number of cells were transduced with the lentivirus leading to the conclusion that 
only a subpopulation was susceptible to viral attachment and integration. Even clonal 
selected cells which should theoretically form a homogenous population with similar 
gene expression patterns etc. can show distinct deviations into subgroups (Datta et al., 
2013; Davies et al., 2013). This heterogeneity could be one reason why some cells show 
multiple integration events despite low viral titres. 
Another reason resulting in a low level of viral transduction could be the efficiency of 
integration. Infection of human osteosarcoma cells with HIV showed that only 0.41 % of 
the virus input is reverse transcribed and integrated into the host’s genome (Thomas, 
Ott, & Gorelick, 2007). If the viral genome is integrated into the host’s genome it has 
been shown that it is preferentially integrated into transcriptionally active units e.g. CpG 
islands and transcriptional start sites (Bushman et al., 2005; Demeulemeester et al., 
2015). However, a low level of transduction would be desirable for this project to ensure 
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single copy integrations but the coverage of the library has to be ensured for an efficient 
screen of all genes in the CHO genome.  
The sgRNA-library contained a mammalian selection marker for puromycin and after 
selection using two different concentrations (10 µg/ml and 20 µg/ml of puromycin) ~50-
60 % of all cells exhibited BFP positive signals. Nevertheless, FACS analysis showed 
that in comparison to the negative control, a shift of the whole cell population was visible. 
This indicates that cells were infected and successfully selected, however, the intensities 
of BFP signal were low. Low intensities could occur due to the BFP/Puromycin fusion 
which shows a weaker fluorescence signal as shown before in the transfection efficiency. 
To validate this result, a standard curve was generated to investigate the number of 
integrated copies using qPCR analysis. Using the CHO-K1 genome size of 
2,447,154,408 base pairs, the number of chromosomes and weight of all DNA in a cell 
allows the calculation of integration events (Maccani et al., 2013; Xu et al., 2011). This 
calculation showed that four integration events per cell occurred without relation to the 
amount of Puromycin used for selection. The low MOI in combination with an unexpected 
higher number of viral integrations agrees with with the observation that CHO-K1 cells 
are relatively resistant to infections by viral systems and only a subpopulation exposed 
with an excessive number of lentiviral particles is able to uptake several particles. Four 
integrations and the low transduction efficiency suggested that the lentiviral system is 
not applicable for CHO-K1 cells. Several library approaches for genome “loss of gene” 
function studies have been reported (Shalem et al., 2015; Wang et al., 2014; Koike-Yusa 
et al., 2014; Gilbert et al., 2014) using a lentiviral delivery system for introduction of the 
sgRNA library. However, it was not demonstrated that transduction efficiency was an 
issue as human cell lines were primarly used including reporter genes which can be used 
to isolate positively transduced cells using FACS.  
To investigate alternative delivery methods, PEI-based transfection as well as 
nucleofection was performed to transfect the sgRNA library. For both approaches 
different numbers of plasmids were used and copy numbers were investigated using 
qPCR (Figure 49). It was observed that copies per cell vary around six to eight and 
transfection efficiencies were reduced with lower amounts of plasmid DNA. The goal was 
to deliver one to two copies per cell suggesting that PEI-based transfection was like the 
lentiviral system not suitable for CHO cells. When nucleofection was used with 0.5µg of 
plasmid DNA, a high transfection efficiency was observed as and resulted in 1-2 
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integrations per cell. Higher amounts of plasmid DNA led to over 7 copies per cell. 
Therefore, nucleofection was chosen for the delivery of the sgRNA library.  
 
5.3.1 Advantage of CRISPR/Cas9 sgRNA libraries over siRNA/shRNA libraries 
For the identification of pathways and biological functions of proteins, RNA interference 
or short RNAi was used in the past. However, RNAi has several drawbacks as for 
example off target effects, cytotoxicity as well as cell line dependent effects (Mohr & 
Perrimon, 2012). Furthermore, RNAi is based on a very similar mechanism to miRNAs 
where short dsRNA is incorporated by Dicer, processed and the mature single strand 
plays its role in transcriptional regulation of mRNAs in the RISC. The approach usually 
depends on a knockdown and if transiently performed will only last for several days. 
Therefore, the delivery using lentiviral systems for a stable expression were developed 
and applied with success (Bassik et al., 2009; Root et al., 2006). However, even with the 
stable expression through a lentiviral system other disadvantages had to be overcome. 
A suggested method was hereby the generation of sgRNA libraries (Koike-Yusa et al., 
2014). Combining the high specificity of Cas9 with high efficacy, sgRNA based screens 
can provide better and more reliant information about pathways and protein function 
through powerful “loss of gene function” studies. Here we proposed a way of using a 
sgRNA library for the identification of genes involved in survival of bioprocess related 
stress conditions as well as gene loss which may lead to higher productivity. 
  
5.3.1.1 Investigation of stress conditions leading to an enrichment or depletion of 
subpopulations with enhanced stress resistance 
To investigate if cells transfected with the library can be adapted to certain stress 
conditions and if exposure to these will lead to an outgrow of subpopulations, we decided 
to apply treatments with NaBu as well as high salt conditions (Figure 53). NaBu as well 
as hyperosmotic conditions have been described in the literature to increase productivity 
of CHO cells expressing recombinant proteins. Treatment with NaBu has been shown to 
increase productivity in CHO cells (Jiang & Sharfstein 2008; Sung et al., 2004) due to 
inhibition of HDAC and subsequent hyperacetylation. Less condensed DNA increases 
accessibility of transcription factors leading to increased gene expression (Vidali et al., 
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1978). Furthermore, apoptosis is induced as well as an inhibition of proliferation due to 
upregulation of several cell cycle regulators i.e. c-Myc (Davie, 2003). Interestingly, NaBu 
was used for induction of apoptosis by overexpression of BCL-2 (Kim et al., 2002). It was 
demonstrated that BCL-2 overexpression can inhibit apoptosis induction using sodium 
butyrate. Therefore, we wanted to use NaBu to induce apoptosis after transfection of the 
library to enrich for subpopulations in which a “loss of gene function” led to resistance to 
apoptosis induction. Apoptosis is well studied and genes identified can be most likely 
related back to either anti- or proapopotic function. Genes can be related back through 
idenfication of which sgRNA was used: treatment in stress conditions will either lead to 
an enrichment or depletion of a subpopulation as the knockout was either beneficial or 
critical to cell survival. SgRNAs used can be then identified using NGS and related back 
to targeted gene. Using apoptosis was proposed to serve as “proof of concept” for our 
library in CHO cells. Concentrations for treatment were hereby between 1-5 mM 
however, treatment of our CHO-K1 mAb cell line led to decreased cell growth and low 
viability even at low concentrations. Consequently, further optimisation would be 
necessary to use NaBu as potential stress condition.  
Another environmental stress that we chose was the adaption to high salt conditions. 
Hyperosmolality has been described as a tool to improve productivity of CHO cell lines 
(Zhang et al., 2010) presumably due to growth inhibition however, with possible effect 
on glycosylation of therapeutic product (Lee at al., 2017). Furthermore, it is well 
characterised that high salt conditions can induce apoptosis and autophagy in CHO cells 
(Han et al., 2010). We proposed that adaption to hyperosmolality could be used to proof 
that our library was working. A knockout of a gene which led to inhibition of apoptosis as 
well as an outgrowth of subpopulations should theoretically be identifed by an enrichment 
of sgRNAs targeting that gene. More or less abundant sgRNAs can then be identified 
using NGS. 
We tested several salt concentrations by adding NaCl to the growth medium and 
monitoring proliferation and viability (Figure 53). High concentrations showed drastic 
effects on proliferation and viability. We used 450 mOsm/kg as a baseline for adaption 
to hyperosmotic conditions. However, after three passages no growth of treated cells 
was observed and as consequence we decreased the osmolality to 400 mOsm/kg. 
Adaption to these hyperosmotic conditions was reflected in a stepwise increase in 
proliferation. This was presumably due to outgrowth of resistant subpopulations (Figure 
54). Besides induction of apoptosis, osmolality might be interesting for certain bioprocess 
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applications i.e. fed-batch cultures. High osmotic pressure due to addition of feed and 
pH regulation is the cause in fed-batch cultures. Genes involved in overcoming this 
stress could be used as cell line engineering targets. After adaption over three passages 
genomic DNA of untreated and treated sgRNA population was isolated and prepared for 
NGS.  
 
5.3.2 Selection of high producing subpopulations using FACS based enrichment 
One possible application of the library is the usage of FACS in combination with low 
temperature cell staining to select high producing clones. SgRNAs which lead to an 
increase in producitivity or secretion should be enriched and identified using NGS. The 
cells transfected with the sgRNA library were sorted twice and a distinct shift in intensity 
was observed for Sort I and Sort II compared to unsorted populations. Furthermore, 
productivity as well as IgG titres were elevated compared to the unsorted sgRNA library 
expressing cell population.  
From the point of translation at the endoplasmic reticulum for secreted proteins, further 
processing as well as PTMs and secretion are limiting steps which can result in low 
productivity. Therefore, the identification of genes which lead to closing this bottleneck 
could be interesting for cell line engineering. As a FACS based method is used for the 
stain of a secreted therapeutic protein on the surface of the cell, cells showing a high 
secretion or productivity can be isolated easily (Brezinksy et al., 2003; Pichler et al., 
2011). For cells where no amplification procedure (no MTX) was used an increase of 25-
fold in specific productivity was observed. Using MTX for amplification resulted even into 
higher Qp of > 100-fold over several sortings (Pichler et al., 2011). In our study, sorting 
the sgRNA library resulted in an increase in Qp of ~1.5 fold. Although a 1.5-fold increase 
was considered to be successful, Qp could be further increased by applying more sorts 
as it was suggested by serval studies. However, applying several sorts may decrease 
the number of genes that can be identified by NGS as knockouts resulting in only a mild 
increase in productivity will be most likely neglected. Furthermore, high specific 
productivity may not be the result of a gene knockout but is the result of clonal variation. 
The amount of sgRNAs identified will most likely reduce with increasing number of sorts. 
After sorting genomic DNA of following populations was isolated and prepared for NGS: 
Unsorted, Sort I, Sort II.  
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6 Conclusions 
6.1 Stable depletion of the miR-23 cluster and its individual miRNA members in a 
panel of industrially relevant cell lines.  
• Depletion of the miR-23 cluster or individual members is cell line dependent.  
• MiR-23b and miR-27b expression in CHO-K1 SEAP expressing cells was shown 
to be ~3-fold higher compared to the CHO-K1 parental cell line. Across the panel 
of cell lines miR-24 was lower expressed compared to a parental CHO-K1 cell 
line. 
• Depletion of miR-23 and the resulting phenotype seems to be highly cell 
line/clone dependent as no cell line tested showed the same effects as in CHO-
K1 SEAP expressing cells.  
• Stable depletion of miR-23-24-27 led to increased Fc-fusion levels and specific 
productivity in CHO-S Fc in batch as well as fed-batch cultures. Viability or growth 
were not affected. This phenotype was only observed in mixed population but not 
in derived single cell clones.  
• The impact of depletion of miR-23-24-27 is highly cell line dependent as no other 
cell line showed beneficial phenotypes.  
• Depletion of miR-24 and miR-27 led to increased productivity in CHO-S Fc  
• The depletion of miR-24 also showed beneficial effects on productivity in six out 
of seven tested cell lines including CHO-K1 Fc, CHO-K1 mAb, CHO-K15 EPO, 
CHO-K1 DP12 and DG44i mAb. Increase in productivity is not product 
dependent. 
• Proteomic profiling and pathway analysis for CHO-K1 mAb and CHO-S Fc after 
depletion of miR-24 revealed that several proteins involved in ribosomal 
biogenesis, ribosome assembly, translation, tRNA synthesis and unfolded protein 
response were significantly upregulated.  
• Depletion of miR-23-24-27 seems to have an impact on mannosylation, 
sialylation and non-sialylated species of Fc-fusion product. Depletion of miR-24 
seems to increase terminal sialic acid, non-sialylated complex glycans as well as 
mannose species. Depletion of miR-23 increased non-sialylated complex glycans 
as well as mannose content and miR-27 depletion showed increased levels of 
non-sialylated complex glycans.  
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• Proteomic profiling combined with pathway analysis showed that the miR-23 
cluster and individual members act cooperately by sharing targets but also have 
individual roles. Especially miR-24 as well as miR-23 showed high level of 
synergetic interactions.  
6.2 CRISPR/Cas9 as a genome engineering tool to target miRNAs in CHO cells 
• All designed sgRNAs targeting miR-23a, miR-23b, miR-27b, miR-27a and miR-
24 were functional and induced indels in or close to the seed region of targeted 
miRNAs. The human codon optimised spCas9 variant was fully functional in 
CHO-K1 mAb expressing cells and the targeting efficiency of CRISPR/Cas9 led 
to a knockdown of 85-99% in mixed populations. 
• Knockdown efficiency of miRNA expression seems to be highly sgRNA 
dependent.  
• Targeting between paralogues was observed due to high sequence 
complementarity of miRNA targets. 
• Single cell clones exhibiting a low expression of the miRNA target were 
identified.  
• Multiplex targeting of miRNAs is possible  
• Phenotype obtained during transient screens as well as for sponge mediated 
depletion seemed comparable to CRISPR/Cas9 knockdowns.  
• Targeting one strand of a microRNA can reduce levels of passenger strand as 
well. This observation seems to be correlated to an increase in precursor and 
indicates impaired processing by Drosha or Dicer.  
• CRISPR/Cas9 mediated depletion of miR-23a as well as miR-23b led to 
prolonged viability in batch mode at the expense of productivity. Depletion of 
miR-27a reduced growth rates in batch culture.  
• Depletion of miR-27b led to a reduction in IgG titre or productivity however, it 
also led to prolonged viable cell densities in late stages of the cultures in batch 
and fed-batch. Prolonged culture times led to increased final titres. Extended 
cultivation times may be due to reduced targeting of anti-apoptotic genes which 
was shown by pathway analysis.  
• Depletion of miR-24 using CRISPR/Cas9 in CHO-K1 mAb increased specific 
productivity as well as proliferation.  
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• Overexpression of miR-24-3p led to decreased proliferation reversing the effect 
observed by depletion. MiR-24-5p overexpression did not have any effect. 
• Proteomic profiling revealed that upregulated proteins due to reduced levels in 
miR-24 are involved in ribosomal biogenesis, ribosome assembly, translation, 
tRNA synthesis and unfolded protein response. The same pathways and 
proteins were identified for sponge mediated depletion with subsequent 
proteomic profiling of CHO-S Fc.  
• Over 60% of upregulated proteins were predicted targets of either miR-24-3p or 
miR-24-5p.  
• Using NGS, 700 mRNAs were significantly DE however, only 17 correlated with 
our proteomics list. When DE mRNAs were analysed for impacted pathways, 
an involvement in ribosomal biogenesis, translation, tRNA synthesis and 
unfolded protein response was observed.  
• Mannose species were negatively affected due to CRISPR mediated 
knockdown of miR-24.  
 
6.3 Genome-wide “loss of gene function” studies in Chinese Hamster Ovary cells 
using a CRISPR/Cas9 library 
• The sgRNA-library which consisted of 87,897 different sgRNAs targeting 19,150 
protein coding genes was successfully amplified and packaged into a lentiviral 
delivery system. 
• Transduction efficiency was very low presumably due to only subpopulations 
which were susceptible to viral integration. This led to a high number of 
integration events (~4) but low number of surviving cells during selection.  
• The lentiviral delivery system does not seem to be suitable to achieve a sufficient 
coverage of the full set of sgRNAs in CHO cells. 
• Transfection of the sgRNA-library using PEI-based TransIT®-X2 showed a high 
amount of integration events concluding it was not suitable to achieve a high 
coverage.  
• Nucleofection led to approximately 2 integration events per cell making it the 
preferred method for delivery of the sgRNA-library. 
• The cloned Cas9-2A-hyg version was fully functional. Integration of the sgRNA 
library led to ~1.5 copies per cell.  
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• High salt conditions and sodium butyrate were tested for the induction of 
apoptosis. Due to the drastic impact of NaBu, hyperosmolality was chosen to 
enrich for knockouts which may lead to outgrowth of resistant subpopulations.  
• FACS based selection for high producing cell subpopulations was successful and 
after two enrichments higher specific productivity as well as IgG titre was 
observed. 
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7 Future work 
7.1 Stable depletion of miR-23-24-27 as well as individual miRNA members in 
industrially relevant cell lines and the impact on growth and productivity 
Using a mixed population of a CHO-S cell line expressing an Fc-fusion showed that 
stable depletion of miR-23-24-27 led to a ~1.5-fold increased productivity compared to 
the negative control in batch culture. Same phenotype was observed in fed-batch mode 
but not on a clonal level. Depletion of miR-24 and miR-27 in CHO-S Fc led to a similar 
increase in productivity and titre. Similar effect of depletion of miR-24 resulting in 
increased specific productivity was observed in 6 out of 7 tested cell lines including CHO-
K1 mAb. Reduced levels of miR-23 led to no impact at all. Following future experiments 
could be performed: 
• Optimisation of fed-batch cultures for CHO-S Fc to further boost productivity after 
sponge mediated depletion.  
• Isolation of more clones for the depletion of miR-23-24-27 as well as miR-24 and 
miR-27 to enhance the observed productivity phenotype if possible as well as 
investigation what led to it.  
• Reduced levels of miR-24 seemed to have a beneficial effect in 7 out of 8 tested 
cell lines. As cell lines are highly variable, proteomic profiling of all 7 cell lines 
could be used to identify key players in resulting phenotype as well as targets for 
cell line engineering.  
• Only CHO-K1 mAb as well as CHO-S Fc have been characterised for the 
depletion of miR-27 with inconclusive results. Impact of reduction of miR-27 could 
be tested in all other cell lines as well.  
• CRISPR/Cas9 was so far only introduced into CHO-K1 mAb showing enhanced 
effects of phenotypes over targeting. Clones exhibiting a complete deletion of a 
miRNA target can be generated to possibly boost phenotype for i.e. miR-24 
depletion.  
• Depletion of the whole cluster as well as each member was investigated in CHO-
S Fc to identify if synergetic effects may exist. Due to the high variability 
proteomic profiling together with RNA sequencing could be performed to 
investigate the molecular function of the miR-23 cluster over a panel of cell lines.  
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• Further studies on how the glycosylation pattern is affected by the usage of 
sponge decoy technology to deplete certain miRNAs and if the effect is 
detrimental on efficacy of the produced protein product.  
7.2 CRISPR/Cas9 as genome engineering tool to target miRNAs in CHO cells 
It was shown, that miRNAs can be successfully targeted using CRISPR/Cas9 in CHO 
cells. Beneficial and comparable phenotypes can also be obtained compared to sponge 
decoy technology. Future work will hereby be focused on investigating mentioned 
phenotypes in a range of other cell lines as well as the introduction of an RNP based 
targeting approach as well as off-target considerations.  
CRISPR/Cas9 targeting miR-23 
It was shown, that a knockdown of miR-23a and miR-23b showed significantly increased 
cultivation times on expense of IgG production. Therefore, miR-23 depletion can be a 
viable tool for miRNA engineering: 
• CRISPR/Cas9 mediated targeting of miR-23a and miR-23b over a panel of cell 
lines. 
• Optimisation of batch and fed-batch cultures to investigate if culture times can be 
prolonged further as well as if titres can be boosted. 
• Characterisation of a clonal panel to investigate if culture length can be boosted 
or reduced productivity can be prevented. 
 
CRISPR/Cas9 targeting miR-24 
It was shown, that a knockdown of miR-24 showed significantly increased proliferation 
as well as productivity in mixed populations. Increased proliferation was also observed 
in a clonal panel. Increase in productivity was presumably due to upregulation of proteins 
involved in ribosomal biogenesis, ribosome assembly, translation, tRNA synthesis and 
unfolded protein response. Future work will aim on further investigation on the molecular 
impact of miR-24 as well as validation of possible cell line engineering targets. 
• Unbiased isolation and characterisation of clones to investigate if productivity 
phenotype can be boosted.  
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• Overexpression of HSPD1, TUFM and GFM1. All three proteins were 
upregulated due to depletion of miR-24. TUFM as well as GFM1 are also 
predicted targets and can potentially play a role in translation. Therefore, an 
overexpression study will be performed using transfections and co-transfections 
to investigate a possible effect on phenotype. 
• Depletion of miR-24 in a panel of cell lines to investigate of effect can be boosted 
as well as compared to sponge decoy results. If a phenotype is exhibited a 
proteomic profiling study over the panel of cell lines would be suitable to identify 
and also to strengthen confidence in selected targets.  
• Implementation and transfection of RNP/crRNA/tracrRNA approach to generate 
a stable cell line without the integration of a Cas9 plasmid.  
 
CRISPR/Cas9 targeting miR-27 
Depletion of miR-27b led to prolonged batch and fed-batch cultures. This phenotype was 
hereby on expense of IgG production however, due to extended cultivation times the 
final product titre was elevated compared to the control. Therefore, future experiments 
will aim on an investigation of the phenotype on protein level as well as an improvement 
with the help of clones.  
• CRISPR/Cas9 mediated targeting of miR-27a and miR-27b over a panel of cell 
lines. 
• Optimisation of batch and fed-batch cultures to investigate if culture times can be 
prolonged further as well as if titres can be boosted. 
• Characterisation of a clonal panel to investigate if culture length can be boosted 
or reduced productivity can be prevented. 
• The molecular impact of the knockdown/knockout of miR-27a and miR-27b will 
be investigated using HPLC-MS/MS. Once differential expressed proteins were 
identified target validation can be performed using a targeted CRISPR/Cas9 
approach.  
• Impact on critical quality attributes due to the knockdown of miR-27b.  
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CRISPR/Cas9 strategy for targeting miR-23a and miR-23b cluster simultaneously 
Besides using CRISPR/Cas9 as tool for only targeting one miRNA at one time another 
approach would be the co-transfection of two CRISPR plasmids with sgRNAs targeting 
up and downstream of each cluster to investigate the whole knockout of one cluster at a 
time. A multiplex approach would be a suitable to target both clusters at the same time 
or to target one miRNA and its paralog simultaneously. Resulting possible phenotype 
will be assessed and the impact on the proteome would be investigated using HPLC-
MS/MS followed up by siRNA knockdowns or CRISPR/Cas9 knockouts.  
 
7.3 Genome-wide “loss of gene function” studies in Chinese Hamster Ovary cells 
using a CRISPR/Cas9 library 
It was shown that the delivery of sgRNAs using a lentiviral system is not suitable for 
CHO-K1 cells. In general cells are transduced and showed several integration events 
however the coverage of the whole sgRNA-library cannot be assured using a viral 
delivery system. Furthermore, it was shown that PEI based transfection results in high 
transfection efficiencies which could ensure coverage but cells exhibit several plasmid 
integrations. Nucleofection seemed to be an efficient way to ensure good coverage as 
well as 1-2 copies per cell. The aim of the sgRNA-library is to deliver one sgRNA per cell 
to ensure an efficient screen for genes which could possible lead to a beneficial 
phenotype. Future experiments will include: 
• Enrichment of sgRNAs which led to survival and outgrow of subpopulations and 
subsequent identification using NGS. Apoptosis is well understood and we 
hypothesised that correlation with adaption and survival of subpopulations after 
treatment in high salt concentrations can be related. 
The overall goal of the sgRNA-library is to perform a genome wide “loss of gene function” 
study. The mixed population of CHO cells expressing ideally one copy per cell will be 
assessed under different stress conditions which are prevalent in a bioprocess 
environment.  
• Hyperosmolality can potentially be used to identifiy genes which lead to survival 
of high-stress condition such as the addition of pH adjustant during fed-batch. 
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Identified genes leading to outgrow and survival can be overexpressed or 
knocked out to validate function and engineer cells towards stress resistance.  
• Cell sorting using an FITC-labelled antibody was proven to be efficient in 
enrichment for high-producing cells. Next step will be the identification of gene 
knockouts which led to increased productivity or secretion. Therefore, NGS will 
be used to identify depleted or enriched sgRNAs. Subsequent overexpression or 
knockout of genes can be used as validation.   
• In addition, genes involved in viral replication and attachment could be identified 
by using Adeno-associated viruses (AAV). As our experiments showed CHO cells 
are resistant to viral infections. However, subpopulations show susceptibility to 
transduction. To investigate genes involved in this process, CHO cells expressing 
the sgRNA-library will be treated with AAV containing GFP and positive 
transfected cells will be isolated using FACS. Cells which favourably integrated 
the viral DNA will be analysed by NGS and genes responsible for higher levels of 
integrations can subsequently be identified. 
If new genes were discovered which are responsible for survival of stress conditions e.g. 
apoptosis or hypoxia, these genes will be validated by siRNAs or CRISPR/Cas9 
knockouts. A CRISPR/Cas9 multiplex approach would be suitable as well to target 
several genes which have shown to lead to a beneficial phenotype. Last step will be the 
generation of knockout cell lines which exhibit enhanced features and validation in larger 
scales.  
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9 Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S 1: Impact of stable depletion of the miR-23-24-27 cluster and miR-23 on CHO-K1 
expressing a Fc fusion protein compared to the control. Cells transfected with eiter a control 
sponge, miR-23 sponge or a miR-23-24-27 sponge were grown in batch cultivation. A) Viable cell 
density. B) Viability of cultures. C) Titre assessed by ELISA. (n=3). 
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Figure S 2: Impact of stable depletion of the miR-23-24-27 cluster and miR-23 on DG44 
producing a difficult express mAb compared to the control. Cells transfected with eiter a control 
sponge, miR-23 sponge or a miR-23-24-27 sponge were grown in batch cultivation. A) Viable cell 
density. B) Viability of cultures. C) Titre assessed by ELISA. (n=3). 
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Figure S 3: Impact of stable depletion of the miR-23-24-27 cluster and miR-23 on 
DG44 expressing a Fc fusion compared to the control. Cells transfected with eiter a 
control sponge, miR-23 sponge or a miR-23-24-27 sponge were grown in batch 
cultivation. A) Viable cell density. B) Viability of cultures. C) Titre assessed by ELISA. 
No phenotype was observed (n=3). 
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Figure S 4: Sequencing of sponge constructs after cloning and selection. Primers 
targeting up and downstream the MBS ligation side were used and PCR products were sent 
for Sanger sequencing. Higher amplicon sizes represent higher number of MBS. For 
experiments insertions exhibiting 10-14 MBS were considered.  
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Figure S 5: Different glycosylation species identified after the depletion of each individual miRNA 
using sponge on the Fc-fusion protein expressed by CHO-S. The Fc fusion was purified by protein A 
chromatography and analysed for changes in glycosylation species. LC/LFR-MS/MS was used according 
to Carillo and colleagues (Carillo et al., 2017) as part of a collaboration with NIBRT. 
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Figure S 6: Impact of depletion of miR-27 and miR-23-24-27 on CHO-K1 mAb. Cells 
transfected with eiter a control sponge, miR-27 sponge or a miR-23-24-27 sponge were 
grown in batch cultivation. A) Viable cell density. B) Viability of cultures. C) Titre assessed 
by ELISA. (n=3). 
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Figure S 7: Expression of all members of the miR-23a and miR-23b cluster in a 
panel of CHO cell lines. Total RNA was extracted from cells grown in exponential 
growth phase and reverse transcribed into cDNA using looped RT primers. TaqMan® 
miRNA assays for miR-23a, miR-23b, miR-27a, miR-27b and miR-24 was performed 
using the TaqMan® probe and corresponding forward/reverse primer implemented in 
the kit. If Ct-values are compared miR-24 together with miR-27a are the highest 
expressed members of the clusters. MiR-23b, miR-23a and miR-27b are in general 
lower expressed (n=3). 
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Figure S 8: Analysis of shared and individual biological processes in which miR-23, miR-24 
and miR-27 are potentially involved. DAVID was used for functional annotation and analysis of 
overrepresented pathways. Subsequently shared targets were analysed for miR-23 compared to 
miR-24 and miR-27. Aditionally miR-24 was compared with miR-27. Furthermore, pathways targeted 
by all three miRNAs were analysed. Shared biological processes seemed to be related to oxidative 
stress and synthesis of nucleotide precursors.  
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Figure S 9: Screen of single cell clones derived from a miR-24 mixed population targeted by CRISPR/Cas9. 
Single cell clones were isolated using limited dilution cloning and analysed for expression using Taqman® assays. 
Total RNA was extracted from cells grown in exponential growth phase and reverse transcribed into cDNA using 
looped RT primers. TaqMan® miRNA assays for miR-24 was performed using the TaqMan® probe and 
corresponding forward/reverse primer implemented in the kit. Higher Ct-values indicate a lower expression of the 
miRNA.  
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Figure S 10: Depletion of miR-27 in CHO-S Fc and pathway analysis showed several 
proteins upregulated which are involved in apoptosis. Differential protein expression was 
assessed by label-free mass spectrometry and analysed for overrepresented pathways using 
DAVID. Depletion of miR-27 indicated an involvement in apoptosis.   
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10 Supplemental Tables 
CHO-K1 mAb sgRNA-miR-24 (CRISPR) – Proteomic Profiling 
Gene ID Name 
More 
abundant in 
Fold-
change 
Anova 
* Histone H3.1t [Cricetulus griseus] Control 1.42 0.03321 
AACS Acetoacetyl-CoA synthetase [Cricetulus griseus] Control 1.43 0.001761 
AASDHPPT 
L-aminoadipate-semialdehyde dehydrogenase-
phosphopantetheinyl transferase [Cricetulus 
griseus] Control 1.4 0.018226 
ACAT2 
Acetyl-CoA acetyltransferase, cytosolic [Cricetulus 
griseus] Control 1.31 0.024372 
ACLY ATP-citrate synthase [Cricetulus griseus] Control 1.26 0.012851 
ACO1 
Cytoplasmic aconitate hydratase [Cricetulus 
griseus] Control 1.27 0.022283 
ACOT7 
Cytosolic acyl coenzyme A thioester hydrolase 
[Cricetulus griseus] Control 1.21 0.009395 
ACSL4 
Long-chain-fatty-acid--CoA ligase 4 [Cricetulus 
griseus] Control 1.31 0.001129 
ACTL1 
Long-chain-fatty-acid--CoA ligase 1 [Cricetulus 
griseus] Control 1.37 0.031514 
ACTR1A Alpha-centractin [Cricetulus griseus] Control 1.23 0.023381 
ACTR2 Actin-related protein 2 [Cricetulus griseus] Control 1.37 0.013113 
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AGFG2 
Arf-GAP domain and FG repeats-containing protein 
2 [Cricetulus griseus] Control 1.49 0.014589 
AKAP12 A-kinase anchor protein 12 [Cricetulus griseus] Control 1.7 0.007255 
ALDH1A1 Retinal dehydrogenase 1 [Cricetulus griseus] Control 2.05 0.015479 
ARF5 ADP-ribosylation factor 5 [Cricetulus griseus] Control 1.46 0.001182 
ARFGAP3 
ADP-ribosylation factor GTPase-activating protein 3 
[Cricetulus griseus] Control 1.38 0.000963 
ARPC4 
Actin-related protein 2/3 complex subunit 4 
[Cricetulus griseus] Control 1.55 0.002764 
ASAH1 Acid ceramidase [Cricetulus griseus] Control 1.23 0.011193 
ASF1B Histone chaperone ASF1B [Cricetulus griseus] Control 2.14 0.020449 
ATP6AP2 
PREDICTED: renin receptor isoform X1 [Cricetulus 
griseus] Control 1.41 0.011032 
BAIAP2 
Brain-specific angiogenesis inhibitor 1-associated 
protein 2 [Cricetulus griseus] Control 1.23 0.029518 
BST2 bone marrow stromal antigen 2 [Cricetulus griseus] Control 1.3 0.023368 
C3PO 
RecName: Full=Translin; AltName: Full=Component 
3 of promoter of RISC; Short=C3PO Control 1.53 0.00217 
CACNA2D1 
Voltage-dependent calcium channel subunit alpha-
2/delta-1 [Cricetulus griseus] Control 1.29 0.016252 
CALD1 Non-muscle caldesmon [Cricetulus griseus] Control 1.22 0.01587 
CALR Calreticulin [Cricetulus griseus] Control 1.31 0.009298 
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CAP1 
Adenylyl cyclase-associated protein 1 [Cricetulus 
griseus] Control 1.33 0.001156 
CCT3 
T-complex protein 1 subunit gamma [Cricetulus 
griseus] Control 1.4 0.009084 
CD36 Platelet glycoprotein 4 [Cricetulus griseus] Control 2.32 0.021724 
CD44 CD44 antigen [Cricetulus griseus] Control 1.46 0.021956 
CDC16 
Cell division cycle protein 16-like [Cricetulus 
griseus] Control 1.26 0.006452 
CDC23 
Cell division cycle protein 23-like, partial [Cricetulus 
griseus] Control 1.35 0.001377 
CDK6 Cell division protein kinase 6 [Cricetulus griseus] Control 1.21 0.002425 
CHCHD2 
Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 2, mitochondrial [Cricetulus griseus] Control 1.61 0.009001 
CHUK 
Inhibitor of nuclear factor kappa-B kinase subunit 
alpha [Cricetulus griseus] Control 1.4 0.023165 
CLU Clusterin [Cricetulus griseus] Control 1.61 0.006931 
CN166 UPF0568 protein C14orf166-like [Cricetulus griseus] Control 1.3 0.00416 
CNN3 Calponin-3 [Cricetulus griseus] Control 1.29 9.77E-05 
CORO1C Coronin-1C [Cricetulus griseus] Control 1.24 0.036848 
CPNE3 Copine-3 [Cricetulus griseus] Control 1.27 0.007471 
CSDE1 
PREDICTED: cold shock domain-containing protein 
E1 isoform X2 [Cricetulus griseus] Control 1.22 0.023011 
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CTLA2B Protein CTLA-2-beta [Cricetulus griseus] Control 1.78 0.030514 
CTNND1 Catenin delta-1 [Cricetulus griseus] Control 1.25 0.006596 
CUL1 Cullin-1 [Cricetulus griseus] Control 1.21 0.012532 
CUL3 Cullin-3 [Cricetulus griseus] Control 1.45 0.004734 
DDB1 DNA damage-binding protein 1 [Cricetulus griseus] Control 1.27 0.007691 
DDOST 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit [Cricetulus 
griseus] Control 1.38 0.001328 
DHFR Dihydrofolate reductase [Cricetulus griseus] Control 1.36 0.01055 
DHRS1 
Dehydrogenase/reductase SDR family member 1 
[Cricetulus griseus] Control 1.41 0.016992 
DHX15 
Putative pre-mRNA-splicing factor ATP-dependent 
RNA helicase DHX15 [Cricetulus griseus] Control 1.28 0.008177 
DLST 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial [Cricetulus griseus] Control 1.28 0.010147 
DNM2 Dynamin [Cricetulus griseus] Control 1.21 0.0085 
DPY30 Protein dpy-30-like [Cricetulus griseus] Control 1.34 0.034863 
DSTN Destrin [Cricetulus griseus] Control 1.54 0.035397 
EDF1 
Endothelial differentiation-related factor 1 
[Cricetulus griseus] Control 1.69 0.034099 
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EML2 
Echinoderm microtubule-associated protein-like 2 
[Cricetulus griseus] Control 1.28 0.011091 
ERP29 
Endoplasmic reticulum protein ERp29 [Cricetulus 
griseus] Control 1.37 0.018304 
FKBP9 FK506-binding protein 9 [Cricetulus griseus] Control 1.21 0.005384 
GALNT2 
Polypeptide N-acetylgalactosaminyltransferase 2 
[Cricetulus griseus] Control 1.34 0.016705 
GCN1 Translational activator GCN1 [Cricetulus griseus] Control 1.31 0.009776 
GDI2 
Rab GDP dissociation inhibitor beta [Cricetulus 
griseus] Control 1.23 0.014774 
GJA1 Gap junction alpha-1 protein [Cricetulus griseus] Control 1.23 0.009077 
GLG1 
latent TGF-beta complexed protein (LTCP) 
[Cricetulus griseus] Control 1.56 0.004873 
GMDS GDP-mannose 4,6 dehydratase [Cricetulus griseus] Control 1.27 0.028927 
GNAI2 
guanine nucleotide-binding protein G(i) subunit 
alpha-2 [Cricetulus griseus] Control 1.23 0.00106 
GNAI3 
guanine nucleotide-binding protein G(k) subunit 
alpha [Cricetulus griseus] Control 1.32 0.011954 
GNB2 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2 [Cricetulus griseus] Control 1.31 0.012915 
GNPDA1 
Glucosamine-6-phosphate isomerase 1, partial 
[Cricetulus griseus] Control 1.98 0.00218 
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GOLIM4 
Golgi integral membrane protein 4 [Cricetulus 
griseus] Control 1.45 0.029387 
GPC1 Glypican-1 [Cricetulus griseus] Control 1.48 0.000206 
GSTM3 Glutathione S-transferase Mu 5 [Cricetulus griseus] Control 1.38 0.002922 
GSTT2 
Glutathione S-transferase theta-2 [Cricetulus 
griseus] Control 1.38 0.018941 
HECTD1 
E3 ubiquitin-protein ligase HECTD1 [Cricetulus 
griseus] Control 1.72 0.010965 
HIST1H2AG Histone H2A type 1 [Cricetulus griseus] Control 1.23 0.014551 
HMGCS1 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic 
[Cricetulus griseus] Control 1.35 0.000757 
HNRNPD 
PREDICTED: heterogeneous nuclear 
ribonucleoprotein D0 isoform X3, partial [Cricetulus 
griseus] Control 1.33 0.012981 
HNRNPK 
PREDICTED: heterogeneous nuclear 
ribonucleoprotein K isoform X5, partial [Cricetulus 
griseus] Control 2.29 0.017203 
IDH3A 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial [Cricetulus griseus] Control 1.32 0.017268 
IDI1 
Isopentenyl-diphosphate Delta-isomerase 1 
[Cricetulus griseus] Control 1.27 0.009032 
KCNAB2 
Voltage-gated potassium channel subunit beta-2 
[Cricetulus griseus] Control 1.46 0.009464 
KIDINS220 
Kinase D-interacting substrate of 220 kDa 
[Cricetulus griseus] Control 1.34 0.018381 
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KIF1B Kinesin-like protein KIF1C [Cricetulus griseus] Control 1.51 0.000601 
KIF1BP KIF1-binding protein [Cricetulus griseus] Control 1.56 0.029917 
KPNA2 Importin subunit alpha-2 [Cricetulus griseus] Control 1.33 0.011142 
KPNA6 Importin subunit alpha-7 [Cricetulus griseus] Control 1.32 0.001128 
LAMC1 Laminin subunit gamma-1 [Cricetulus griseus] Control 1.22 0.010014 
LIMS1 
LIM and senescent cell antigen-like-containing 
domain protein 1 [Cricetulus griseus] Control 1.22 0.019254 
LMAN1 Protein ERGIC-53 [Cricetulus griseus] Control 1.27 0.000625 
LMNB1 Lamin-L(I) [Cricetulus griseus] Control 1.35 0.021303 
MAGOH Protein mago nashi-like [Cricetulus griseus] Control 1.23 0.002573 
MAN2A1 Alpha-mannosidase 2 [Cricetulus griseus] Control 1.38 0.038155 
MAN2C1 Alpha-mannosidase 2C1 [Cricetulus griseus] Control 1.34 0.000945 
MANF 
Mesencephalic astrocyte-derived neurotrophic 
factor [Cricetulus griseus] Control 1.22 0.013162 
MAPRE1 
Microtubule-associated protein RP/EB family 
member 1 [Cricetulus griseus] Control 1.41 0.015235 
MCM2 
DNA replication licensing factor MCM2 [Cricetulus 
griseus] Control 1.37 0.006212 
MRPL21 
39S ribosomal protein L21, mitochondrial [Cricetulus 
griseus] Control 1.27 0.014106 
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NAA15 
NMDA receptor-regulated protein 1 [Cricetulus 
griseus] Control 1.48 0.002675 
NAGA 
Alpha-N-acetylgalactosaminidase [Cricetulus 
griseus] Control 1.27 0.00978 
NASP 
PREDICTED: nuclear autoantigenic sperm protein 
isoform X1 [Cricetulus griseus] Control 2.86 0.025303 
NCAM1 Neural cell adhesion molecule 1 [Cricetulus griseus] Control 1.29 0.006087 
NDC80 Kinetochore protein NDC80-like [Cricetulus griseus] Control 1.43 0.01866 
NPC2 Epididymal secretory protein E1 [Cricetulus griseus] Control 1.23 0.030912 
NQO1 
NAD(P)H dehydrogenase [quinone] 1 [Cricetulus 
griseus] Control 1.45 0.003176 
NUFIP2 
Nuclear fragile X mental retardation-interacting 
protein 2 [Cricetulus griseus] Control 1.56 0.039179 
NUP37 Nucleoporin Nup37 [Cricetulus griseus] Control 1.29 0.038329 
NUP54 Nucleoporin p54 [Cricetulus griseus] Control 1.62 0.011231 
OCIAD2 
OCIA domain-containing protein 2 [Cricetulus 
griseus] Control 1.88 0.007278 
PCYOX1 Prenylcysteine oxidase [Cricetulus griseus] Control 1.24 0.007896 
PDCD10 
Programmed cell death protein 10 [Cricetulus 
griseus] Control 1.53 0.024899 
PDIA5 Protein disulfide-isomerase A5 [Cricetulus griseus] Control 1.3 0.04612 
PDIA6 Protein disulfide-isomerase A6 [Cricetulus griseus] Control 1.41 0.006104 
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PDWD1 
Peptidylprolyl isomerase domain and WD repeat-
containing protein 1 [Cricetulus griseus] Control 1.61 0.009743 
PLEC Plectin-1 [Cricetulus griseus] Control 1.24 0.001179 
PLS3 RecName: Full=Plastin-3; AltName: Full=T-plastin Control 1.39 0.00678 
PPP1R12A 
Protein phosphatase 1 regulatory subunit 12A 
[Cricetulus griseus] Control 1.21 0.025775 
PPP2CB 
Serine/threonine-protein phosphatase 2A catalytic 
subunit beta isoform, partial [Cricetulus griseus] Control 1.21 0.033596 
PPP6C 
Serine/threonine-protein phosphatase 6 catalytic 
subunit [Cricetulus griseus] Control 1.43 0.022204 
PREP Prolyl endopeptidase [Cricetulus griseus] Control 1.3 0.021064 
PRKACA 
cAMP-dependent protein kinase catalytic subunit 
alpha [Cricetulus griseus] Control 1.64 0.033851 
PRUNE2 Protein prune-like 2 [Cricetulus griseus] Control 1.24 0.02083 
PSMA2 
Proteasome subunit alpha type-2 [Cricetulus 
griseus] Control 1.49 0.014121 
PSMD1 
26S proteasome non-ATPase regulatory subunit 1 
[Cricetulus griseus] Control 1.22 0.007224 
PTPN11 
Tyrosine-protein phosphatase non-receptor type 11 
[Cricetulus griseus] Control 1.56 0.046553 
PXDN Peroxidasin-like [Cricetulus griseus] Control 1.54 0.017734 
PYCR2 
Pyrroline-5-carboxylate reductase 2 [Cricetulus 
griseus] Control 1.26 0.009166 
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RAB1B Ras-related protein Rab-1B [Cricetulus griseus] Control 1.47 0.004065 
RAB35 Ras-related protein Rab-35 [Cricetulus griseus] Control 1.5 0.014282 
RECQL 
ATP-dependent DNA helicase Q1 [Cricetulus 
griseus] Control 1.53 0.011103 
RFC5 Replication factor C subunit 5 [Cricetulus griseus] Control 1.23 0.005033 
RPA1 
PREDICTED: replication protein A 70 kDa DNA-
binding subunit isoform X1 [Cricetulus griseus] Control 1.27 0.022337 
RPL29 60S ribosomal protein L29 [Cricetulus griseus] Control 1.28 0.012051 
RPN1 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 [Cricetulus griseus] Control 1.27 0.006898 
RPN2 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 [Cricetulus griseus] Control 1.27 0.012258 
RPS16 
PREDICTED: 40S ribosomal protein S16 isoform X2 
[Cricetulus griseus] Control 1.49 0.016712 
RPS6 
PREDICTED: 40S ribosomal protein S6 isoform X1 
[Cricetulus griseus] Control 1.29 0.00015 
RPS9 40S ribosomal protein S9 [Cricetulus griseus] Control 1.25 0.016141 
SAR1B GTP-binding protein SAR1b [Cricetulus griseus] Control 1.24 0.034956 
SBSN Suprabasin [Cricetulus griseus] Control 1.57 0.007512 
SCD2 Acyl-CoA desaturase 2 [Cricetulus griseus] Control 1.66 0.027411 
SEC13 Protein SEC13-like [Cricetulus griseus] Control 1.21 0.030987 
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SEC23A 
Protein transport protein Sec23A [Cricetulus 
griseus] Control 1.34 0.023133 
SEC24D 
Protein transport protein Sec24D [Cricetulus 
griseus] Control 1.27 0.00712 
SEPT11 Septin-11 [Cricetulus griseus] Control 1.46 0.027881 
SEPT8 Septin-8 [Cricetulus griseus] Control 1.35 0.009728 
SERPINB6 Serpin B6 [Cricetulus griseus] Control 1.28 0.006652 
SLC25A10 
Mitochondrial dicarboxylate carrier [Cricetulus 
griseus] Control 1.23 0.00179 
SLC25A13 
Calcium-binding mitochondrial carrier protein 
Aralar2 [Cricetulus griseus] Control 1.35 0.005871 
SNRPB2 
U2 small nuclear ribonucleoprotein B'' [Cricetulus 
griseus] Control 1.21 0.024064 
SRP68 
Signal recognition particle 68 kDa protein 
[Cricetulus griseus] Control 1.34 0.013687 
TK1 Thymidine kinase, cytosolic [Cricetulus griseus] Control 1.9 0.033041 
TOP2A DNA topoisomerase 2-alpha [Cricetulus griseus] Control 1.23 0.014307 
TPM2 
PREDICTED: tropomyosin beta chain isoform X1 
[Cricetulus griseus] Control 1.47 0.031053 
TTC37 
Tetratricopeptide repeat protein 37 [Cricetulus 
griseus] Control 1.31 0.010334 
TUBB5 beta-tubulin isotype I [Cricetulus griseus] Control 1.33 0.023229 
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UBC Ubiquitin [Cricetulus griseus] Control 1.73 0.019879 
UBE2C 
Ubiquitin-conjugating enzyme E2 C [Cricetulus 
griseus] Control 1.23 0.029222 
UGGT1 
UDP-glucose:glycoprotein glucosyltransferase 1 
[Cricetulus griseus] Control 1.33 0.005405 
UNC45A Protein unc-45-like A [Cricetulus griseus] Control 1.27 0.024863 
VAT1 
Synaptic vesicle membrane protein VAT-1-like 
[Cricetulus griseus] Control 1.26 0.011097 
WDR43 WD repeat-containing protein 43 [Cricetulus griseus] Control 1.22 0.028529 
YKT6 Synaptobrevin-like YKT6 [Cricetulus griseus] Control 1.8 0.006997 
YWHAB 14-3-3 protein beta/alpha [Cricetulus griseus] Control 1.79 0.01887 
ZFAND5 AN1-type zinc finger protein 5 [Cricetulus griseus] Control 1.95 0.008301 
* hypothetical protein I79_001369 [Cricetulus griseus] CRISPR 1.36 0.000599 
AARS 
Alanyl-tRNA synthetase, cytoplasmic [Cricetulus 
griseus] CRISPR 1.24 0.002764 
AARS 
Alanyl-tRNA synthetase, cytoplasmic [Cricetulus 
griseus] CRISPR 1.33 0.001675 
ACAA1B 
3-ketoacyl-CoA thiolase B, peroxisomal, partial 
[Cricetulus griseus] CRISPR 1.64 0.00816 
ACADVL 
Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial [Cricetulus griseus] CRISPR 1.3 0.025717 
ACTN4 Alpha-actinin-4 [Cricetulus griseus] CRISPR 1.24 0.012471 
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ADK Adenosine kinase [Cricetulus griseus] CRISPR 1.37 0.001233 
ADPRH 
[Protein ADP-ribosylarginine] hydrolase [Cricetulus 
griseus] CRISPR 1.22 0.010897 
ADSL mutant adenylosuccinate lyase [Cricetulus griseus] CRISPR 1.22 0.025559 
ADSS 
adenylosuccinate synthetase isozyme 2 [Cricetulus 
griseus] CRISPR 1.45 0.030153 
AIP AH receptor-interacting protein [Cricetulus griseus] CRISPR 1.21 0.034149 
AIRE Autoimmune regulator [Cricetulus griseus] CRISPR 1.42 0.029258 
APIP APAF1-interacting protein [Cricetulus griseus] CRISPR 1.49 0.028185 
APOOL Apolipoprotein O-like [Cricetulus griseus] CRISPR 1.23 0.01292 
ATAD3A 
ATPase family AAA domain-containing protein 3 
[Cricetulus griseus] CRISPR 1.27 0.007938 
ATIC 
Bifunctional purine biosynthesis protein PURH 
[Cricetulus griseus] CRISPR 1.29 0.01346 
BAG6 Large proline-rich protein BAT3 [Cricetulus griseus] CRISPR 1.24 0.003435 
BCLAF1 
Bcl-2-associated transcription factor 1 [Cricetulus 
griseus] CRISPR 1.28 0.00557 
BRIX1 Brix domain-containing protein 2 [Cricetulus griseus] CRISPR 1.27 0.02393 
BYSL Bystin [Cricetulus griseus] CRISPR 1.45 0.002827 
CALU Calumenin [Cricetulus griseus] CRISPR 1.52 0.009195 
CAPN2 Calpain-2 catalytic subunit [Cricetulus griseus] CRISPR 1.31 0.008083 
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CCDC86 
Coiled-coil domain-containing protein 86 [Cricetulus 
griseus] CRISPR 1.25 0.004686 
CES1 Liver carboxylesterase 4 [Cricetulus griseus] CRISPR 1.23 0.007857 
CHORDC1 
Cysteine and histidine-rich domain-containing 
protein 1 [Cricetulus griseus] CRISPR 1.24 0.000391 
CHTF18 
Chromosome transmission fidelity protein 18-like 
[Cricetulus griseus] CRISPR 1.31 0.001018 
CPT2 
Carnitine O-palmitoyltransferase 2, mitochondrial 
[Cricetulus griseus] CRISPR 1.21 0.009102 
CTTN Src substrate cortactin [Cricetulus griseus] CRISPR 1.26 0.013676 
CYC1 
Cytochrome c1, heme protein, mitochondrial 
[Cricetulus griseus] CRISPR 1.24 0.038317 
DCTN1 Dynactin subunit 1 [Cricetulus griseus] CRISPR 1.41 0.019829 
DCTN1 Dynactin subunit 1 [Cricetulus griseus] CRISPR 1.31 0.02996 
DDX10 
putative ATP-dependent RNA helicase DDX10 
[Cricetulus griseus] CRISPR 1.28 0.008085 
DDX21 Nucleolar RNA helicase 2 [Cricetulus griseus] CRISPR 1.44 0.0003 
DDX27 
putative ATP-dependent RNA helicase DDX27 
[Cricetulus griseus] CRISPR 1.3 0.016398 
DDX39A 
ATP-dependent RNA helicase DDX39 [Cricetulus 
griseus] CRISPR 1.25 0.004534 
DDX46 
putative ATP-dependent RNA helicase DDX46 
[Cricetulus griseus] CRISPR 1.3 0.018143 
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DHX30 
Putative ATP-dependent RNA helicase DHX30 
[Cricetulus griseus] CRISPR 1.26 0.000854 
DHX9 
PREDICTED: ATP-dependent RNA helicase A 
isoform X2 [Cricetulus griseus] CRISPR 1.21 0.006301 
DKC1 
H/ACA ribonucleoprotein complex subunit 4 
[Cricetulus griseus] CRISPR 1.72 0.033292 
DNAJA3 
DnaJ-like subfamily A member 3, mitochondrial 
[Cricetulus griseus] CRISPR 1.38 0.038158 
DNAJC8 
DnaJ-like subfamily C member 8 [Cricetulus 
griseus] CRISPR 1.21 0.012468 
EBNA1BP2 
putative rRNA-processing protein EBP2 [Cricetulus 
griseus] CRISPR 1.33 0.023375 
EDC4 
Enhancer of mRNA-decapping protein 4 [Cricetulus 
griseus] CRISPR 1.39 0.030688 
EEF1B2 Elongation factor 1-beta [Cricetulus griseus] CRISPR 1.27 0.019678 
EFHD2 
EF-hand domain-containing protein D2 [Cricetulus 
griseus] CRISPR 1.27 0.011877 
EHD3 EH domain-containing protein 3 [Cricetulus griseus] CRISPR 1.25 0.036722 
EIF2S1 
Eukaryotic translation initiation factor 2 subunit 1 
[Cricetulus griseus] CRISPR 1.21 0.005102 
EIF3G 
Eukaryotic translation initiation factor 3 subunit G 
[Cricetulus griseus] CRISPR 1.23 0.023204 
EIF3I 
Eukaryotic translation initiation factor 3 subunit I 
[Cricetulus griseus] CRISPR 1.32 0.025181 
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EIF5A2 
Eukaryotic translation initiation factor 5A-2 
[Cricetulus griseus] CRISPR 1.33 0.011208 
EIF6 
Eukaryotic translation initiation factor 6 [Cricetulus 
griseus] CRISPR 1.25 0.042275 
ESF1 ESF1-like [Cricetulus griseus] CRISPR 1.25 0.018449 
EXOSC2 
Exosome complex exonuclease RRP4 [Cricetulus 
griseus] CRISPR 1.21 0.021361 
FAM103A1 Protein FAM103A1 [Cricetulus griseus] CRISPR 1.23 0.045944 
FAM98B Protein FAM98B [Cricetulus griseus] CRISPR 1.29 0.003239 
FARSB 
Phenylalanyl-tRNA synthetase beta chain 
[Cricetulus griseus] CRISPR 1.56 0.006058 
FBL 
rRNA 2'-O-methyltransferase fibrillarin [Cricetulus 
griseus] CRISPR 1.24 0.007149 
FBXO6 F-box only protein 6 [Cricetulus griseus] CRISPR 1.37 0.020647 
FH 
Fumarate hydratase, mitochondrial [Cricetulus 
griseus] CRISPR 1.33 0.003742 
FLNB Filamin-B [Cricetulus griseus] CRISPR 1.27 0.006279 
FTSJ3 
Putative rRNA methyltransferase 3 [Cricetulus 
griseus] CRISPR 1.49 0.018471 
FXR1 
RecName: Full=Fragile X mental retardation 
syndrome-related protein 1 CRISPR 1.27 0.012796 
FXR2 
Fragile X mental retardation syndrome-related 
protein 2 [Cricetulus griseus] CRISPR 1.22 0.016988 
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GARS Glycyl-tRNA synthetase [Cricetulus griseus] CRISPR 1.21 0.015705 
GLRX3 Glutaredoxin-3 [Cricetulus griseus] CRISPR 1.39 0.006653 
GNL1 
Guanine nucleotide-binding protein-like 1, partial 
[Cricetulus griseus] CRISPR 1.41 0.002033 
GSPT2 
Eukaryotic peptide chain release factor GTP-binding 
subunit ERF3B [Cricetulus griseus] CRISPR 1.42 0.010913 
GTF2F1 
General transcription factor IIF subunit 1 [Cricetulus 
griseus] CRISPR 1.31 0.025717 
H2AFV Histone H2A.V [Cricetulus griseus] CRISPR 1.25 0.019768 
HADHA 
Trifunctional enzyme subunit alpha, mitochondrial 
[Cricetulus griseus] CRISPR 1.22 0.015423 
HIBADH 
3-hydroxyisobutyrate dehydrogenase, mitochondrial 
[Cricetulus griseus] CRISPR 1.36 0.013455 
HMGB1 
PREDICTED: high mobility group protein B1 isoform 
X2 [Cricetulus griseus] CRISPR 1.25 0.000256 
HMGN5 Nucleosome-binding protein 1 [Cricetulus griseus] CRISPR 1.28 0.018927 
HNRNPA2B1 
Heterogeneous nuclear ribonucleoproteins A2/B1 
[Cricetulus griseus] CRISPR 1.33 0.021037 
HNRNPAB 
Heterogeneous nuclear ribonucleoprotein A/B 
[Cricetulus griseus] CRISPR 1.21 0.013762 
HP1BP3 
Heterochromatin protein 1-binding protein 3 
[Cricetulus griseus] CRISPR 1.36 0.030462 
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HSD17B10 
3-hydroxyacyl-CoA dehydrogenase type-2 
[Cricetulus griseus] CRISPR 1.25 0.005037 
HSP90AA1 
heat shock protein HSP 90-alpha [Cricetulus 
griseus] CRISPR 1.21 0.015809 
HSP90AB1 Heat shock protein HSP 90-beta [Cricetulus griseus] CRISPR 1.49 0.034098 
HSPD1 
60 kDa heat shock protein, mitochondrial [Cricetulus 
griseus] CRISPR 1.24 0.023391 
HUWE1 
E3 ubiquitin-protein ligase HUWE1, partial 
[Cricetulus griseus] CRISPR 1.24 0.044871 
IARS 
PREDICTED: isoleucine--tRNA ligase, cytoplasmic 
isoform X2 [Cricetulus griseus] CRISPR 1.28 0.015959 
IARS 
PREDICTED: isoleucine--tRNA ligase, cytoplasmic 
isoform X2 [Cricetulus griseus] CRISPR 1.23 0.001292 
ILF2 
Interleukin enhancer-binding factor 2 [Cricetulus 
griseus] CRISPR 1.25 0.014053 
ILF3 
Interleukin enhancer-binding factor 3 [Cricetulus 
griseus] CRISPR 1.23 0.002212 
KLC1 Kinesin light chain 1 [Cricetulus griseus] CRISPR 1.21 0.025125 
KPNB1 Importin subunit beta-1 [Cricetulus griseus] CRISPR 1.21 0.027856 
LANCL1 LanC-like protein 1, partial [Cricetulus griseus] CRISPR 1.42 0.040789 
LETM1 
LETM1 and EF-hand domain-containing protein 1, 
mitochondrial, partial [Cricetulus griseus] CRISPR 1.43 0.001145 
LHPP Inorganic pyrophosphatase [Cricetulus griseus] CRISPR 1.21 0.003911 
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LONP1 Lon protease-like, mitochondrial [Cricetulus griseus] CRISPR 1.34 0.003481 
LRPPRC 
Leucine-rich PPR motif-containing protein, 
mitochondrial [Cricetulus griseus] CRISPR 1.28 0.000808 
LRRFIP1 
Leucine-rich repeat flightless-interacting protein 1 
[Cricetulus griseus] CRISPR 1.27 0.00672 
MAP1B 
Microtubule-associated protein 1B [Cricetulus 
griseus] CRISPR 1.3 0.00378 
MCM4 
DNA replication licensing factor MCM4 [Cricetulus 
griseus] CRISPR 1.22 0.04087 
MEMO1 
PREDICTED: protein MEMO1 isoform X2 
[Cricetulus griseus] CRISPR 1.96 0.026159 
MPHOSPH10 
U3 small nucleolar ribonucleoprotein protein MPP10 
[Cricetulus griseus] CRISPR 1.35 0.015285 
MPST 
3-mercaptopyruvate sulfurtransferase [Cricetulus 
griseus] CRISPR 1.58 0.007714 
MRPL18 
39S ribosomal protein L18, mitochondrial [Cricetulus 
griseus] CRISPR 1.26 0.011376 
MRPS22 
28S ribosomal protein S22, mitochondrial 
[Cricetulus griseus] CRISPR 1.56 0.008447 
MRPS6 
28S ribosomal protein S6, mitochondrial [Cricetulus 
griseus] CRISPR 1.36 0.007319 
MRPS7 
28S ribosomal protein S7, mitochondrial [Cricetulus 
griseus] CRISPR 1.24 2.82E-05 
MSI2 
RNA-binding protein Musashi-like 2 [Cricetulus 
griseus] CRISPR 1.62 0.023029 
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MYBBP1A Myb-binding protein 1A [Cricetulus griseus] CRISPR 1.33 0.008405 
NAA50 N-acetyltransferase NAT13 [Cricetulus griseus] CRISPR 1.33 0.013926 
NAXE 
Apolipoprotein A-I-binding protein [Cricetulus 
griseus] CRISPR 1.28 0.007794 
NDUFA8 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 8 [Cricetulus griseus] CRISPR 1.45 0.001742 
NDUFB8 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 8, mitochondrial [Cricetulus 
griseus] CRISPR 1.39 0.005821 
NDUFS1 
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial [Cricetulus griseus] CRISPR 1.38 0.002623 
NDUFS2 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 2, mitochondrial [Cricetulus griseus] CRISPR 1.39 0.002759 
NDUFS3 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 3, mitochondrial [Cricetulus griseus] CRISPR 1.27 0.028795 
NDUFS6 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 6, mitochondrial [Cricetulus griseus] CRISPR 1.22 0.021147 
NDUFV1 
NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial [Cricetulus griseus] CRISPR 1.26 0.000198 
NDUFV3 
NADH dehydrogenase [ubiquinone] flavoprotein 3, 
mitochondrial [Cricetulus griseus] CRISPR 1.27 0.003061 
NIF3L1 NIF3-like protein 1 [Cricetulus griseus] CRISPR 1.36 0.003077 
NIFK 
MKI67 FHA domain-interacting nucleolar 
phosphoprotein [Cricetulus griseus] CRISPR 1.21 0.015381 
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NOL11 Nucleolar protein 11 [Cricetulus griseus] CRISPR 1.59 0.011023 
NOP2 
Putative ribosomal RNA methyltransferase NOP2 
[Cricetulus griseus] CRISPR 1.25 0.007907 
NOP56 Nucleolar protein 56 [Cricetulus griseus] CRISPR 1.28 0.011064 
NUDC Nuclear migration protein nudC [Cricetulus griseus] CRISPR 1.27 0.024114 
OPA1 
Dynamin-like 120 kDa protein, mitochondrial 
[Cricetulus griseus] CRISPR 1.43 0.000515 
P4HB 
protein disulfide-isomerase precursor [Cricetulus 
griseus] CRISPR 1.29 0.022742 
PA2G4 
Proliferation-associated protein 2G4 [Cricetulus 
griseus] CRISPR 1.34 0.001522 
PAK2 
Serine/threonine-protein kinase PAK 2 [Cricetulus 
griseus] CRISPR 1.29 0.001131 
PALM Paralemmin [Cricetulus griseus] CRISPR 1.22 0.004249 
PALM2 A-kinase anchor protein 2 [Cricetulus griseus] CRISPR 1.44 0.010043 
PARN 
Poly(A)-specific ribonuclease PARN [Cricetulus 
griseus] CRISPR 1.44 0.007075 
PDCD6IP 
Programmed cell death 6-interacting protein 
[Cricetulus griseus] CRISPR 1.22 0.00084 
PEBP1 
Phosphatidylethanolamine-binding protein 1 
[Cricetulus griseus] CRISPR 1.31 0.030115 
PFKL 
6-phosphofructokinase, liver type [Cricetulus 
griseus] CRISPR 1.23 0.014398 
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PGLS 6-phosphogluconolactonase [Cricetulus griseus] CRISPR 1.4 0.00773 
PITPNA 
Phosphatidylinositol transfer protein alpha isoform 
[Cricetulus griseus] CRISPR 2.25 0.005313 
PITRM1 
Presequence protease, mitochondrial [Cricetulus 
griseus] CRISPR 1.21 0.020618 
PLAA 
Phospholipase A-2-activating protein [Cricetulus 
griseus] CRISPR 1.22 0.005832 
PLIN2 Adipophilin [Cricetulus griseus] CRISPR 1.55 0.005063 
POLRMT 
DNA-directed RNA polymerase, mitochondrial 
[Cricetulus griseus] CRISPR 1.45 0.048488 
PPFIBP1 Liprin-beta-1 [Cricetulus griseus] CRISPR 1.52 0.031311 
PPM1F Protein phosphatase 1F [Cricetulus griseus] CRISPR 1.38 0.001041 
PPM1G Protein phosphatase 1G [Cricetulus griseus] CRISPR 1.23 0.0337 
PPP1R10 
Serine/threonine-protein phosphatase 1 regulatory 
subunit 10 [Cricetulus griseus] CRISPR 1.45 0.009177 
PRDX5 Peroxiredoxin-5, mitochondrial [Cricetulus griseus] CRISPR 1.24 0.015035 
PRMT5 
Protein arginine N-methyltransferase 5 [Cricetulus 
griseus] CRISPR 1.39 0.043131 
PRPF8 
Pre-mRNA-processing-splicing factor 8 [Cricetulus 
griseus] CRISPR 1.21 0.005923 
PSMB2 Proteasome subunit beta type-2 [Cricetulus griseus] CRISPR 1.33 0.005688 
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PSMD2 
26S proteasome non-ATPase regulatory subunit 2 
[Cricetulus griseus] CRISPR 1.28 0.006574 
PSMD6 
26S proteasome non-ATPase regulatory subunit 6 
[Cricetulus griseus] CRISPR 1.25 0.031914 
PSME1 
PREDICTED: proteasome activator complex subunit 
1 isoform X2 [Cricetulus griseus] CRISPR 1.22 0.000405 
PSMF1 
Proteasome inhibitor PI31 subunit [Cricetulus 
griseus] CRISPR 1.3 0.024361 
PSPC1 Paraspeckle component 1 [Cricetulus griseus] CRISPR 1.27 0.019659 
PTBP1 
Polypyrimidine tract-binding protein 1 [Cricetulus 
griseus] CRISPR 1.21 0.00645 
PYCR1 
Pyrroline-5-carboxylate reductase 1, mitochondrial 
[Cricetulus griseus] CRISPR 1.23 0.000878 
RACK1 
Guanine nucleotide-binding protein subunit beta-2-
like 1 [Cricetulus griseus] CRISPR 1.45 0.025487 
RCC2 Protein RCC2 [Cricetulus griseus] CRISPR 1.34 0.002603 
RCN2 Reticulocalbin-2 [Cricetulus griseus] CRISPR 1.3 0.039155 
RCN3 Reticulocalbin-3 [Cricetulus griseus] CRISPR 1.27 0.010397 
RIOX2 Myc-induced nuclear antigen [Cricetulus griseus] CRISPR 1.24 0.024601 
RNPEP Aminopeptidase B [Cricetulus griseus] CRISPR 1.3 0.010691 
RPL23 60S ribosomal protein L23 [Cricetulus griseus] CRISPR 1.3 0.042536 
RPL32 60S ribosomal protein L32 [Cricetulus griseus] CRISPR 1.35 0.001604 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
295 
RPL4 60S ribosomal protein L4 [Cricetulus griseus] CRISPR 1.31 0.030893 
RPL7A 60S ribosomal protein L7a [Cricetulus griseus] CRISPR 1.29 0.017233 
RPLP0 60S acidic ribosomal protein P0 [Cricetulus griseus] CRISPR 1.25 0.002178 
RPS20 40S ribosomal protein S20 [Cricetulus griseus] CRISPR 1.26 0.004883 
RTCB 
PREDICTED: tRNA-splicing ligase RtcB homolog 
[Cricetulus griseus] CRISPR 1.24 0.001332 
RUVBL2 RuvB-like 2 [Cricetulus griseus] CRISPR 1.22 6.34E-05 
SAMHD1 
SAM domain and HD domain-containing protein 1 
[Cricetulus griseus] CRISPR 1.47 0.028087 
SDHB 
Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial [Cricetulus griseus] CRISPR 1.4 0.001606 
SET Protein SET [Cricetulus griseus] CRISPR 1.82 0.005147 
SHMT2 
Serine hydroxymethyltransferase, mitochondrial 
[Cricetulus griseus] CRISPR 1.33 0.006493 
SKIV2L Helicase SKI2W [Cricetulus griseus] CRISPR 1.21 0.010774 
SLK 
STE20-like serine/threonine-protein kinase 
[Cricetulus griseus] CRISPR 1.27 0.026675 
SMC3 
Structural maintenance of chromosomes protein 3 
[Cricetulus griseus] CRISPR 1.31 0.001503 
STUB1 
STIP1-likey and U box-containing protein 1 
[Cricetulus griseus] CRISPR 1.24 0.005487 
SUN2 Protein unc-84-like B [Cricetulus griseus] CRISPR 1.29 0.012685 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
296 
SUPT6H 
Transcription elongation factor SPT6 [Cricetulus 
griseus] CRISPR 1.4 0.008911 
SUPV3L1 
ATP-dependent RNA helicase SUPV3L1, 
mitochondrial [Cricetulus griseus] CRISPR 1.28 0.012164 
SURF6 Surfeit locus protein 6 [Cricetulus griseus] CRISPR 1.44 0.023124 
TCOF1 Treacle protein [Cricetulus griseus] CRISPR 1.47 0.03177 
TFRC Transferrin receptor protein 1 [Cricetulus griseus] CRISPR 1.21 0.029422 
TGM2 
Protein-glutamine gamma-glutamyltransferase 2 
[Cricetulus griseus] CRISPR 1.3 0.02635 
TMEM43 Transmembrane protein 43 [Cricetulus griseus] CRISPR 2.54 0.002434 
TPD52L2 
Uncharacterized protein C20orf135-like [Cricetulus 
griseus] CRISPR 1.24 0.00328 
TTLL12 
Tubulin--tyrosine ligase-like protein 12 [Cricetulus 
griseus] CRISPR 1.35 0.003879 
TUFM 
Elongation factor Tu, mitochondrial [Cricetulus 
griseus] CRISPR 1.21 0.018946 
U2AF2 
PREDICTED: splicing factor U2AF 65 kDa subunit 
isoform X1, partial [Cricetulus griseus] CRISPR 1.41 0.01606 
UQCRC7 
Cytochrome b-c1 complex subunit 7, partial 
[Cricetulus griseus] CRISPR 1.88 0.032707 
USP15 
Ubiquitin carboxyl-terminal hydrolase 15 [Cricetulus 
griseus] CRISPR 1.24 0.003445 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
297 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VMN2R1 
GMP synthase [glutamine-hydrolyzing] [Cricetulus 
griseus] CRISPR 1.26 0.010444 
VWA8 
Uncharacterized protein KIAA0564-like [Cricetulus 
griseus] CRISPR 1.21 0.001299 
WDR12 
Ribosome biogenesis protein WDR12 [Cricetulus 
griseus] CRISPR 1.25 0.036868 
WDR81 WD repeat-containing protein 81 [Cricetulus griseus] CRISPR 1.24 0.021081 
YARS 
Tyrosyl-tRNA synthetase, cytoplasmic [Cricetulus 
griseus] CRISPR 1.27 0.034077 
     
___________________________________________________________________________ 
___________________________________________________________________________ 
 
298 
CHO-K1 mAb sgRNA-miR-24 (CRISPR)/ predicted and validated targets 
Gene ID Predicted/Validated miR-24-3p miR-24-5p 
TMEM43 Predicted X  
PPFIBP1 Predicted/Validated X  
SAMHD1 Predicted X  
BYSL Predicted X X 
SURF6 Predicted X  
PALM2 Predicted X  
LETM1 Predicted X  
LANCL1 Predicted X  
PGLS Predicted X  
GLRX3 Predicted X  
PPM1F Predicted X  
NDUFS1 Predicted X X 
ADK Predicted X  
HP1BP3 Predicted X  
NIF3L1 Predicted X  
TTLL12 Predicted X  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
299 
RCC2 Predicted X  
EBNA1BP2 Predicted X  
PSMB2 Predicted X  
NAA50 Predicted X  
MYBBP1A Predicted X  
EIF5A2 Predicted X  
EIF3I Predicted X  
RPL4 Predicted X  
GTF2F1 Predicted X  
CAPN2 Predicted X  
MAP1B Predicted X X 
PSMF1 Predicted X X 
TGM2 Predicted X  
RCN2 Predicted X  
RPL23 Predicted X  
RNPEP Predicted X  
DDX46 Predicted X  
SUN2 Predicted X  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
300 
ATIC Predicted X  
PAK2 Predicted X  
LRPPRC Predicted X  
FLNB Predicted X X 
BRIX1 Predicted X  
NDUFV3 Predicted X X 
RCN3 Predicted X  
ATAD3A Predicted X X 
DHX30 Predicted X  
H2AFV Predicted X  
ESF1 Predicted X X 
EHD3 Predicted X X 
ACTN4 Predicted X  
CHORDC1 Predicted X  
AARS Predicted X  
TPD52L2 Predicted X  
RTCB Predicted X  
APOOL Predicted X  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
301 
PPM1G Predicted X  
ILF3 Predicted X X 
ADSL Predicted X  
PLAA Predicted X  
PALM Predicted X  
MCM4 Predicted X  
EXOSC2 Predicted X  
EIF2S1 Predicted X  
LHPP Predicted X  
WDR12 Predicted X  
DNAJA3 Predicted X  
TMEM43 Predicted X  
PPFIBP1 Predicted X  
SAMHD1 Predicted X  
BYSL Predicted X  
SURF6 Predicted X  
PALM2 Predicted X  
LETM1 Predicted X  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
302 
LANCL1 Predicted X  
PGLS Predicted X  
GLRX3 Predicted X  
PPM1F Predicted X  
NDUFS1 Predicted X  
ADK Predicted X  
HP1BP3 Predicted X  
NIF3L1 Predicted X  
TTLL12 Predicted X  
RCC2 Predicted X  
EBNA1BP2 Predicted X  
PSMB2 Predicted X  
NAA50 Predicted X  
MYBBP1A Predicted X  
EIF5A2 Predicted X  
EIF3I Predicted X  
RPL4 Predicted X  
GTF2F1 Predicted X  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
303 
CAPN2 Predicted X  
MAP1B Predicted X  
PSMF1 Predicted X  
TGM2 Predicted X  
RCN2 Predicted X  
RPL23 Predicted X  
RNPEP Predicted X  
DDX46 Predicted X  
SUN2 Predicted X  
ATIC Predicted X  
PAK2 Predicted X  
LRPPRC Predicted X  
FLNB Predicted X  
BRIX1 Predicted X  
NDUFV3 Predicted X  
RCN3 Predicted X  
ATAD3A Predicted X  
DHX30 Predicted X  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
304 
H2AFV Predicted X  
ESF1 Predicted X  
EHD3 Predicted X  
ACTN4 Predicted X  
CHORDC1 Predicted X  
AARS Predicted X  
TPD52L2 Predicted X  
RTCB Predicted X  
APOOL Predicted X  
PPM1G Predicted X  
ILF3 Predicted X  
ADSL Predicted X  
PLAA Predicted X  
PALM Predicted X  
MCM4 Predicted X  
EXOSC2 Predicted X  
EIF2S1 Predicted X  
LHPP Predicted X  
___________________________________________________________________________ 
___________________________________________________________________________ 
 
305 
WDR12 Predicted X  
DNAJA3 Predicted X  
PITPNA Predicted  X 
FARSB Predicted  X 
CALU Predicted  X 
DDX21 Predicted  X 
SHMT2 Predicted  X 
PEBP1 Predicted  X 
FAM98B Predicted  X 
DDX10 Predicted  X 
BCLAF1 Predicted  X 
MRPL18 Predicted  X 
CTTN Predicted  X 
USP15 Predicted  X 
HSP90AA1 Predicted  X 
TFRC Predicted  X 
NARS Predicted/Validated X  
PPM1F Predicted/Validated X X 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
306 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NCBP2 Predicted/Validated X  
NOP56 Predicted/Validated X  
PA2G4 Predicted/Validated X  
PCK2 Predicted/Validated X  
CCDC58 Predicted/Validated X  
    
___________________________________________________________________________ 
___________________________________________________________________________ 
 
307 
CHO-K1 mAb sgRNA-miR-24 (RNASeq) 
Gene ID 
Log2 fold 
change 
Anova Abundance Control 
Abundance 
CRISPR 
A2ML1 0.812235 0.008235 7076.79 5692.44 
AATK 0.485439 0.002864 2563.3 2161.07 
ABCA1 0.467905 0.03518 20.36 40.39 
ABCC2 -1.2543 0.004506 200.36 310.85 
ABCD1 0.387186 0.003813 1457.01 1077.48 
ABCD2 -0.44258 0.024434 14.57 30.62 
ABHD11 -0.43211 2.01E-05 23.03 38.31 
ABHD2 0.372604 0.000252 43.21 23.64 
ACAA2 0.662733 0.007831 772.31 603.71 
ACACB -0.68446 0.002069 350.55 246.32 
ACKR3 1.238888 0.001798 106.52 70.25 
ACO2 -0.3143 1.07E-06 5.77 25.76 
ACP5 -0.48017 2.05E-42 490.59 353.85 
ACSBG1 -0.24601 0.019032 627.74 826.16 
ACY3 0.352191 0.009111 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
308 
ADAMTS7 0.290051 1.63E-12 68.37 97.22 
ADCK1 -0.63283 0.016616 592.06 931.83 
ADCY6 0.500092 0.010372 168.52 231.87 
ADD2 4.331363 8.23E-11 7420.41 6281.97 
ADH5 0.34556 0.039527 5944.91 9388.88 
ADSSL1 0.694325 0.004071 522.88 413.69 
AGAP1 0.537581 0.006976 179.96 282.82 
AHCYL1 -0.27158 3.35E-07 98.49 62.39 
AHNAK 0.712402 0.04843 1191.87 902.27 
AKR1B8 0.373602 0.008264 1189.76 1858.95 
ALDH4A1 0.334598 4.34E-05 6086.49 7562.61 
ALS2CL 0.324978 0.006791 30.37 47.45 
ANGPT4 0.985762 0.027952 179.56 251.1 
ANKH 0.386293 0.007521 453.68 336.15 
ANKRD13A 0.311653 0.000716 51.66 84.64 
ANKRD27 0.371663 0.010835 3327.33 2678.57 
ANKRD39 0.630641 0.00101 194.36 280.55 
ANXA1 -0.43409 0.03289 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
309 
APLP2 -0.45408 0.019856 17.57 31.47 
AQP10 -0.35291 3.07E-15 503.77 1087.18 
AQP3 0.819515 0.001268 719.13 1001.95 
ARAP3 0.563271 0.01847 70.19 109.2 
ARFRP1 -0.40189 0.034638 607.26 497.35 
ARHGAP22 1.033536 0.009895 622.18 495.23 
ARHGAP24 -0.90182 0.001903 72.71 106.49 
ARHGAP27 0.931419 0.000402 131.95 89.44 
ARHGEF17 0.281863 0.000825 8.69 21.41 
ARL4C 0.299904 0.012477 20.66 5.65 
ARNTL2 1.061464 0.044597 1433.79 1219.06 
ARTN 0.728132 0.015615 349.65 553.18 
ASAP3 0.609258 8.65E-24 37.3 20.75 
ATF3 -0.7113 0.045149 616.17 747.4 
ATF4 -0.26675 0.035851 99.49 68.07 
ATF5 -0.53501 0.039954 1260.07 1576.36 
ATG14 -0.7203 0.012353 1306.52 1681.5 
ATG2B 0.307582 0.002383 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
310 
ATP2B4 0.474301 0.028159 227.71 169.1 
ATP4A -1.44323 0.041544 20.33 7.39 
ATP6V1G1 0.729517 0.006432 3926.4 5535.83 
ATP8B2 -0.43862 0.000376 7076.79 5692.44 
BCL9L 0.424764 0.008235 2563.3 2161.07 
BCO2 -0.79384 0.002864 20.36 40.39 
BEND4 -0.27323 0.03518 200.36 310.85 
BEST1 0.691279 0.004506 1457.01 1077.48 
BMF 0.352665 0.003813 14.57 30.62 
BMP1 0.337314 0.024434 23.03 38.31 
BNIP3 -0.34303 2.01E-05 43.21 23.64 
BRAT1 0.363191 0.000252 772.31 603.71 
BZRAP1 -0.42947 0.007831 350.55 246.32 
C1QTNF1 -1.06532 0.002069 106.52 70.25 
C3 -0.87355 0.001798 5.77 25.76 
CACNA1C 0.455732 1.07E-06 490.59 353.85 
CAD -0.35711 2.05E-42 627.74 826.16 
CAPN5 0.427929 0.019032 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
311 
CAPN9 0.686353 0.009111 68.37 97.22 
CARD10 0.606556 1.63E-12 592.06 931.83 
CASKIN1 -0.60833 0.016616 168.52 231.87 
CCBE1 -0.62337 0.010372 7420.41 6281.97 
CCDC137 -0.28011 8.23E-11 5944.91 9388.88 
CCDC65 -0.32599 0.039527 522.88 413.69 
CCKAR -0.76667 0.004071 179.96 282.82 
CCND1 0.519264 0.006976 98.49 62.39 
CCNE1 -1.12639 3.35E-07 1191.87 902.27 
CCNI 0.787593 0.04843 1189.76 1858.95 
CCS -0.37606 0.008264 6086.49 7562.61 
CD40LG 0.46381 4.34E-05 30.37 47.45 
CD47 0.510398 0.006791 179.56 251.1 
CDC42BPB 0.337871 0.027952 453.68 336.15 
CDC42EP2 0.780657 0.007521 51.66 84.64 
CDCA4 0.708383 0.000716 3327.33 2678.57 
CDH16 -0.59164 0.010835 194.36 280.55 
CDON 0.431125 0.00101 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
312 
CDS1 -0.50644 0.03289 17.57 31.47 
CHD7 -0.78861 0.019856 503.77 1087.18 
CIB2 -0.58474 3.07E-15 719.13 1001.95 
CIRBP 0.309752 0.001268 70.19 109.2 
CNBP -0.59962 0.01847 607.26 497.35 
CNKSR1 -0.83136 0.034638 622.18 495.23 
CNN3 -0.31792 0.009895 72.71 106.49 
COL16A1 0.602875 0.001903 131.95 89.44 
COL17A1 0.516172 0.000402 8.69 21.41 
COL27A1 1.696222 0.000825 20.66 5.65 
COL3A1 1.173342 0.012477 1433.79 1219.06 
COL4A1 2.136309 0.044597 349.65 553.18 
COL6A1 1.556977 0.015615 37.3 20.75 
CORNIFIN-A -1.77186 8.65E-24 616.17 747.4 
CPT1A 0.376488 0.045149 99.49 68.07 
CRB3 -0.47546 0.035851 1260.07 1576.36 
CREB1 0.305551 0.039954 1306.52 1681.5 
CREB3 0.646881 0.012353 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
313 
CRIP1 0.366888 0.002383 227.71 169.1 
CSE1L -0.31315 0.028159 20.33 7.39 
CSF3 -0.93873 0.041544 3926.4 5535.83 
CSTF2 -0.27011 0.006432 7076.79 5692.44 
CTNND1 0.270156 0.000376 2563.3 2161.07 
CTSE 0.874699 0.008235 20.36 40.39 
CTU2 0.324535 0.002864 200.36 310.85 
CYR61 -0.86395 0.03518 1457.01 1077.48 
DAB2IP -0.45097 0.004506 14.57 30.62 
DCTPP1 -0.36935 0.003813 23.03 38.31 
DDX27 -0.3488 0.024434 43.21 23.64 
DENND1C -0.45457 2.01E-05 772.31 603.71 
DENND3 0.351901 0.000252 350.55 246.32 
DFNA5 0.414422 0.007831 106.52 70.25 
DGAT1 1.011326 0.002069 5.77 25.76 
DGAT2 -0.56365 0.001798 490.59 353.85 
DGKD 0.311809 1.07E-06 627.74 826.16 
DLG1 0.512812 2.05E-42 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
314 
DNAJB13 -1.26434 0.019032 68.37 97.22 
DNAJC14 0.604542 0.009111 592.06 931.83 
DNMT3A 0.397099 1.63E-12 168.52 231.87 
DNTTIP1 -1.11019 0.016616 7420.41 6281.97 
DST 0.520615 0.010372 5944.91 9388.88 
DTX4 -1.81275 8.23E-11 522.88 413.69 
DUSP16 -0.43716 0.039527 179.96 282.82 
DUSP8 -0.80569 0.004071 98.49 62.39 
DYNC1H1 0.29862 0.006976 1191.87 902.27 
DZIP1 0.484625 3.35E-07 1189.76 1858.95 
EIF4E2 0.895989 0.04843 6086.49 7562.61 
EIF4G3 1.018229 0.008264 30.37 47.45 
EMP1 0.430022 4.34E-05 179.56 251.1 
ENDOD1 0.627488 0.006791 453.68 336.15 
ENDOV 0.32394 0.027952 51.66 84.64 
ENOSF1 0.490311 0.007521 3327.33 2678.57 
ENTPD5 0.375798 0.000716 194.36 280.55 
EPAS1 -5.17427 0.010835 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
315 
EPHB3 -0.49113 0.00101 17.57 31.47 
EPS8 0.40262 0.03289 503.77 1087.18 
ERRFI1 0.404 0.019856 719.13 1001.95 
ESYT2 0.38125 3.07E-15 70.19 109.2 
ETS2 -0.36209 0.001268 607.26 497.35 
ETV1 0.509657 0.01847 622.18 495.23 
EXO1 -0.43174 0.034638 72.71 106.49 
EXOC3 0.346905 0.009895 131.95 89.44 
EXTL1 -0.59626 0.001903 8.69 21.41 
F2RL2 0.513566 0.000402 20.66 5.65 
FABP4 0.653895 0.000825 1433.79 1219.06 
FADS3 0.435676 0.012477 349.65 553.18 
FAH 0.341604 0.044597 37.3 20.75 
FAM102A 0.330038 0.015615 616.17 747.4 
FAM115A 0.456543 8.65E-24 99.49 68.07 
FAM13C -1.83393 0.045149 1260.07 1576.36 
FAM161A -0.24017 0.035851 1306.52 1681.5 
FAM167B -0.69933 0.039954 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
316 
FAM20C -0.50039 0.012353 227.71 169.1 
FAM83A 1.190008 0.002383 20.33 7.39 
FAXDC2 0.549456 0.028159 3926.4 5535.83 
FBLIM1 0.281327 0.041544 7076.79 5692.44 
FBXL18 0.365647 0.006432 2563.3 2161.07 
FBXO32 0.666871 0.000376 20.36 40.39 
FBXW7 0.964333 0.008235 200.36 310.85 
FER1L5 0.287784 0.002864 1457.01 1077.48 
FGFR2 -3.28894 0.03518 14.57 30.62 
FIBP 0.305093 0.004506 23.03 38.31 
FLNC 0.324697 0.003813 43.21 23.64 
FMNL3 0.33706 0.024434 772.31 603.71 
FN1 0.760327 2.01E-05 350.55 246.32 
FOLR1 -1.81709 0.000252 106.52 70.25 
FOSL1 0.374402 0.007831 5.77 25.76 
FSTL1 0.233109 0.002069 490.59 353.85 
FTH1 0.659128 0.001798 627.74 826.16 
FTSJ3 -1.68137 1.07E-06 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
317 
FUK -0.3497 2.05E-42 68.37 97.22 
GALNT2 0.462951 0.019032 592.06 931.83 
GARS -0.28357 0.009111 168.52 231.87 
GBA2 0.497137 1.63E-12 7420.41 6281.97 
GCAT 0.404976 0.016616 5944.91 9388.88 
GGCX 0.267706 0.010372 522.88 413.69 
GLIPR2 0.306832 8.23E-11 179.96 282.82 
GLS2 -0.79758 0.039527 98.49 62.39 
GNPTAB -0.33432 0.004071 1191.87 902.27 
GPATCH8 -0.42583 0.006976 1189.76 1858.95 
GPD1 1.453052 3.35E-07 6086.49 7562.61 
GPD2 -0.36237 0.04843 30.37 47.45 
GPNMB -0.34137 0.008264 179.56 251.1 
GPR108 -0.7042 4.34E-05 453.68 336.15 
GPR133 -1.68851 0.006791 51.66 84.64 
GPR176 -0.73599 0.027952 3327.33 2678.57 
GPR182 0.5979 0.007521 194.36 280.55 
GPR56 0.502342 0.000716 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
318 
GPS2 -0.87345 0.010835 17.57 31.47 
GPSM1 -0.53148 0.00101 503.77 1087.18 
GRAMD1B 1.653203 0.03289 719.13 1001.95 
GRAMD4 0.513153 0.019856 70.19 109.2 
GRIA4 -0.36166 3.07E-15 607.26 497.35 
GRIP2 0.505002 0.001268 622.18 495.23 
GSDMD 0.987189 0.01847 72.71 106.49 
GSN 0.351863 0.034638 131.95 89.44 
GTF3C2 0.875765 0.009895 8.69 21.41 
GTPBP6 -0.40556 0.001903 20.66 5.65 
GYS1 0.310706 0.000402 1433.79 1219.06 
HAUS8 0.364633 0.000825 349.65 553.18 
HDAC4 0.351422 0.012477 37.3 20.75 
HDAC7 0.384787 0.044597 616.17 747.4 
HERC3 -0.42562 0.015615 99.49 68.07 
HIP1 0.277872 8.65E-24 1260.07 1576.36 
HIPK2 0.793127 0.045149 1306.52 1681.5 
HK2 -0.35915 0.035851 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
319 
HMGCR 0.248385 0.039954 227.71 169.1 
HMGCS2 0.648475 0.012353 20.33 7.39 
HMOX1 0.742432 0.002383 3926.4 5535.83 
HNF4A -0.67171 0.028159 7076.79 5692.44 
HOMER1 -0.50407 0.041544 2563.3 2161.07 
HOXC6 0.359422 0.006432 20.36 40.39 
HOXC8 -0.50174 0.000376 200.36 310.85 
HPSE -0.3656 0.008235 1457.01 1077.48 
HSPG2 0.265989 0.002864 14.57 30.62 
HTR6 -0.63422 0.03518 23.03 38.31 
HUNK 0.774776 0.004506 43.21 23.64 
HYAL2 -0.57503 0.003813 772.31 603.71 
IARS -0.31235 0.024434 350.55 246.32 
IER5L 0.882492 2.01E-05 106.52 70.25 
IFFO2 0.475239 0.000252 5.77 25.76 
IGDCC3 -0.7692 0.007831 490.59 353.85 
IGDCC4 -0.56934 0.002069 627.74 826.16 
IKBKAP -0.23432 0.001798 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
320 
IMP3 0.583391 1.07E-06 68.37 97.22 
INPP5J -0.48659 2.05E-42 592.06 931.83 
IP6K3 -1.51769 0.019032 168.52 231.87 
IQGAP2 0.379908 0.009111 7420.41 6281.97 
IRS2 0.555096 1.63E-12 5944.91 9388.88 
ITGA2B -0.83457 0.016616 522.88 413.69 
ITGB4 0.3224 0.010372 179.96 282.82 
ITPR3 0.45155 8.23E-11 98.49 62.39 
JADE1 -0.42703 0.039527 1191.87 902.27 
JAK3 0.456521 0.004071 1189.76 1858.95 
JUN -0.55307 0.006976 6086.49 7562.61 
KANK2 0.376212 3.35E-07 30.37 47.45 
KANSL2 -0.24224 0.04843 179.56 251.1 
KCNK5 0.513713 0.008264 453.68 336.15 
KCNS2 1.577716 4.34E-05 51.66 84.64 
KCTD12 0.367852 0.006791 3327.33 2678.57 
KCTD15 -0.76392 0.027952 194.36 280.55 
KCTD21 0.511734 0.007521 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
321 
KIAA0319 -0.45052 0.000716 17.57 31.47 
KIAA1522 -0.40188 0.010835 503.77 1087.18 
KIF27 -0.88872 0.00101 719.13 1001.95 
KIRREL 0.24478 0.03289 70.19 109.2 
KLHDC1 -0.51376 0.019856 607.26 497.35 
KLHL21 -0.3711 3.07E-15 622.18 495.23 
KLHL22 0.375451 0.001268 72.71 106.49 
KMT2A 0.444194 0.01847 131.95 89.44 
KMT2C 0.424529 0.034638 8.69 21.41 
KRT80 -0.47918 0.009895 20.66 5.65 
LARS -0.35944 0.001903 1433.79 1219.06 
LASP1 0.386554 0.000402 349.65 553.18 
LAYN 0.643106 0.000825 37.3 20.75 
LGALS1 1.181909 0.012477 616.17 747.4 
LGR6 -0.44647 0.044597 99.49 68.07 
LIMA1 0.357068 0.015615 1260.07 1576.36 
LIPA 0.368245 8.65E-24 1306.52 1681.5 
LMBR1L 0.757323 0.045149 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
322 
LOC100689270 0.272288 0.035851 227.71 169.1 
LOC100750560 0.475289 0.039954 20.33 7.39 
LOC100750688 0.398999 0.012353 3926.4 5535.83 
LOC100750719 0.356338 0.002383 7076.79 5692.44 
LOC100750843 1.017969 0.028159 2563.3 2161.07 
LOC100751267 -2.50978 0.041544 20.36 40.39 
LOC100752605 0.789775 0.006432 200.36 310.85 
LOC100752702 0.695703 0.000376 1457.01 1077.48 
LOC100752852 -0.32401 0.008235 14.57 30.62 
LOC100753154 -0.32449 0.002864 23.03 38.31 
LOC100753183 0.565097 0.03518 43.21 23.64 
LOC100753203 0.464849 0.004506 772.31 603.71 
LOC100753390 0.421115 0.003813 350.55 246.32 
LOC100753628 -0.79257 0.024434 106.52 70.25 
LOC100753650 0.308198 2.01E-05 5.77 25.76 
LOC100753871 0.281209 0.000252 490.59 353.85 
LOC100754104 0.531868 0.007831 627.74 826.16 
LOC100754429 0.624484 0.002069 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
323 
LOC100754526 0.313135 0.001798 68.37 97.22 
LOC100754646 -1.56592 1.07E-06 592.06 931.83 
LOC100755494 -2.36432 2.05E-42 168.52 231.87 
LOC100756292 0.476098 0.019032 7420.41 6281.97 
LOC100756494 -1.28467 0.009111 5944.91 9388.88 
LOC100756672 -0.35238 1.63E-12 522.88 413.69 
LOC100756967 0.336979 0.016616 179.96 282.82 
LOC100757535 -0.27887 0.010372 98.49 62.39 
LOC100757664 0.516981 8.23E-11 1191.87 902.27 
LOC100757825 -0.32805 0.039527 1189.76 1858.95 
LOC100757863 0.898288 0.004071 6086.49 7562.61 
LOC100758352 -0.51205 0.006976 30.37 47.45 
LOC100758409 0.344744 3.35E-07 179.56 251.1 
LOC100759179 0.695578 0.04843 453.68 336.15 
LOC100759598 0.567214 0.008264 51.66 84.64 
LOC100760306 0.780732 4.34E-05 3327.33 2678.57 
LOC100761082 -1.17915 0.006791 194.36 280.55 
LOC100762429 0.863855 0.027952 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
324 
LOC100762503 2.036139 0.007521 17.57 31.47 
LOC100762980 1.546724 0.000716 503.77 1087.18 
LOC100763569 0.387315 0.010835 719.13 1001.95 
LOC100764240 0.468802 0.00101 70.19 109.2 
LOC100764436 -0.32974 0.03289 607.26 497.35 
LOC100765869 0.707596 0.019856 622.18 495.23 
LOC100766020 -0.84744 3.07E-15 72.71 106.49 
LOC100766243 0.645212 0.001268 131.95 89.44 
LOC100766840 0.361769 0.01847 8.69 21.41 
LOC100767397 1.068817 0.034638 20.66 5.65 
LOC100767511 1.309742 0.009895 1433.79 1219.06 
LOC100767645 0.588983 0.001903 349.65 553.18 
LOC100767691 1.393346 0.000402 37.3 20.75 
LOC100768011 2.269969 0.000825 616.17 747.4 
LOC100768019 0.541282 0.012477 99.49 68.07 
LOC100768454 0.486824 0.044597 1260.07 1576.36 
LOC100768487 0.387642 0.015615 1306.52 1681.5 
LOC100768534 0.331004 8.65E-24 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
325 
LOC100768732 1.171037 0.045149 227.71 169.1 
LOC100768899 -0.79823 0.035851 20.33 7.39 
LOC100768961 0.88518 0.039954 3926.4 5535.83 
LOC100769643 -0.35501 0.012353 7076.79 5692.44 
LOC100769997 1.109077 0.002383 2563.3 2161.07 
LOC100770111 0.488838 0.028159 20.36 40.39 
LOC100770228 0.318044 0.041544 200.36 310.85 
LOC100770323 -0.38076 0.006432 1457.01 1077.48 
LOC100770632 0.46057 0.000376 14.57 30.62 
LOC100770794 -0.43627 0.008235 23.03 38.31 
LOC100770841 0.582796 0.002864 43.21 23.64 
LOC100771510 0.280032 0.03518 772.31 603.71 
LOC100771813 -2.33696 0.004506 350.55 246.32 
LOC100772312 -1.00465 0.003813 106.52 70.25 
LOC100772325 1.1543 0.024434 5.77 25.76 
LOC100772483 0.723871 2.01E-05 490.59 353.85 
LOC100772624 -0.42985 0.000252 627.74 826.16 
LOC100772948 -0.66002 0.007831 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
326 
LOC100773017 -0.45722 0.002069 68.37 97.22 
LOC100773107 0.441871 0.001798 592.06 931.83 
LOC100773301 -0.45367 1.07E-06 168.52 231.87 
LOC100773569 0.837716 2.05E-42 7420.41 6281.97 
LOC100773725 0.537708 0.019032 5944.91 9388.88 
LOC100773785 -0.31353 0.009111 522.88 413.69 
LOC100774337 0.397813 1.63E-12 179.96 282.82 
LOC100774451 0.490335 0.016616 98.49 62.39 
LOC100774515 0.64344 0.010372 1191.87 902.27 
LOC100774629 -0.71517 8.23E-11 1189.76 1858.95 
LOC100774659 0.404432 0.039527 6086.49 7562.61 
LOC100774914 -1.0484 0.004071 30.37 47.45 
LOC103158575 -0.93143 0.006976 179.56 251.1 
LOC103158589 0.667938 3.35E-07 453.68 336.15 
LOC103158648 1.162566 0.04843 51.66 84.64 
LOC103158703 2.395627 0.008264 3327.33 2678.57 
LOC103158724 0.864212 4.34E-05 194.36 280.55 
LOC103158729 -0.87103 0.006791 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
327 
LOC103158731 0.392697 0.027952 17.57 31.47 
LOC103158749 -0.33488 0.007521 503.77 1087.18 
LOC103158782 0.970759 0.000716 719.13 1001.95 
LOC103158821 0.376259 0.010835 70.19 109.2 
LOC103158822 0.400236 0.00101 607.26 497.35 
LOC103158840 0.526191 0.03289 622.18 495.23 
LOC103158906 -0.38679 0.019856 72.71 106.49 
LOC103158907 -0.80478 3.07E-15 131.95 89.44 
LOC103158935 3.053748 0.001268 8.69 21.41 
LOC103159029 -0.48181 0.01847 20.66 5.65 
LOC103159166 -0.41098 0.034638 1433.79 1219.06 
LOC103159462 -0.52182 0.009895 349.65 553.18 
LOC103159467 1.403451 0.001903 37.3 20.75 
LOC103159578 1.051093 0.000402 616.17 747.4 
LOC103159771 -0.34617 0.000825 99.49 68.07 
LOC103160298 -0.6311 0.012477 1260.07 1576.36 
LOC103160606 0.942138 0.044597 1306.52 1681.5 
LOC103160739 0.669903 0.015615 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
328 
LOC103161096 0.627933 8.65E-24 227.71 169.1 
LOC103161097 0.740045 0.045149 20.33 7.39 
LOC103161223 1.025204 0.035851 3926.4 5535.83 
LOC103161382 0.45784 0.039954 7076.79 5692.44 
LOC103161428 1.152744 0.012353 2563.3 2161.07 
LOC103161455 1.36857 0.002383 20.36 40.39 
LOC103161733 -1.00066 0.028159 200.36 310.85 
LOC103161831 1.047627 0.041544 1457.01 1077.48 
LOC103162177 -0.4632 0.006432 14.57 30.62 
LOC103162198 0.993474 0.000376 23.03 38.31 
LOC103162849 0.668556 0.008235 43.21 23.64 
LOC103162851 0.930666 0.002864 772.31 603.71 
LOC103162884 -1.07559 0.03518 350.55 246.32 
LOC103162906 0.498778 0.004506 106.52 70.25 
LOC103163028 0.72285 0.003813 5.77 25.76 
LOC103163200 -0.62145 0.024434 490.59 353.85 
LOC103163374 -1.25439 2.01E-05 627.74 826.16 
LOC103163594 1.425435 0.000252 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
329 
LOC103163628 2.410664 0.007831 68.37 97.22 
LOC103163823 0.740002 0.002069 592.06 931.83 
LOC103163825 0.740532 0.001798 168.52 231.87 
LOC103163866 0.635887 1.07E-06 7420.41 6281.97 
LOC103163905 -0.7395 2.05E-42 5944.91 9388.88 
LOC103164085 -0.36609 0.019032 522.88 413.69 
LOC103164093 1.303953 0.009111 179.96 282.82 
LOC103164151 1.374021 1.63E-12 98.49 62.39 
LOC103164153 0.569981 0.016616 1191.87 902.27 
LOC103164186 -2.42693 0.010372 1189.76 1858.95 
LOC103164219 0.337014 8.23E-11 6086.49 7562.61 
LOC103164247 0.864932 0.039527 30.37 47.45 
LOC103164338 0.75266 0.004071 179.56 251.1 
LOC103164432 0.498343 0.006976 453.68 336.15 
LOC103164434 0.444701 3.35E-07 51.66 84.64 
LOC103164479 0.905789 0.04843 3327.33 2678.57 
LOC103164483 0.836451 0.008264 194.36 280.55 
LOC103164570 1.108182 4.34E-05 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
330 
LOC103164585 1.863466 0.006791 17.57 31.47 
LOC103164586 1.087147 0.027952 503.77 1087.18 
LPIN3 -0.36348 0.007521 719.13 1001.95 
LPL 0.47887 0.000716 70.19 109.2 
LRIG1 0.370298 0.010835 607.26 497.35 
LRP10 0.298661 0.00101 622.18 495.23 
LRPAP1 0.392946 0.03289 72.71 106.49 
LRPPRC -0.34677 0.019856 131.95 89.44 
LRRN3 0.686543 3.07E-15 8.69 21.41 
LRWD1 0.936936 0.001268 20.66 5.65 
LSMEM1 -0.46283 0.01847 1433.79 1219.06 
LTBP1 0.438481 0.034638 349.65 553.18 
MADD 0.527226 0.009895 37.3 20.75 
MAN1C1 0.633307 0.001903 616.17 747.4 
MAP3K10 -0.32907 0.000402 99.49 68.07 
MAP3K14 0.455647 0.000825 1260.07 1576.36 
MAPK8 1.151056 0.012477 1306.52 1681.5 
38777 0.521448 0.044597 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
331 
MAST1 -0.78763 0.015615 227.71 169.1 
MB -0.77931 8.65E-24 20.33 7.39 
MBD6 -0.28942 0.045149 3926.4 5535.83 
MEDAG 0.398884 0.035851 7076.79 5692.44 
MESDC1 -0.33079 0.039954 2563.3 2161.07 
METTL7B 0.560045 0.012353 20.36 40.39 
MFF 0.558969 0.002383 200.36 310.85 
MICAL2 0.619419 0.028159 1457.01 1077.48 
MIR23B 6.091509 0.041544 14.57 30.62 
MLPH 0.774353 0.006432 23.03 38.31 
MMD 0.465227 0.000376 43.21 23.64 
MMP14 0.359336 0.008235 772.31 603.71 
MMP17 -0.93633 0.002864 350.55 246.32 
MMP28 0.815489 0.03518 106.52 70.25 
MOGAT3 1.200788 0.004506 5.77 25.76 
MRGBP 0.753712 0.003813 490.59 353.85 
MRPL4 -0.41846 0.024434 627.74 826.16 
MSN 0.428194 2.01E-05 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
332 
MTSS1 0.578105 0.000252 68.37 97.22 
MVP 0.330212 0.007831 592.06 931.83 
MYBBP1A -0.2775 0.002069 168.52 231.87 
MYBL2 -0.40137 0.001798 7420.41 6281.97 
MYH9 0.223272 1.07E-06 5944.91 9388.88 
MYLK2 0.565741 2.05E-42 522.88 413.69 
MYLPF -0.57273 0.019032 179.96 282.82 
MYO10 0.677362 0.009111 98.49 62.39 
MYOF 0.376021 1.63E-12 1191.87 902.27 
MYZAP 1.476586 0.016616 1189.76 1858.95 
N4BP1 -0.43378 0.010372 6086.49 7562.61 
NCKAP5L 0.473701 8.23E-11 30.37 47.45 
NCOR2 0.276904 0.039527 179.56 251.1 
NDRG1 0.76393 0.004071 453.68 336.15 
NEO1 0.325697 0.006976 51.66 84.64 
NFAT5 0.623163 3.35E-07 3327.33 2678.57 
NHLRC2 0.345115 0.04843 194.36 280.55 
NHSL2 1.145188 0.008264 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
333 
NLRC5 -2.0276 4.34E-05 17.57 31.47 
NPDC1 -0.43375 0.006791 503.77 1087.18 
NQO1 0.552379 0.027952 719.13 1001.95 
NRSN2 -0.36227 0.007521 70.19 109.2 
NSDHL 0.57344 0.000716 607.26 497.35 
NT5DC3 -0.4 0.010835 622.18 495.23 
NTAN1 0.407495 0.00101 72.71 106.49 
NUDT22 -0.43362 0.03289 131.95 89.44 
NUFIP1 -0.45265 0.019856 8.69 21.41 
NUPR1 0.744065 3.07E-15 20.66 5.65 
NUTM1 -0.34261 0.001268 1433.79 1219.06 
NXPE4 0.871258 0.01847 349.65 553.18 
OLFM1 0.387879 0.034638 37.3 20.75 
OLFML2B -0.77162 0.009895 616.17 747.4 
OSTF1 0.283907 0.001903 99.49 68.07 
OXSR1 -0.30292 0.000402 1260.07 1576.36 
PAK6 1.295712 0.000825 1306.52 1681.5 
PANK2 0.464452 0.012477 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
334 
PAQR5 -0.48299 0.044597 227.71 169.1 
PARVA 0.37605 0.015615 20.33 7.39 
PCIF1 -0.82483 8.65E-24 3926.4 5535.83 
PDCD6 0.472816 0.045149 7076.79 5692.44 
PDE1C -7.9132 0.035851 2563.3 2161.07 
PDE2A 0.899 0.039954 20.36 40.39 
PDGFRA 0.554967 0.012353 200.36 310.85 
PDGFRB 1.399838 0.002383 1457.01 1077.48 
PDIA6 0.273147 0.028159 14.57 30.62 
PDXDC1 0.409353 0.041544 23.03 38.31 
PDZD4 -1.22424 0.006432 43.21 23.64 
PHLDB1 0.323713 0.000376 772.31 603.71 
PHLPP2 0.545634 0.008235 350.55 246.32 
PHOSPHO1 1.249053 0.002864 106.52 70.25 
PHYHIPL -1.83116 0.03518 5.77 25.76 
PICALM 0.902056 0.004506 490.59 353.85 
PIGG 0.393337 0.003813 627.74 826.16 
PIK3CB -0.58477 0.024434 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
335 
PIP4K2B 0.298813 2.01E-05 68.37 97.22 
PIPOX 0.987589 0.000252 592.06 931.83 
PKD2 0.367427 0.007831 168.52 231.87 
PKP1 -1.25161 0.002069 7420.41 6281.97 
PLBD2 -0.2946 0.001798 5944.91 9388.88 
PLCG1 -0.32792 1.07E-06 522.88 413.69 
PLEC 0.465937 2.05E-42 179.96 282.82 
PLXDC1 1.598545 0.019032 98.49 62.39 
PLXNA1 0.401492 0.009111 1191.87 902.27 
PNKD 0.414503 1.63E-12 1189.76 1858.95 
PNLIPRP1 -0.2605 0.016616 6086.49 7562.61 
POLB -0.30579 0.010372 30.37 47.45 
POLE2 -0.44501 8.23E-11 179.56 251.1 
POLR1A -0.23393 0.039527 453.68 336.15 
POLR3H -0.38424 0.004071 51.66 84.64 
PPARG 0.467913 0.006976 3327.33 2678.57 
PPP1R2 0.664318 3.35E-07 194.36 280.55 
PRAMEF12 4.879678 0.04843 412.34 247.3 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
336 
PRKAG2 -0.55254 0.008264 17.57 31.47 
PRKCA 0.427013 4.34E-05 503.77 1087.18 
PRNP -1.10915 0.006791 719.13 1001.95 
PRPS1 -0.27948 0.027952 70.19 109.2 
PSAT1 -0.33297 0.007521 607.26 497.35 
PSMB8 -0.44738 0.000716 622.18 495.23 
PSMC5 -1.1004 0.010835 72.71 106.49 
PTCD2 -0.4217 0.00101 131.95 89.44 
PTCH2 -0.28746 0.03289 8.69 21.41 
PTGFRN 0.400917 0.019856 20.66 5.65 
PTGR1 -0.40932 3.07E-15 1433.79 1219.06 
PTK2 0.934534 0.001268 349.65 553.18 
PTPN13 0.36284 0.01847 37.3 20.75 
PTPN18 -0.88133 0.034638 616.17 747.4 
PTPRM 0.575629 0.009895 99.49 68.07 
PTPRO 0.284745 0.001903 1260.07 1576.36 
PTPRZ1 0.593719 0.000402 1306.52 1681.5 
PTRF 0.393371 0.000825 406.28 320.61 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
337 
PXDN 0.303985 0.012477 227.71 169.1 
PXK -0.43185 0.044597 20.33 7.39 
RAD51D -0.31974 0.015615 3926.4 5535.83 
RANGAP1 -0.44935 8.65E-24 7076.79 5692.44 
RASGRP4 -0.44881 0.045149 2563.3 2161.07 
RBMX2 -0.36997 0.035851 20.36 40.39 
RBPJL -1.00908 0.039954 200.36 310.85 
RBX1 0.312578 0.012353 1457.01 1077.48 
RCC2 -0.28556 0.002383 14.57 30.62 
RDH13 -0.34664 0.028159 23.03 38.31 
RELB -0.62927 0.041544 43.21 23.64 
RELT -0.36434 0.006432 772.31 603.71 
RETSAT 0.372565 0.000376 350.55 246.32 
RGL2 -0.26716 0.008235 106.52 70.25 
RGS19 -0.52319 0.002864 5.77 25.76 
RNASEH2B 1.044553 0.03518 490.59 353.85 
RNF114 -0.83001 0.004506 627.74 826.16 
RNF166 0.277855 0.003813 968.28 1256.31 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
338 
RNF170 -0.55349 0.024434 68.37 97.22 
RNF216 0.285542 2.01E-05 592.06 931.83 
RPS6KL1 -0.40995 0.000252 168.52 231.87 
RREB1 0.47257 0.007831 7420.41 6281.97 
RRN3 0.323229 0.002069 5944.91 9388.88 
RRP12 -0.38602 0.001798 522.88 413.69 
RRP9 -0.33171 1.07E-06 179.96 282.82 
RTN4IP1 -0.93874 2.05E-42 98.49 62.39 
RXRA 0.363273 0.019032 1191.87 902.27 
SAMHD1 -0.40156 0.009111 1189.76 1858.95 
SART1 -0.28114 1.63E-12 6086.49 7562.61 
SBK1 -0.47929 0.016616 30.37 47.45 
SCGB1A1 0.958656 0.010372 179.56 251.1 
SDK2 0.405537 8.23E-11 453.68 336.15 
SEMA3C -0.74753 0.039527 51.66 84.64 
SEMA6B -0.32984 0.004071 3327.33 2678.57 
SEPHS2 -0.31764 0.006976 194.36 280.55 
37135 -0.90046 3.35E-07 412.34 247.3 
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40787 0.465981 0.04843 17.57 31.47 
37865 -1.54865 0.008264 503.77 1087.18 
SERPINH1 0.453712 4.34E-05 719.13 1001.95 
SFXN5 0.560778 0.006791 70.19 109.2 
SH2B3 0.480202 0.027952 607.26 497.35 
SH3BP4 0.266219 0.007521 622.18 495.23 
SH3GLB1 0.354165 0.000716 72.71 106.49 
SH3PXD2A 0.378422 0.010835 131.95 89.44 
SHD -0.53828 0.00101 8.69 21.41 
SHROOM3 0.291544 0.03289 20.66 5.65 
SIGMAR1 -0.50134 0.019856 1433.79 1219.06 
SIPA1L2 0.55035 3.07E-15 349.65 553.18 
SIRT4 0.472976 0.001268 37.3 20.75 
SIVA1 0.647551 0.01847 616.17 747.4 
SLC15A5 0.634791 0.034638 99.49 68.07 
SLC1A3 -0.49282 0.009895 1260.07 1576.36 
SLC22A18 0.895334 0.001903 1306.52 1681.5 
SLC23A1 -0.33937 0.000402 406.28 320.61 
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SLC25A30 -0.32394 0.000825 227.71 169.1 
SLC25A32 -0.32778 0.012477 20.33 7.39 
SLC25A33 -0.42962 0.044597 3926.4 5535.83 
SLC25A44 -0.41704 0.015615 7076.79 5692.44 
SLC25A45 0.395802 8.65E-24 2563.3 2161.07 
SLC3A2 -0.33054 0.045149 20.36 40.39 
SLC6A6 0.567841 0.035851 200.36 310.85 
SLC7A5 -0.34822 0.039954 1457.01 1077.48 
SLIT1 0.398171 0.012353 14.57 30.62 
SLURP1 -0.4599 0.002383 23.03 38.31 
SMARCD2 -1.15243 0.028159 43.21 23.64 
SNX16 -0.41175 0.041544 772.31 603.71 
SNX21 -0.29573 0.006432 350.55 246.32 
SNX33 0.703475 0.000376 106.52 70.25 
SOD2 -0.2489 0.008235 5.77 25.76 
SORBS1 0.866336 0.002864 490.59 353.85 
SORCS2 0.316488 0.03518 627.74 826.16 
SPATC1L 0.339152 0.004506 968.28 1256.31 
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SPR 0.341497 0.003813 68.37 97.22 
SPRED2 0.553944 0.024434 592.06 931.83 
SPTA1 -1.47012 2.01E-05 168.52 231.87 
SPTBN1 0.373367 0.000252 7420.41 6281.97 
SPTBN5 0.447895 0.007831 5944.91 9388.88 
SREBF2 0.370089 0.002069 522.88 413.69 
SRGAP3 0.665602 0.001798 179.96 282.82 
SRM -0.38743 1.07E-06 98.49 62.39 
ST3GAL1 0.495378 2.05E-42 1191.87 902.27 
ST3GAL3 0.702618 0.019032 1189.76 1858.95 
STAB2 -0.64841 0.009111 6086.49 7562.61 
STK10 0.392487 1.63E-12 30.37 47.45 
STRBP -0.46922 0.016616 179.56 251.1 
STYK1 1.258077 0.010372 453.68 336.15 
SULF2 2.724332 8.23E-11 51.66 84.64 
SWSAP1 0.613063 0.039527 3327.33 2678.57 
SYCP3 -0.52552 0.004071 194.36 280.55 
SYNE3 0.833729 0.006976 412.34 247.3 
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SYNPO2 -0.83363 3.35E-07 17.57 31.47 
SYTL4 0.66287 0.04843 503.77 1087.18 
TAF10 0.382954 0.008264 719.13 1001.95 
TANC1 0.574852 4.34E-05 70.19 109.2 
TBC1D16 -0.83259 0.006791 607.26 497.35 
TBCCD1 -0.37623 0.027952 622.18 495.23 
TCF7 0.612683 0.007521 72.71 106.49 
TCN2 -0.95654 0.000716 131.95 89.44 
TDGF1 0.385851 0.010835 8.69 21.41 
TERT 0.400668 0.00101 20.66 5.65 
TESK2 -0.4203 0.03289 1433.79 1219.06 
THBS1 0.968187 0.019856 349.65 553.18 
TLE3 0.525706 3.07E-15 37.3 20.75 
TLR1 -1.13286 0.001268 616.17 747.4 
TMBIM1 0.356512 0.01847 99.49 68.07 
TMBIM6 0.27122 0.034638 1260.07 1576.36 
TMC1 0.552726 0.009895 1306.52 1681.5 
TMC4 -0.56265 0.001903 406.28 320.61 
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TMEM240 -0.28872 0.000402 227.71 169.1 
TMEM245 0.444777 0.000825 20.33 7.39 
TMEM25 0.630167 0.012477 3926.4 5535.83 
TMEM51 0.575057 0.044597 7076.79 5692.44 
TMOD1 -1.18003 0.015615 2563.3 2161.07 
TNFAIP2 0.471916 8.65E-24 20.36 40.39 
TNKS 0.703878 0.045149 200.36 310.85 
TNS1 1.327192 0.035851 1457.01 1077.48 
TNS3 0.7203 0.039954 14.57 30.62 
TPCN1 0.310424 0.012353 23.03 38.31 
TREH 0.370574 0.002383 43.21 23.64 
TRERF1 0.343976 0.028159 772.31 603.71 
TRIM35 0.410377 0.041544 350.55 246.32 
TRIM54 -0.33503 0.006432 106.52 70.25 
TRIM8 0.286288 0.000376 5.77 25.76 
TRIOBP 0.512485 0.008235 490.59 353.85 
TRIP10 -0.89922 0.002864 627.74 826.16 
TRMT61B -0.31439 0.03518 968.28 1256.31 
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TSC1 0.263634 0.004506 68.37 97.22 
TSPAN11 1.088778 0.003813 592.06 931.83 
TSPAN3 1.039814 0.024434 168.52 231.87 
TTN -0.36391 2.01E-05 7420.41 6281.97 
TUFT1 -0.61286 0.000252 5944.91 9388.88 
TULP2 -0.32492 0.007831 522.88 413.69 
TXNDC17 -0.50255 0.002069 179.96 282.82 
UBR5 0.323425 0.001798 98.49 62.39 
UCP2 -0.79579 1.07E-06 1191.87 902.27 
VANGL2 -0.42502 2.05E-42 1189.76 1858.95 
VARS -0.34559 0.019032 6086.49 7562.61 
VCAN 0.712189 0.009111 30.37 47.45 
VMP1 0.926339 1.63E-12 179.56 251.1 
VWA7 -0.36748 0.016616 453.68 336.15 
WARS 0.315501 0.010372 51.66 84.64 
WBP2NL -1.87187 8.23E-11 3327.33 2678.57 
WDFY4 0.898595 0.039527 194.36 280.55 
WDR12 -0.36613 0.004071 412.34 247.3 
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WDR43 -0.6218 0.006976 17.57 31.47 
WNT4 0.687391 3.35E-07 503.77 1087.18 
XAB2 -0.45938 0.04843 719.13 1001.95 
ZBTB2 -0.30796 0.008264 70.19 109.2 
ZBTB47 -4.44721 4.34E-05 607.26 497.35 
ZCCHC24 -0.29752 0.006791 622.18 495.23 
ZDHHC24 -0.47172 0.027952 72.71 106.49 
ZDHHC7 0.816782 0.007521 131.95 89.44 
ZFHX2 -0.32112 0.000716 8.69 21.41 
ZFHX3 -0.76508 0.010835 20.66 5.65 
ZHX3 -0.36169 0.00101 1433.79 1219.06 
ZMAT2 -0.43165 0.03289 349.65 553.18 
ZMIZ1 0.591245 0.019856 37.3 20.75 
ZNF334 -0.63152 3.07E-15 616.17 747.4 
ZNF358 -0.79451 0.001268 99.49 68.07 
ZNF395 0.421706 0.01847 1260.07 1576.36 
ZNF7 0.374907 0.034638 1306.52 1681.5 
ZXDC 1.265381 0.009895 406.28 320.61 
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ZZEF1 0.357985 0.001903 227.71 169.1 
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CHO-S Fc miR-24 (Sponge) – Proteomic Profiling 
Gene ID Name 
More 
abundant in 
Fold-
change 
Anova 
ACADVL 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial [Cricetulus 
griseus] Control 1.33 0.006855 
ACSL1 
Long-chain-fatty-acid--CoA ligase 1 
[Cricetulus griseus] Control 1.78 0.014342 
ACTB Actin, cytoplasmic 1 [Cricetulus griseus] Control 1.4 0.000662 
ACTN1 Alpha-actinin-1 [Cricetulus griseus] Control 1.29 0.020151 
AFAP1 
Actin filament-associated protein 1 
[Cricetulus griseus] Control 2.2 0.002112 
AHNAK2 Protein AHNAK2 [Cricetulus griseus] Control 2.08 0.000334 
AIMP2 
Aminoacyl tRNA synthetase complex-
interacting multifunctional protein 2 
[Cricetulus griseus] Control 1.49 0.048247 
ALCAM CD166 antigen [Cricetulus griseus] Control 3.13 1.63E-06 
ARF4 
ADP-ribosylation factor 4 [Cricetulus 
griseus] Control 1.45 0.009632 
ARHGAP1 
Rho GTPase-activating protein 1 
[Cricetulus griseus] Control 1.62 0.036126 
ARHGEF2 
Rho guanine nucleotide exchange factor 
2 [Cricetulus griseus] Control 1.57 0.015172 
___________________________________________________________________________ 
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ARPC4 
Actin-related protein 2/3 complex subunit 
4 [Cricetulus griseus] Control 1.5 0.001712 
CAP1 
Adenylyl cyclase-associated protein 1 
[Cricetulus griseus] Control 1.74 0.013458 
CARMIL1 
Leucine-rich repeat-containing protein 
16A [Cricetulus griseus] Control 3.18 0.013164 
CASP12 Caspase-12, partial [Cricetulus griseus] Control 1.63 0.014284 
CCT7 
T-complex protein 1 subunit eta 
[Cricetulus griseus] Control 1.56 0.048791 
CCT8 
T-complex protein 1 subunit theta 
[Cricetulus griseus] Control 1.51 0.027222 
CD36 Platelet glycoprotein 4 [Cricetulus griseus] Control 7 3.58E-06 
CDK1 
Cell division control protein 2-like 
[Cricetulus griseus] Control 1.68 0.002758 
CHD4 
Chromodomain-helicase-DNA-binding 
protein 4 [Cricetulus griseus] Control 1.42 0.049299 
CKAP5 
Cytoskeleton-associated protein 5 
[Cricetulus griseus] Control 1.86 0.010288 
CLIC4 
Chloride intracellular channel protein 4 
[Cricetulus griseus] Control 1.28 0.031041 
CNN2 Calponin-2 [Cricetulus griseus] Control 2.03 0.000837 
COPA 
Coatomer subunit alpha [Cricetulus 
griseus] Control 1.56 0.016266 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
349 
CORO1C Coronin-1C [Cricetulus griseus] Control 1.43 0.012681 
CSPG4 
Chondroitin sulfate proteoglycan 4 
[Cricetulus griseus] Control 1.68 2.53E-05 
CTLA2B Protein CTLA-2-beta [Cricetulus griseus] Control 14.58 0.000369 
CTLA2B Protein CTLA-2-beta [Cricetulus griseus] Control 2.37 0.003369 
CTSZ Cathepsin Z [Cricetulus griseus] Control 1.43 0.009848 
CYFIP1 
Cytoplasmic FMR1-interacting protein 1 
[Cricetulus griseus] Control 1.61 0.001795 
DAB2 Disabled-like 2 [Cricetulus griseus] Control 1.57 0.005282 
DCTN2 Dynactin subunit 2 [Cricetulus griseus] Control 1.3 0.002976 
DLAT 
Dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
[Cricetulus griseus] Control 1.48 0.004367 
DLG1 Disks large-like 1 [Cricetulus griseus] Control 1.36 0.025768 
DSTN Destrin [Cricetulus griseus] Control 1.85 0.002351 
DYNC1H1 
Cytoplasmic dynein 1 heavy chain 1, 
partial [Cricetulus griseus] Control 1.44 0.007737 
EIF4A1 
Eukaryotic initiation factor 4A-I [Cricetulus 
griseus] Control 1.2 0.084736 
ENO1 
PREDICTED: alpha-enolase isoform X2 
[Cricetulus griseus] Control 2.43 0.021904 
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EPHA2 
Ephrin type-A receptor 2 [Cricetulus 
griseus] Control 1.57 0.000114 
ETF1 
Eukaryotic peptide chain release factor 
subunit 1 [Cricetulus griseus] Control 1.34 0.008763 
FAAH 
Fatty-acid amide hydrolase 1 [Cricetulus 
griseus] Control 1.71 0.006811 
FASN Fatty acid synthase [Cricetulus griseus] Control 1.71 0.002266 
FERMT2 Fermitin family-like 2 [Cricetulus griseus] Control 1.69 0.007001 
FLNB Filamin-B [Cricetulus griseus] Control 2.29 0.00924 
GALNT2 
PREDICTED: polypeptide N-
acetylgalactosaminyltransferase 2 
[Cricetulus griseus] Control 1.67 0.005331 
GAPDH 
glyceraldehyde-3-phosphate 
dehydrogenase [Cricetulus griseus] Control 1.5 0.000611 
GDI2 
Rab GDP dissociation inhibitor beta 
[Cricetulus griseus] Control 1.33 0.00019 
GLG1 
latent TGF-beta complexed protein 
(LTCP) [Cricetulus griseus] Control 1.32 0.004413 
GLO1 
Lactoylglutathione lyase [Cricetulus 
griseus] Control 1.53 0.017488 
GPC1 Glypican-1 [Cricetulus griseus] Control 1.62 8.76E-05 
GPDH 
Glycerol-3-phosphate dehydrogenase 
[NAD+], cytoplasmic [Cricetulus griseus] Control 2 0.00016 
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GSTM6 
Glutathione S-transferase Mu 6 
[Cricetulus griseus] Control 1.72 0.016092 
GSTM7 
Glutathione S-transferase Mu 7 
[Cricetulus griseus] Control 1.89 0.010407 
HDGFL2 
Hepatoma-derived growth factor-related 
protein 2 [Cricetulus griseus] Control 1.72 0.015263 
HDLBP Vigilin [Cricetulus griseus] Control 1.55 0.004727 
HMGCS1 
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic [Cricetulus griseus] Control 1.59 0.000349 
IDH1 
Isocitrate dehydrogenase [NADP] 
cytoplasmic [Cricetulus griseus] Control 1.92 0.002038 
IPO4 Importin-4 [Cricetulus griseus] Control 1.82 0.029183 
IPO5 Importin-5 [Cricetulus griseus] Control 1.65 0.030691 
ITGA3 Integrin alpha-3 [Cricetulus griseus] Control 2.11 0.000909 
ITGA5 Integrin alpha-5 [Cricetulus griseus] Control 1.51 0.007201 
ITGAV Integrin alpha-V [Cricetulus griseus] Control 1.5 0.020807 
ITGB1 Integrin beta-1 [Cricetulus griseus] Control 1.44 0.000265 
KIF5B 
PREDICTED: kinesin-1 heavy chain 
isoform X2 [Cricetulus griseus] Control 1.3 0.004739 
KLC1 Kinesin light chain 1 [Cricetulus griseus] Control 1.78 0.016381 
KPNB1 
Importin subunit beta-1 [Cricetulus 
griseus] Control 1.29 0.008704 
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LAMP2 
lysosome-associated membrane 
glycoprotein 2 precursor [Cricetulus 
griseus] Control 1.47 0.012262 
LAP3 
Cytosol aminopeptidase [Cricetulus 
griseus] Control 1.38 0.039703 
LDHA 
L-lactate dehydrogenase A chain 
[Cricetulus griseus] Control 2.22 0.006102 
LDLR 
RecName: Full=Low-density lipoprotein 
receptor; Short=LDL receptor; Flags: 
Precursor Control 1.36 0.021391 
LGALS1 Lectin galactoside-binding soluble 1 Control 1.58 0.001334 
LGALS3 Galectin-3 [Cricetulus griseus] Control 1.37 0.003448 
LOC100757491 Histone H3 [Cricetulus griseus] Control 12.04 0.017064 
MAP1S 
Microtubule-associated protein 1S 
[Cricetulus griseus] Control 1.26 0.027674 
MEMO1 
PREDICTED: protein MEMO1 isoform X2 
[Cricetulus griseus] Control 1.6 0.027637 
MFGE8 
PREDICTED: lactadherin isoform X1 
[Cricetulus griseus] Control 1.37 0.023936 
MMS19 
MMS19 nucleotide excision repair 
protein-like [Cricetulus griseus] Control 2.28 0.019004 
MPP1 
55 kDa erythrocyte membrane protein 
[Cricetulus griseus] Control 1.54 0.001624 
MTHFD1 
C-1-tetrahydrofolate synthase, 
cytoplasmic [Cricetulus griseus] Control 1.14 0.040844 
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MVP Major vault protein [Cricetulus griseus] Control 1.64 0.013223 
MYADM 
Myeloid-associated differentiation marker 
[Cricetulus griseus] Control 1.27 0.004059 
MYH10 Myosin-10 [Cricetulus griseus] Control 2.31 1.83E-05 
MYH9 
PREDICTED: myosin-9 isoform X2 
[Cricetulus griseus] Control 2.83 5.63E-06 
MYL12B 
Myosin regulatory light chain 12B 
[Cricetulus griseus] Control 1.9 0.000293 
MYL6 
Myosin light polypeptide 6 [Cricetulus 
griseus] Control 1.42 0.000236 
MYO1C Myosin-Ic [Cricetulus griseus] Control 1.52 0.011441 
MYOF Myoferlin [Cricetulus griseus] Control 1.42 0.013826 
NDRG3 Protein NDRG3 [Cricetulus griseus] Control 2.7 0.004605 
NDUFA8 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 8 [Cricetulus 
griseus] Control 1.54 0.018605 
NDUFS1 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial [Cricetulus griseus] Control 2.56 0.038355 
NDUFV1 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial [Cricetulus 
griseus] Control 1.38 0.003759 
NHLRC2 
NHL repeat-containing protein 2 
[Cricetulus griseus] Control 1.34 0.000227 
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P4HB 
protein disulfide-isomerase precursor 
[Cricetulus griseus] Control 1.92 0.030905 
PCCA 
Propionyl-CoA carboxylase alpha chain, 
mitochondrial [Cricetulus griseus] Control 2 3.01E-05 
PCNA 
proliferating cell nuclear antigen 
[Cricetulus griseus] Control 1.51 0.010597 
PDLIM7 
PDZ and LIM domain protein 7 [Cricetulus 
griseus] Control 1.87 0.001146 
PGAM1 
Phosphoglycerate mutase 1 [Cricetulus 
griseus] Control 1.39 0.007127 
PLA2G4E 
EH domain-containing protein 4 
[Cricetulus griseus] Control 1.78 0.000654 
PLAA 
Phospholipase A-2-activating protein 
[Cricetulus griseus] Control 1.36 0.056936 
PLEC Plectin-1 [Cricetulus griseus] Control 1.5 0.011258 
PLEC 
hypothetical protein I79_015376 
[Cricetulus griseus] Control 1.5 9.38E-05 
PLIN3 
Mannose-6-phosphate receptor-binding 
protein 1 [Cricetulus griseus] Control 2.06 0.005715 
PRKACA 
cAMP-dependent protein kinase catalytic 
subunit alpha [Cricetulus griseus] Control 2.37 0.023361 
PRKAR1A 
cAMP-dependent protein kinase type I-
alpha regulatory subunit [Cricetulus 
griseus] Control 2.31 0.022856 
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PSMB7 
Proteasome subunit beta type-7 
[Cricetulus griseus] Control 1.27 0.01611 
PSMC4 
26S protease regulatory subunit 6B, 
partial [Cricetulus griseus] Control 1.61 0.041244 
PSMD2 
26S proteasome non-ATPase regulatory 
subunit 2 [Cricetulus griseus] Control 1.37 0.011375 
PSMG1 
Proteasome assembly chaperone 1 
[Cricetulus griseus] Control 1.5 0.028846 
PTBP3 
Regulator of differentiation 1 [Cricetulus 
griseus] Control 1.84 0.0123 
PTGFRN 
Prostaglandin F2 receptor negative 
regulator [Cricetulus griseus] Control 1.65 0.000482 
RAB11B 
Ras-related protein Rab-11B [Cricetulus 
griseus] Control 1.47 0.007697 
RAB2B 
Ras-related protein Rab-2B [Cricetulus 
griseus] Control 1.37 0.011692 
RAB5C 
Ras-related protein Rab-5C [Cricetulus 
griseus] Control 1.45 0.004813 
RANSET2 Ribonuclease T2 [Cricetulus griseus] Control 2.01 0.002388 
RPLP0 
60S acidic ribosomal protein P0 
[Cricetulus griseus] Control 1.45 0.008041 
RRM2 
Ribonucleoside-diphosphate reductase 
subunit M2 [Cricetulus griseus] Control 2.15 0.000477 
S100A16 Protein S100-A16 [Cricetulus griseus] Control 1.81 0.00206 
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S100A5 Protein S100-A5 [Cricetulus griseus] Control 1.93 0.000367 
S100A6 Protein S100-A6 [Cricetulus griseus] Control 1.32 0.019891 
SEPT6 Septin-6 [Cricetulus griseus] Control 2.05 0.000125 
SF1 
PREDICTED: splicing factor 1 [Cricetulus 
griseus] Control 1.32 0.037637 
SF3A3 
Splicing factor 3A subunit 3 [Cricetulus 
griseus] Control 1.46 0.039789 
SLC1A4 
neutral amino acid transporter type 1 
[Cricetulus griseus] Control 1.58 0.00493 
SLC25A20 
Mitochondrial carnitine/acylcarnitine 
carrier protein [Cricetulus griseus] Control 2.18 0.040367 
SLC25A24 
Calcium-binding mitochondrial carrier 
protein SCaMC-1 [Cricetulus griseus] Control 2.06 0.007961 
SNX9 Sorting nexin-9 [Cricetulus griseus] Control 1.49 0.002421 
SPTAN1 
Spectrin alpha chain, brain [Cricetulus 
griseus] Control 1.79 0.037511 
SPTBN1 
Spectrin beta chain, brain 1 [Cricetulus 
griseus] Control 1.65 0.000175 
STUB1 
STIP1-likey and U box-containing protein 
1 [Cricetulus griseus] Control 1.77 0.001039 
TGM2 
Protein-glutamine gamma-
glutamyltransferase 2 [Cricetulus griseus] Control 1.47 0.006735 
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TPP2 
PREDICTED: tripeptidyl-peptidase 2 
isoform X6 [Cricetulus griseus] Control 1.44 0.010295 
TRA2B 
Transformer-2 protein-like beta 
[Cricetulus griseus] Control 1.28 0.00668 
TUBB4A Tubulin beta-4 chain [Cricetulus griseus] Control 1.47 0.010237 
UBE2C 
Ubiquitin-conjugating enzyme E2 C 
[Cricetulus griseus] Control 1.52 0.001476 
UGDH 
UDP-glucose 6-dehydrogenase 
[Cricetulus griseus] Control 1.8 0.002139 
USP10 
Ubiquitin carboxyl-terminal hydrolase 10 
[Cricetulus griseus] Control 1.33 0.015262 
USP15 
Ubiquitin carboxyl-terminal hydrolase 15 
[Cricetulus griseus] Control 1.42 0.001316 
UTP15 
U3 small nucleolar RNA-associated 
protein 15-like [Cricetulus griseus] Control 1.29 0.032082 
VNN1 Pantetheinase [Cricetulus griseus] Control 2.07 0.000488 
VPS35 
Vacuolar protein sorting-associated 
protein 35 [Cricetulus griseus] Control 1.44 0.038762 
VWA5A 
von Willebrand factor A domain-
containing protein 5A [Cricetulus griseus] Control 1.72 8.09E-05 
WDR1 
PREDICTED: WD repeat-containing 
protein 1 isoform X2 [Cricetulus griseus] Control 1.6 0.001642 
YWHAH 14-3-3 protein eta [Cricetulus griseus] Control 1.47 0.009735 
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* 
Glycosyltransferase 25 family member 1 
[Cricetulus griseus] mIR-24 1.36 0.012099 
ABCE1 
ATP-binding cassette sub-family E 
member 1 [Cricetulus griseus] mIR-24 1.26 0.004335 
ABCF1 
ATP-binding cassette sub-family F 
member 1 [Cricetulus griseus] mIR-24 1.54 0.017853 
ACAD9 
Acyl-CoA dehydrogenase family member 
9, mitochondrial [Cricetulus griseus] mIR-24 1.47 0.009745 
ACAT1 
Acetyl-CoA acetyltransferase, 
mitochondrial [Cricetulus griseus] mIR-24 1.3 0.011472 
ADRM1 
Proteasomal ubiquitin receptor ADRM1 
[Cricetulus griseus] mIR-24 1.29 0.015862 
AFG3L2 AFG3-like protein 2 [Cricetulus griseus] mIR-24 1.58 0.006681 
AHCY 
Adenosylhomocysteinase [Cricetulus 
griseus] mIR-24 1.31 0.001541 
AHCYL1 
Putative adenosylhomocysteinase 2 
[Cricetulus griseus] mIR-24 1.43 0.01648 
AHSA1 
Activator of 90 kDa heat shock protein 
ATPase-like 1 [Cricetulus griseus] mIR-24 1.27 0.027662 
AIMP1 
multisynthetase complex auxiliary 
component p43 [Cricetulus griseus] mIR-24 1.54 0.031332 
AIRE Autoimmune regulator [Cricetulus griseus] mIR-24 1.42 0.018937 
AKR1B1 Aldose reductase [Cricetulus griseus] mIR-24 1.34 0.000104 
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AKR1B10 
Aldo-keto reductase family 1 member B10 
[Cricetulus griseus] mIR-24 3.08 0.000317 
AKR1B8 
aldose reductase-related protein 2 
[Cricetulus griseus] mIR-24 1.96 0.000183 
ALDH2 
Aldehyde dehydrogenase, mitochondrial 
[Cricetulus griseus] mIR-24 1.36 8.59E-05 
ALDH7A1 
Alpha-aminoadipic semialdehyde 
dehydrogenase [Cricetulus griseus] mIR-24 1.3 0.02933 
ALDOA 
Fructose-bisphosphate aldolase A 
[Cricetulus griseus] mIR-24 1.32 0.033149 
ANXA1 Annexin A1 [Cricetulus griseus] mIR-24 1.5 0.013146 
ANXA11 Annexin A11 [Cricetulus griseus] mIR-24 1.4 0.007018 
APEX1 
DNA-(apurinic or apyrimidinic site) lyase 
[Cricetulus griseus] mIR-24 1.53 0.001498 
ASUN 
Cell cycle regulator Mat89Bb-like 
[Cricetulus griseus] mIR-24 2.49 0.000379 
ATAD3A 
ATPase family AAA domain-containing 
protein 3 [Cricetulus griseus] mIR-24 1.42 0.003156 
ATP2A1 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 1 [Cricetulus griseus] mIR-24 1.31 0.007275 
ATP2A2 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 [Cricetulus griseus] mIR-24 1.41 0.026601 
ATP5B 
ATP synthase subunit beta, mitochondrial 
[Cricetulus griseus] mIR-24 1.33 0.032882 
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ATP5C1 
ATP synthase subunit gamma, 
mitochondrial [Cricetulus griseus] mIR-24 1.35 0.002065 
ATP5D 
ATP synthase subunit delta, 
mitochondrial [Cricetulus griseus] mIR-24 1.28 0.070538 
ATP5F1 
PREDICTED: ATP synthase F(0) 
complex subunit B1, mitochondrial 
isoform X1 [Cricetulus griseus] mIR-24 1.29 0.000639 
ATP5H 
ATP synthase subunit d, mitochondrial 
[Cricetulus griseus] mIR-24 1.29 0.017302 
ATXN2 Ataxin-2, partial [Cricetulus griseus] mIR-24 1.28 0.016439 
ATXN2L 
PREDICTED: ataxin-2-like protein isoform 
X13 [Cricetulus griseus] mIR-24 1.26 0.018663 
BAG3 
BAG family molecular chaperone 
regulator 3 [Cricetulus griseus] mIR-24 1.52 0.005742 
BUB3 
Mitotic checkpoint protein BUB3 
[Cricetulus griseus] mIR-24 1.3 0.028922 
BZW2 
Basic leucine zipper and W2 domain-
containing protein 2 [Cricetulus griseus] mIR-24 1.42 0.000283 
CALR Calreticulin [Cricetulus griseus] mIR-24 1.3 0.000276 
CALU Calumenin [Cricetulus griseus] mIR-24 1.71 0.002119 
CAND1 
Cullin-associated NEDD8-dissociated 
protein 1 [Cricetulus griseus] mIR-24 1.31 0.011178 
CANX Calnexin [Cricetulus griseus] mIR-24 1.48 0.002229 
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CAT Catalase [Cricetulus griseus] mIR-24 1.35 0.002814 
CBR3 
Carbonyl reductase [NADPH] 3 
[Cricetulus griseus] mIR-24 1.26 0.010759 
CCT8 
T-complex protein 1 subunit theta 
[Cricetulus griseus] mIR-24 1.3 0.001556 
CEBPZ 
CCAAT/enhancer-binding protein zeta 
[Cricetulus griseus] mIR-24 1.69 0.011993 
CLPP 
Putative ATP-dependent Clp protease 
proteolytic subunit, mitochondrial 
[Cricetulus griseus] mIR-24 1.46 0.039538 
CMAS 
N-acylneuraminate cytidylyltransferase 
[Cricetulus griseus] mIR-24 2.05 1.84E-05 
CNBP 
Cellular nucleic acid-binding protein 
[Cricetulus griseus] mIR-24 1.85 0.004321 
CSE1L Exportin-2 [Cricetulus griseus] mIR-24 1.36 0.026768 
CSNK2B 
Casein kinase II subunit beta [Cricetulus 
griseus] mIR-24 1.37 0.001843 
CSTF2 
Cleavage stimulation factor 64 kDa 
subunit [Cricetulus griseus] mIR-24 1.7 0.007249 
CTSA 
Lysosomal protective protein [Cricetulus 
griseus] mIR-24 1.32 0.015781 
DAP3 
28S ribosomal protein S29, mitochondrial 
[Cricetulus griseus] mIR-24 1.49 0.009249 
DDB1 
DNA damage-binding protein 1 
[Cricetulus griseus] mIR-24 1.31 0.001222 
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DDX1 
ATP-dependent RNA helicase DDX1 
[Cricetulus griseus] mIR-24 1.26 0.000182 
DDX19A 
ATP-dependent RNA helicase DDX19A 
[Cricetulus griseus] mIR-24 1.28 0.010245 
DDX21 
Nucleolar RNA helicase 2 [Cricetulus 
griseus] mIR-24 1.3 0.003036 
DDX39B 
Spliceosome RNA helicase BAT1 
[Cricetulus griseus] mIR-24 1.3 0.015989 
DDX3X 
ATP-dependent RNA helicase DDX3X 
[Cricetulus griseus] mIR-24 1.32 3.81E-05 
DDX47 
putative ATP-dependent RNA helicase 
DDX47 [Cricetulus griseus] mIR-24 1.76 0.000812 
DDX5 
putative ATP-dependent RNA helicase 
DDX5 [Cricetulus griseus] mIR-24 2.01 0.012501 
DDX56 
putative ATP-dependent RNA helicase 
DDX56 [Cricetulus griseus] mIR-24 1.57 0.008844 
DHFR 
Dihydrofolate reductase [Cricetulus 
griseus] mIR-24 4.22 0.000152 
DNAJA2 
PREDICTED: dnaJ homolog subfamily A 
member 2 isoform X2 [Cricetulus griseus] mIR-24 1.37 0.002452 
DNAJC11 
DnaJ-like subfamily C member 11 
[Cricetulus griseus] mIR-24 1.29 0.011819 
DNAJC8 
DnaJ-like subfamily C member 8 
[Cricetulus griseus] mIR-24 1.31 0.012966 
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DNTTIP2 
Deoxynucleotidyltransferase terminal-
interacting protein 2 [Cricetulus griseus] mIR-24 1.46 0.011345 
DPP7 
Dipeptidyl-peptidase 2 [Cricetulus 
griseus] mIR-24 1.28 0.012718 
DRG1 
Developmentally-regulated GTP-binding 
protein 1 [Cricetulus griseus] mIR-24 1.43 0.026052 
EEF1D 
Elongation factor 1-delta [Cricetulus 
griseus] mIR-24 1.39 0.019266 
EEF1G 
Elongation factor 1-gamma [Cricetulus 
griseus] mIR-24 1.4 0.027449 
EEF2 Elongation factor 2 [Cricetulus griseus] mIR-24 1.23 0.000277 
EFHD2 
EF-hand domain-containing protein D2 
[Cricetulus griseus] mIR-24 1.45 0.003517 
EHD1 
EH domain-containing protein 1 
[Cricetulus griseus] mIR-24 1.49 0.000101 
EIF2B4 
Translation initiation factor eIF-2B subunit 
delta [Cricetulus griseus] mIR-24 1.36 0.013214 
EIF2S2 
Eukaryotic translation initiation factor 2 
subunit 2 [Cricetulus griseus] mIR-24 1.19 0.062663 
EIF3G 
Eukaryotic translation initiation factor 3 
subunit G [Cricetulus griseus] mIR-24 2.01 0.004199 
EIF3L 
Eukaryotic translation initiation factor 3 
subunit L [Cricetulus griseus] mIR-24 1.4 0.001022 
EIF5A2 
Eukaryotic translation initiation factor 5A-
2 [Cricetulus griseus] mIR-24 1.39 0.01664 
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EIF5B 
Eukaryotic translation initiation factor 5B 
[Cricetulus griseus] mIR-24 1.41 0.003758 
EIF6 
Eukaryotic translation initiation factor 6 
[Cricetulus griseus] mIR-24 1.4 0.001529 
ELP1 
Elongator complex protein 1 [Cricetulus 
griseus] mIR-24 1.29 0.001873 
ELP3 
Elongator complex protein 3 [Cricetulus 
griseus] mIR-24 1.38 0.021238 
EML4 
Echinoderm microtubule-associated 
protein-like 4, partial [Cricetulus griseus] mIR-24 1.87 0.009485 
EPDR1 
Mammalian ependymin-related protein 1 
[Cricetulus griseus] mIR-24 1.76 0.000419 
EPHX1 Epoxide hydrolase 1 [Cricetulus griseus] mIR-24 1.34 0.009354 
ERP29 
Endoplasmic reticulum protein ERp29 
[Cricetulus griseus] mIR-24 1.36 0.017371 
ESD 
S-formylglutathione hydrolase [Cricetulus 
griseus] mIR-24 1.32 0.018366 
EXOSC9 
Exosome complex exonuclease RRP45 
[Cricetulus griseus] mIR-24 1.42 0.016084 
FKBP10 
FK506-binding protein 10 [Cricetulus 
griseus] mIR-24 1.39 0.003103 
FKBP4 
FK506-binding protein 4 [Cricetulus 
griseus] mIR-24 1.28 0.000155 
FLNC Filamin-C [Cricetulus griseus] mIR-24 4.09 7.87E-05 
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FTSJ3 
Putative rRNA methyltransferase 3 
[Cricetulus griseus] mIR-24 1.35 0.023726 
GAA 
PREDICTED: lysosomal alpha-
glucosidase isoform X2 [Cricetulus 
griseus] mIR-24 1.41 0.003153 
GALK1 Galactokinase [Cricetulus griseus] mIR-24 1.28 0.008349 
GART 
Trifunctional purine biosynthetic protein 
adenosine-3 [Cricetulus griseus] mIR-24 1.31 0.000991 
GFM1 
Elongation factor G, mitochondrial 
[Cricetulus griseus] mIR-24 1.35 0.008702 
GOT1 
Aspartate aminotransferase, cytoplasmic 
[Cricetulus griseus] mIR-24 1.31 0.009104 
GOT2 
Aspartate aminotransferase, 
mitochondrial [Cricetulus griseus] mIR-24 1.3 0.02913 
GPI 
glucose phosphate isomerase [Cricetulus 
griseus] mIR-24 1.36 0.024393 
GRPEL1 
GrpE protein-like 1, mitochondrial 
[Cricetulus griseus] mIR-24 1.28 0.006868 
GSPT1 
Eukaryotic peptide chain release factor 
GTP-binding subunit ERF3B [Cricetulus 
griseus] mIR-24 1.32 0.000724 
GSTA3 
Glutathione S-transferase alpha-3 
[Cricetulus griseus] mIR-24 1.5 0.00032 
GSTA4 
Glutathione S-transferase A4 [Cricetulus 
griseus] mIR-24 1.5 0.00082 
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GSTP1 
Glutathione S-transferase P [Cricetulus 
griseus] mIR-24 1.37 0.005148 
GTPBP4 
Nucleolar GTP-binding protein 1 
[Cricetulus griseus] mIR-24 1.44 0.001507 
H1F0 Histone H1.0 [Cricetulus griseus] mIR-24 1.34 0.003095 
HARS2 
putative histidyl-tRNA synthetase, 
mitochondrial [Cricetulus griseus] mIR-24 1.32 0.000492 
HEATR1 
hypothetical protein I79_015294 
[Cricetulus griseus] mIR-24 1.54 0.000842 
HEBP1 
Heme-binding protein 1 [Cricetulus 
griseus] mIR-24 1.63 0.01115 
HMGCS2 
Hydroxymethylglutaryl-CoA synthase, 
mitochondrial [Cricetulus griseus] mIR-24 1.62 0.010528 
HNRNPA1 
Putative heterogeneous nuclear 
ribonucleoprotein A1-like protein 3 
[Cricetulus griseus] mIR-24 1.46 0.004402 
HNRNPA2B1 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 [Cricetulus 
griseus] mIR-24 1.44 0.007648 
HNRNPA3 
PREDICTED: heterogeneous nuclear 
ribonucleoprotein A3 isoform X2 
[Cricetulus griseus] mIR-24 1.3 0.019314 
HNRNPAB 
Heterogeneous nuclear ribonucleoprotein 
A/B [Cricetulus griseus] mIR-24 1.4 0.003547 
HNRNPM 
Heterogeneous nuclear ribonucleoprotein 
M [Cricetulus griseus] mIR-24 1.32 0.000462 
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HNRNPR 
Heterogeneous nuclear ribonucleoprotein 
R [Cricetulus griseus] mIR-24 1.4 0.021491 
HNRNPU 
PREDICTED: heterogeneous nuclear 
ribonucleoprotein U, partial [Cricetulus 
griseus] mIR-24 1.27 0.007209 
HNRNPUL2 
Heterogeneous nuclear ribonucleoprotein 
U-like protein 2 [Cricetulus griseus] mIR-24 1.44 0.015738 
HSD17B10 
3-hydroxyacyl-CoA dehydrogenase type-
2 [Cricetulus griseus] mIR-24 1.49 0.000441 
HSP90B1 Endoplasmin [Cricetulus griseus] mIR-24 1.23 0.001374 
HSPA4 
Heat shock 70 kDa protein 4, partial 
[Cricetulus griseus] mIR-24 1.44 0.015464 
HSPA5 
78 kDa glucose-regulated protein 
precursor [Cricetulus griseus] mIR-24 1.34 0.00864 
HSPA9 
stress-70 protein, mitochondrial 
[Cricetulus griseus] mIR-24 1.29 0.000673 
HSPE1 
PREDICTED: 10 kDa heat shock protein, 
mitochondrial [Cricetulus griseus] mIR-24 1.3 0.011299 
HUWE1 
E3 ubiquitin-protein ligase HUWE1, 
partial [Cricetulus griseus] mIR-24 1.29 0.002081 
IARS 
PREDICTED: isoleucine--tRNA ligase, 
cytoplasmic isoform X2 [Cricetulus 
griseus] mIR-24 1.63 0.006384 
ILF3 
Interleukin enhancer-binding factor 3 
[Cricetulus griseus] mIR-24 1.71 0.019111 
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IMPDH1 
Inosine-5'-monophosphate 
dehydrogenase 1 [Cricetulus griseus] mIR-24 1.28 0.001861 
IMPDH2 
RecName: Full=Inosine-5'-
monophosphate dehydrogenase 2; 
Short=IMP dehydrogenase 2; 
Short=IMPD 2; Short=IMPDH 2; AltName: 
Full=IMPDH-II mIR-24 1.36 0.007728 
ISYNA1 
Inositol-3-phosphate synthase 1 
[Cricetulus griseus] mIR-24 1.4 0.001108 
ITPR3 
Inositol 1,4,5-trisphosphate receptor type 
3 [Cricetulus griseus] mIR-24 1.98 0.000222 
KARS 
Lysyl-tRNA synthetase [Cricetulus 
griseus] mIR-24 1.33 0.001164 
KHSRP 
Far upstream element-binding protein 2 
[Cricetulus griseus] mIR-24 1.32 0.004545 
KLHDC4 
Kelch domain-containing protein 4 
[Cricetulus griseus] mIR-24 1.63 0.030509 
LAMC1 
Laminin subunit gamma-1 [Cricetulus 
griseus] mIR-24 1.32 0.007947 
LARS 
Leucyl-tRNA synthetase, cytoplasmic 
[Cricetulus griseus] mIR-24 1.34 0.011782 
LARS 
Leucyl-tRNA synthetase, cytoplasmic 
[Cricetulus griseus] mIR-24 1.34 0.000158 
LBHD1 
hypothetical protein I79_016739 
[Cricetulus griseus] mIR-24 1.46 0.018541 
LBR Lamin-B receptor [Cricetulus griseus] mIR-24 1.32 0.001199 
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LCT 
Lactase-phlorizin hydrolase [Cricetulus 
griseus] mIR-24 1.66 0.034181 
LOC100772531 
Suppressor of SWI4 1-like [Cricetulus 
griseus] mIR-24 1.52 0.012511 
LONP1 
Lon protease-like, mitochondrial 
[Cricetulus griseus] mIR-24 1.32 0.00272 
LRPPRC 
Leucine-rich PPR motif-containing 
protein, mitochondrial [Cricetulus griseus] mIR-24 1.35 0.000234 
LTA4H 
Leukotriene A-4 hydrolase [Cricetulus 
griseus] mIR-24 1.4 0.008993 
LUC7L3 
PREDICTED: luc7-like protein 3 isoform 
X1 [Cricetulus griseus] mIR-24 1.29 0.019802 
LYAR 
Cell growth-regulating nucleolar protein 
[Cricetulus griseus] mIR-24 2.77 0.020454 
MATR3 Matrin-3 [Cricetulus griseus] mIR-24 1.38 0.001022 
MCM5 
DNA replication licensing factor MCM5 
[Cricetulus griseus] mIR-24 3.56 3.89E-05 
MDH2 
Malate dehydrogenase, mitochondrial, 
partial [Cricetulus griseus] mIR-24 1.27 0.013815 
MRPS27 
28S ribosomal protein S27, mitochondrial 
[Cricetulus griseus] mIR-24 1.62 0.012011 
MRPS35 
28S ribosomal protein S35, mitochondrial 
[Cricetulus griseus] mIR-24 2.14 0.000934 
MRPS9 
28S ribosomal protein S9, mitochondrial 
[Cricetulus griseus] mIR-24 1.51 0.032616 
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MRTO4 
mRNA turnover protein 4-like, partial 
[Cricetulus griseus] mIR-24 1.34 0.004978 
MYBBP1A 
Myb-binding protein 1A [Cricetulus 
griseus] mIR-24 1.37 0.002094 
NAA15 
NMDA receptor-regulated protein 1 
[Cricetulus griseus] mIR-24 1.3 0.012901 
NAA50 
N-acetyltransferase NAT13 [Cricetulus 
griseus] mIR-24 1.35 8.16E-05 
NARS 
Asparaginyl-tRNA synthetase, 
cytoplasmic [Cricetulus griseus] mIR-24 1.43 0.003182 
NASP 
PREDICTED: nuclear autoantigenic 
sperm protein isoform X1 [Cricetulus 
griseus] mIR-24 1.34 0.001532 
NAT10 
N-acetyltransferase 10 [Cricetulus 
griseus] mIR-24 1.48 0.001676 
NCLN Nicalin [Cricetulus griseus] mIR-24 1.53 0.008406 
NIFK 
MKI67 FHA domain-interacting nucleolar 
phosphoprotein [Cricetulus griseus] mIR-24 1.64 0.031959 
NME2 
Nucleoside diphosphate kinase B 
[Cricetulus griseus] mIR-24 1.34 0.001638 
NOC2L 
Nucleolar complex protein 2-like 
[Cricetulus griseus] mIR-24 1.56 0.036155 
NOL10 Nucleolar protein 10 [Cricetulus griseus] mIR-24 1.8 0.003445 
NOLC1 
Nucleolar phosphoprotein p130 
[Cricetulus griseus] mIR-24 1.55 0.000564 
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NOMO1 
PREDICTED: nodal modulator 1 isoform 
X2, partial [Cricetulus griseus] mIR-24 1.37 0.000969 
NOP2 
Putative ribosomal RNA 
methyltransferase NOP2 [Cricetulus 
griseus] mIR-24 1.27 0.015608 
NPM1 Nucleophosmin [Cricetulus griseus] mIR-24 1.33 0.00651 
NSUN2 
tRNA (cytosine-5-)-methyltransferase 
NSUN2 [Cricetulus griseus] mIR-24 1.47 0.004212 
NT5C2 
Cytosolic purine 5'-nucleotidase 
[Cricetulus griseus] mIR-24 1.28 0.021542 
NUCB1 Nucleobindin-1 [Cricetulus griseus] mIR-24 2.67 0.04012 
NUDC 
Nuclear migration protein nudC 
[Cricetulus griseus] mIR-24 1.29 0.009453 
NUMA1 
Nuclear mitotic apparatus protein 1 
[Cricetulus griseus] mIR-24 1.38 0.015185 
NUP153 
Nuclear pore complex protein Nup153 
[Cricetulus griseus] mIR-24 1.35 0.01522 
NUP93 
Nuclear pore complex protein Nup93 
[Cricetulus griseus] mIR-24 1.36 0.003455 
PA2G4 
Proliferation-associated protein 2G4 
[Cricetulus griseus] mIR-24 1.29 0.002106 
PARP1 
poly [ADP-ribose] polymerase 1 
[Cricetulus griseus] mIR-24 1.37 0.000557 
PCBP1 
Poly(rC)-binding protein 1 [Cricetulus 
griseus] mIR-24 1.45 0.00115 
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PCK2 
Phosphoenolpyruvate carboxykinase 
[GTP], mitochondrial [Cricetulus griseus] mIR-24 1.4 0.012219 
PCYT2 
Ethanolamine-phosphate 
cytidylyltransferase [Cricetulus griseus] mIR-24 2.03 0.040112 
PDIA4 
Protein disulfide-isomerase A4 [Cricetulus 
griseus] mIR-24 1.36 0.01444 
PFAS 
Phosphoribosylformylglycinamidine 
synthase [Cricetulus griseus] mIR-24 1.56 0.004929 
PGD 
6-phosphogluconate dehydrogenase, 
decarboxylating [Cricetulus griseus] mIR-24 1.29 0.001711 
PHB Prohibitin [Cricetulus griseus] mIR-24 1.32 0.019767 
PHB2 Prohibitin-2 [Cricetulus griseus] mIR-24 1.53 0.014341 
PLCD1 
1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase delta-1 [Cricetulus 
griseus] mIR-24 1.55 0.031416 
PLOD1 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1 [Cricetulus griseus] mIR-24 1.51 0.013623 
PMPCA 
PREDICTED: mitochondrial-processing 
peptidase subunit alpha isoform X1 
[Cricetulus griseus] mIR-24 1.53 0.002638 
PNN Pinin [Cricetulus griseus] mIR-24 1.37 0.000221 
POLDIP3 
Polymerase delta-interacting protein 3, 
partial [Cricetulus griseus] mIR-24 1.46 0.008521 
PPFIBP1 Liprin-beta-1 [Cricetulus griseus] mIR-24 2.96 2.37E-05 
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PPM1G 
Protein phosphatase 1G [Cricetulus 
griseus] mIR-24 1.45 0.009857 
PPP2R1A 
Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha 
isoform, partial [Cricetulus griseus] mIR-24 1.32 0.016659 
PRDX1 
thioredoxin peroxidase II [Cricetulus 
griseus] mIR-24 1.31 0.005345 
PRDX3 
Thioredoxin-dependent peroxide 
reductase, mitochondrial [Cricetulus 
griseus] mIR-24 1.43 0.000715 
PRKCSH 
Glucosidase 2 subunit beta [Cricetulus 
griseus] mIR-24 1.32 0.024168 
PRMT1 
Protein arginine N-methyltransferase 1 
[Cricetulus griseus] mIR-24 1.45 0.022119 
PRPS2 
Ribose-phosphate pyrophosphokinase 2 
[Cricetulus griseus] mIR-24 1.37 0.030915 
PSMA1 
Proteasome subunit alpha type-1 
[Cricetulus griseus] mIR-24 1.37 0.012945 
PSMA3 
Proteasome subunit alpha type-3 
[Cricetulus griseus] mIR-24 1.58 2.98E-05 
PSMA7 
Proteasome subunit alpha type-7, partial 
[Cricetulus griseus] mIR-24 1.44 0.000213 
PSMB4 
Proteasome subunit beta type-4 
[Cricetulus griseus] mIR-24 1.36 0.031699 
PSME2 
Proteasome activator complex subunit 2 
[Cricetulus griseus] mIR-24 1.3 0.011584 
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PSPH 
Phosphoserine phosphatase [Cricetulus 
griseus] mIR-24 1.37 0.008783 
PUM3 
Pumilio domain-containing protein 
KIAA0020-like [Cricetulus griseus] mIR-24 1.57 0.002624 
RACK1 
Guanine nucleotide-binding protein 
subunit beta-2-like 1 [Cricetulus griseus] mIR-24 1.31 0.008033 
RAD23B 
PREDICTED: LOW QUALITY PROTEIN: 
UV excision repair protein RAD23 
homolog B isoform X2 [Cricetulus griseus] mIR-24 1.26 0.011592 
RALY 
RNA-binding protein Raly [Cricetulus 
griseus] mIR-24 1.39 0.00679 
RANBP2 
E3 SUMO-protein ligase RanBP2 
[Cricetulus griseus] mIR-24 1.4 0.006817 
RBM14 
RNA-binding protein 14 [Cricetulus 
griseus] mIR-24 1.28 0.009196 
RCC1 
Regulator of chromosome condensation 
[Cricetulus griseus] mIR-24 1.26 0.011764 
RCC2 Protein RCC2 [Cricetulus griseus] mIR-24 1.29 0.011654 
RCN3 Reticulocalbin-3 [Cricetulus griseus] mIR-24 1.62 0.000845 
RINL 
Ras and Rab interactor-like protein 
[Cricetulus griseus] mIR-24 1.32 0.000117 
RNMT 
mRNA cap guanine-N7 methyltransferase 
[Cricetulus griseus] mIR-24 1.28 0.0077 
RP7 
60S ribosomal protein L7 [Cricetulus 
griseus] mIR-24 1.27 0.001628 
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RPL10 
60S ribosomal protein L10 [Cricetulus 
griseus] mIR-24 1.47 0.030368 
RPL13 
60S ribosomal protein L13 [Cricetulus 
griseus] mIR-24 1.32 0.000879 
RPL13A 
60S ribosomal protein L13a [Cricetulus 
griseus] mIR-24 1.3 0.026852 
RPL15 
60S ribosomal protein L15 [Cricetulus 
griseus] mIR-24 1.28 0.005215 
RPL17 
60S ribosomal protein L17 [Cricetulus 
griseus] mIR-24 1.38 0.008468 
RPL18A 
PREDICTED: 60S ribosomal protein L18a 
isoform X2 [Cricetulus griseus] mIR-24 1.26 0.038705 
RPL23A 
60S ribosomal protein L23a [Cricetulus 
griseus] mIR-24 1.3 0.02266 
RPL3 
60S ribosomal protein L3 [Cricetulus 
griseus] mIR-24 1.22 0.020758 
RPL36A 
60S ribosomal protein L36a [Cricetulus 
griseus] mIR-24 1.28 0.004358 
RPN1 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 
[Cricetulus griseus] mIR-24 1.35 0.001804 
RPS11 
40S ribosomal protein S11 [Cricetulus 
griseus] mIR-24 1.48 0.001304 
RPS18 
40S ribosomal protein S18 [Cricetulus 
griseus] mIR-24 1.3 0.015964 
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RPS23 
40S ribosomal protein S23 [Cricetulus 
griseus] mIR-24 1.37 0.01405 
RPS3A 
40S ribosomal protein S3a [Cricetulus 
griseus] mIR-24 1.3 0.001585 
RPS4 
40S ribosomal protein S4 [Cricetulus 
griseus] mIR-24 1.32 0.005539 
RPS6 
PREDICTED: 40S ribosomal protein S6 
isoform X1 [Cricetulus griseus] mIR-24 1.81 0.00682 
RRM1 
Ribonucleoside-diphosphate reductase 
large subunit [Cricetulus griseus] mIR-24 1.82 0.007666 
RRP12 RRP12-like protein [Cricetulus griseus] mIR-24 1.38 0.008418 
RRP9 
U3 small nucleolar RNA-interacting 
protein 2 [Cricetulus griseus] mIR-24 1.56 0.01127 
RUVBL1 RuvB-like 1 [Cricetulus griseus] mIR-24 1.58 0.005994 
RUVBL2 RuvB-like 2 [Cricetulus griseus] mIR-24 1.52 0.003174 
SEC22B 
Vesicle-trafficking protein SEC22b 
[Cricetulus griseus] mIR-24 1.29 0.009604 
SERBP1 
PREDICTED: plasminogen activator 
inhibitor 1 RNA-binding protein isoform 
X1 [Cricetulus griseus] mIR-24 1.36 0.007496 
SF3B1 
Splicing factor 3B subunit 1 [Cricetulus 
griseus] mIR-24 1.67 0.014404 
SF3B2 
Splicing factor 3B subunit 2 [Cricetulus 
griseus] mIR-24 1.42 0.007007 
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SFPQ 
Splicing factor, proline- and glutamine-
rich [Cricetulus griseus] mIR-24 1.35 0.012404 
SFXN1 Sideroflexin-1 [Cricetulus griseus] mIR-24 1.31 0.024124 
SLC7A11 
Cystine/glutamate transporter [Cricetulus 
griseus] mIR-24 2.59 0.001724 
SLK 
STE20-like serine/threonine-protein 
kinase [Cricetulus griseus] mIR-24 1.46 0.00836 
SND1 
nuclease domain-containing protein 1 
[Cricetulus griseus] mIR-24 1.41 0.00885 
SNRNP70 
U1 small nuclear ribonucleoprotein 70 
kDa [Cricetulus griseus] mIR-24 1.34 0.002377 
SNRPA1 
U2 small nuclear ribonucleoprotein A' 
[Cricetulus griseus] mIR-24 1.29 0.00788 
SNRPB2 
U2 small nuclear ribonucleoprotein B'' 
[Cricetulus griseus] mIR-24 1.35 0.000558 
SNRPD2 
Small nuclear ribonucleoprotein Sm D2 
[Cricetulus griseus] mIR-24 1.26 0.007542 
SNRPN 
Small nuclear ribonucleoprotein-
associated protein N [Cricetulus griseus] mIR-24 1.42 0.000441 
SNX2 Sorting nexin-2 [Cricetulus griseus] mIR-24 1.32 0.022697 
SORD 
Sorbitol dehydrogenase [Cricetulus 
griseus] mIR-24 1.34 0.000987 
SRP68 
Signal recognition particle 68 kDa protein 
[Cricetulus griseus] mIR-24 1.33 0.005184 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
378 
SRPRB 
Signal recognition particle receptor 
subunit beta [Cricetulus griseus] mIR-24 1.33 0.003504 
SRSF1 
Splicing factor, arginine/serine-rich 1 
[Cricetulus griseus] mIR-24 1.51 0.005298 
STIP1 
Stress-induced-phosphoprotein 1 
[Cricetulus griseus] mIR-24 1.19 0.011514 
STK38L 
Serine/threonine-protein kinase 38-like 
[Cricetulus griseus] mIR-24 2.85 8.53E-05 
STOML2 
Stomatin-like protein 2 [Cricetulus 
griseus] mIR-24 1.48 0.024219 
SUPT16H 
FACT complex subunit SPT16 [Cricetulus 
griseus] mIR-24 1.29 0.000632 
TARDBP 
TAR DNA-binding protein 43 [Cricetulus 
griseus] mIR-24 1.3 0.00873 
TARS 
Threonyl-tRNA synthetase, cytoplasmic 
[Cricetulus griseus] mIR-24 1.31 0.000868 
TCOF1 Treacle protein [Cricetulus griseus] mIR-24 1.35 0.031868 
THOP1 Thimet oligopeptidase [Cricetulus griseus] mIR-24 1.43 0.01074 
TIMM44 
PREDICTED: mitochondrial import inner 
membrane translocase subunit TIM44 
[Cricetulus griseus] mIR-24 1.51 0.019012 
TIMM8A 
Mitochondrial import inner membrane 
translocase subunit Tim8 A [Cricetulus 
griseus] mIR-24 1.67 0.024256 
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TKT 
PREDICTED: transketolase isoform X2 
[Cricetulus griseus] mIR-24 1.26 0.002741 
TPD52L2 
Uncharacterized protein C20orf135-like 
[Cricetulus griseus] mIR-24 1.32 0.001167 
TPM3 
Tropomyosin alpha-3 chain [Cricetulus 
griseus] mIR-24 1.27 0.006601 
TRAP1 
Heat shock protein 75 kDa, mitochondrial 
[Cricetulus griseus] mIR-24 1.34 0.0013 
TRMT1L TRM1-like protein [Cricetulus griseus] mIR-24 1.52 0.003691 
TSFM 
Elongation factor Ts, mitochondrial 
[Cricetulus griseus] mIR-24 1.31 0.00579 
TSTS 
RecName: Full=Thiosulfate 
sulfurtransferase; AltName: 
Full=Rhodanese mIR-24 1.61 0.000119 
TTLL12 
Tubulin--tyrosine ligase-like protein 12 
[Cricetulus griseus] mIR-24 1.45 0.000194 
TUFM 
Elongation factor Tu, mitochondrial 
[Cricetulus griseus] mIR-24 1.35 0.002292 
UBAP2L 
Ubiquitin-associated protein 2-like 
[Cricetulus griseus] mIR-24 1.43 0.021691 
UPF1 
Regulator of nonsense transcripts 1 
[Cricetulus griseus] mIR-24 1.38 0.006308 
USP5 
Ubiquitin carboxyl-terminal hydrolase 5 
[Cricetulus griseus] mIR-24 1.4 0.015407 
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VARS 
Valyl-tRNA synthetase [Cricetulus 
griseus] mIR-24 1.31 0.003383 
VCP 
Transitional endoplasmic reticulum 
ATPase [Cricetulus griseus] mIR-24 1.35 0.00528 
VDAC2 
Voltage-dependent anion-selective 
channel protein 2 [Cricetulus griseus] mIR-24 1.29 0.009657 
WARS 
PREDICTED: tryptophan--tRNA ligase, 
cytoplasmic isoform X2 [Cricetulus 
griseus] mIR-24 1.52 0.007185 
WDR12 
Ribosome biogenesis protein WDR12 
[Cricetulus griseus] mIR-24 1.31 0.012643 
WDR5 
WD repeat-containing protein 5 
[Cricetulus griseus] mIR-24 1.61 0.004475 
XPNPEP1 
Xaa-Pro aminopeptidase 1 [Cricetulus 
griseus] mIR-24 1.42 0.0179 
XPO5 Exportin-5 [Cricetulus griseus] mIR-24 3.41 0.000122 
YARS 
Tyrosyl-tRNA synthetase, cytoplasmic 
[Cricetulus griseus] mIR-24 1.27 0.006098 
YTHDF1 
YTH domain family protein 1 [Cricetulus 
griseus] mIR-24 1.47 0.002222 
ZC3H14 
Zinc finger CCCH domain-containing 
protein 14 [Cricetulus griseus] mIR-24 2 0.032746 
ZC3H4 
Zinc finger CCCH domain-containing 
protein 4, partial [Cricetulus griseus] mIR-24 1.4 0.010908 
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ZCCHC3 
Zinc finger CCHC domain-containing 
protein 3 [Cricetulus griseus] mIR-24 1.86 0.00191 
ZPR1 
Zinc finger protein ZPR1 [Cricetulus 
griseus] mIR-24 1.91 0.020843 
     
